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3Abstract
Many patients with inactive inflammatory bowel disease (IBD) continue to experience functional
gastrointestinal symptoms (FGS) despite minimal objective evidence of GI inflammation, with a
significant impact upon health-related quality of life. The low FODMAP diet is effective for the
management of irritable bowel syndrome (IBS) and retrospective and prospective uncontrolled
studies indicate that it may reduce FGS in patients with inactive IBD. However, this is yet to be
confirmed in a randomised placebo-controlled trial. The low FODMAP diet reduces abundance
of immune-modulatory Bifidobacteria and Faecalibacterium prausnitzii in IBS, alterations that
may have clinical implications were they to occur in IBD.
The aim of this thesis was to establish the role of FODMAPs in FGS in IBD. Firstly, a case-control
study was conducted to establish FODMAP intakes in patients with active IBD, inactive IBD with
FGS and inactive IBD without FGS compared to healthy controls. This showed that patients with
inactive IBD with FGS had lower GOS and polyol intakes than healthy controls, although whether
FODMAPs induce symptoms in patients with inactive IBD remained unclear.
Therefore, a randomised, placebo-controlled re-challenge trial was designed to establish the
effects of pure FODMAP challenges on GI symptoms. A pure fructan challenge induced FGS in
patients with inactive IBD, proving FODMAPs as possible inducers of FGS in IBD. However, this
trial did not establish efficacy of the low FODMAP diet compared to a placebo diet.
Therefore,  a  randomised  controlled  trial  was  conducted  to  investigate  the  effect  of  the  low
FODMAP diet on FGS in patients with inactive IBD. Patients with Crohn’s disease and ulcerative
colitis with minimal GI inflammation were randomised to either low FODMAP or placebo sham
dietary advice, which was followed for 4 weeks. At end of trial, significantly more patients
reported adequate relief of GI symptoms in the low FODMAP diet group (14/27, 52%) than the
sham diet  group (4/25,  16%;  P=0.007).  There was a  greater  reduction in  IBS  Severity  Scoring
System score in the low FODMAP diet group (-67 SD 78) compared to the sham diet group (-34
SD 50) although this failed to reach significance (P=0.075). There was significantly lower
Bifidobacterium longum (P=0.006), Bifidobacterium adolescentis (P=0.005) and
Faecalibacterium prausnitzii (0.038)  following the low FODMAP diet  compared to  sham diet.
Reassuringly, inflammatory markers and gut-homing T-cells were not different between the diet
groups.
This thesis has established that patients with IBD restrict dietary fermentable carbohydrates,
and that certain types induce FGS in patients with inactive IBD. Additionally, a low FODMAP diet
improves FGS in these patients but reduces immune-regulatory GI bacteria abundance, a finding
that requires further investigation.
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1.1 Inflammatory bowel disease
1.1.1 Introduction
Inflammatory bowel disease (IBD) includes Crohn’s disease (CD), characterised by discontinuous
transmural inflammation that can affect all regions of the gastrointestinal (GI) tract and
ulcerative colitis (UC), characterised by continuous mucosal inflammation that is isolated to the
colon beginning in the rectum and extending to varying degrees. Patients with IBD generally
experience periods of remission (i.e. absence of objective evidence of GI inflammation),
interspersed with periods of active inflammation. Symptoms of abdominal pain, diarrhoea,
anaemia and weight loss are characteristic of active CD. Transmural inflammation can result in
complications such as fistulas between one part of the GI tract and: another part of the GI tract;
other organs; or the skin. Intestinal obstruction can also occur as a result of strictures and may
necessitate intestinal resections. Hallmark symptoms of active UC are rectal bleeding, diarrhoea
and urgency, and many patients also experience abdominal pain.
Inflammatory bowel disease represents a significant individual and societal burden since it
typically presents at a young age and a lifetime of medical management is required. Despite
medical management, many patients continue to live with considerable GI symptoms and
disability, which can result in loss of education and difficulty attaining employment.
Inflammation can also lead to growth failure and delayed puberty in young people. Lifetime
costs of IBD are comparable to other chronic diseases and indirect costs on society may exceed
direct costs of medical management, although with the increasing use of biologic therapies the
contribution of medical management to the overall financial burden of IBD are likely to increase
(Mowat et al., 2011, Luces and Bodger, 2006).
1.1.2 Prevalence and incidence
Traditionally, IBD was considered a disease of the economically-developed world. However,
rising incidence in areas that were previously of low incidence, such as Asia, South America and
Southern and Eastern Europe suggests that the classic geographic distribution of IBD is changing
(Burisch and Munkholm, 2013, Ananthakrishnan, 2015). Worldwide IBD incidence and
prevalence are increasing with time, with the highest annual incidence in Europe and North
America, reported at 12.7 and 20.2 cases per 100,000 person-years for CD and 24.3 and 19.2
cases per 100,000 person-years for UC (Molodecky et al., 2012). The prevalence of IBD in Europe
is estimated at 322 per 100,000 for CD and 505 per 100,000 persons for UC (Molodecky et al.,
2012). An East-West gradient of IBD incidence was established in an inception cohort of 1515
European patients, with greater incidence rates in Western than Eastern Europe (Burisch et al.,
2014a). The reasons for this remain unclear but may relate to different environmental exposures
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in Western Europe. Furthermore, an early European study (Economou and Pappas, 2008) and a
more recent North American study (Schultz and Butt, 2012) observed a north-south gradient in
IBD incidence, hypothesised to relate to vitamin D status.
1.1.3 Pathogenesis of IBD
The pathogenesis of IBD remains elusive, however it is likely to arise as a result of a combination
of genetics, GI microbiota, dysregulated immune function and environmental exposures
including smoking, diet and antibiotics (Figure 1.1) (Ananthakrishnan, 2015). The generally
accepted notion is that IBD results from an inappropriate and uncontrolled inflammatory
response to the GI microbiota in a genetically susceptible host (Khor et al., 2011). In this section,
the major factors hypothesised to be involved in IBD pathogenesis are discussed.
Figure 1.1 Factors potentially involved in the pathogenesis of IBD. Green boxes: environmental factors
potentially involved in IBD pathogenesis include vitamin D exposure, smoking, hygiene, diet,
medications and appendectomy; blue box: stress is hypothesised to play a role in the risk of IBD and
IBD relapse through the brain-gut axis; red box: some individuals with IBD possess single-nucleotide
polymorphisms associated with susceptibility to IBD; yellow box: an aberrant microbiome composition
or function may play a role in IBD development.
1.1.3.1 Genetics
Familial aggregation studies and genome-wide association studies (GWAS) support the role of
genetic predisposition in the development of IBD. However, IBD-associated loci explain only












play a predominant role (Liu et al., 2015). In line with these findings, only 2-14% of patients with
CD and 8-14% of patients with UC report a family history of IBD and the risk of a first-degree
relative developing IBD is 5% with a CD proband and 1.6% for a UC proband (Ananthakrishnan,
2015). Twin studies have shed further insight into the genetic basis of IBD, with relatively high
CD concordance of 20-50% in monozygotic twins. This is considerable but not 100%
concordance, thus further supporting the involvement of other risk factors in IBD development.
To date, GWAS including individuals of European and non-European descent have identified 200
IBD risk loci, many of which encode genes relating to intestinal barrier function, microbial
defence, innate immune regulation, reactive oxygen species generation, autophagy and
regulation of adaptive immunity (Liu et al., 2015). Some are protective and some predisposing
alleles, and most are shared between CD and UC, with some that are specific to one or the other.
The first genetic locus to be associated with CD risk was that of NOD2 (also known as caspase
recruitment domain-containing protein 15 or CARD15), with three variants associated with
greater risk (Hugot et al., 2001). This is an intracellular protein found in antigen-presenting cells
and Paneth cells, bearing a leucine-rich repeat domain responsible for the recognition of the
microbial ligand, muramyl dipeptide. The NOD domain is crucial in the activation of the protein
following ligand recognition and the downstream activation of the pro-inflammatory
transcription factor NF-κB (nuclear factor kappa B) (Strober et al., 2007). Impaired activation of
pro-inflammatory NF-κB with NOD2 mutations should presumably reduce inflammation, but
clearly the opposite is observed. This is postulated to relate to an impaired host defence and
greater bacterial colonisation of the mucosa. Alternatively, NOD2 may in fact downregulate NF-
κB. Interestingly, mice with NOD2 mutations do not develop spontaneous colitis until exposed
to an antigen recognised by a large proportion of T-cells, suggesting bacterial involvement
(Watanabe et al., 2006). Some IBD risk loci are involved in common immunological pathways,
for example ATG16L1, NOD2, IRGM and LRRK2 all play a role in autophagy, indicating a role for
dysregulated immune function in IBD risk.
1.1.3.2 Gastrointestinal microbiota
The GI microbiota plays numerous roles important to the human host, including the inhibition
of pathogen colonisation, the digestion of substrates that are inaccessible to humans, and the
priming and development of the immune system. The colonic microbiota consists of 1011 or 1012
bacterial cells per gram of luminal contents, representing the most densely populated region of
the GI tract (Sender et al., 2016).
There are several lines of evidence suggesting a role for the GI microbiota in IBD pathogenesis.
Firstly, as discussed above, many of the genetic loci associated with IBD risk relate to pathways
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involved in microbial defence. Secondly, studies indicate a lower risk of IBD associated with
larger family size, early life exposure to animals, and breastfeeding, exposures that could modify
the GI microbiota (Ng et al., 2015, Timm et al., 2014, Xu et al., 2017). Thirdly, germ-free mice fail
to spontaneously develop colitis and therefore the microbiota are assumed to be required for
IBD development (Sartor and Mazmanian, 2012). Fourthly, restoration of the faecal stream after
reversal of a diverting ileostomy results in CD recurrence, implicating a role for the luminal
contents in disease initiation (Rutgeerts et al., 1991). Finally, a systematic review and meta-
analysis concluded that antibiotic therapy is effective for inducing remission in IBD, suggesting
that the GI microbiota may have some role in GI inflammation (Khan et al., 2011).
The altered microbiota consistently observed in IBD provides further evidence of a potential role
of the microbiome in IBD pathogenesis. This so-called ‘dysbiosis’ is characterised by reduced
microbial diversity, particularly within the Firmicutes phylum, which is generally more marked
in CD than in UC. Reduced Firmicutes and increased Proteobacteria are commonly observed in
CD, while in UC reduced Roseburia and Faecalibacterium prauznitzii have been observed
(Machiels et al., 2013) (Table 1.1). The microbiome may vary according to disease activity, with
lower diversity in inflamed compared to non-inflamed tissue in CD (Sepehri et al., 2007, Walker
et al., 2011). Adherent invasive Escherichia coli is enriched in ileal CD particularly, and this may
relate to its preference for and ability to thrive in an inflammatory environment (Rolhion and
Darfeuille-Michaud, 2007). Recent studies have utilised 16S rRNA sequencing to establish that
the IBD microbiome displays greater temporal instability than that of healthy controls and that
a CD-associated microbial signature exists (Halfvarson et al., 2017, Pascal et al., 2017).
The bacterium most consistently shown to be reduced in IBD, particularly in ileal CD, is F.
prausnitzii of the Clostridiaceae family (Table 1.1). This is a strictly anaerobic butyrate-producing
bacterium that resides in the colon and represents around 5% of the faecal microbiota (Hold et
al.,  2003). The growth of F. prausnitzii in the colon is influenced by substrate availability, pH,
oxygen levels and bile acid concentrations, and the study of F. prausnitzii has been hindered by
its extreme oxygen-sensitivity (Lopez-Siles et al., 2017). In vitro and in vivo (TNBS and DNBS
colitis models) studies have demonstrated anti-inflammatory effects of F. prausnitzii with the
release of metabolites capable of blocking NF-κB activation and pro-inflammatory IL-8
production (Martin et al., 2014, Rossi et al., 2016, Sokol et al., 2008, Sokol et al., 2009). A protein
secreted by F. prausnitzii, termed microbial anti-inflammatory molecule, has been isolated and
identified as responsible for its anti-inflammatory effects (Quévrain et al., 2015). Strain
specificity in the immunomodulatory properties of F. prausnitzii has recently been identified
(Martín et al., 2017).
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There may be functional consequences of GI microbiome aberrations in IBD. In gnotobiotic mice
harbouring only F. prausnitzii and E. coli, a metabolic signature was associated with the anti-
inflammatory effects of F. prausnitzii (Miquel et al., 2015). A lower F. prausnitzii abundance at
the point of intestinal resection is associated with greater risk of post-operative recurrence at 6
months in patients with CD (Sokol et al., 2008). Furthermore, a study of the mucosa-associated
microbiota in patients with CD at the point of intestinal resection and at recurrence revealed
that patients with post-operative recurrence at 6 months exhibited a microbiota with greater
proteolytic fermentation capacity, while those remaining in remission retained saccharolytic
genera including Bacteroides, Prevotella and butyrate-producing Firmicutes that may include F.
prausnitzii (De Cruz et al., 2015).
Although numerous studies have assessed the GI microbiome in patients with established IBD
(Table 1.1), they are limited by small sample sizes, an assessment of only the luminal microbiota,
variation in the patients recruited (CD vs. UC; active vs. inactive; surgery vs. no surgery) and the
method used to characterise the microbiota. In addition, case-control studies are inherently
confounded by the effect of prolonged inflammation and medication on the GI microbiota,
posing the question as to whether microbiota alterations are a cause or consequence of IBD. A
large study of the luminal and mucosal GI microbiota of 1,742 newly diagnosed, treatment naïve
paediatric and adult patients with CD attempted to address some of these limitations (Gevers
et al., 2014). Furthermore, an analysis of siblings of CD probands observed a dysbiosis mirroring
that of CD, characterised by reduced F. prausnitzii, suggesting that dysbiosis may precede CD
development (Hedin et al., 2014, Hedin et al., 2016).
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Table 1.1 Studies assessing the luminal and/or mucosal gastrointestinal microbiota composition in adult patients with IBD
Patients Sample
site
Method of bacterial analysis Species or genera increased in
IBD




17 CD (9 inactive, 8 active)
16 healthy controls
Faeces Quantitative dot blot hybridisation Enterobacteria
Bifidobacterium (active CD)
Clostridium coccoides (Seksik et al., 2003)
6 CD
6 healthy controls




Faeces FISH Clostridium coccoides (UC)
Clostridium leptum (CD)




Faeces qPCR Clostridium leptum (active IBD)




(Sokol et al., 2009)
6 CD
6 healthy controls












(Kang et al., 2010)
127 UC
87 healthy controls








Faeces qPCR Faecalibacterium prausnitzii (IBD
and relatives)
(Varela et al., 2013)
10 inactive CD
10 healthy controls












Method of bacterial analysis Species or genera increased in
IBD











(Pascal et al., 2017)
49 CD (1-10 samples each)
60 UC (1-10 samples each)
9 healthy controls (1-10
samples each)




Prevotella copri (ileal CD)













Mucosa 16S rRNA sequencing Escherchia fergusonii Faecalibacterium prausnitzii (Hedin et al., 2016)

















qPCR Bifidobacteria (active UC mucosa)
Lactobacillus (active CD mucosa)
Escherchia coli
Faecalibacterium prausnitzii
(all IBD, faecal and mucosal)




The mucosal GI barrier is composed of the epithelial layer, including a web of tight junction
proteins, and the overlying mucus, that selectively permits passage of nutrients while excluding
the majority of the luminal contents. One theory for IBD pathogenesis is that an impaired GI
mucosal barrier results in bacterial translocation and immune activation with a subsequent
inflammatory cascade. Reduced expression of tight junction proteins, including occludins,
claudins and junctional adhesion molecules and altered structure of tight junctions have been
shown in IBD (Schmitz et al., 1999) (Zeissig et al., 2007). However, altered permeability in the
presence of active GI inflammation is likely an effect of tumour necrosis factor alpha (TNFα) and
other cytokines involved in the inflammatory cascade on tight junction protein expression and
epithelial apoptosis (Marini et al., 2003). That said, impaired intestinal permeability has been
shown to precede inflammation in murine models of chemically-induced colitis. Furthermore,
murine models with genetically impaired GI barrier function spontaneously develop
inflammation (Pastorelli et al., 2013). However, this is not consistent among all animal models
with impaired tight junctions, suggesting that other factors are involved in initiating an
inflammation. Furthermore, animal colitis models do not perfectly replicate human IBD. In
support of increased GI permeability as a causative factor in human IBD, increased GI
permeability has been observed in siblings of IBD probands (Hollander et al., 1986), although
this is inconsistent between studies (Hedin et al., 2014). A greater likelihood of CD relapse was
observed in patients with increased GI permeability (Arnott et al., 2000). However, this was in a
small number of patients and it remains unclear whether impaired intestinal permeability
precedes human IBD or is simply a consequence of elevated inflammatory cytokines during
inflammation.
1.1.3.4 Immune dysregulation
Chronic inflammation in IBD relates to a dysregulated immune response and therefore the
immune system has been thoroughly investigated as a major factor in the pathogenesis of IBD.
With the classical view that IBD is T-cell mediated, adaptive immunity has been the focus of this
research. Accumulation of T helper 1 and T helper 17 cells (expressing cytokines including IFN-
γ, IL-17A and IL-22) is observed in IBD, and some investigators have suggested an accumulation
of T helper 2 cells in UC specifically (Fuss et al., 1996). There is increasing interest in the role of
T regulatory cells, which under normal circumstances would suppress inflammation, a function
that appears defective in IBD. The T regulatory cell response may be insufficient to suppress
inflammation in IBD, which could relate to intrinsic cellular defects or a result of the extrinsic
cytokine milieu in IBD. Furthermore, T regulatory cells are influenced by the GI microbiota,
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forging a link between microbiota aberrations and immune suppressive function in IBD (Mayne
and Williams, 2013).
Although evidence to date has focussed on the role of adaptive immunity in IBD, emerging
evidence suggests a role of the innate immune system in IBD. This includes an altered GI mucosal
barrier, antimicrobial peptide production, and dysregulated innate lymphoid cell (ILC) function
(de Souza and Fiocchi, 2016). The latter innate lymphocytes are found in mucosal tissues and
produce IBD-specific cytokines but lack the antigen-specific receptors found on T and B-cells. In
animal models of IBD, ILC’s have been implicated in GI inflammation. Furthermore, altered
numbers of ILC’s have been observed in IBD (Goldberg et al., 2015). Research in this field will
likely focus on ILC’s as therapeutic targets in IBD.
Dendritic cells (DC) are innate antigen-presenting cells, capable of sampling GI antigen by
extending dendrites into the lumen. Upon presentation of antigen by intestinal DC to naïve T-
cells in mesenteric lymph nodes and Peyer’s patches, T-cells differentiate into either a regulatory
or effector phenotype. In IBD mucosa, DC express increased levels of TLR-2, TLR-4, IL-12 and IL-
6 compared to controls, compatible with an enhanced ability to sample microbial antigen and
being in an activated state (Hart et al., 2005). Given that DC phenotype and cytokine production
has a role in the subsequent T-cell phenotype, an altered DC phenotype could play a role in IBD
pathogenesis (Stagg et al., 2003).
Leukocytes must traffic to the appropriate tissues of the body in order to carry out the required
effects. Naïve T-cells express receptors permitting entry to lymphoid organs but are usually
excluded from peripheral tissues such as the GI tract. In contrast, antigen-experienced effector
T-cells acquire expression of molecules allowing migration into tissues. The major homing
molecule  required  for  T-cell  entry  to  the  GI  tract  is  the  integrin  α4β7  (Berlin  et  al.,  1993).
Interaction with its ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1) on
intestinal high endothelial venules facilitates T-cell entry into the GI tract. T-cells activated by
DC in the gut-associated lymphoid tissue acquire a gut-homing phenotype, suggesting a role of
DC or the environment in inducing this phenotype. Retinoic acid appears crucial in inducing a
gut-homing phenotype in T-cells and in contrast to DC from other tissues, intestinal DC (likely
specifically CD103+ DC) express retinol dehydrogenases required for retinoic acid generation
(Iwata et al., 2004). In IBD, there is an abnormal and persisting infiltration of T-cells into the GI
mucosa. Upregulation of MAdCAM-1 on high endothelial venules in animal models of colitis and
human IBD and redistribution of gut-homing T-cells from the circulation to the GI mucosa in IBD





Numerous environmental exposures have been associated with the risk of developing IBD,
including smoking, appendectomy, GI infection, antibiotic use, diet (which will be discussed in
section 1.2), non-steroidal anti-inflammatory use, oral contraceptives, stress, physical activity
and sleep. None of these exposures appear sufficient to induce IBD in isolation but may interact
with other risk factors such as genetic predisposition and immune dysregulation to increase IBD
risk (Ananthakrishnan, 2015). Some of these environmental exposures will be discussed below.
Smoking has long been identified as a factor associated with IBD risk. A meta-analysis revealed
a twofold increased risk of CD associated with current and previous smoking, while current
smoking was inversely associated with UC risk (Mahid et al., 2006). Continued smoking is also
associated with a worse prognosis and more complex disease in CD, while in UC smoking
cessation can be associated with relapse (To et al., 2016b, To et al., 2016a). The aetiology of the
relationship between smoking and IBD risk remains unclear, however hypotheses include the
effects of nitric oxide on endothelial function, a possible effect on epithelial barrier integrity,
oxidative stress or the GI microbiota (Ananthakrishnan, 2015). Recently, 64 single nucleotide
polymorphisms associated with IBD risk were identified as being modified by smoking status,
suggesting that the impact of smoking on IBD risk may be genetically determined (Yadav et al.,
2017).
Appendectomy displays a divergent association with CD and UC risk, similar to smoking, with a
greater risk of CD and a lower risk of UC in patients who have had an appendectomy (Andersson
et  al.,  2001,  Andersson  et  al.,  2003),  although  a  reduced  risk  of  CD  once  controlled  for
appendectomy at the point of CD diagnosis has also been demonstrated (Radford-Smith et al.,
2002). Appendectomy for perforating appendicitis appears to be associated with greater risk of
intestinal resection in CD, whereas appendectomy for other indications is associated with
reduced CD risk (Andersson et al., 2003).
Several epidemiological and animal studies indicate a greater risk of IBD development and IBD
relapse following GI infection, including Salmonella, Campylobacter, E. coli, Helicobacter pylori
and Clostridium difficile (Schultz et al., 2017). The increased risk of IBD is greatest in the year
after GI infection, suggesting this association may be partly associated with detection bias (Jess
et al., 2011). This association is hypothesised to relate to lasting effects of infection on the GI
microbiota, barrier function or GI immune responses to the GI microbiota (Schultz et al., 2017).
A common theory relating to IBD pathogenesis is the ‘hygiene hypothesis’, referring to the
increase in autoimmune and chronic inflammatory conditions alongside an improvement in
sanitation and a decrease in infectious diseases. This hypothesis suggests that a diverse GI
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microbiota promotes differentiation of GI mucosal DC into tolerogenic DC, which in turn
promote the development of T regulatory cells. Excessive hygiene measures and antibiotic use
is proposed to limit the GI microbiota repertoire and to promote immunogenic DC, leading to
effector T-cell generation and an inflammatory response (Rook, 2012). However, this hypothesis
has recently come under scrutiny, and a new hypothesis has emerged suggesting that
commensal environmental microbial exposures are more important in the development of the
immune system than GI infections (Bloomfield et al., 2016). Greater IBD risk is associated with
antibiotic use in early life in a dose-dependent fashion, at least in Western populations (Shaw et
al., 2010, Kronman et al., 2012), an association hypothesised to relate to a perturbation of the
developing microbiota. Interestingly, early childhood antibiotic use in Asia, where children are
likely to be exposed to more GI pathogens, appears to be protective against IBD (Ng et al., 2015).
1.1.4 Diagnosis and monitoring
Diagnosis of IBD is through a combination of clinical symptoms and objective evidence from
endoscopic, radiological and histologic examinations. Upon presentation, a history including
recent travel, medications, smoking, family history of IBD, previous appendectomy and recent
GI infections should be taken (Mowat et al., 2011). A thorough assessment of GI symptoms,
physical examination and laboratory tests are important in a diagnosis of IBD. On endoscopy and
histology, Crohn’s disease is characterised by the presence of focal and often granulomatous
inflammation, while in UC continuous inflammation with basal plasmacytosis, crypt architectural
distortion and mucosal atrophy is observed (Magro et al., 2017). Imaging, such as magnetic
resonance imaging (MRI), ultrasound and computed tomography imaging may be used to assist
diagnosis. This is particularly useful to examine the small intestine and for the detection of
abscesses (Mowat et al., 2011). Magnetic resonance imaging is particularly useful in assessing
perianal CD.
Correct classification of IBD is vital since it influences clinical decision-making, monitoring and
the assessment of the risk of long-term complications. Inflammatory bowel disease phenotype
can be classified using the Montreal criteria, based upon age of diagnosis, location of
inflammation in the GI tract and the behaviour of disease for CD, and based upon the extent and
severity of inflammation in the colon for UC (Table 1.2).
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Table 1.2 The Montreal Classification of Crohn’s disease and ulcerative colitis (Satsangi et al., 2006)
Crohn’s disease Ulcerative colitis
Age at diagnosis A1: <16 years Extent E1: Ulcerative proctitis
A2: 17-40 years E2: left-sided UC (distal)
A3: >40 years E3: extensive UC (pancolitis)
Location L1: ileal Severity S0: clinical remission
L2: colonic S1: mild UC
L3: ileocolonic S2: moderate UC
L4: isolated upper disease* S3: severe UC
Behaviour B1: non-stricturing, non-penetrating
B2: stricturing
B3: penetrating
p: perianal disease modifierϮ
*L4 is a modifier that can be added to L1-L3 when concomitant upper GI disease is present
Ϯ”p” is added to B1-B3 when concomitant perianal disease is present
Frequency of IBD monitoring partly depends upon the course of disease and IBD medications.
Patients receiving, for example, biologic therapies will be monitored regularly for clinical
response and safety of the drug.
1.1.5 Impact of IBD on health-related quality of life
Chronic health conditions often impact upon health-related quality of life (HR-QOL).
Inflammatory bowel disease induces significant GI symptoms and, in some cases, long-term
complications of GI inflammation, which in many patients have psychosocial consequences. A
large study across seven European countries revealed that patients with IBD and GI symptoms
at the time of the study had poorer HR-QOL compared to the healthy population, though it is
unknown whether GI symptoms related to active IBD or were functional gastrointestinal
symptoms (Huppertz-Hauss et al., 2015). This study used a generic HR-QOL measure and
therefore likely underestimated the impact of IBD specifically on HR-QOL. This is in contrast to
IBD-specific HR-QOL measures, the most widely used being the IBD Questionnaire that
encompasses issues determined to be important in IBD (Cheung et al., 2000). Characteristics
identified to predict poor HR-QOL in IBD include higher perceived stress, high number of
hospitalisations and relapses, low perceived support, low income, unemployment and female
gender (Moradkhani et al., 2013). In another large cross-sectional study of patients with IBD,
high levels of anxiety, depression and stress were associated with poor HR-QOL, suggesting that
psychological parameters may influence HR-QOL (Iglesias-Rey et al., 2014).
Certain interventions have proven effective in improving HR-QOL in IBD, including drug
treatments such as infliximab (Casellas et al., 2012) and non-pharmacological treatments such
as exercise (Klare et al., 2015) and breathing and meditation (Gerbarg et al., 2015). Since poor
HR-QOL is associated with a greater number of relapses and disease severity (Graff et al., 2006),
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it is likely that any treatments effective in maintaining remission and reducing inflammation
would improve HR-QOL.
A systematic review identified patients with emotion-focussed and problem-focussed coping
styles, the former being associated with poorer psychological outcomes and the latter
associated with better psychological outcomes (McCombie et al., 2013). Likewise, a prospective
analysis of patients within the first 6 months of IBD diagnosis observed both adaptive and
maladaptive coping strategies, the latter of which was associated with worse outcomes
(McCombie et al., 2015). These findings suggest that coping styles and strategies, which vary
among patients, may have an influence on the impact of IBD on quality of life and psychological
interventions targeted at manipulating coping styles may improve psychological outcomes.
1.1.6 Treatment of IBD
1.1.6.1 Medical and surgical treatment
The aims of medical management of IBD are to induce and maintain clinical and endoscopic
remission, and to prevent the natural progression of the disease and the development of
complications (Baumgart and Sandborn, 2012). Corticosteroids, 5-aminosalicylic acid (5-ASA),
immune-suppressive drugs and biologics such as anti-TNFα antibodies are used to manage
inflammation, either alone or in combination. The choice of medical therapy is multifactorial,
taking into account disease activity, location and behaviour, possible side effects and previous
response to medication. Within 10 years of diagnosis, 20-30% of patients with UC require
surgery (Ordas et al.,  2012), most commonly subtotal colectomy with a temporary ileostomy
and subsequent reversal and formation of an ileo-anal pouch. In CD, multiple small intestinal
and colonic resections may be required for the management of intestinal obstruction,
penetration or treatment-refractory disease (Bemelman et al., 2018).
1.1.6.2 Microbial treatment
With  the  overwhelming  evidence  for  a  role  of  the  GI  microbiota  in  IBD,  much  research  has
focussed on the possible therapeutic benefit of its modification. One method of doing so is
through supplementing with probiotic bacteria. Probiotics are defined as “live microorganisms
which when administered in adequate amounts confer a health benefit to the host” (Hill et al.,
2014), the most common being Bifidobacteria and Lactobacilli. Probiotics may confer benefit
through a range of mechanisms including exclusion of pathogenic bacteria, normalisation of a
perturbed microbiota, direct modulation of the GI immune system and SCFA production (Hill et
al., 2014). Cellular and animal models support the potential anti-inflammatory effects of
probiotics. For example, a comparative in vitro assessment of six probiotic Lactobacillus and
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Bifidobacteria strains revealed that all strains influenced immune cell activation and cytokine
production, however Bifidobacteria strains tended to induce greater anti-inflammatory IL-10
production (Dong et al., 2012). Furthermore, Bifidobacterium infantis induced a strong anti-
inflammatory cytokine profile, characterised by an increase in the IL-10/IL-12 ratio, in peripheral
blood mononuclear cells from older subjects (You and Yaqoob, 2012). Lactobacilli and
Bifidobacteria modulate DC cytokine production in vitro (You et  al.,  2014).  In  line with  these
findings, probiotic treatment in patients with UC increased mucosal DC IL-10 and reduced IL-
12p40 production, suggesting that anti-inflammatory effects of probiotics may be mediated by
DC (Ng et al., 2010). In vivo, a mixture of Bifidobacterium and Lactobacillus species reduced the
severity of dextran sodium sulphate (DSS) colitis (Nanda Kumar et al., 2008).
The most conclusive evidence for probiotics in IBD is for a combination probiotic containing
Bifidobacterium and Lactobacillus species (VSL#3®) in maintaining remission in pouchitis (Singh
et al., 2015). In contrast, there is no evidence supporting the use of probiotics in CD, but in UC
there appears to be some benefit in the induction and maintenance of remission. A recent
systematic review and meta-analysis concluded that VSL#3 was more effective in inducing
remission in UC compared to placebo, and equally effective compared to 5-ASA for maintenance
of  remission  (Derwa  et  al.,  2017).  The  effectiveness  of  probiotics  in  UC  but  not  CD  may  be
explained by differences in baseline microbiota, different disease pathogenesis and greater
heterogeneity in terms of CD location and behaviour.
The GI microbiota may also be altered by supplementation with prebiotic carbohydrates. The
definition of a prebiotic has recently been updated by consensus and is now defined as “a
substrate that is selectively utilised by host microorganisms conferring a health benefit” (Gibson
et al., 2017). Fructans and galacto-oligosaccharides are the only carbohydrates that have been
consistently shown to meet prebiotic criteria. Prebiotics likely exert effects on the host through
increasing the abundance of GI bacteria with putative benefits to host health, which has been
substantiated in healthy individuals (Ramirez-Farias et al., 2009, Ramnani et al., 2015, Lomax et
al., 2012, Vandeputte et al., 2017). However, prebiotic effects may also be mediated through
SCFA production or direct ligation of pattern recognition receptors on immune cells, although
there  is  currently  sparse  evidence  for  the  latter  mechanism  (Roberfroid  et  al.,  2010).
Traditionally, prebiotics were assumed to predominantly stimulate the growth of Bifidobacteria
and Lactobacilli, however molecular methods of microbiota characterisation have revealed that
many other species utilise prebiotic substrates or may be increased due to cross-feeding
reactions (Moens et al., 2016).
In terms of the clinical effectiveness of prebiotics in IBD, a large placebo-controlled trial showed
no effect of fructan supplementation on disease activity or GI microbiota composition
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(measured using FISH) in active CD, although analysis using a more comprehensive technique
such as sequencing could have revealed bacterial alterations (Benjamin et al., 2011b). An RCT of
patients with active UC revealed similar effects of fructan supplementation and placebo on
disease activity, although faecal calprotectin significantly reduced in the fructan group only
(Casellas et al., 2007). Supplementation was only for a duration of two weeks and the trial had
a small sample size and failed to monitor the effect of fructan supplementation on the GI
microbiota. Thus, the current evidence suggests that prebiotics are unlikely to be effective in
the treatment of active IBD. However, the role of prebiotic supplementation in maintaining
remission remains unexplored.
Finally, in recent years there has been considerable interest in the transfer of GI microbiota from
a healthy donor to a recipient with a perturbed microbiota, termed faecal microbiota transplant
(FMT). For the management of Clostridium difficile infection, FMT is extremely effective and is
now part of clinical guidelines as an approved therapy . However, the current evidence for FMT
in IBD is less conclusive. A systematic review and meta-analysis identified 14 cohort studies and
four RCTs of FMT in active UC, and revealed a remission rate of 28% following FMT compared to
9% following placebo in the RCTs (Costello et al., 2017). Although this is promising data, there
are numerous questions that remain unanswered, including the optimal dosing regimen, route
of administration and long-term efficacy and safety of FMT in UC. Furthermore, the choice of
donor may have an influence on response to FMT, with some donors inducing remission in a
greater proportion of patients (Moayyedi et al., 2015). A meta-analysis revealed that FMT may
be effective in CD, however the included studies in CD were uncontrolled and RCTs are needed
to confirm the findings (Colman and Rubin, 2014).
1.1.6.3 Dietary treatment
Undoubtedly the most widely used dietary treatment for IBD is exclusive enteral nutrition (EEN),
in which patients obtain their nutritional requirements from liquid formula administered either
orally or via a feeding tube. Interest in EEN as primary therapy for CD emerged following studies
showing an improvement in IBD activity in pre-surgical patients given enteral formula as
nutrition support (Voitk et al., 1973).
Trials of EEN in CD have, justifiably, lacked a placebo control arm, since it is extremely difficult
to design a placebo treatment that mimics the appearance and flavour of EEN. Further
limitations of these trials include the high withdrawal rates (particularly in trials of orally
administered EEN), inclusion of patients with heterogeneous disease duration, location and
severity, varied EEN duration and a lack of blinding, even in trials comparing different types of
formula where blinding could realistically be employed. A systematic review and meta-analysis
Chapter 1: Introduction
30
established no differences in response to EEN according to fat composition (type or quantity) or
protein source (elemental, semi-elemental or polymeric formula) (Narula et al.,  2018). In the
same meta-analysis, EEN was less effective than corticosteroids for inducing remission in active
CD, however several of the trials combined corticosteroids with other medication such as 5-ASA.
Furthermore, most of the studies employed an intention-to-treat analysis. In the context of a
high withdrawal rate this does not adequately reflect the effectiveness of the therapy when
followed optimally. In clinical practice, EEN is generally recommended only to patients likely to
be able to adhere. As expected, the per-protocol analysis of the aforementioned meta-analysis
revealed  no  significant  difference  between  EEN  and  corticosteroids  (Narula  et  al.,  2018).
Mechanisms of EEN in CD are hypothesised to include an effect on the GI microbiota, with
studies indicating drastic bacterial alterations following EEN (Kaakoush et al., 2015, Quince et
al., 2015), including a paradoxical decline in anti-inflammatory F. prausnitzii. Other mechanisms
might include direct anti-inflammatory effects, reduction in food-derived antigens and delivery
of essential nutrients to the GI mucosa (Lee et al., 2015).
A meta-analysis revealed EEN and corticosteroids to have equal effectiveness in inducing
remission  of  active  CD  in  children  (Swaminath  et  al.,  2017).  However,  EEN  remains  first-line
therapy for CD in children, in whom corticosteroids are contraindicated (Ruemmele et al., 2014).
In adults with active CD, EEN may be used in patients wishing to avoid medical treatments or in
whom corticosteroids are contraindicated, or as a bridge to other treatments. There is evidence
that EEN may enhance post-surgical outcomes when administered prior to surgery (Wang et al.,
2016, Li et al., 2014a) and that it may enhance mucosal healing, which is associated with better
long-term outcomes (Grover et al., 2016, Berni Canani et al., 2006).
In one study of adults and children with active CD, combining partial enteral nutrition (providing
50% of energy requirements) with a diet excluding foods hypothesised to alter the GI microbiota
or intestinal permeability resulted in 62% of participants entering remission (Sigall Boneh et al.,
2017). This trial suggests that diets combining enteral nutrition and exclusion diets may have a
role in CD management, although this was an uncontrolled study and requires confirmation in
controlled trials.
The Specific Carbohydrate Diet (SCD) manipulates dietary carbohydrates with the proposed
purpose of modifying the GI microbiota, permitting only monosaccharides and excluding
disaccharides and polysaccharides. The SCD was initially developed for the management of
coeliac disease prior to the development of a gluten-free diet. It has since gained popularity for
the management of IBD, although evidence for the effectiveness of this diet is limited to small
retrospective and prospective uncontrolled studies (Obih et al., 2016, Suskind et al., 2014, Cohen
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et al., 2014). Randomised controlled trial evidence of the effectiveness and safety of the SCD is
required before widespread use in clinical practice.
Recently, interest in so-called ‘anti-inflammatory’ diets, that increase and decrease putative
anti- and pro-inflammatory dietary components, has emerged in IBD. In a recent prospective
uncontrolled study, improvements in clinical and endoscopic disease activity were observed
following one such ‘anti-inflammatory’ diet, however without a control group the effectiveness
of the diet remains to be established (Konijeti et al., 2017). Another ‘anti-inflammatory’ diet had
no impact on relapse rates in patients with quiescent UC compared to Canadian national healthy
eating guidelines but faecal calprotectin was maintained in the anti-inflammatory diet group
(Keshteli et al.). However, to date this has been published only in abstract form, and a major
limitation is the likely overlap between the dietary interventions. Furthermore, the proposed
mechanisms and justification for the inclusion and restriction of certain dietary components in
the dietary protocols are unclear, and the impact of these diets on nutritional adequacy is a
major concern in the context of IBD. Whole diet interventions aiming to reduce intestinal
inflammation warrant further investigation.
1.2 Diet and nutritional intake in IBD
A range of dietary components and patterns have been associated with the development of IBD
and  the  risk  of  relapse,  although  no  clear  evidence  exists  that  indicates  the  restriction  of  a
particular foodstuff would prevent the onset or relapse of IBD (Hou et al., 2011). Numerous
studies indicate that patients with IBD consider diet an important factor in the initiation of IBD
relapse and GI symptoms in general, as well as reporting difficulties maintaining body weight
and enjoying food and mealtimes (Triggs et al., 2010, Prince et al., 2011, Zallot et al., 2013, Limdi
et al., 2016). Patients with IBD are at heightened risk of malnutrition, the cause of which is multi-
factorial. Furthermore, treatment for IBD can involve dietary manipulation, namely exclusive
enteral  nutrition  (EEN),  which  was  discussed  in  section  1.1.6.3.  The  role  of  diet  in  the
pathogenesis and perpetuation of IBD, and nutritional concern in IBD, will be discussed in this
section.
1.2.1 Diet in IBD pathogenesis
Several dietary components have been associated with IBD risk. These include dietary patterns
characteristic of a ‘Western’ diet including high sugar and fat intake and low fruit and vegetable
intake (Hou et al., 2011). Prospective cohort studies reveal an inverse association between fibre
intake and CD risk (Ananthakrishnan et al., 2013, Amre et al., 2007), which could relate to the
effects  of  fibre  on  the  GI  microbiota  and  SCFA  production  or  direct  immunological  effects.
Several studies, including those prospectively assessing dietary intake, reveal a greater IBD risk
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with higher total protein and meat consumption, although this association is not consistent
(Jantchou et al., 2010). In addition to assessing the risk of developing IBD associated with dietary
components, some studies have investigated dietary factors associated with risk of relapse. For
example, a recent prospective evaluation revealed that patients with CD in the highest quartile
of fibre intake were less likely to relapse, although disease activity was measured using
symptom-based, non-objective disease activity indices and dietary assessment was limited to a
food frequency questionnaire (Brotherton et al., 2016). High intakes of red and processed meat,
protein, alcoholic beverages, sulphur and sulphates have also been associated with greater risk
of UC relapse (Jowett et al., 2004a). Observational studies assessing the role of dietary
components and patterns in IBD risk carry methodological limitations, including but not limited
to the measurement of dietary intake (food frequency questionnaires rather than more robust
food records), recall bias associated with assessing pre-diagnosis dietary intake following a
diagnosis of IBD, and possible reverse causality associated with assessing dietary patterns
directly preceding diagnosis. Difficulties in interpreting the results of epidemiological studies of
dietary risk factors arise from the complexity of foods and the co-existence of nutrients.
Vitamin D has an established role in calcium absorption and bone mineralisation and is
recommended  for  the  prevention  and  treatment  of  osteoporosis  in  IBD  (Scott  et  al.,  2000).
However, the vitamin D receptor is expressed by cells of at least thirty different tissues in the
body, including intestinal tissue and immune cells. Emerging evidence from epidemiological, in
vitro, in vivo and several human intervention studies indicate a potential role for vitamin D in
IBD. Vitamin D deficiency is common in IBD and poor vitamin D status is associated with greater
disease activity, however it is impossible to establish a causal relationship in the context of
established disease, where reduced intestinal absorption and poor sunlight exposure may play
a role in suboptimal vitamin D levels (Suibhne et al., 2012, O'Sullivan, 2015). The geographical
distribution of IBD prevalence and the observed north-south gradient is reflective of vitamin D
status. Furthermore, a lower risk of CD was estimated in women with a higher predicted vitamin
D status in an analysis of the prospective Nurses’ Health Studies, although caution must be
exerted in drawing conclusions from predicted vitamin D status  (Ananthakrishnan et al., 2012).
Three  RCTs  have  investigated  vitamin  D  supplementation  in  CD.  Two  of  these  RCTs
demonstrated no effect of vitamin D3 supplementation on IBD activity (Jorgensen et al., 2010,
Raftery et al.,  2015), and the third was a pilot study (Narula et al.,  2017). These trials vary in
duration, vitamin D dose, and outcomes, and do not provide convincing evidence for vitamin D
as an anti-inflammatory therapy.
Natural and synthetic emulsifying agents are added to foods during manufacturing to stabilise
water and lipid mixtures. A strong positive correlation is observed between emulsifier
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consumption and CD incidence, leading to increased interest in emulsifier consumption as a
possible factor in CD pathogenesis (Roberts et al., 2013). Emulsifiers are present in ice-creams
and mayonnaise. Major emulsifying agents include lecithin, derived from egg whites, mono- and
diglycerides, carrageenan and the synthetic compounds polysorbate-80 (P80) and
carboxymethylcellulose (CMC).
In vitro, P80 increases E. coli translocation across epithelia, in contrast to plantain and broccoli
fibre which reduces translocation (Roberts et al.,  2010). Furthermore, P80 and CMC result in
greater bacterial epithelial encroachment in mice, reduced mucus thickness, greater numbers
of mucosa-adherent bacteria and altered microbiota composition, the latter of which is
characterised by reduced Bacteroidales and increased mucolytic Ruminococcus gnavus
(Chassaing et al., 2015). Interestingly, emulsifier treatment led to subtle inflammation in wild-
type mice while overt colitis was observed in mice with a genetic immune defect (IL-10 or TLR5
ablation), suggesting a potential genetic predisposition to inflammation following emulsifier
consumption. In a subsequent study utilising the mucosal simulator of the human intestinal
microbial ecosystem (M-SHIME) model, emulsifier treatment increased bioactive flagella
expression and this was replicated when the microbiota from CMC-treated mice was transferred
into germ-free mice, indicating that emulsifiers may induce a more inflammatory microbiota
(Chassaing et al., 2017). According to these landmark studies, proposed mechanisms of
emulsifiers in the pathogenesis of CD include enhanced bacterial translocation and immune
stimulation and an increase in the inflammatory potential of the GI microbiota, potentially on
the  background  of  genetic  immune  defects.  The  effect  of  emulsifiers  on  GI  inflammation  in
humans is yet to be elucidated. Furthermore, whether emulsifier restriction could represent an
effective therapeutic option for IBD remains to be investigated.
1.2.2 Nutritional status and concerns in IBD
Given that IBD is a disease of the GI tract, the site of digestion, it is logical to expect that diet
and nutrition will be in some way impacted by the disease, and in particular CD where active
disease can occur anywhere in the GI tract. As expected, patients with IBD are more at risk of
protein energy malnutrition and specific nutrient deficiencies than the general population. This
is particularly prevalent in patients with active IBD but can persist in phases of disease remission.
Compared with patients admitted to hospital for non-IBD problems, patients with IBD were
more than 5 times more likely to be malnourished, and this was greater in penetrating CD and
patients who had undergone bowel resection (Nguyen et al., 2008). The prevalence of
malnutrition in IBD depends on the method used to assess it, which includes body mass index
(BMI), weight changes, anthropometric measurements and biochemical markers, and the cut-
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offs used. One study reported 25%-70% of patients with IBD were malnourished, depending
upon the method used (Mijac et al., 2010).
Figure 1.2 Aetiology of malnutrition in IBD  (Gerasimidis et al., 2011)
There may be aberrant body composition and impaired muscle strength in IBD despite normal
BMI, suggesting the need to assess body composition within malnutrition assessment in IBD
(Valentini et al., 2008, Bryant et al., 2013). Malnutrition in IBD is multi-factorial and contributory
factors include poor dietary intake resulting from GI symptoms and reduced appetite, increased
nutrient requirements due to active inflammation, reduced intestinal nutrient absorption
relating to GI inflammation and resections and increased intestinal nutrient losses (Figure 1.2)
(Gerasimidis et al., 2011).
Despite the increased risk of malnutrition among patients with IBD, the prevalence of
overweight and obesity among IBD is increasing in parallel to the general population. A
prospective case-control study revealed 40% of patients with CD had a BMI of ≥25 kg/m2, which
was not significantly different from healthy controls. High BMI in patients with Crohn’s disease
was significantly associated with markers of stable disease (a low CDAI), older age and reduced
physical activity, but not with the need for corticosteroids (Nic Suibhne et al., 2013). A
retrospective case note review revealed a shorter time to first surgery for CD complications in
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patients with a BMI ≥25 kg/m2 compared to patients with a BMI ≤18 kg/m2 (Hass et al., 2006). In
contrast, other studies have observed no adverse effects of obesity on post-surgical outcomes
(Guardado et al., 2016) or on healthcare utilisation and IBD-related surgeries (Seminerio et al.,
2015).
The term malnutrition encompasses micronutrient deficiencies as well as protein-energy
malnutrition. The most common micronutrient deficiencies in IBD are iron, vitamin D and
vitamin B12. A meta-analysis revealed an overall prevalence of iron deficiency anaemia of 27% in
CD and 21% in UC, although a recent large prospective study revealed prevalence of 49% in CD
and 20% in UC at diagnosis with the strongest predictor being a high CRP (Hoivik et al., 2014). A
further large study supports the high prevalence of anaemia at diagnosis, especially in CD, and
showed an association with colonic disease involvement and disease extent in UC (Sjoberg et
al., 2014). Vitamin B12 deficiency in IBD likely relates to ileal resections or inflammation, small
intestinal bacterial overgrowth and increased requirements. A systematic review revealed that
only  ileal  resections  >20  cm  predispose  to  B12 deficiency,  whereas  CD  and  UC  alone  do  not
(Battat et al., 2014). However, the included studies used only serum B12, of which only a small
proportion is biologically active, to detect deficiency. Subsequently, a study utilising
holotranscobalamin combined with methylmalonic acid to define B12 deficiency revealed
deficiency in 33% in CD and 16% in UC (Ward et al., 2015).
A further measure of malnutrition relevant to IBD is bone health. Patients with IBD are at greater
risk of fractures, particularly hip fracture, compared to the general population (Targownik et al.,
2013, van Staa et al., 2003). This may relate to inadequate dietary calcium intake or intestinal
absorption, reduced BMI and the use of corticosteroids. Inadequate dietary calcium intake may
relate to dairy food restrictions, which as discussed in section 1.3.3 are commonly imposed by
patients with IBD. In line with this, a cross-sectional study revealed 65% of patients with IBD had
inadequate calcium intakes (Vidarsdottir et al., 2016). Due to the greater risk of osteoporosis
and fracture, national guidelines suggest that patients with IBD consume 1000 mg/d of calcium,
with supplementary calcium administered in patients unable to reach this through dietary
sources. Furthermore, vitamin D should be supplemented in patients exhibiting inadequate
serum concentrations (Scott et al., 2000).
The interpretation of blood micronutrient concentrations is often troublesome since several are
altered during active inflammation as a result of the systemic inflammatory response, during
which micronutrients are redistributed and sequestered in tissues. For example, plasma zinc and
selenium are significantly associated with CRP and albumin (Ghashut et al., 2016). This obstacle
can be overcome by measuring micronutrients in erythrocytes or platelets, although routine
access to these analyses may be limited (Oakes et al., 2008).
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Numerous studies have investigated nutrient intakes in patients with IBD. These reveal
inadequate intakes of a range of nutrients that vary across studies but which include energy,
fibre, vitamins C, D, B1 and B6, calcium, β-carotene, phosphorous and magnesium, among others
(Hartman et  al.,  2016,  Geerling  et  al.,  2000,  Filippi  et  al.,  2006,  Benjamin et  al.,  2008,  Sousa
Guerreiro et al., 2007, Aghdassi et al., 2007, Vagianos et al., 2007). Studies investigating nutrient
intakes in IBD vary in terms of dietary assessment, using food frequency questionnaires, diet
histories and food diaries. The patients recruited also varies (CD, UC, active, inactive), as does
the software used to analyse nutrient intakes. Those studies that have used prospective food
records, which minimise recall bias and permit detailed assessment of portion sizes, mainly
collect 3-4 day food records. While this is justified in terms of participant burden and investigator
burden, a longer diary may better capture dietary fluctuations.
Fructan intakes have been investigated using a food-frequency questionnaire in patients with
CD (Anderson et al., 2015). Patients with active CD had significantly lower fructan intakes than
patients with inactive CD and healthy controls. However, since this study lacked an assessment
of overall energy intake, it remains to be established whether the low fructan intakes in active
CD reflect a specific avoidance of high fructan foods (presumably due to GI symptoms induced
by these foods) or are simply a result of reduced overall energy intake. This suggests that
patients with IBD may already have compromised dietary prebiotic (especially fructan) intake
and further restriction with the low FODMAP diet will further reduce this. This study also
suggests that patients with IBD may already identify that high FODMAP foods (or high fructan
foods) exacerbate GI symptoms and may therefore restrict them, at least during active IBD.
However, this requires further investigation.
1.2.3 Patients’ perceptions of diet in IBD
Most patients with IBD consider at least some aspects of diet and nutrition to be important in
the disease. Dietary issues experienced by patients encompass the ability to maintain an ideal
body weight, dietary GI symptom triggers, lethargy and fatigue, social activities involving food
and micronutrient deficiencies (Prince et al., 2011). Some issues, for example maintaining body
weight, are particularly experienced by patients with CD and those who have had prior GI
surgery. One prospective study of 400 patients with IBD revealed that 48% believed that diet
could be the initiating factor in IBD, 57% believed dietary factors could trigger a flare and 60%
reported symptom exacerbation following certain foods (Limdi et al., 2016). Specific foods
perceived to be inducers of GI symptoms or IBD relapse vary considerably among patients but
may include dairy foods, spicy foods, fatty foods, certain fruits and vegetables, wheat, alcohol
and high fibre foods (Prince et al., 2011, Limdi et al., 2016, Triggs et al., 2010, Zallot et al., 2013,
Kinsey and Burden, 2016). Beliefs regarding the role of diet in IBD may be influenced by IBD
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subtype, ethnicity and prior dietary advice and result in dietary restrictions in the majority of
patients (Limdi et al., 2016, Jowett et al., 2004b). Food restrictions are also more common in
patients with prior GI surgery and stricturing CD (Holt et al., 2017).
Despite most patients considering diet an important factor in IBD, there appears to be a
discrepancy between patients’ and their treating physicians’ attitudes and perceptions towards
diet. A recent questionnaire survey of 928 Australian patients and IBD specialists revealed 61%
of patients felt their IBD specialist disregarded the role of diet and only 26% had received dietary
advice from them, meanwhile 98% of gastroenterologists reported providing dietary advice
(Holt et al., 2017). Furthermore, in a large survey of UK and New Zealand gastroenterologists
significantly more considered dietary exclusion to be effective in the management of IBS than in
IBD (Inns and Emmanuel, 2013), which is discordant with the vast majority of IBD patients
implementing dietary exclusions.
1.3 Functional gastrointestinal symptoms in IBD
Inflammatory bowel disease typically follows a relapsing and remitting pattern. Periods of
remission, as well as the severity and length of relapses, can vary considerably among patients.
However, patients in remission are not necessarily asymptomatic. Often, despite objective
evidence of inactive disease (e.g. biomarkers of inflammation or endoscopy), patients continue
to experience potentially significant GI symptoms, such as abdominal pain, bloating, flatulence,
faecal urgency and altered bowel habits. In the absence of GI inflammation and with no
identifiable organic cause, these symptoms are referred to as functional GI symptoms (FGS).
Persistent FGS can impact psychological well-being and impair quality of life to an equal or
greater extent than short-lived IBD relapses. Furthermore, FGS present a treatment dilemma for
clinicians since treatment with anti-inflammatory or immune-modulatory medication is
inappropriate  in  this  instance.  The  aetiology  of  FGS  is  likely  more  complex  than  that  of
inflammatory symptoms and therefore management of FGS is likely more challenging.
1.3.1 Functional bowel disorders
Bowel disorders, formerly known as ‘functional bowel disorders’ are defined by the Rome IV
criteria within the functional gastrointestinal disorders (FGID) (Drossman, 2016). The most
common bowel disorder is irritable bowel syndrome (IBS), but functional abdominal bloating,




Table 1.3 Rome IV criteria; Bowel disorders, as defined within the functional gastrointestinal disorders
C. Bowel disorders
C1. Irritable bowel syndrome
C2. Functional constipation
C3. Functional diarrhoea
C4. Functional abdominal bloating/distension
C5. Unspecified functional bowel disorders
C6. Opioid-induced constipation
The bowel disorders are chronic GI disorders characterised by GI symptoms occurring in the
absence of obvious anatomic or physiologic abnormalities (Mearin et al., 2016). In the
movement from the Rome III to the Rome IV criteria, several important changes were made to
the IBS criteria, as depicted in Table 1.4. The term ‘discomfort’ was felt to be variably interpreted
and to encompass a different sensation to abdominal pain, and was therefore removed from
the definition of IBS. The frequency of abdominal pain has increased and this now must be
related to defaecation rather than specifically ‘improving’ with defaecation, since many patients
report a deterioration or no change in GI symptoms following defaecation (Schmulson and
Drossman, 2017).
Table 1.4 Rome III vs Rome IV diagnostic criteria for IBS
Rome III diagnostic criterion* Rome IV diagnostic criterion*
Recurrent abdominal pain or discomfort**, on
average, at least 3 days per month in the last 3
months, associated with 2 or more of the
following criteria:
Recurrent abdominal pain, on average, one day
per week in the last 3 months, associated with 2
or more of the following criteria:
1. Improved with defaecation 1. Related to defaecation
2. Onset associated with a change in
frequency of stool
2. Associated with a change in frequency
of stool
3. Onset associated with a change in
form (appearance) of stool
3.  Associated  with  a  change  in  form
(appearance) of stool
*Criterion fulfilled for the last 3 months with
symptom onset at least 6 months prior to
diagnosis
**“Discomfort” means an uncomfortable
sensation not described as pain
In pathophysiology research and clinical trials, a
pain/discomfort frequency of at least 2 days per
week during screening evaluation is
recommended for subject eligibility
Irritable bowel syndrome is experienced by around 10% of the UK population, while global
prevalence is 11.2% (Lovell and Ford, 2012). More women are affected than men, and younger
people are more likely to be affected than those over 50 years old. Poor quality of life at baseline
was also associated with the development of IBS within 10 years in 3,659 healthy individuals
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(Ford et al., 2008). Irritable bowel syndrome is classified into 4 subtypes according to the
predominant stool form; diarrhoea-predominant (IBS-D), constipation-predominant (IBS-C),
mixed type (IBS-M) and unsubtyped (IBS-U) (Mearin et al., 2016). The pathophysiology of IBS is
complex and likely multifactorial, involving psychosocial factors such as stress and anxiety,
disordered motility, visceral hypersensitivity, immune dysregulation, GI microbiota aberrations
and GI barrier dysfunction (Drossman, 2016). The brain-gut axis describes the interactions
between the cognitive centres of the brain via neurotransmitters with the enteric nervous
system and vice versa (Jones et al., 2006). This is thought to play a major role in IBS
pathophysiology, and in recent years a possible microbiome-gut-brain axis has emerged
(illustrated in Figure 1.3 from evidence that the GI microbiota produce neurotransmitters
capable of communicating with the central nervous system and that host-derived
neurotransmitters influence the GI microbiota (Mayer et al., 2014).
Figure 1.3 Proposed mechanisms of a microbiome-gut-brain axis in IBS pathophysiology (Mayer et al.,
2014)
Treatment of IBS begins with explanation and reassurance as to the benign nature of the
condition. Pharmacological treatment of IBS is mainly symptom-targeted, including anti-
spasmodic agents for abdominal pain, anti-motility agents for diarrhoea and laxatives for
constipation. Centrally-acting tricyclic antidepressants and selective serotonin reuptake
inhibitors may be effective in reducing abdominal pain (Ford et al., 2014a). Lifestyle
modifications, including exercise, stress reduction and improving sleep may be effective,
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although objective evidence for these approaches is limited. Based upon evidence of altered GI
microbiota in IBS (Rajilic-Stojanovic et al., 2015), commonly characterised by reduced
Bifidobacteria, many studies have investigated the potential therapeutic benefit of manipulating
the microbiota for GI symptom management. The most recent meta-analysis of probiotics in IBS
showed an improvement in GI symptoms with all probiotics, although analysis of individual
genera did not reveal any significant benefit of Lactobacillus, Saccharomyces or Bifidobacterium
(Ford et al., 2014b). The same meta-analysis concluded that there is currently no evidence for a
benefit of prebiotics in IBS.
First-line dietary management of IBS includes, where relevant, general healthy eating, reduction
of caffeine, alcohol, fatty foods and spicy foods, and dietary fibre manipulation (McKenzie et al.,
2016). However, in the last decade, dietary management of IBS has focussed on dietary
fermentable carbohydrate restriction, discussed in detail in section 1.4.
1.3.2 Prevalence of FGS in IBD
Gastrointestinal symptoms are common in patients with inactive IBD, although it is debateable
whether patients with IBD can truly meet the criteria for a functional bowel disorder, since the
Rome IV guidelines state that functional symptoms occur in the absence of obvious anatomic or
physiologic  abnormalities  (Mearin  et  al.,  2016).  However,  it  could  be  argued  that  where  GI
inflammation is controlled in IBD, persisting GI symptoms could be IBS-like symptoms, which will
be referred to as functional gastrointestinal symptoms (FGS) in this thesis.
A systematic review and meta-analysis identified 13 studies reporting FGS prevalence ranging
from 20-65%, with a pooled IBS prevalence of 35% in patients in remission (Halpin and Ford,
2012). Further studies of the prevalence of FGS in IBD have since been published (Vivinus-Nébot
et al., 2014, Jonefjäll et al., 2016, Berrill et al., 2013, Gracie et al., 2017, Jelsness-Jorgensen et
al., 2014, Tomita et al., 2016, Fukuba et al., 2014). Despite abundant data on the prevalence of
FGS in IBD (Table 1.5), these studies are heterogeneous in terms of study design (cross-sectional,
case-control, prospective cohort), sample size, patients recruited (CD, UC, active or inactive) and
criteria used to define IBS or FGS (Manning, Rome, or other). There is also bias associated with
varying criteria for disease activity, with some requiring as little as stable medications to define
remission and some requiring more reliable endoscopic remission. Furthermore, some studies
used clinical disease activity indices to determine activity, which could be raised due to FGS.
Therefore, patients with a high score despite being in remission would be categorised as having
active IBD and the proportion meeting the criteria for IBS in remission may in fact be greater
than  35%.  The  variety  of  criteria  to  define  IBS  also  introduces  bias.  Interestingly,  a  study  of
patients with longstanding UC used a combination of measures to define remission (clinical,
endoscopic and faecal calprotectin) and revealed no difference in GI symptoms compared to
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controls  (Lundgren  et  al.,  2016).  However,  GI  symptoms  were  measured  using  the
Gastrointestinal Symptom Rating Scale and not the Rome criteria for functional bowel disorders.
One recent study categorised patients according to clinical disease activity indices, IBS criteria
and faecal calprotectin. Among the patients with CD, 27.7% met IBS criteria and had a low faecal
calprotectin, while the corresponding figure for UC was 19.8% (Gracie et al., 2017). The faecal
calprotectin cut-off was 250 μg/g. While this is a commonly cited cut-off for determining active
IBD (Lin et al., 2014), it is possible that some patients had low-grade inflammation responsible
for the FGS. The prevalence of FGS appears to be greater in CD (35.1%) than in UC (23.9%), which
may relate to greater difficulty in identifying active small intestinal inflammation and the lasting
effects of complications such as strictures, previous GI surgery and bile acid malabsorption
(Halpin and Ford, 2012). Prevalence of FGS does not appear to vary according to initial disease




Table 1.5 Studies reporting the prevalence of functional gastrointestinal symptoms in IBD




IBD activity assessment IBS
assessment
criteria
Prevalence of IBS in
remission
UC CD
Isgar et al., 1983 Case-control UC (n=98) Remission Colonoscopy Manning 33 -
Simrén et al., 2002 Cross-sectional UC (n=43)
CD (n=40)
Remission Colonoscopy; CRP/ESR; Clinical
signs
GSRS 33 57







Barratt et al., 2005 Cross-sectional UC (n=88)
CD (n=76)





Farrokhyar et al., 2006 Cross-sectional UC (n=44)
CD (n=105)
remission Modified DAI Rome II 50 52.4
Mikocka-Walus et al., 2008 Cross-sectional UC (n=30)
CD (n=31)
Active and remission SCCAI
CDAI
Rome III 31a 31a
Ansari et al., 2008 Case-control UC (n=95) Active and remission Mayo score Rome II 46 -
Piche et al., 2010 Cross-sectional CD (n=92) Remission CDAI; colonoscopy; CRP/ESR Rome III 45.6
Keohane et al., 2010 Cross-sectional UC (n=44)
CD (n=62)
Remission PGA; CRP; No steroids or biologics
in 6/12; CDAI/UCAI
Rome II 38.6 59.7
Case-control UC (n=63)
CD (n=93)










IBD activity assessment IBS
assessment
criteria
Prevalence of IBS in
remission
UC CD
Vivinus-Nébot et al., 2014 Cross-sectional UC (n=18)
CD (n=31)
Remission PGA; CRP/ESR; No steroids 1 year;
CDAI/UCAI; Colonoscopy
Rome III 38 35.4
Jonefjäll et al., 2013 Prospective UC (n=94) Remission Mayo score Rome II 27 -
Berrill et al., 2013 Cross-sectional UC (n=101)
CD (n=68)
Active and remission SCCAI and CRP
HBI and CRP
Rome III 58c 42c
Fukuba et al., 2014 Cross-sectional UC (n=172) Remission CAI Rome III 27 -
Gracie et al., 2017 Cross-sectional UC (n=172)
CD (n=206)
Remission HBI/SCCAI; FCP Rome III 20 28
Henrikson et al., 2018 Prospective UC (n=260) Active and remission Mayo score; FCP Rome III 25 -
Tomita et al., 2016 Case-control UC (n=40)
CD (n=107)





Remission SCCAI/SCDAI Rome II/
Rome III
22e 8e
a Subgroup analyses for CD and UC not reported, b According to Rome II criteria, c Patients in remission only, d Continuous GSRS score compared between groups, e Rome III criteria
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; GSRS, Gastrointestinal Symptom Rating Scale; CDAI, Crohn’s Disease Activity Index; SCDAI, short Crohn’s Disease
Activity Index; CAI, Clinical Activity Index; HBI, Harvey-Bradshaw Index; DAI, Disease Activity Index; SCCAI, Simple Clinical Colitis Activity Index; PGA, Physician Global Assessment;
UCAI, Ulcerative Colitis Activity Index; FCP, faecal calprotectin
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1.3.3 Pathogenesis of FGS in IBD
The pathogenesis of FGS in IBD and the explanation for a greater prevalence compared to the
general population (35% vs. 10.0%) remains elusive. Statistically, due to the high prevalence of
IBS  in  the  general  population,  some  patients  with  IBD  will  also  have  IBS.  In  support  of  this,
females  and  those  with  anxiety  are  more  likely  to  have  IBS  in  IBD,  mirroring  the  general
population (Berrill et al., 2013, Jonefjall et al., 2013). Furthermore, physiological features
observed in IBS have also been detected in patients with inactive IBD with FGS. For example,
rectal perception with electronic barostat was shown to correlate positively with FGS in patients
with inactive UC (van Hoboken et al.,  2011), similar to patients with IBS (Chang et al.,  2000).
However, co-existing IBS seems unlikely to be the sole explanation, given the increased
prevalence of IBS in IBD compared to the general population.
An alternative hypothesis is that FGS in IBD may represent low-grade inflammation. One study
of 62 patients with inactive IBD revealed that faecal calprotectin concentrations were elevated
in patients fulfilling the Rome II criteria for IBS (Keohane et al., 2010), while several subsequent
studies observed no difference in faecal calprotectin between patients with and without IBS-like
symptoms (Berrill et al., 2013, Jonefjall et al., 2013, Jonefjäll et al., 2016, Lundgren et al., 2016).
In line with the latter studies, a similar prevalence of IBS-like symptoms has been observed in
patients with no signs of inflammation on colonic biopsies (i.e. patients in deep remission) (29%)
compared to the whole cohort (27%) (Henriksen et al., 2017), although a prior study revealed a
lower rate  of  IBS-like  symptoms when more stringent  histological  remission thresholds  were
applied (Fukuba et al., 2014). Despite no difference in faecal calprotectin, one study revealed
elevated serum cytokines including IL-6, IL-8, IL-10 and IL-13 in patients with FGS compared to
those without (Jonefjäll et al., 2016). Together, these findings suggest that low-grade
inflammation may be responsible for IBS-like symptoms in some, but not all, patients with IBD.
Numerous studies associate IBS-like symptoms in IBD with heightened anxiety and depression
and poorer HR-QOL, although the direction of this association is unclear (Jonefjäll et al., 2016,
Simrén et al., 2002, Jonefjall et al., 2015, Bryant et al., 2011). It is accepted that the brain-gut
axis  functions  in  a  bidirectional  manner  and  it  is  possible  that,  similar  to  IBS  in  the  general
population, psychological comorbidity may play a role in inducing FGS in IBD, either directly or
through the GI microbiota (Jones et al., 2006). The burden of living with a chronic condition such
as IBD is known to impact psychological well-being (Walker et al., 2008), therefore it is possible
that psychological comorbidity induces FGS in some patients in remission.
Surprisingly, to date there has been no investigation of the GI microbiota in patients with FGS in
IBD, but given the apparent dysbiosis in both IBD and IBS, it seems logical to investigate whether
a distinct microbial profile exists in patients with inactive IBD and FGS.
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It has been proposed that, resulting from the effects of underlying IBD, FGS in IBD have a
different pathophysiology from IBS in the general population. This is supported by evidence of
pro-inflammatory features such as an enhanced TNF-α response to bacterial lipopolysaccharide
and elevated cytokines in at least a subset of patients with IBS in IBD (Vivinus-Nébot et al., 2014,
Jonefjäll et al., 2016). It could be that the inflammatory response during active IBD upregulates
components of the brain-gut axis, resulting in disordered gut motility, visceral hypersensitivity
and dysregulated brain-gut signalling (Quigley, 2016). Transient receptor potential vanilloid type
1 (TRPV1) is expressed on primary afferent neurones and is activated by capsaicin, lipids,
resinferatoxin, endocannabinoids and noxious heat (Caterina et al., 1997). This leads to pain
sensation and initiation of neurogenic inflammation and is thought to contribute to visceral
hypersensitivity. Expression of TRPV1 in colonic mucosa is greater in patients with IBD
experiencing pain and in patients with IBS, where TRPV1 expression correlated with abdominal
pain severity (Akbar et al., 2008, Yiangou et al., 2001). In patients with histologically inactive IBD,
TRPV1 expression was 5.3-fold higher in patients with abdominal pain compared to without
abdominal pain (Akbar et al., 2010). The potential role of TRPV1 in visceral hypersensitivity
following active inflammation is supported by a murine study in which pain-related behaviours
following experimental colitis correlate with TRPV1 expression, and is reduced following TRPV1
deletion (Lapointe et al., 2015). Furthermore, upregulated transient receptor potential ankyrin-
1 may mediate visceral pain following experimental colitis (Yang et al., 2008). The role of these
molecules in the pathophysiology of IBS-like symptoms in patients following resolution of active
inflammation remains to be explored.
1.3.4 Treatment of FGS in IBD
Effective management of IBS in IBD is important given the likely impact of these symptoms on
HR-QOL.  Furthermore,  persistent  GI  symptoms  are  likely  to  lead  to  a  greater  number  of
physician visits, thus increasing the healthcare resource burden associated with IBD, although
objective evidence for this is lacking.
Theoretically, in the absence of active inflammation, management of IBS in IBD could encompass
strategies used in IBS in the general population, which in terms of pharmacological and first-line
dietary management has been discussed in section 1.3.1 (McKenzie et al., 2016).
Few studies to date have investigated the management of FGS in IBD specifically. A randomised
controlled trial revealed that a mindfulness and cognitive behavioural therapy intervention
directly improved HR-QOL in patients with inactive IBD and IBS (Berrill et al., 2014). As will be
discussed in section 1.4.6, dietary fermentable carbohydrate restriction is the most promising
management strategy for IBS in IBD.
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1.4 The low FODMAP diet
1.4.1 Introduction
The manipulation of dietary carbohydrates has been used to manage FGS for several years. For
example, a meta-analysis revealed 22 RCTs investigating dietary fibre manipulation for the
management of IBS symptoms, demonstrating that soluble fibre may be of benefit for global GI
symptoms compared with placebo (Nagarajan et al., 2015).
Studies suggesting fructose, lactose and sorbitol to be GI symptom inducers in functional bowel
disorders were first published almost 30 years ago (Rumessen and Gudmand-Hoyer, 1988,
Fernández-Bañares et al., 1993). Fructans were also identified as capable of inducing GI
symptoms. A retrospective study revealed improvements in GI symptoms following dietary
fructose and fructan restriction in patients with fructose malabsorption, albeit with obvious
limitations in study design (Shepherd and Gibson, 2006). However, there is a substantial placebo
response in IBS and foods contain a complex a mixture of nutrients and bioactive components,
any of which could affect GI symptoms. Therefore, it remained unclear whether fermentable
carbohydrates were responsible for GI symptoms. To address this, an Australian group
conducted a randomised, placebo-controlled, crossover re-challenge trial to investigate whether
pure fermentable carbohydrate challenges induced GI symptoms on the background of a low
FODMAP diet. Fructans and fructose both induced GI symptoms compared to a glucose placebo,
and greater symptom severity was evident following consumption of a mixture of fructans and
fructose, suggesting an additive effect of different FODMAPs (Shepherd et al., 2008). From here,
the  concept  of  a  broad  dietary  restriction  of  poorly-absorbed,  osmotically  active  and
fermentable short-chain carbohydrates was proposed, involving the restriction of
oligosaccharides (fructans and the rapidly fermented galacto-oligosaccharides; GOS),
disaccharides (lactose), monosaccharides (fructose) and polyols (sugar alcohols including
sorbitol and mannitol). Thus, this approach has been termed the ‘low FODMAP diet’ (Staudacher
and Whelan, 2017).
Table 1.6 Major food sources of fermentable carbohydrates in a typical UK diet
Fermentable carbohydrate Major food sources (UK diet)
Fructans Bread, pasta, wheat-based breakfast cereals, onions, garlic
GOS Pulses, cashew nuts, pistachio nuts
Lactose Milk, yoghurt
Fructose Certain fruits e.g. mango, honey, certain sweetened products





Table 1.6 presents an overview of the dietary sources of each fermentable carbohydrate in a UK
diet. The remainder of section 1.3 will describe the individual carbohydrates restricted on the
low FODMAP diet, the proposed mechanisms of action of the diet, the evidence for the
effectiveness of the diet in both IBS and IBD and the potential safety considerations of the diet
with reference specifically to IBD.
1.4.2 Fermentable carbohydrates
Dietary carbohydrates include those that are rapidly digested and/or absorbed in the small
intestine (glucose, sucrose and starch), as well as those that are partially or totally undigested
in the small intestine due to a limited expression or total lack of the appropriate enzymes to
hydrolyse them to monosaccharides for absorption. Carbohydrates that are minimally digested
and absorbed include non-starch polysaccharides (NSP), resistant starch (RS), certain
oligosaccharides (such as fructans and GOS), polyols, and in some individuals, fructose and
lactose (Cummings and Stephen, 2007). Under normal physiologic conditions, little rapidly
digested carbohydrate (e.g. glucose, sucrose, starch) enters the colon, whereas most of the
minimally digested and absorbed carbohydrates (e.g. NSP, RS, oligosaccharides) reach the colon
intact and are utilised to varying degrees as substrates for bacterial fermentation. The
carbohydrates restricted during a low FODMAP diet fall under the umbrella of minimally or
incompletely digested carbohydrates. Each of the short-chain carbohydrates restricted on a low
FODMAP diet are reviewed below.
1.4.2.1 Fructans
Fructans include inulin and oligofructose and are polymers of fructose units linked by β2→1
bonds, usually with a terminal glucose unit.  The term ‘inulin’ refers to fructans with a degree of
polymerisation (DP) 2-60, with an average DP of 12, while oligofructose is typically DP 2-8, with
an average DP 3-6 (Roberfroid et al., 2010).  Fructans are produced within certain plants through
the action of fructosyltransferases and act as a carbohydrate storage reservoir by the plant (Vijn
and Smeekens, 1999). Humans lack the appropriate fructanases to hydrolyse the fructosyl-
fructose links and thus, it has been demonstrated through patients with an ileostomy that >85%
of  fructans  pass  through  the  small  intestine  intact  and  enter  the  colon  (Barrett  et  al.,  2010,
Knudsen and Hessov, 1995, Ellegard et al., 1997).
Some foods, such as artichokes and chicory, are particularly rich sources of fructans. However,
the majority of fructans in a Western diet derive from wheat, onions and garlic, since these foods
are consumed in large quantities (Table 1.6) (van Loo et al., 1995, Dunn et al., 2011, Moshfegh
et al., 1999, Anderson et al., 2015). The fructan content of foods may vary depending on variety,
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soil characteristics in the place of cultivation, and processing applied. Typical daily intake of
fructans in the UK is around 4.0 g/day in healthy individuals (Dunn et al., 2011, Anderson et al.,
2015), 2.3-5.0 g/day in patients with IBS (Staudacher et al., 2012, Bohn et al., 2015, Staudacher
et al., 2017b) and 2.9-3.6 g/day in patients with CD (depending on disease activity) (Anderson et
al., 2015). It should be noted that studies assessing the intake of fermentable carbohydrates in
IBS are scarce and mainly utilise food frequency questionnaires rather than a more robust
prospective food record.
In the colon, fructans are fermented by bacteria, with inulin and oligofructose displaying slightly
different fermentation profiles for gas and SCFA production (Koecher et al., 2014). Fructans are
considered ‘prebiotic’, defined as ‘a substrate that is selectively utilised by host microorganisms
conferring a health benefit’ (Gibson et al., 2017). Bifidobacteria and Lactobacilli are the most
widely regarded as exerting health benefits and their growth is stimulated by fructans. It has
been suggested from in vitro studies that inulin has a more pronounced and prolonged
Bifidogenic effect than oligofructose (van de Wiele et al., 2007, Pompei et al., 2008). Bacterial
fermentation of fructans also results in SCFA generation, which have beneficial effects on the
host, and the stimulation of bacterial growth increases biomass which in turn contributes to
stool bulking (Smith et al., 2013). Furthermore, increasing evidence from murine and human
studies suggests that fructans can increase mineral absorption in the GI tract (for example,
calcium) and have lipid-lowering effects (Roberfroid et al., 2010, Van Loo et al., 1999).
1.4.2.2 Galacto-oligosaccharides
Non-digestible oligo-saccharides also include GOS, polymers of galactose units linked by varying
bonds. Galacto-oligosaccharides derived from plants consist of galactose units linked by α1→6
bonds, with a terminal sucrose (α-GOS) (Cummings and Stephen, 2007). The major types of α-
GOS are raffinose, stachyose and verbascose and are found predominantly in pulses and nuts
(Table 1.6). The human GI tract does not possess α-galactosidase to hydrolyse α-GOS and
therefore >85% enters the colon intact (Saunders and Wiggins, 1981). Typical intakes of α-GOS
are 1.0 g/day in patients with IBS in the UK and around 0.5 g/day in patients with IBS in Sweden
(Staudacher et al., 2012, Bohn et al., 2015).
A distinction should be made between the plant-derived α-GOS and β-GOS or trans-galacto-
oligosaccharides, produced commercially through the action of β-galactosidase on lactose
(Wilson  and  Whelan,  2017).  In  contrast  to  α-GOS,  which,  due  to  a  variety  of  bonds,  can  be
fermented by a range of GI bacteria, β-GOS selectively stimulate the growth of Bifidobacteria
and are therefore argued to be prebiotics (Vulevic et al., 2004).
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Similar to fructans, GOS exert benefits on health through the stimulation of beneficial GI bacteria
and stool bulking (Fernando et al., 2010). Furthermore, systemic benefits of α-GOS have been
observed. Bean consumption has been shown to reduce serum total and LDL cholesterol in
individuals with raised cholesterol. However, it is difficult to attribute the health benefits of
pulses to α-GOS specifically, rather than other constituents such as fibre or polyphenols
(Trinidad et al., 2010). Addressing this, supplementation with pure α-GOS, that lacks the other
constituents of beans, reduced appetite, food intake and inflammatory markers in obese adults
compared to controls (Morel et al., 2015).
1.4.2.3 Lactose
Lactose is a disaccharide of galactose and glucose linked by a β1→4 bond and is found exclusively
in mammalian milks. Lactose is hydrolysed by lactase situated in the brush border of the small
intestine. Unsurprisingly, the major dietary sources of lactose are dairy products but a small
amount is added during manufacturing of certain foods.
Lactose malabsorption has been demonstrated through hydrogen breath testing in 51% of
patients with functional bowel disorders (Wilder-Smith et al., 2013). However, malabsorption
does not necessarily result in intolerance, and in line with this in the aforementioned study
malabsorption did not correlate with symptoms evoked during testing. Similarly, breath
hydrogen was comparable between patients with IBS and healthy controls following a lactose
challenge, while lactose intolerance (lactose malabsorption plus the presence of symptoms
upon ingestion) was more frequent in IBS (Zhu et al., 2013). Together, these findings suggest
lactose malabsorption can occur without intolerance, and does not appear to be elevated in
patients with functional bowel disorders compared to healthy controls.
A systematic review and meta-analysis has shown greater odds of lactose malabsorption among
patients with IBD compared to healthy controls (OR 1.61, P=0.048), with sub-group analysis
revealing this to be significant in CD only (Szilagyi et al., 2016). This may relate to the effects of
previous small intestinal inflammation on lactase concentration in the brush border. Concordant
with studies in IBS, lactose malabsorption and intolerance were often discrepant.
1.4.2.4 Fructose
Fructose  is  a  hexose  sugar  that  is  present  in  increasing  quantities  in  the  Western  diet.   It  is
absorbed in the small intestine via facilitative transport. The first is via the facultative
transporter GLUT5, which appears to be specific to fructose, expressed predominantly on the
apical membrane of intestinal epithelial cells and may be up-regulated by dietary fructose
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consumption. Fructose absorption via this route is dose dependent and displays inter-individual
variation, possibly relating to variable GLUT5 expression
(Jones et al., 2011).
The second mechanism of fructose absorption is via the facilitative GLUT2 transporter, which
co-transports glucose and fructose across both the apical and basolateral membranes of
intestinal epithelial cells and is up-regulated by the presence of glucose in the lumen. Thus, the
presence of glucose likely enhances fructose absorption through the recruitment of GLUT2 to
the brush border, and fructose in excess of glucose likely relies upon the GLUT5 pathway for
absorption (Jones et al., 2011). In support of this, adding glucose to fructose solutions or fruit
juices improves fructose absorption (measured using hydrogen breath tests) in healthy controls
(Truswell et al., 1988) and patients with functional bowel disorders (Tuck et al., 2017).
Fructose malabsorption is prevalent in healthy individuals, with >50% incompletely absorbing a
25-50 g dose of fructose, although fructose intolerance can occur independently of
malabsorption (Gibson et al., 2007).
Fructose derives predominantly from fruits, fruit juices and honey, but is also added during food
manufacturing in varying forms including fructose, fructose syrup, glucose-fructose syrup and
high-fructose corn syrup. Fructose intakes vary across the world depend upon food processing
practices. For example, fructose intake in the US appears much higher than in UK (49 g vs. 12-
17 g/day) (Marriott et al., 2009, Staudacher et al., 2012, Staudacher et al., 2017b), likely a result
of the use of high-fructose corn syrup in the US. However, these figures refer to total fructose
intake, whereas the intake of fructose in excess of glucose (i.e. a greater than 1:1 ratio of
fructose:glucose) is likely to be considerably lower.
1.4.2.5 Polyols
Polyols, or sugar alcohols, such as sorbitol, mannitol and xylitol are naturally present in some
foods and can also be added during manufacturing. For example, sugar-free chewing gum
contains a considerable quantity of xylitol. Polyols are passively absorbed to varying degrees in
the small intestine, and absorption is influenced by the molecular size of the polyol, pore size in
different regions of the small intestine and the presence of organic disease. An ileostomy study
showed that 24-40% of a 30 g dose of each of sorbitol, isomalt and maltitol was recovered in
ileostomy effluent, and absorption was dose-dependent (Langkilde et al., 1994). Studies using
breath hydrogen have shown that 67-71% of healthy volunteers and 60% of IBS patients
incompletely absorbed 10 g sorbitol (Yao et al., 2014, Hyams, 1983).
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The major naturally-occurring polyols are sorbitol, found in stone fruits, avocado and broccoli,
and mannitol, found in mushrooms and cauliflower (Yao et al., 2014). Owing to poor intestinal
absorption, polyols have lower caloric value than sucrose and are therefore used as sweeteners
in sugar-free and reduced-calorie products. Furthermore, polyols do not increase the risk of
dental caries and are thus added to sugar-free chewing gum at relatively high doses (Zumbe et
al., 2001). Polyol intakes in the UK are estimated at around 1 g/d in IBS (Staudacher et al., 2012,
Staudacher et al., 2017b, Bohn et al., 2015) and a recent survey based on UK National Diet and
Nutrition Survey data suggested a daily intake of 2.7 g polyols in the general population
(Tennant, 2014). The discrepancy between the IBS and general population intakes likely reflects
differences in data collection, with the former established through individual-level food diaries
and food frequency questionnaires and the latter a population-based survey of estimated
exposure.
1.4.3 Mechanisms of effects of FODMAPs on gastrointestinal symptoms
The mechanisms through which fermentable carbohydrates induce GI symptoms have been
increasingly investigated in recent years, following evidence that the diet is effective in
managing FGS. Figure 1.4 illustrates the major hypothesised mechanisms through which
FODMAPs induce GI symptoms.
1.4.3.1 Small intestinal water
Collectively FODMAPs increase small bowel water content. A study of patients with an ileostomy
showed a greater effluent volume and water content following a 4-day high FODMAP diet
compared to a 4-day low FODMAP diet, during which participants were provided with all food
consumed (Barrett et al., 2010). However, this study did not investigate the effect of individual
FODMAPs on small bowel water, only a complete diet.
The effects of the smaller, osmotically active FODMAPs (fructose, lactose and polyols) on small
bowel water have been investigated on the basis that slow absorption results in their high
luminal concentration, drawing water into the lumen along a concentration gradient. A study in
healthy volunteers demonstrated through functional MRI scanning that a 40 g fructose challenge
led to greater small bowel water compared to rapidly-absorbed glucose, while inulin had no
effect on small bowel water (Murray et al., 2014). These results were mirrored in a more recent
similar study , reporting a significant increase in small bowel water following a 40 g fructose
challenge in both healthy volunteers and patients with IBS (Major et al., 2017). Interestingly,
following the fructose challenge GI symptom induction was observed only in patients with IBS,
demonstrating for the first time that an increase in small bowel water per se does not induce
symptoms, but rather an increase in small bowel water in the context of visceral hypersensitivity.
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In both of the aforementioned studies, the addition of glucose to the fructose challenge
significantly reduced small bowel water, further confirming that glucose facilitates fructose
absorption, as described above.
Although these studies indicate that inulin has little effect on small bowel water, the effect of
short-chain oligofructose on small bowel water is yet to be clarified, which may differ to inulin
due to smaller molecular weight. Oligofructose contributes a greater proportion of dietary
fructans than inulin (Dunn et al., 2011, Anderson et al., 2015), and therefore the physiological
effects of these carbohydrates is clinically relevant. Furthermore, the pure carbohydrate
challenges in the described mechanistic studies were administered to participants who were
fasted, and were not given alongside a meal. The effects of the carbohydrates may differ when
given in pure form compared to when they are consumed as part of a food, where the complex
mixture of nutrients and other dietary components may influence osmolality and gastric
emptying (Chaudhuri and Fink, 1991).
Figure 1.4 The proposed mechanisms of GI symptom improvement with a low FODMAP diet. Poorly
absorbed, fermentable carbohydrates, such as fructans, fructose and lactose are eaten within a normal
diet. Smaller, osmotically active carbohydrates (fructose, lactose and polyols) encourage water to enter
the lumen (panel 1). Fructans and GOS reach the colon intact where they undergo bacterial
fermentation, with the production of hydrogen, methane and carbon dioxide, along with SCFA (panel
2). The gases and water in the lumen cause luminal distension which can be felt as GI symptoms in the
context of visceral hypersensitivity (panel 3). GOS, galacto-oligosaccharides; SCFA, short-chain fatty
acids. From Staudacher and Whelan (Staudacher and Whelan, 2017)
Similar effects on small bowel water have been demonstrated for the polyol mannitol.
Significantly greater small bowel water was observed on MRI in healthy volunteers following
17.5 g mannitol compared to a glucose placebo challenge (Marciani et al., 2010). The effect of
sorbitol on small bowel water has not been directly measured using MRI, although increased
ileostomy output was demonstrated following the consumption of sorbitol, isomalt and maltitol
challenges (Langkilde et al., 1994).
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1.4.3.2 Fermentation and gas production
The second mechanism through which FODMAPs are hypothesised to induce GI symptoms is
bacterial fermentation of undigested carbohydrates reaching the colon, the associated
hydrogen, carbon dioxide and methane generation, and the resulting luminal distension. As
described above, all FODMAPs have the capacity to reach the colon for bacterial fermentation
due to almost non-existent hydrolysis in the small intestine (fructans, GOS), varying expression
of enzymes for hydrolysis (lactose) or limited absorption in the small intestine (fructose, polyols).
Hydrogen produced during colonic bacterial fermentation is absorbed into the blood and
eventually expelled in the breath and is the major source of breath hydrogen. This can therefore
be used as a marker of substrate fermentation by the colonic microbiota, although the
reproducibility and clinical relevance of hydrogen breath tests have been questioned in recent
years (Yao and Tuck, 2017, Wilder-Smith et al., 2013). Nonetheless, a 2-day high FODMAP diet
increased breath hydrogen in healthy controls and patients with IBS compared to a 2-day low
FODMAP diet, although GI symptoms were significantly greater in IBS only during the high
FODMAP diet (Ong et al., 2010).
An increase in colonic gas following FODMAPs is supported by studies using MRI. Greater colonic
gas volume was observed in healthy individuals following 40 g inulin, but not fructose, challenge,
suggesting that a greater proportion of certain FODMAPs reach the colon intact and are
fermented to a greater extent than others (Murray et al., 2014). These findings were replicated
in a further study in healthy volunteers and patients with IBS. In addition, fructose significantly
increased colonic gas compared to glucose in patients with IBS. Interestingly, peak symptom
intensity correlated with peak colonic gas in patients meeting a pre-defined symptom threshold,
indicating for the first time an association between the physiological effects of FODMAPs and GI
symptoms (Major et al., 2017).
1.4.3.3 Other possible mechanisms of effects of FODMAPs on gastrointestinal symptoms
There are mechanisms, other than a reduction in luminal water and gas, through which the low
FODMAP diet may improve GI symptoms, although currently these are simply observations from
RCTs of the low FODMAP diet and require further research to establish these mechanisms. One
is via changes to the GI microbiota, which are known to occur following a low FODMAP diet in
IBS (Staudacher  et  al.,  2017b,  Staudacher  et  al.,  2012,  Halmos et  al.,  2014a,  McIntosh et  al.,
2016). Following a 3-week low FODMAP diet in patients with IBS, the abundance of a hydrogen-
utilising genus Adlercreutzia was significantly higher than compared to a 3-week high FODMAP
diet (McIntosh et al., 2016). This may suggest that as well as reduced fermentation of FODMAPs
and reduced hydrogen production, the response to the low FODMAP diet may also relate to a
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greater abundance of bacteria capable of using hydrogen, thus further reducing hydrogen
concentration.
The patients in the low FODMAP and high FODMAP diet groups could be discriminated via
metabolomic analysis of urine, on the basis of three metabolites including histamine, which was
significantly lower on the low FODMAP diet (McIntosh et al., 2016). Histamine is produced by
mast cells, which have previously been shown to be elevated in number, activated and in closer
proximity to nerve fibres in IBS mucosa compared to healthy controls (Barbara et al., 2004, Park
et al., 2006). Furthermore, correlations were observed between microbiota, GI symptoms,
hydrogen production and the urine metabolome, indicating that these factors may have some
role in mechanisms of the diet.
1.4.4 The low FODMAP diet delivery
The low FODMAP diet requires significant dietary changes for most patients. Foods are excluded
from most of the recognised food groups, including cereals/starchy foods, fruits, vegetables and
dairy. Thus far, evidence for the low FODMAP diet has predominantly involved dietitian-led
advice (Staudacher et al., 2017b, Staudacher et al., 2012, Halmos et al., 2014b, De Roest et al.,
2013, Chumpitazi et al., 2015, Pedersen et al., 2017), although two studies have utilised nurse-
led low FODMAP dietary  advice  (Mazzawi  et  al.,  2013,  Ostgaard et  al.,  2012).  Neither  of  the
nurse-led studies were RCTs and thus do not provide high-quality evidence for the effectiveness
of this method of low FODMAP diet delivery. Therefore, it is currently unclear whether other
methods of diet delivery (other healthcare professionals e.g. nurses and doctors, leaflets or
mobile phone applications) would be equally as effective as dietitian-led (O'Keeffe and Lomer,
2017). It is for this reason that IBS guidelines specify that the low FODMAP diet should preferably
be delivered by a healthcare professional with expertise in dietary management of IBS (NICE,
2008).
The  low  FODMAP  diet  consists  of  three  phases.  A  FODMAP  restriction  phase  of  4  weeks  is
recommended (Whelan et al., 2018), although in clinical practice it can last up to twelve weeks
depending upon patient preference and availability of appointments. Following a thorough
assessment including anthropometry, medical history, diet history and symptom assessment,
patients are educated on high-FODMAP foods to exclude and low-FODMAP foods to consume
instead. Certain foods (e.g. avocado, broccoli), contain intermediate quantities of FODMAPs and
are permitted in limited portion sizes. Patients are usually provided with written resources
containing information on restricted and permitted foods and ingredients, recipes and
additional information such as high-fibre foods. Patients experiencing significant GI symptom
improvement following the restriction phase proceed to the FODMAP reintroduction phase, the
aim of which is twofold. Firstly, reintroducing individual high-FODMAP foods in isolation while
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continuing to exclude other high-FODMAP foods enables patients to establish tolerance to the
reintroduced foods. Secondly, the personalisation phase that follows the reintroduction phase
increases the variety of the diet and reduces the risk of nutritional inadequacy. The final phase
is personalisation, during which tolerated foods are consumed, while those inducing significant
GI symptoms upon reintroduction continue to be excluded, with the hope of managing GI
symptoms in the long term.
1.4.5 Evidence for the low FODMAP diet in IBS
At least eight RCTs of the effect of the low FODMAP diet on GI symptoms in IBS have now been
published (Table 1.7). There are four meta-analyses of the low FODMAP diet in IBS, indicating
the growing number of trials in this field (Marsh et al., 2016, Rao et al., 2015, Varju et al., 2017,
Altobelli et al., 2017). Many of the studies are retrospective or prospective uncontrolled trials
and many of the RCTs have clear methodological limitations, as outlined by a recent systematic
review (Krogsgaard et al., 2017). Several RCTs have been published, including one blinded
feeding study and one large placebo-controlled dietary advice trial. The RCTs of the low FODMAP
diet in IBS will be discussed below.
The  first  RCT  of  the  low  FODMAP  diet  in  IBS  was  conducted  by  our  group  in  the  UK  and
investigated the effect of low FODMAP dietary advice compared to continuing with a habitual
diet  (Staudacher  et  al.,  2012).  More patients  in  the low FODMAP diet  group (68%) reported
adequate relief of FGS compared with habitual diet (23%), and more experienced an
improvement in bloating, borborygmi, faecal urgency and overall symptoms during the trial,
compared to the control group. Although this trial provided the first RCT evidence of the
effectiveness  of  the  low  FODMAP  diet  in  IBS  there  were  considerable  limitations,  most
importantly that the control group received no treatment and, as such, participants could not
be blinded to group allocation. Designing or choosing suitable control dietary advice is extremely
challenging, however the lack of treatment in the control group means that a placebo response
cannot be accounted for and increases the risk of expectation bias in both groups (Staudacher
et al., 2017a). This is particularly problematic with regards to functional bowel disorders, where
placebo responses are considerable, and the low FODMAP diet that involves intensive
counselling from a dietitian and is likely susceptible to enhanced placebo responses (Elsenbruch
and Enck, 2015). Our group recently addressed the issue pertaining to placebo control
treatments  in  low  FODMAP  diet  trials  by  performing  a  trial  comparing  low  FODMAP  dietary
advice to sham dietary advice in 104 patients with IBS. Gastrointestinal symptom severity was
significantly lower and significantly more patients were defined as responders to the low
FODMAP (73%) compared to the sham diet (42%) (Staudacher et al., 2017b). To date, this is the
only trial of the low FODMAP diet in IBS to allow an assessment of the placebo response, since
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the sham dietary advice was designed to generate a placebo response through dietary advice,
while maintaining unchanged nutrient and FODMAP intakes.
A feeding study compared the low FODMAP diet (3.1 g total FODMAPs) to a diet with a FODMAP
content reflective of a ‘typical’ Australian diet (23.7 g total FODMAPs) (Halmos et al., 2014b).
Participants completed both diets for 3 weeks in a random order, during which all food was
provided, separated by a 3-week washout period. During the low FODMAP diet arm, overall GI
symptoms, and individual symptoms including bloating, pain and flatulence, were significantly
lower in severity compared to the typical Australian diet. Such ‘feeding’ trial design enables
blinding of participants since foods can be designed to be indistinguishable in appearance and
taste on the different diets and also enhances compliance. While this design is ideal for proof-
of-concept, it does not mimic the effectiveness of the diet in clinical practice where patients are
required to implement dietary advice. It is unlikely that in clinical practice, patients will achieve
the low FODMAP intakes observed in this feeding study, in which very low FODMAP foods are
provided.  This  is  evident  from  low  FODMAP  dietary  advice  trials  (Staudacher  et  al.,  2017a,
Staudacher et al., 2017b, Staudacher et al., 2012). Therefore, symptom responses in clinical
practice may be lower than those observed in this trial.
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Table 1.7 Randomised controlled trials and randomised comparative trials of the effectiveness of the low FODMAP diet in adults with IBS and IBD























4 weeks AR question
GSRS
BSFS
↑% patients reporting AR in LFD (68%) vs. habitual (23%)
↑% patients reporting improved bloating, borborygmi,
urgency and overall symptoms in LFD vs. habitual
↓ Stool frequency and ↑% normal stool consistency in LFD
vs. habitual
















6 weeks IBS-SSS (web-
based)
↓ Total IBS-SSS score in low FODMAP diet vs. habitual diet






















No significant difference in AR between the groups
↑% patients achieved ≥30% reduction in pain in LFD vs.
standard diet
↑ Improvement in pain, bloating, stool consistency, stool




















↓ Total IBS-SSS score in LFD and standard diet between week
0 and week 4



















↓ Total IBS-SSS and stool frequency score in LFD and standard
diet between week 0 and week 4
↓ Total IBS-SSS in LFD vs. standard diet at end of trial
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↓ Overall GI symptom severity on LFD vs. Typical Australian


















3 weeks IBS-SSS ↓ IBS-SSS in LFD vs. baseline
↓ urinary histamine in LFD




















No difference in AR between diets
↓ Total IBS-SSS score in LFD vs. sham
↑ % responders (50 point reduction IBS-SSS) in LFD vs. sham
↓ Severity abdominal pain, overall symptoms in LFD vs. sham
↓ Stool consistency in LFD vs. sham
LFD, low FODMAP diet;  AR, adequate relief;  LGG, Lactobacillus rhamnosus GG; IBS-SSS, IBS Severity Scoring System; VAS, visual analogue scale; GI,  gastrointestinal;  IBS-D, IBS
diarrhoea subtype; IBS-M, IBS mixed subtype; IBS-U, IBS unsubtyped; BSFS, Bristol Stool Form Scale; GSRS, Gastrointestinal Symptom Rating Scale
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Two studies to date have utilised existing dietary IBS treatments as controls to establish
superiority or inferiority of the low FODMAP diet (Bohn et al., 2015, Eswaran et al., 2016). The
first trial randomised patients with IBS to follow either low FODMAP dietary advice or standard
IBS  advice  for  4  weeks  (NICE,  2008,  McKenzie  et  al.,  2016,  Bohn  et  al.,  2015).  GI  symptom
severity significantly improved on both diets with no difference between the groups at end of
trial, suggesting equal efficacy (50% defined as responders following low FODMAP diet vs. 46%
following standard IBS advice). However, the standard IBS advice also involved restriction of
some high-FODMAP foods (e.g. onions, pulses, sugar-free chewing gum) therefore potentially
limiting the comparative effect size of the low FODMAP diet. The second trial also randomised
patients to follow low FODMAP dietary advice or standard IBS advice, but in contrast to the first
trial, the standard IBS advice did not restrict any high-FODMAP foods. Therefore, the results of
this  trial  likely  represent  the  true  effectiveness  of  the  two  dietary  approaches.  There  was  a
similar proportion of ‘responders’ in both diet groups, however there were more pain
responders in the low FODMAP diet group compared to the standard IBS advice group. Both
trials are limited by the lack of placebo-control group.
One  trial  compared  the  low  FODMAP  diet  to  a  probiotic, Lactobacillus rhamnosus GG (LGG)
(Pedersen et al., 2014). Patients with IBS were randomised to one of three groups for 6 weeks;
low FODMAP dietary advice, LGG, or to continue with a habitual diet. There was a significantly
greater reduction in symptom severity score in the low FODMAP diet and LGG groups at end of
trial compared to the habitual diet group, although there was a significant reduction in score in
all  three  groups  between  baseline  and  end  of  trial  (likely  a  result  of  the  Hawthorne  effect
(Sedgwick and Greenwood, 2015). The results should, however, be interpreted with caution due
to a number of limitations. The trial was unblinded and there was likely an uneven expectation
bias across the three groups; the expectation of a positive effect in the two treatment groups
and expectation of lack of benefit in the control group (Staudacher et al., 2017a). Furthermore,
patients who discontinued the trial prematurely were excluded from the final analysis, and this
analysis may not represent the true effectiveness of the treatments. The low FODMAP diet has
also been compared to gut-directed hypnotherapy (Peters et al., 2016) and yoga (Schumann et
al., 2018), both of which revealed similar efficacy of the control treatments compared to the low
FODMAP diet.
Collectively, trials comparing the low FODMAP diet to active control groups generally indicate
that other treatments may also improve GI symptoms in IBS and are a viable option for patients
in whom the low FODMAP diet is not clinically indicated or in non-responders. However, all three
trials lack a placebo-control group (Staudacher et al., 2017a).
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Rather than comparing the low FODMAP diet to a no-treatment control group, a ‘typical’
FODMAP intake or an alternative treatment, a Canadian research group used a high FODMAP
diet as the control treatment (McIntosh et al., 2016). Patients were randomised to one of two
diets which were provided as dietary advice and were blinded to group allocation. Promisingly,
end of trial symptom severity score was significantly lower in the low FODMAP compared to the
high FODMAP diet group. However, the use of the high FODMAP diet control likely inflates the
effect size of the low FODMAP diet since the high FODMAP diet could induce GI symptoms.
1.4.6 Impact of the low FODMAP diet on gut microbiota
Dietary patterns have been associated with GI microbiota profiles and with microbial
enterotypes. A comparative study revealed that the GI microbiota of children from a rural
African village was enriched in Bacteroidetes and Prevotella and low in Firmicutes, while that of
European children was higher in Enterobacteriaceae (De Filippo et al., 2010). A subsequent
analysis suggested that the GI microbiota of African children living in urban areas resembles that
of European children, a microbiota adept at metabolising animal protein and fat rather than
polysaccharides (De Filippo et al., 2017). A similar pattern was observed in a study of Filipino
children living in a rural region compared to those living in an urban region, with the former
exhibiting a Prevotella-dominant and the latter a Bacteroides-dominant microbiota (Nakayama
et al., 2017). Similarly, healthy American volunteers with a predominantly animal-based diet
displayed a Bacteroides enterotype, while a carbohydrate-rich diet associated with a Prevotella
enterotype (Wu et al., 2011), although others have argued that the notion of enterotypes is an
oversimplification of diet-associated GI microbiota profiles (De Filippis et al., 2016). Rapid
changes in the GI microbiota were observed following low-fat/high-fibre diets and high-fat/low-
fibre dietary interventions, although did not shift the enterotypes associated with long-term
dietary  patterns  (Wu  et  al.,  2011).  A  further  study  revealed  that  a  short-term  dietary
intervention composed entirely of animal products rapidly increased the abundance of bile-
tolerant bacteria (Alistipes, Bilophila, Bacteroides) while a plant-based diet increased Firmicutes
adapted to metabolising carbohydrates (Roseburia, Eubacterium rectale, Ruminococcuss bromii)
(David et al., 2014). These studies utilise extreme dietary patterns (for example, based entirely
upon animal or plant products) that are unlikely to reflect the actual habitual dietary intake of
the majority of the population. Nonetheless, it is evident from these studies that long-term and
short-term dietary patterns are associated with distinct microbial profiles and modification of
dietary components, including carbohydrates and proteins, markedly alter these profiles.
A low FODMAP diet involves the manipulation of dietary carbohydrates, although fibre is not
restricted and it should not be a low fibre diet. That said, some trials have also observed a lower
overall  fibre  intake following the low FODMAP diet  compared to  a  control  diet  (Bohn et  al.,
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2015). Fructans and GOS are considered prebiotic carbohydrates and a low FODMAP diet could
therefore be considered a prebiotic-restricted diet (Gibson et al., 2017). The change in dietary
substrate is likely to alter the composition of the GI bacterial community (Sonnenburg and
Sonnenburg, 2014). It is therefore unsurprising that changes in GI microbiota composition have
been observed following a low FODMAP diet in patients with IBS.
In the first ever trial of low FODMAP dietary advice, patients with IBS were randomised to either
the low FODMAP diet  or  to  continue with their  habitual  diet  for  4  weeks  (Staudacher  et  al.,
2012). Faecal samples were collected before and after 4 weeks of the diet. Total bacterial
abundance and the relative and absolute abundance of several bacterial groups were quantified
using FISH. Compared to patients with IBS following their habitual diet, those following low
FODMAP dietary advice had lower relative abundance of faecal Bifidobacteria. None of the other
measured bacterial groups were affected by the diet, including Faecalibacterium prausnitzii or
Lactobacillus. Interestingly, the change in Bifidobacteria abundance in the low FODMAP diet
group was negatively correlated with baseline abundance. Similarly, in healthy individuals, a
lower baseline Bifidobacteria abundance is correlated with a greater increase in abundance
following prebiotic supplementation (Rycroft et al., 2001). This was the first trial to demonstrate
an effect of the low FODMAP diet on the GI microbiota, however there are thousands of other
bacterial groups that were not captured in this analysis and which may be influenced by diet.
The aforementioned feeding study compared the effect of the low FODMAP diet to a typical
Australian  diet  on  the  GI  microbiota  (Halmos  et  al.,  2014a),  with  some  discrepant  findings
compared to the previous trial. Quantitative polymerase chain reaction (qPCR) was used to
quantify the absolute and relative abundance of a selection of bacterial groups at baseline and
after each intervention period. The absolute abundance of total bacteria and most of the
measured bacterial groups was significantly lower following the low FODMAP diet compared to
the typical Australian diet. The relative abundance of Clostridium cluster XIVa was significantly
greater on the typical Australian diet compared to both the low FODMAP diet and the habitual
diet, although there was no difference between the low FODMAP diet and habitual diet.
Compared to the habitual diet, the absolute abundance of F. prausnitzii was significantly lower
following the low FODMAP diet, whereas the relative abundance of Akkermansia muciniphila
was greater following the typical Australian diet compared to the habitual diet. Ruminococcus
torques abundance was significantly greater on the low FODMAP diet compared to the typical
Australian diet. The FODMAP content of the typical Australian diet was slightly higher than that
of the habitual diet and this could have had a prebiotic effect. Furthermore, similar to the
previous trial, the analysis was biased to the bacterial groups chosen for analysis.
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A trial in Canada measured the effects of low FODMAP diet compared to high FODMAP dietary
advice  on  the  GI  microbiota  in  patients  with  IBS  (McIntosh  et  al.,  2016).  In  contrast  to  the
previously described trials, 16S rRNA sequencing was used to characterise the GI microbiota in
faecal samples collected before and after the 3-week intervention. Bacterial richness was
significantly  greater  following  the  low  FODMAP  diet.  However,  there  was  no  difference  in
Bifidobacteria abundance between the diet groups at end of trial, although the high FODMAP
diet appeared to have a prebiotic effect since there was an increase in Bifidobacteria abundance
in this group during the trial. In addition, abundance of Adlercreutzia, a hydrogen-utilising
bacterium, and Dorea were significantly greater following the low FODMAP diet compared to
the high FODMAP diet. Sequencing the 16S rRNA gene permits a comprehensive analysis of all
of the GI bacteria, rather than just species of interest, thus having the potential to capture
unanticipated effects of the diet (Morgan and Huttenhower, 2012). However, it provides no
information on the functions of the microbiota.
Finally, a large placebo-controlled trial compared low FODMAP to placebo sham dietary advice
in IBS and a stool sample was collected prior to and following the intervention (Staudacher et
al.,  2017b).  Similar  to  the  trial  above,  16S  rRNA  sequencing  was  used  to  characterise  the
microbiota and showed significantly lower Bifidobacteria abundance following the low FODMAP
diet compared to the sham diet, with no effect on alpha diversity.
All the trials to investigate the effect of a low FODMAP diet on GI microbiota have been of 3-4
weeks’ duration and the longer-term effects require investigation since the use of a low
FODMAP  diet  exceeding  4  weeks  is  common  in  clinical  practice.  Furthermore,  the  effect  of
FODMAP reintroduction and possible reversal of the microbiota changes should be explored.
1.4.7 Impact of the low FODMAP diet on nutrient intake
The low FODMAP diet requires many dietary modifications and restricts foods from several food
groups, therefore it can have an impact upon nutrient intakes. The nutrients most likely to be
compromised during the low FODMAP diet are calcium (due to the restriction of lactose in dairy
products), iron (due to the restriction of iron-fortified cereals) and fibre (due to the restriction
of certain grains and certain fruits and vegetables). Additionally, overall energy intake may be
compromised, particularly considering the restriction of staple foods such as bread and pasta.
Trials in which patients are instructed to incorporate low FODMAP dietary advice into the
habitual diets are more representative of the effect of the diet on nutrient intakes as opposed
to trials in which all food is provided to participants . Unfortunately, not all trials of the low
FODMAP diet have presented a comprehensive nutritional analysis, often omitting
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micronutrients  (Bohn  et  al.,  2015,  Eswaran  et  al.,  2016)  or  entirely  omitting  nutrient  and
FODMAP intakes (McIntosh et al., 2016, Pedersen et al., 2014, Pedersen et al., 2017).
Compared to patients continuing to follow a habitual diet, patients with IBS following low
FODMAP dietary advice had lower calcium intakes after 4 weeks (Staudacher et al.,  2012). A
further trial showed that compared to patients following traditional IBS advice, those following
low FODMAP dietary advice had significantly lower energy intake, as well as lower carbohydrate
and fibre intakes (Bohn et al., 2015). In a recent trial of 95 patients with IBS, calcium intake was
not different between the low FODMAP and sham diet groups at end of trial, although fewer
patients at end of trial reached the calcium dietary reference value (DRV) compared to baseline
in the low FODMAP diet group (Staudacher et al., 2015).
The long-term effects of the low FODMAP diet on nutrient intakes were investigated in a study
of patients 6-18 months after receiving FODMAP reintroduction advice (O'Keeffe et al., 2018).
At the long-term follow-up, 82% continued to follow an ‘adapted FODMAP’ diet, while 18% had
returned to the habitual diet. In the adapted FODMAP group, total FODMAP intakes were
significantly lower while nutrient intakes were similar to the habitual diet group. Another study
showed that fibre intake declined on the low FODMAP diet but returned to normal following
FODMAP  reintroduction  (Harvie  et  al.,  2017).  These  findings  suggest  that  FODMAP
reintroduction may resolve nutritional inadequacies occurring with the low FODMAP diet,
however both studies used a food frequency questionnaire to estimate nutrient and FODMAP
intakes, which lacks accuracy compared to prospective food records (Bingham et al., 2007,
Prentice et al., 2011).
1.4.8 Evidence for the low FODMAP diet in IBD
There is evidence supporting the effectiveness of the low FODMAP diet in IBS, including a large
placebo-controlled trial (Staudacher et al., 2017b). Since a large proportion of patients with
inactive IBD continue to experience FGS (Halpin and Ford, 2012), it is unsurprising that interest
in  the  low  FODMAP  diet  has  grown  in  recent  years.  Indeed,  the  first  RCT  in  this  patient
population has been published recently (Pedersen et al., 2017). Prior to this, two uncontrolled
studies had indicated the potential effectiveness of the diet in IBD (Gearry et al., 2009a, Prince
et al., 2016).
An Australian retrospective study investigated the effect of low FODMAP dietary advice
provided to patients with IBD as part of routine clinical practice (Gearry et al., 2009a). Patients
who had received low FODMAP dietary advice were telephoned up to 18 months later and a
telephone questionnaire, regarding the advice provided, symptom responses to dietary
changes, and adherence to the advice, was administered. Following the low FODMAP diet, most
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GI symptoms had reportedly improved in both CD and UC. However, this study was uncontrolled,
meaning that the magnitude of placebo response to the diet cannot be estimated. Furthermore,
due to the retrospective nature, changes in disease activity, medication and other dietary
components during the low FODMAP diet cannot be accurately assessed.
The second study was a prospective uncontrolled study of low FODMAP dietary advice
performed by our group to a UK population as part of routine clinical practice in a dietetic
gastroenterology outpatient clinic (Prince et al., 2016). Following the advice, 78% of patients
reported adequate relief of FGS compared to 16% at baseline, in addition to a large proportion
experiencing an improvement in individual FGS such as abdominal pain, bloating and flatulence
following the advice. This study was uncontrolled and, hence, carries the same limitation as the
aforementioned retrospective study. The results of this study may also be subject to referral and
selection bias and responder bias, as well as potential confounding variables that cannot be
accounted for, such as changes in disease activity and medications during the diet.
The first RCT of the low FODMAP diet in IBD was conducted in Denmark and recruited 89 patients
with inactive or mild-to-moderate IBD (Pedersen et al., 2017). Participants were randomised to
either low FODMAP dietary advice or to continue habitual dietary intake for 6 weeks. Functional
GI symptoms and health-related quality of life were evaluated before and after the diet. The
primary outcome was the proportion of patients classified as ‘responders’ to the low FODMAP
diet, defined as at least a 50-point reduction in total IBS Severity Scoring System score between
baseline and end of trial. Significantly more patients responded to the intervention in the low
FODMAP diet (81%) compared to the control group (46%) (P<0.01), indicating a large placebo
response considering that participants in the control group received no intervention. This may
represent the fluctuating nature of FGS or the placebo response induced through inclusion in a
trial, the Hawthorne effect (Sedgwick and Greenwood, 2015). Health-related quality of life was
significantly greater in the low FODMAP diet group than the control group at end of trial, in line
with the improvement in GI symptoms (Gracie et al., 2017).
There are some noteworthy limitations to this trial. Firstly, the control group were not a placebo
intervention or an active comparator, and therefore the trial was unblinded. The lack of placebo
dietary advice renders it impossible to account for the placebo response, although the response
rate in the control group was surprisingly high. Secondly, although the primary outcome was
analysed based on intention to treat, all other outcomes were analysed per protocol. The
findings of the secondary outcomes therefore do not represent the effectiveness of the diet in
clinical practice, although they do demonstrate efficacy when the diet is followed optimally.
Thirdly, a food frequency questionnaire was used to measure baseline dietary intake in all
participants, which correlates poorly with the more robust prospective food record (Key et al.,
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2011). Furthermore, since dietary intake was not measured at follow-up, intake of FODMAPs
and other potentially clinically relevant dietary components (e.g. fibre) during the trial cannot
be established. Finally, clinical disease activity indices were used alone to determine IBD activity
for trial inclusion. Although these correlate well with disease activity and avoid more invasive
measures such as endoscopy, the value of symptom-based measures in the context of functional
symptoms is questionable (Quigley, 2016). Patients experiencing FGS may be incorrectly
classified as having active IBD as a result of FGS elevating disease activity scores, and hence
incorrect inferences may be made in analysis, for example when performing sub-group analyses
by  disease  activity.  Thus,  it  is  likely  that  a  combination  of  active  and  inactive  patients  were
included in this trial.
A  placebo-controlled  trial  of  the  low  FODMAP  diet  is  warranted.  However,  it  would  still  be
unclear whether fermentable carbohydrates are responsible for FGS in IBD, and a randomised,
placebo-controlled re-challenge trial using pure fermentable carbohydrates, as has been
conducted in IBS, would help to address this (Shepherd et al., 2008)
1.4.9 Concerns surrounding the low FODMAP diet in IBD
The  low  FODMAP  diet  is  gaining  considerable  interest  in  IBD  with  the  emergence  of  studies
suggesting it may be effective for the management of IBS-like symptoms (Prince et al.,  2016,
Gearry et al., 2009a, Pedersen et al., 2017). There are two major concerns regarding the use of
the low FODMAP diet in IBD.
The first concern relates to the theoretical detrimental effect of restricting dietary prebiotic
carbohydrates during the low FODMAP diet and the associated decline in immune-modulatory
bacteria. The low FODMAP diet paradoxically improves GI symptoms while causing a decline in
numerous bacteria, in particular Bifidobacteria, but also Faecalibacterium prausnitzii and
Clostridium cluster XIVa. These immune-modulatory bacteria can interact with the GI immune
system through pattern-recognition receptors on host epithelial and immune cells, and this in
turn may influence the enteric nervous system and the central nervous system. Furthermore,
Bifidobacteria abundance correlates with number of days of abdominal pain in patients with IBS,
suggesting an association between this bacterium and GI symptoms (Parkes et al., 2008).
Bacterial dysbiosis is present in IBD, generally characterised by a decline in Firmicutes, especially
F. prausnitzii, and an increase in Proteobacteria, especially Escherichia coli in CD (Kostic et al.,
2014). Although it is unclear whether this is a cause or consequence of inflammation, there is
evidence that altered microbiota may play a role in the generation of GI inflammation (Kolho et
al., 2015, Prosberg et al., 2016, Rooks et al., 2014, Sokol et al., 2008). Moreover, several studies
have revealed reduced Bifidobacteria abundance in IBD, although this finding is not consistent
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(Maukonen et al., 2015, Gevers et al., 2014). Bifidobacteria are known to have anti-inflammatory
effects in vitro and in vivo (Riedel et al., 2006, Sarkar and Mandal, 2016, Fanning et al., 2012,
Turroni et al., 2016, Gibson and Wang, 1994, Picard et al., 2005). Fructan supplementation,
effectively representing the opposite intervention to fructan restriction on the low FODMAP
diet, increases faecal Bifidobacteria and F. prausnitzii abundance in healthy volunteers (Ramirez-
Farias et al., 2009). Conversely, fructan supplementation had no effect on faecal microbiota in
active CD but lamina propria immune cell phenotype was altered, with reduced pro-
inflammatory IL-6-positive DC and higher anti-inflammatory IL-10-positive DC (Benjamin et al.,
2011b). Furthermore, inulin-enriched oligofructose supplementation resulted in reduced faecal
calprotectin in patients with UC in a small group of patients, and therefore restricting these
prebiotic carbohydrates in the diet may increase faecal calprotectin (Casellas et al., 2007).
Therefore, reducing dietary prebiotics could exacerbate the existing dysbiosis in IBD and may
even alter GI immune cell function irrespective of microbiota alterations. These changes could,
in turn, impact upon intestinal inflammation and IBD course. The effect of the low FODMAP diet
on GI microbiota and immune function in IBD should therefore be investigated prior to
widespread implementation of the diet.
In a low FODMAP diet feeding study, nine patients with CD were also recruited and subjected to
the same study protocol  as  the patients  with  IBS  (Halmos et  al.,  2016).  The microbiota  were
altered in IBD in a similar fashion to the patients with IBS. In contrast to the other trials assessing
the GI microbiota following the low FODMAP diet in IBS (Staudacher et al., 2017b, Staudacher
et  al.,  2012),  relative  abundance of  Bifidobacteria  was not  altered in  patients  with  IBS  or  CD
following the low FODMAP diet, although absolute abundance was reduced. Although the trial
was not powered to detect differences in patients with CD and these patients represented a
small proportion of the total sample size, this provides preliminary evidence that the low
FODMAP diet may detrimentally impact upon immune-modulatory bacteria in IBD.
The second concern regarding the use of the low FODMAP diet in IBD relates to nutritional
adequacy.  As  discussed  above,  the  low  FODMAP  diet  may  compromise  intakes  of
macronutrients and micronutrients, although nutritional adequacy may be restored following
FODMAP reintroduction. Patients with IBD are at heightened risk of malnutrition resulting from
the effects of chronic GI inflammation on food intake, nutrient absorption and metabolism
(Gerasimidis et al., 2011). Owing to the elevated risk of osteoporosis and anaemia in IBD, it is
particularly important that calcium and iron intakes are adequate (Lomer, 2011). Reduced
energy intake could exacerbate existing malnutrition and reduced fibre intake could have clinical
implications since lower fibre consumption has been associated with a greater risk of CD relapse
(Brotherton  et  al.,  2016).  Therefore,  all  the  ‘at  risk’  nutrients  on  a  low  FODMAP  diet  are
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especially important in IBD. Particular care should be taken to ensure that excluded foods are
replaced with nutritionally equivalent alternatives and future research should establish the
effect of the low FODMAP diet on nutrient intakes in IBD.
1.5 Conclusion and future research
Many patients with IBD report persistent GI symptoms in the absence of GI inflammation, which
may detrimentally impact upon HR-QOL. Scarce evidence exists on the management of these
common and debilitating FGS in IBD. The most promising approach is the modification of dietary
fermentable carbohydrates (the low FODMAP diet), which improves GI symptoms in 50-80% of
patients  with  IBS.  Little  evidence  exists  on  FODMAP  intakes  in  patients  with  IBD,  with  and
without FGS, although one case-control study revealed lower fructan intakes in active IBD
compared to healthy controls. Two uncontrolled studies and a non-placebo controlled trial
indicate potential effectiveness of the low FODMAP diet for FGS in IBD. However, it is unclear
from these studies whether fermentable carbohydrates per se are responsible for the
improvement in FGS. This challenge can be overcome by using a FODMAP restriction and re-
challenge approach. These studies also do not account for the placebo response that can be
considerable in IBS and IBD. Additionally, concerns regarding the consequences of the
microbiota  alterations  on  immunology,  as  well  as  the  effect  of  the  low  FODMAP  diet  on
nutritional adequacy in IBD, warrant a placebo-controlled trial to confirm both the effectiveness
and safety of the diet in IBD.
1.6 Aims of thesis
The aim of this thesis was to explore the role of fermentable carbohydrates in FGS in IBD using
a variety of methodological approaches. This was achieved by addressing the following aims:
1. To conduct a case-control study to investigate FODMAP, nutrient and fibre intakes in
patients with active IBD (inflammatory GI symptoms), inactive IBD with FGS (functional
GI symptoms), inactive IBD without FGS (no GI symptoms) and healthy controls (no GI
symptoms).
2. To conduct a randomised, double-blinded, placebo-controlled, crossover, re-challenge
trial to determine whether individual fermentable carbohydrates exacerbate FGS in
patients with inactive IBD.
3. To  conduct  a  randomised  controlled  trial  to  investigate  the  effect  of  low  FODMAP
dietary advice compared to placebo ‘sham’ dietary advice on FGS, GI microbiota,
circulating T-cell gut-homing phenotype and markers of intestinal inflammation in
patients with inactive IBD with FGS.
2 FODMAP and nutrient intake in inflammatory bowel disease
and the association with functional gastrointestinal symptoms
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2.1 Introduction
The  low  FODMAP  diet  is  a  potential  therapy  for  common  FGS  in  patients  with  inactive  IBD
(Gearry et al., 2009a, Prince et al., 2016, Pedersen et al., 2017). It is unclear whether patients
with IBD intentionally or unintentionally manipulate dietary FODMAP intake for the
management of GI symptoms. Data on FODMAP intakes in IBD are limited to one case-control
study in which a validated food-frequency questionnaire (FFQ) (Dunn et al., 2011) was used to
demonstrate that fructan intakes were significantly lower in active CD compared to inactive IBD
and healthy controls (Anderson et al., 2015). However, energy intakes were not estimated,
making it impossible to attribute lower fructan intakes to avoidance of fructans specifically
rather than to a reduced overall food intake. Indeed, lower energy intake in children,
adolescents and adults with IBD compared to healthy controls has been observed (Hartman et
al., 2016, Benjamin et al., 2011a). Nonetheless, reduced fructan intake in active IBD could relate
to  dietary  restrictions  commonly  practiced  for  symptom  control  or  due  to  perceived  risk  of
relapse  associated  with  certain  foods  (Prince  et  al.,  2011,  Limdi  et  al.,  2016).  Furthermore,
intakes of FODMAPs besides fructans could be influenced by restrictions commonly observed in
IBD, including dairy products (lactose), beans (galacto-oligosaccharides; GOS) and certain fruits
and vegetables (fructose, polyols) (Vagianos et al., 2016, Zallot et al., 2013).
There remains a major knowledge gap regarding fructan intakes in UC, as well as the intakes of
other FODMAPs, in both CD and UC. It is also unclear whether FODMAP restriction relates to
active IBD per se,  or  due to  GI  symptoms of  any aetiology.  Investigating FODMAP intakes  in
patients with active IBD (inflammatory GI symptoms), inactive IBD who have concurrent FGS
(functional GI symptoms) and inactive IBD without FGS (no GI symptoms) would help delineate
these behaviours. Establishing whether IBD patients with GI symptoms specifically avoid foods
high in FODMAPs despite being naïve to a low FODMAP diet would lend further support to
FODMAPs as inducers of GI symptoms and is an important consideration since the long-term
microbial and clinical implications of chronic FODMAP restriction are unknown.
Previous studies have also reported a range of nutrient inadequacies in IBD, including vitamin D,
calcium, iron and B vitamin intakes (Vagianos et al., 2007, Vidarsdottir et al., 2016, Filippi et al.,
2006), and evidence exists of altered macronutrient distribution (Geerling et al., 2000).
However, studies have generally featured small sample sizes, limited dietary assessment
methods, heterogeneity in patients recruited, inconsistent nutrient reporting and the lack of a
non-IBD  control  group  (Vagianos  et  al.,  2007,  Vidarsdottir  et  al.,  2016).  Therefore,  a
comprehensive assessment of nutrient intakes using a robust dietary assessment method in a
large group of patients with active and inactive CD and UC, and healthy controls, is warranted.
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2.2 Aims and objectives of the case-control study
The aim of this case-control study was to investigate the effect of GI symptoms on FODMAP,
nutrient and fibre intakes in patients with active IBD (inflammatory GI symptoms), inactive IBD
with FGS (functional GI symptoms), inactive IBD without FGS (no GI symptoms) and healthy
controls (no GI symptoms).
Primary objective: to compare fructan intakes in patients with active IBD, inactive IBD with FGS,
inactive IBD without FGS and healthy controls
Secondary objectives: in patients with active IBD, inactive IBD with FGS, inactive IBD without FGS
and healthy controls:
1. To compare GOS, lactose, fructose and polyol intakes
2. To compare energy, macronutrient, micronutrient and fibre intakes
3. To compare food-related quality of life




There is no difference in FODMAP, nutrient and fibre intakes or food-related quality of life in
patients with active IBD, inactive IBD with FGS, inactive IBD without FGS and healthy controls.
Alternative hypothesis:
There is a difference in FODMAP, nutrient and fibre intakes or food-related quality of life in
patients with active IBD, inactive IBD with FGS, inactive IBD without FGS and healthy controls.
2.4 Methodology
2.4.1 Study design
This was a 7-day case-control study of dietary intake in patients with IBD and healthy controls.
This duration of food diary was chosen, rather than the typical 3-day or 4-day food diary
(Vidarsdottir  et  al.,  2016,  Vagianos et  al.,  2007,  Filippi  et  al.,  2006,  Hartman et  al.,  2016),  to
control for inter-diurnal variation in eating behaviour and to improve precision of global food
intake assessment. It was felt that a duration exceeding 7-days would compromise the quality
of diary completion and rates of diary return. Although a 7-day diary could theoretically induce
participant fatigue and compromise completion rates compared to a 3-day or 4-day diary, a 7-
day food diary accounts for a change in dietary habits and inaccurate recording that may occur
upon beginning a food diary and the fatigue that may occur towards the end, leaving several
days in the middle of the diary that may more accurately represent dietary intake (Biltoft-Jensen
et al., 2009).
2.4.2 Study sites
Patients  with  IBD were recruited from gastroenterology clinics  at  Guy’s  and St  Thomas’  NHS
Foundation Trust, Barts Health NHS Trust and King’s College Hospital NHS Foundation Trust,
London, UK between September 2016 and March 2018. Visits were conducted either in the
hospital clinic or in the Department of Nutritional Sciences, King’s College London. All
participants were recruited by the author of this thesis (SC), except for three patients with active
UC who provided a baseline food diary for a clinical trial and consented to food diary data being
used in subsequent studies. Diaries from patients with inactive IBD with FGS were baseline
diaries collected as part of the RCT described in Chapters 4-6 of this thesis. These diaries were
identical and completed to the same level of detail as the other study groups.
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2.4.3 Patient selection, inclusion and exclusion criteria
Inclusion and exclusion criteria for patients with active IBD, inactive IBD with FGS, inactive IBD
without FGS, and healthy controls was different and the criteria for each group are detailed in
Table 2.1. Justification for the use of the Harvey-Bradshaw Index (HBI) for CD activity is described
in detail in section 4.4.2. The Simple Clinical Colitis Activity Index (SCCAI) was chosen as a non-
invasive measure of UC activity that appears to be the strongest of a range of non-invasive
indices in reflecting UC activity (Walsh et al., 2014, Turner et al., Higgins et al., 2005).
The HBI thresholds for active (HBI ≤3) and inactive CD (HBI ≥5) were chosen as those showing
good correlation with the Crohn’s Disease Activity Index (CDAI) thresholds for active and inactive
CD (Vermeire et al., 2010, Foti et al., 2015, Falvey et al., 2015). The SCCAI thresholds for active
(SCCAI ≥4) and inactive UC (SCCAI ≤2) were chosen in light of evidence that these reflect disease
activity with optimal sensitivity and specificity (Walsh et al., 2016, Marin-Jimenez et al., 2016,
Walsh et al., 2014). Due to issues of accuracy of the scoring systems in detecting active and
inactive disease, there was a risk of active patients being in the inactive group, and vice versa,
Therefore, to create a clear distinction between patients with active and inactive IBD, patients
on the borderline of the cut offs for these scores (HBI 4, SCCAI 3) were not eligible for the study.
For the same reasons, an objective marker of the presence or absence of inflammation (CRP,
calprotectin imaging) was also required to define active or inactive disease, respectively.
The HBI and SCCAI could not be used to establish inactive IBD in patients with FGS as the
presence of FGS could elevate scores despite the absence of GI inflammation (and thus, would
incorrectly exclude from the study or incorrectly allocate to the active IBD group), a flaw with
symptom-based diseases activity indices which has been highlighted previously (Gracie et al.,
2017). Therefore, inactive IBD was established in this group using inflammatory markers (CRP
and/or faecal calprotectin). In a large proportion of patients, only a recent serum CRP
concentration was available, since this is routinely collected in clinic. While a high serum CRP
indicates  active  IBD (in  combination with clinical  indices),  a  low CRP may be present  in  both
active and inactive IBD as this marker has poor sensitivity for identifying disease activity (Mosli
et al., 2015). However, a low HBI or SCCAI in addition to a low CRP increases the likelihood of
inactive disease.
Patients currently taking medications for IBD (5-ASA, thiopurines, biologics, steroids) were
eligible, however patients with changes in medication in the 2 weeks preceding screening were
excluded, in order to prevent any effects of medication dose changes on disease activity, with a
subsequent effect on dietary intake. Patients with current stricturing CD were excluded from all
IBD groups since it was assumed that the presence of a stricture could lead to a change in dietary
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intake  distinct  from  inflammatory  GI  symptoms  or  FGS.  However,  patients  with  a  history  of
stricturing CD were eligible, but those with a current stricture were not due to the potential
impact of that on current intake. With similar rationale, patients with a current stoma or with
short bowel syndrome, as well as those currently following a special diet (e.g. Paleolithic diet,
gluten-free diet) were excluded. Patients implementing changes in IBD medications in the
preceding 2 weeks were excluded to prevent confounding associated with drug side-effects.
Patients with other major co-morbidities were assessed on a case-by-case basis. Conditions
judged to have a potential impact on dietary intake (such as diabetes and coeliac disease) were
excluded.
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Table 2.1 Inclusion and exclusion criteria for the different groups of the case-control study





· Aged 18-75 years old
· Able to give informed consent
· IBD (CD or UC) diagnosed by standard clinical, histological and
radiological criteria
· Diagnosis of IBD ≥3 months
Standard inclusion criteria plus, active IBD as defined by:
· A subjective measure of active disease: HBI score ≥5 for CD,
or SCCAI ≥4 for UC
· An objective measure of active disease: CRP >10 mg/L and/or
faecal calprotectin >250 μg/g and/or endoscopic or imaging
investigations (in the last 4 weeks).
Standard exclusion criteria
· Current stricturing CD
· Extensive intestinal resection indicating short bowel syndrome
· Current stoma
· Changes in dose or initiation of the following in the past 2 weeks:
immunosuppressant or biological therapy, oral 5-ASA or rectal
preparations
· Gastrointestinal surgery thought to be imminent
· Other gastrointestinal disorders
· Significant comorbidities (including hepatic, renal,
cardiovascular, endocrine, respiratory or neurological)
· Diabetes mellitus
· Patients following a special or restrictive diet other than
specifically IBD-related diets
· Pregnant or lactating




Standard inclusion criteria (as list for active IBD), plus inactive IBD
with FGS as defined by:
· A subjective measure of FGS: experiencing symptoms
meeting the Rome III criteria for IBS-D, IBS-M, IBS-U,
functional bloating or functional diarrhoea
An objective measure of inactive disease: CRP <10 mg/L and/or faecal
calprotectin <250 µg/g and/or recent endoscopic evidence of inactive
disease (last 4/52)




Standard inclusion criteria (as list for active IBD), plus inactive IBD as
defined by:
· A subjective measure of inactive disease: HBI score ≤3 for CD,
or SCCAI ≤2 for UC
Standard exclusion criteria (as listed above for active IBD) plus:
Experiencing GI symptoms meeting the Rome III criteria for IBS, functional
bloating or functional diarrhoea
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· An objective measure of inactive disease: CRP <10 mg/L
and/or faecal calprotectin <250 μg/g and/or endoscopic or
imaging investigations (in the last 4 weeks).
Healthy controls (no
GI symptoms)
· Aged 18-75 y
· Able to give informed consent
· IBD or other gastrointestinal disorder (including any functional
bowel disorder or coeliac disease)
· Experiencing gastrointestinal symptoms meeting the Rome III
criteria for IBS, functional bloating or functional diarrhoea
· Previous gastrointestinal resection
· Significant comorbidities (including hepatic, renal,
cardiovascular, endocrine, respiratory or neurological)
· Diabetes mellitus
· Patients following a special or restrictive diet
· Pregnant or lactating
· Lack of ability to give informed consent
FGS, functional gastrointestinal symptoms; HBI, Harvey Bradshaw Index; SCCAI, Simple Clinical Colitis Activity Index; CRP, C-reactive protein; 5-ASA, 5-aminosalicylic acid;
IBS-D, irritable bowel syndrome diarrhoea subtype; IBS-A, irritable bowel syndrome mixed subtype; IBS-U, irritable bowel syndrome unsubtyped
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2.4.4 Ethics approval
Ethics  approval  was  granted  for  the  study  by  London  –  City  and  East  Research  Ethics
Committee on 17th May 2016 (16/LO/0976). Health Research Authority approval was granted
on 22nd July 2016. Local approvals were granted shortly thereafter. King’s College Hospital
was opened as a new site after study initiation in November 2017, to enhance recruitment.
2.4.5 Trial protocol and procedures
2.4.5.1 Patients with IBD
Most patients were recruited to the study in gastroenterology clinics. Patients were either
identified by the researcher prior to appointments with the gastroenterology team, or were
referred to the researcher by gastroenterologists, nurses and pharmacists after
consultations. Some patients were also identified in IBD infusion units, which were attended
regularly by the researcher.
Patients were screened against inclusion and exclusion criteria in Table 2.1 and those
meeting the eligibility criteria were provided with a full description of the study by the
researcher and a participant information sheet (PIS). Patients were offered as long as they
needed to consider participation. Individuals fulfilling all the eligibility criteria were invited
to attend a 20-minute study visit.
2.4.5.2 Healthy controls
Healthy controls were identified through fortnightly circular emails to staff and students at
King’s College London and Guy’s and St Thomas’ NHS Foundation Trust (GSTT). These were
selected as they would likely be similar in geographical reach as the IBD patients.
The advertisement at King’s College London was included on four emails at different times
of the year. The advertisement at GSTT was included on two news bulletin emails several
months apart. To limit sampling bias inevitable from recruiting students (younger, higher
educational status) and academic and clinical staff (higher socio-economic status, higher
educational status), attempts were made to recruit from a diverse staff population including
from emailing and posting leaflets to professional services staff and building maintenance
staff.
Individuals contacting the researcher via email were screened against the eligibility criteria
in  Table  2.1  and were sent  the PIS  and were offered as  long as  they needed to  consider
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participation. Individuals fulfilling all the eligibility criteria were invited to attend a 20-minute
study visit.
2.4.6 Protocol for visit (patients with IBD and healthy controls)
During the study visit, the information contained within the PIS was reiterated and
participants provided informed consent. Once participants had provided informed consent,
demographic information was gathered (age, ethnicity, education level, smoking status), as
well as information on any current medications. The researcher then provided participants
with  a  7-day  food  diary  to  complete  consecutively  for  the  following  7-days.  If  patients
planned holidays in the next few days or other circumstances likely to interfere with diary
completion, they were asked to delay recording the diary until the next possible 7-day period
in which they were carrying out normal activities. For the same reason, patients were not
recruited between the 15th December and the 1st January, since dietary habits often deviate
from normal during this period and diary completion would likely be poorer.
Patients with IBD were provided with three questionnaires for the measurement of Food-
related Quality of Life (FR-QOL) and patient-perceived control of IBD and completion was
permitted at any time during the food diary completion week. Healthy controls were also
provided with a version of the FR-QOL questionnaire worded and validated for healthy
individuals, and the instructions for completion were identical to those provided to patients
with IBD.
Between three to four days into the recording period, participants were contacted by the
researcher to provide an opportunity to ask any further questions and to address any
concerns in completing the food diary and questionnaires.
Participants returned the food diary and questionnaires either in person or via post (e.g.
patients living outside of London, work/study during office hours). Those returning via post
were provided with a stamped addressed envelope. All diaries were checked for
completeness and detail by the researcher (SC, thesis author) and any outstanding
information required was gathered by direct questioning (those returning in person) or via
telephone or email (returning in person or by post).
2.4.7 Energy reporting
Studies involving self-reported dietary intake are subject to misreporting energy and nutrient
intakes, which may result from conscious or unconscious omission of foods and misreporting
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portion sizes (Black, 2000a). This phenomenon has been established by comparing reported
energy intake with the energy required to maintain body weight in long-term studies and by
comparing reported energy intake with energy expenditure measured using doubly-labelled
water (Lichtman et al., 1992, Black et al., 1993). This common problem in dietary assessment
may result in under-estimation (or indeed over-estimation) of nutrient intakes and may even
lead to spurious conclusions, particularly where under-reporting is more prevalent in one
study group. Excluding under-reporters from analyses has been shown to alter study
outcomes (Stallone et al., 1997).
A number of methods exist for estimating the extent of energy and nutrient misreporting.
The Goldberg method calculates the likelihood of misreporting using the agreement
between the ratio of energy intake (EI) to basal metabolic rate (BMR) and the ratio of energy
expenditure to physical activity level (PAL). This method has limitations including under-
estimating the proportion of under-reporters and only identifying individuals at the extremes
of  misreporting  (Black,  2000b).  A  similar  approach  is  to  calculate  the  ratio  of  EI  to  the
estimated energy requirement (EER), which has an expected value of 1. Several cut-offs for
under-reporters, acceptable reporters and over-reporters have been proposed, including
<0.78, 0.78-1.22, and >1.22 (Huang et al.,  2005). Similar cut-offs have been used by other
authors; for example, classifying acceptable reporters as falling between 0.74 and 1.28
(Black, 2000b).
In this study, EER was calculated by multiplying the BMR (Henry, 2005) by a PAL to calculate
EER. Since occupational and exercise activity levels were not available for the participants, a
PAL of 1.4 was applied for all participants, relating to a sedentary job (i.e. office work) and
no regular exercise. This was based on evidence that less than half of the UK population meet
current physical activity guidelines, and therefore the PAL of 1.4 provides a more
conservative  estimate  or  activity  levels  and  to  avoid  over-estimating  the  prevalence  of
under-reporting (DoH, 2011, Black, 2000b) . The ratio of EI to EER was calculated and patients
were classified as either under-reporter (ratio below 0.78), ‘acceptable’ (ratio between 0.78-
1.22), or over-reporter (ratio above 1.22).
However, under-reporters and over-reporters were not excluded from the intake analysis
because the presence of IBD may cause a true deviation from a EI/EER of 1.0 not related to
under- or over-reporting. There are two reasons for this. Firstly, actual BMR may be elevated
in those with active IBD and thus calculated BMR and EER are likely to be under-estimated.
Secondly, EI may legitimately be lower than EER in those with IBD due to pain, GI symptoms
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and psychological state (Sousa Guerreiro et al., 2007, Benjamin et al., 2011a). Thus, a EI/EER
deviating from 1.0 may simply be a manifestation of IBD.
2.4.8 Outcome measures and rationale: dietary assessment
2.4.8.1 Food diaries
A 7-d prospective food diary was used to measure dietary intake in this study. Dietary intake
can be measured retrospectively or prospectively. Retrospective methods include 24-hour
diet recall, which captures recent dietary intake and does not rely on respondent literacy,
and food-frequency questionnaires (FFQ), which are quick and inexpensive and can capture
longer term dietary intake. However, 24-hour recall may not reflect usual intake and requires
a skilled interviewer. Likewise, FFQ pose issues relating to the number of included food items
and potential recall bias. Prospective methods overcome some of the limitations associated
with retrospectively assessing dietary intake, for example eliminating recall bias, although
these methods may induce unwanted behaviour change. Weighed food diaries are
considered the gold standard dietary assessment method, but are burdensome to the
respondent and require the equipment and skills to weigh all food consumed. Estimated
(unweighed) food diaries are generally less cumbersome to the respondent, have shown to
be comparable to weighed food diaries, and correlate more strongly with energy and protein
biomarkers than FFQ (Bingham et al., 2007, Prentice et al., 2011). Portion-size estimation
aids such as food models or food photographs may improve the accuracy of portion-size
estimation in unweighed food diaries (Nelson et al., 1996).
The food record used in this study (Appendices 8.14 and 8.15) was based upon that used in
an RCT conducted by a previous PhD student, and was originally developed based upon the
National Diet and Nutrition Survey (NDNS) diary. This includes an example food diary page
to demonstrate the level of detail required in the diary, and food photographs to aid in
portion size estimation. The seven days of the diary were coded in different colours to
facilitate easier navigation through the diary.
2.4.8.2 Food diary administration
Detailed instruction on completing the food diary was provided to participants at the study
visit. Participants were advised to improve accuracy of food records through the following
measures:
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1. Record all meals, snacks and drinks (including water) between getting up and going
to bed on each diary day.
2. Take the diary to work or other activities and record dietary intake prospectively to
minimise recall bias. Failing this, participants were to make a note of dietary intake
on a phone, computer or notepad.
3. Provide brand name information for as many foods as possible.
4. Use the food portion photographs, household measures (cups, tablespoons,
teaspoons),  number  of  units  (e.g.  1  biscuit)  or  food  packaging  (e.g.  weight)  for
portion sizes.
5. Describe the ingredients and quantities, the number of servings and the cooking
method for home-cooked dishes (specifying dry or cooked weight).
6. For foods eaten outside the home, describe the food in detail, provide the brand or
restaurant name, estimated portion size and how much was eaten.
7. Record vitamin, mineral and other nutritional supplements.
Diaries were reviewed by the researcher upon return. Where additional information was
required, this was requested in person or over the phone depending upon the method of
diary return.
2.4.8.3 Data input and analysis
Several software packages are available for dietary analysis, including Dietplan, WinDiet and
Nutritics, all with merits and limitations. Nutritics, which is based upon McCance and
Widdowson’s composition of foods integrated dataset (CoFID) (PHE, 2015) was used in the
current study. The ability to export dietary reports in batch was a desirable feature given the
number of participant diaries collected in this study. Finally, Nutritics is regularly updated
with new foods based upon information provided by manufacturers or publications and is
therefore more likely to contain a comprehensive and current list of foods.
Dietary data was entered by two coders, Charlotte Howard and Alice Wright (student
dietitians, King’s College London). Dietary input protocols previously used in the research
group were followed, adapted and expanded for the purposes of this study. The coders had
previous training and experience in using Nutritics. Regular meetings were held with the
author of this thesis (SC) to resolve any data queries.
A ‘hierarchy’ was established for determining portion sizes that were not clearly specified in
the diary, to ensure consistency in data entry. The ‘demographic average’ portion in Nutritics
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was preferably used, and if this was not available, the Food Standards Agency portion size
guide was consulted (FSA, 2008).
Foods were entered into Nutritics as the closest existing food. For example, ‘Cheerios’ would
be entered as ‘multigrain hoops’. Where no existing food adequately matched the food in
the diary, a new food was created with nutrient content adapted according to online
information for the product. Composite foods were added as new recipes, unless individual
foods could be sufficiently representative. For example, a cheese and ham sandwich was
added as: bread + cheddar + ham + butter, rather than creating a recipe.
Following data  entry  all  food records  were batch exported into Microsoft  Excel  and data
checking was performed. Daily (average of the 7-day diary) intakes of energy, carbohydrate,
protein, fat, fibre, calcium, iron and vitamin C falling outside the 2.5th or 97.5th percentile
ranges for age and gender-matched 2008/2009 and 2011/2012 NDNS data were checked
against the food diaries for potential errors in data entry. Outliers were additionally
identified through constructing boxplots of the daily intakes of the aforementioned nutrients
in SPSS. Food diaries of individuals with an average daily intake falling outside 1.5 times the
interquartile range were checked for potential errors in data entry.
2.4.8.4 FODMAP intake analysis
The aim of this case-control study was to estimate FODMAP and nutrient intakes.
Researchers at Monash University have performed extensive analyses of the fermentable
carbohydrate content of foods using high-performance liquid chromatography (Yao et al.,
2014, Muir et al.,  2007, Muir et al.,  2009, Biesiekierski et al.,  2011b). From this published
data, FODMAPs have been incorporated into the FoodWorks database (Xyris Software,
Australia), access to which is now available online. This database permits researchers to
enter foods consumed and generate a report of total and individual fermentable
carbohydrate intakes of each individual.
The FODMAP database was used to determine fermentable carbohydrate intakes of
participants at baseline and end of trial. All diaries were entered into the database by the
author of this thesis.
During data entry, the following assumptions and practices were followed for all diaries:
1. For composite foods where no recipe was provided by the participant, a typical
recipe for this food was used to estimate quantities of each ingredient. Should the
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same food appear in a subsequent diary with no recipe provided, the same recipe
was assumed. A popular UK recipe website was used consistently.
2. Where  an  exact  match  for  a  particular  food  was  not  available  in  the  FODMAP
database (largely due to the differences in UK and Australian dietary practices), the
closest matching food was chosen. For example, ‘malted wheat breakfast cereal’ was
entered as ‘plain wheat-based cereal’ in the FODMAP database.
3. Conversions were made for differences in cooked/uncooked foods between the
diaries and the calculator. For example, if the diary stated ‘broccoli, boiled’ but the
calculator contained only raw broccoli, the weight of broccoli entered was reduced
by an appropriate factor, as outlined by the McCance and Widdowson’s Composition
of Foods
4. Foods devoid of carbohydrates (and therefore devoid of FODMAPs), such as plain
eggs, meat and fish, are not included in the calculator and were not entered. Added
ingredients that may contain FODMAPs, such as marinades and coatings, were
entered following the practices described above.
Once all foods had been entered for each participant, the records were submitted
electronically and checked for potential errors by Erin Dwyer (Research dietitian, Monash
University). A report was then generated in Microsoft Excel containing total and individual
fermentable carbohydrate intakes for each participant, which was used for further analysis.
2.4.8.5 Nutrient intake analysis
Once data had been checked for errors in data entry (section 2.4.8.3), the four study groups
were compared for absolute intakes of all major macronutrients, micronutrients, fibre and
FODMAPs.
Nutritional adequacy was explored by investigating the proportion of participants achieving
nutrient recommendations. For micronutrients, this was defined as meeting or exceeding
recommendations outlined by the Scientific Advisory Committee on Nutrition (SACN, 2016,
DoH, 1991, PHE, 2016). Calcium requirements are greater in IBD (1000 mg/day) (Scott et al.,
2000) than in the general adult population (700 mg/day), therefore these requirements were
used for patients with IBD, however to enable consistent cut-offs for achievement of the RNI
calcium was also compared against 700 mg/d for all participants. Macronutrient
recommendations are expressed as either the minimum (e.g. carbohydrate) or maximum
(e.g. fat) proportion of energy they should contribute to the diet (SACN, 2015).




The concept and measurement of IBD control will be discussed in Chapter 4 (section 4.4.3).
The validated IBD-control questionnaire was completed by patients in this study in order to
correlate  dietary  intake and FR-QOL with patient-perceived control  of  IBD (Bodger  et  al.,
2013).
2.4.9.2 Food-related quality of life
Inflammatory bowel disease can have an impact not only upon nutritional adequacy but also
on the psychosocial aspects of food and mealtimes. Food-related quality of life (FR-QOL)
encompasses the pleasure derived from food and the social activities involving eating and
drinking, as well as the ability to achieve nutritional adequacy (Gustafsson and Draper, 2009,
Whit, 2001). Food-related quality of life can be impacted by the GI symptoms characteristic
of IBD and food restrictions imposed by many patients. A validated questionnaire designed
to assess issues relating to food and nutrition in IBD has shown that FR-QOL is significantly
poorer in IBD than in asthma and healthy controls (Hughes et al., 2016). This validated
questionnaire will be used to assess FR-QOL in the current trial and is based upon 29
questions with responses on a 5-point Likert scale from ‘strongly agree’ to ‘strongly disagree’,
pertaining to the impact of IBD on enjoyment of mealtimes, social activities involving food
and the ability to maintain adequate nutrition.
For the healthy controls, the wording of the questionnaire was adapted, for example, instead
of “I have regretted eating and drinking things that have upset my IBD”, the wording in the
healthy control version is “I have regretted eating and drinking things that have upset my
digestion”.
2.4.10 Sample size calculation
There is a paucity of data regarding fermentable carbohydrate intakes in patients with IBD.
A previous case-control study from our group established a significant difference in fructan
intakes between patients with active IBD and healthy controls (Anderson et al., 2015).
However, due to the small differences in fructan intakes relative to the standard deviations
observed between the two groups (active IBD 3.3 SD 2.2 g/day vs. healthy controls 4.2 SD
2.0 g/day), a power-based sample size calculation would result in unfeasible numbers of
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participants required to provide sufficient power to detect a difference in fructan intakes
across the groups.
For this reason, a precision-based sample size estimation was performed. It was determined
that a sample size of 80 participants per group (400 total) would allow an estimation of the
mean fructan intakes in the different groups with a reasonable precision (±0.074 g/d of the
population mean) (Janet and Philip). Therefore, the aim was to obtain food diaries from 80
patients per group (active IBD, inactive IBD with FGS, inactive IBD without FGS and healthy
controls).
2.4.11 Statistical analysis
Data analysis was performed by the thesis author using IBM SPSS Statistics for Windows
Version 24.0, after the last participant’s data was collected. Prior to statistical analysis,
continuous data were explored for normality via visual inspection of histograms. An analysis
of variance (ANOVA) was used to compare normally-distributed continuous variables and a
Kruskal-Wallis test was used to compare non-normally distributed continuous variables
across the four groups, with Bonferroni correction for pairwise comparisons between two
groups. A Chi-squared test was used to compare categorical variables across groups. Pearson
or Spearman correlations were used to investigate correlations between outcomes and
multiple linear regression analysis was used to investigate factors (e.g. age, gender, IBD
diagnosis and disease activity) associated with fermentable carbohydrate intake.
2.5 Results: FODMAP and nutrient intakes in patients with active and inactive IBD
compared to healthy controls
2.5.1 Patient recruitment and progress
Recruitment, data collection, data entry and statistical analysis was conducted by the author
of this thesis, except for a subset of 10 healthy controls who were recruited with the
assistance of Alice Wright (student dietitian, King’s College London).
Figure 2.1 displays the numbers of patients that were screened, consented and returned
food diaries, per study group. The target sample size of 80 participants per group was not
obtained in time to include in this thesis, and therefore data for participants recruited to
date was analysed and the findings are presented in this section.
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Figure 2.1 Participant flow through the case-control study. Diaries for participants with inactive IBD
and FGS were the baseline food diaries collected as part of a randomised controlled trial of the low
FODMAP diet in patients with inactive IBD (Chapters 4-6 of this thesis).
Upon initial screening, four patients with active IBD were excluded; two with a stoma, one
with current stricturing CD and one with a significant comorbidity. Of the patients with
inactive IBD with FGS screened (n=155), the major reasons for exclusion were declining to
participate or loss during screening, elevated inflammatory markers, taking antibiotics or
probiotics, or GI symptoms not meeting the specified criteria (for further details see section
5.2.1.3 and 5.2.1). Six patients with inactive IBD without FGS were excluded; three with a
high serum CRP, one with a significant comorbidity, one currently following a low FODMAP
diet and one due to pregnancy. The numbers of patients screened and excluded in this group
are higher than the other study groups because these patients were recruited as part of a
RCT with additional inclusion and exclusion criteria. One healthy control was excluded due
to fulfilling the criteria for irritable bowel syndrome.
Diaries and questionnaires were returned by twenty-one patients in the active IBD group
(34% of those consented), thirty-eight in the inactive IBD without FGS group (35%), fifty-two
in the inactive IBD with FGS group (100% of consented; these were collected as part of the
RCT described in Chapters 4-6) and thirty-six (68%) in the healthy control group. These diaries
and questionnaires were analysed and the findings are presented in this section.
Active IBD
Screened (n=68)





























Excluded (n=103) Excluded (n=1)
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2.5.2  Demographic and disease characteristics of participants
The demographic characteristics of the participants in the four study groups are presented
in Table 2.2. The proportion of males and females was different across the groups (P=0.004).
Pairwise comparisons revealed more females among patients with inactive IBD without FGS
(26/38, 68%) and healthy controls (27/36, 75%) than patients with active IBD (6/21, 29%).
There was a difference in the maximum educational qualification between the groups with
higher numbers with advanced qualifications in the healthy controls (Table 2.2).














Age (years), median (IQR) 40 (21) 35 (18) 34 (18) 32 (21) 0.483
Female 6 (29)a 29 (56)a,b 26 (68)b 27 (75)b 0.004
Ethnicity 0.467
White British 15 (71) 30 (58) 25 (66) 20 (56)
White Irish 0 (0) 0 (0) 2 (5) 1 (3)
Any other white 3 (14) 14 (27) 8 (21) 6 (17)
White and black Caribbean 0 (0) 2 (4) 0 (0) 0 (0)
White and Asian 0 (0) 0 (0) 0 (0) 2 (6)
Indian 1 (5) 2 (4) 1 (3) 0 (0)
Pakistani 1 (5) 0 (0) 0 (0) 0 (0)
Bangladeshi 0 (0) 1 (2) 0 (0) 1 (3)
Any other Asian 0 (0) 1 (2) 0 (0) 2 (6)
Caribbean 1 (5) 1 (2) 1 (3) 2 (6)
African 0 (0) 1 (2) 0 (0) 0 (0)
Any other ethnic group 0 (0) 0 (0) 1 (3) 1 (3)
Arab 0 (0) 0 (0) 0 (0) 1 (3)
Maximum education level 0.017
No formal qualifications 1 (5) 0 (0) 1 (3) 1 (3)
Vocational 0 (0) 3 (6) 0 (0) 1 (3)
School-level (e.g. GCSE) 3 (14)a,b 14 (27)a 9 (24)a 0 (0)b
Advanced (e.g. A-level) 6 (29) 9 (17) 3 (8) 7 (19)
University degree 8 (38) 23 (44) 17 (45) 13 (36)
Postgraduate degree 2 (10)a,b 3 (6)a 6 (16)a,b 12 (33)b
PhD 1 (5) 0 (0) 2 (5) 2 (6)
Smoking status 0.051
Current smoker 0 (0) 5 (10) 1 (3) 1 (3)
Previous smoker 8 (38) 13 (25) 7 (18) 3 (8)
Non-smoker 13 (62) 34 (65) 30 (79) 32 (89)
Body weight (kg), median (IQR) 71 (16)a,b 70 (21)a 68 (17)a,b 62 (15)b 0.039
Height (m), median (IQR) 1.8 (0.2)a,b 1.7 (0.2)a,b 1.7 (0.1)a 1.7 (0.1)b 0.022
BMI (kg/m2), median (IQR) 23 (4)a,b 24 (6)a 23 (4)a,b 22 (4)b 0.028
Values are number of participants (% of group), unless otherwise stated. Groups were compared using
Chi-squared test except for continuous variables, compared across groups using Kruskal-Wallis test.
Columns without superscript letters in common are significantly different at the 0.05 level
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Body weight was different across the study groups (P=0.039), with greater body weight in
inactive IBD with FGS compared to healthy controls. In line with this, body mass index (BMI)
was different across the groups (P=0.028), with greater BMI in patients with inactive IBD with
FGS compared to healthy controls.
Table 2.3 displays the disease characteristics of patients with IBD. Across the IBD groups,
there was a difference in the proportion of patients with CD (P=0.029), with fewer CD in the
active IBD group (7/21, 33%) than the inactive IBD without FGS group (26/38, 68%). Of the
patients with inactive IBD with FGS, 29% met criteria for diarrhoea-predominant irritable
bowel syndrome (IBS), 8% mixed IBS, 2% unsubtyped IBS, 54% functional bloating and 8%
functional diarrhoea. As expected, significantly more patients in the active IBD group were
currently taking steroids, compared to patients with inactive IBD (P<0.001 across groups).
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Crohn’s disease 7/21 (33)a 26/52 (50)a,b 26/38 (68)b 0.029
Crohn’s disease location 0.917
Ileal 1/7 (14) 6/26 (12) 5/26 (19)
Colonic 3/7 (43) 8/26 (15) 11/26 (42)
Ileocolonic 3/7 (43) 12/26 (23) 10/26 (38)
Perianal disease 1/7 (14) 6/26 (12) 6/26 (23) 0.451
Crohn’s disease behaviour 0.594
Non-stricturing, non-penetrating 4/7 (19) 17/26 (33) 15/26 (58)
Stricturing 3/7 (14) 5/26 (10) 6/26 (23)
Penetrating 0/7 (0) 4/26 (8) 5/26 (19)
HBI score (CD only), median (IQR) 8 (4)a 4 (2)a 0 (1)b <0.001
Surgery (CD) 4/7 (57) 5/26 (19) 11/26 (42) 0.062
Ulcerative colitis 14/21 (67) 26/52 (50) 12/38 (32)
Ulcerative colitis extent 0.221
Proctitis 3/14 (21) 9/26 (35) 0/12 (0)
Distal 7/14 (50) 11/26 (42) 7/12 (58)
Extensive 4/14 (29) 6/26 (23) 5/12 (42)
Ulcerative colitis severity 0.001
Remission 0/14 (0)a 26/26 (100)c 6/12 (50)b
Mild 3/14 (21)a 0 (0)b 6/12 (50)a
Moderate 7/14 (50)a 0 (0)b 0/12 (0)b
Severe 3/14 (21)a 0 (0)b 0/12 (0)a,b
SCCAI score (UC only), median (IQR) 7 (3)a 2 (2)b 0 (1)c <0.001
Medications
5-ASA 12 (57) 18 (35) 23 (61) 0.606
Thiopurines 8 (38) 18 (35) 21 (55) 0.730
Biologics 7 (33) 15 (29) 21 (55) 0.849
Steroids 7 (33)a 0 (0)b 0 (0)b <0.001
All values are number of participants (percent of group) unless otherwise stated. Groups were
compared using a Chi-squared test or Kruskal-Wallis test. Columns without superscript letters in
common are significantly different at the 0.05 level
Chapter 2: Case-control study of dietary intake in IBD
89
2.5.3 Under-reporting and over-reporting
There was no difference across the study groups in the proportion of participants classified
as under-reporting, acceptable-reporting or over-reporting of energy intake (P=0.756) (Table
2.4). For the participants classified as acceptable energy reporters, an average of 2% of
energy intake was under-reported, while in under-reporters an average of 34% energy intake
was under-reported, and in over-reporters an average of 34% energy intake was over-
reported.














Under-reporters 7 (33) 15 (29) 6 (16) 8 (22)
0.756Acceptable 11 (52) 31 (60) 27 (71) 24 (67)
Over-reporters 3 (14) 6 (12) 5 (13) 4 (11)
Groups were compared using a Chi-squared test
2.5.4 FODMAP intake
All food diaries were analysed for individual and total FODMAP intakes for the four study
groups are presented in Table 2.5. Across the four study groups, there were significant
differences in GOS (P=0.023), total polyol (P=0.005) and sorbitol (P=0.001) intakes. Pairwise
comparisons revealed significantly lower GOS intakes in patients with inactive IBD with FGS
compared to healthy controls (0.6 IQR 0.9 g/day vs. 1.0 IQR 1.4 g/day, P=0.019). In terms of
total  polyol  intakes,  compared  to  healthy  controls  (1.3  IQR  1.4  g/day),  intakes  were
significantly lower in inactive IBD with FGS (0.6 IQR 1.0 g/day, P=0.010) and inactive IBD
without FGS (0.8 IQR 0.9 g/day, P=0.015). Compared to sorbitol intakes in healthy controls
(0.7  IQR  1.2),  intakes  were  significantly  lower  in  patients  with  active  IBD  (0.3  IQR  0.4,
P=0.008), inactive IBD with FGS (0.3 IQR 0.7, P=0.009) and inactive IBD without FGS (0.2 IQR
0.7, P=0.001). The difference across the groups in total FODMAP intake expressed per 1000
kcal of energy intake was approaching significance (P=0.056), with a lower intake in patients
with active IBD than in the other three groups.
Across the groups, there was no significant difference in the intake of excess fructose,
lactose, mannitol or fructans per 1000 kcal of energy intake. Reflecting the findings of the
total fermentable carbohydrate intakes, there was significantly lower GOS intake per 1000
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kcal  in  inactive  IBD  with  FGS  compared  to  healthy  controls  (P=0.009).  There  was  also
significantly lower total polyol intake per 1000 kcal in in inactive IBD with FGS (P=0.013) and
inactive  IBD  without  FGS  compared  to  healthy  controls  (P=0.014).  Compared  to  sorbitol
intakes per 1000kcal in healthy controls, intakes were significantly lower in active IBD
(P=0.007), inactive IBD with FGS (P=0.011) and inactive IBD without FGS (P=0.001).














Total FODMAPs 9.0 (14.7) 12.5 (10.0) 15.5 (9.5) 16.8 (8.1) 0.068
Fructans 2.6 (1.9) 2.8 (1.9) 2.8 (1.2) 3.0 (1.6) 0.749
Galacto-
oligosaccharides
0.9 (1.1)a,b 0.6 (0.9)a 0.8 (0.9)a,b 1.0 (1.4)b 0.023
Lactose 3.1 (15.0) 4.7 (9.5) 7.7 (10.1) 7.9 (12.8) 0.344
Excess fructosea 1.1 (1.5) 1.0 (1.1) 1.2 (1.5) 1.6 (2.1) 0.207
Total polyols 0.6 (0.9)a,b 0.6 (1.0)a 0.8 (0.9)a 1.3 (1.4)b 0.005
Sorbitol 0.3 (0.4)a 0.3 (0.7)a 0.2 (0.7)a 0.7 (1.2)b 0.001
Mannitol 0.3 (0.6) 0.2 (0.4) 0.2 (0.6) 0.3 (0.7) 0.435
Intakes, g/1000 kcal/d
Total FODMAPs 5.3 (6.9) 7.0 (6.7) 7.8 (5.6) 8.6 (4.5) 0.056
Fructans 1.4 (0.7) 1.6 (0.5) 1.5 (0.5) 1.6 (0.7) 0.144
Galacto-
oligosaccharides
0.5 (0.6)a,b 0.3 (0.4)a 0.4 (0.4)a 0.5 (0.7)b 0.009
Lactose 2.3 (7.4) 2.4 (6.0) 3.8 (6.4) 4.4 (6.4) 0.288
Excess fructose† 0.5 (0.7) 0.5 (0.6) 0.6 (0.9) 0.8 (0.9) 0.163
Total polyols 0.4 (0.5)a,b 0.3 (0.5)a 0.4 (0.5)a 0.6 (1.0)b 0.014
Sorbitol 0.2 (0.2)a 0.2 (0.4)a 0.1 (0.3)a 0.4 (0.5)b <0.001
Mannitol 0.2 (0.4) 0.1 (0.2) 0.1 (0.3) 0.1 (0.4) 0.544
All values are median (interquartile range). Groups were compared using Kruskal-Wallis test with
pairwise comparisons and Bonferroni correction. Columns without superscript letters in common
are significantly different at the 0.05 level. †Fructose in excess of a 1:1 fructose to glucose ratio
There were no differences in fructan intakes between the groups, either in g/d or in g/1000
kcal/d. A Pearson correlation showed total energy and fructan intakes to be strongly
positively correlated (r=0.609, P<0.001). To investigate factors that may predict fructan and
total FODMAP intakes multiple regression was conducted. First, two separate multiple
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regression analyses including all participants were performed with daily fructan intake and
total FODMAP intake as dependent variables. The independent variables for each regression
analysis were age, gender, a diagnosis of IBD and the presence of FGS. The multiple
regression did not significantly predict fructan intakes F(4, 142) = 1.99, P=0.099 or total
FODMAP intakes F(4,  139)  =  1.30,  P=0.274.  Next,  a  multiple  regression  analysis  was
conducted in patients with IBD only to predict any IBD characteristics or non-IBD
characteristics predicting fructan and total FODMAP intakes in patients. Again, two separate
multiple regression analyses were conducted with fructan intake and total FODMAP intake
as the dependent variables, while in both analyses the independent variables were gender,
diagnosis (CD or UC), the presence of active IBD, the presence of colonic disease (including
UC, ileocolonic CD and colonic CD), the presence of FGS and the total IBD control score. The
model significantly predicted fructan intakes F(5, 105) = 2.63, P=0.028. The overall model
had an adjusted R2 value of 0.069, suggesting it to explain 6.9% of the variation in fructan
intakes in IBD. The independent variables that significantly predicted fructan intake were the
presence of colonic disease (regression coefficient, B, -0.99, standard error, 0.38, P=0.010)
and gender (regression coefficient, B, -0.60, standard error, 0.24, P=0.015).
2.5.5 Nutrient intake
Daily energy, macronutrient and fibre intakes are displayed in Table 2.6. Across the groups,
there was a difference in non-starch polysaccharide (NSP) (P=0.014) and total fibre (AOAC
method) intake (P=0.032). Pairwise comparisons revealed significantly lower NSP intake in
inactive IBD with FGS compared to healthy controls (12 g/d IQR 11 vs. 17 g/d IQR 10, P=0.018)
and in inactive IBD without FGS compared to healthy controls (15 g/d IQR 6 vs. 17 g/d IQR
10, P=0.037), which also corresponded to different intakes of NSP/1000 kcal/d. Pairwise
comparisons revealed significantly lower total fibre (AOAC) intake in inactive IBD with FGS
compared to healthy controls (17 IQR 16 g/d vs. 22 IQR 15 g/d, P=0.025). Across groups there
were no differences in the proportion of energy derived from different macronutrients,
except for starch (P=0.011), which contributed a greater proportion of energy in active IBD
than healthy controls (26 IQR 8% vs. 21 IQR 8%, P=0.033).
Daily micronutrient intakes are displayed in Table 2.7. There were differences across groups
in potassium (P=0.021), copper (P=0.006), manganese (P=0.006), biotin (vitamin B7)
(P=0.024) and vitamin C (P=0.012) intakes. Following pairwise comparison all differences
were driven by lower  intakes  in  inactive  IBD with FGS compared to  healthy controls.  For
example, there was significantly lower intake of potassium (3059.0 mg/d IQR 1444.7 vs.
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3482.0 mg/d IQR 2040.3, P=0.032), copper (1.5 mg/d IQR 0.9 vs. 1.9 mg/d IQR 2.0, P=0.006),
manganese (3.2 mg/d IQR 2.6 vs. 4.3 mg/d IQR 4.4, 0.004), biotin (36.2 μg/d IQR 19.0 vs. 46.5
μg/d IQR 20.7, P=0.017) and vitamin C (84.5 mg/d IQR 75.6 vs. 137.0 mg/d IQR 55.1, P=0.010).
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Table 2.6 Daily macronutrient and fibre intakes across the four study groups







Energy (kcal) 2260 (949) 1961 (838) 2131 (629) 1876 (603) 0.504
Protein (g) 77 (36) 78 (55) 85 (23) 76 (37) 0.883
Protein (% of total E) 15 (4) 17 (5) 16 (6) 16 (5) 0.832
Total fat (g) 83 (39) 77 (44) 81 (32) 84 (37) 0.261
Fat (% of total E) 38 (12) 37 (5) 35 (5) 38 (6) 0.370
Saturated fat (g) 29 (8) 26 (15) 26 (12) 26 (15) 0.440
Saturated fat (% of total E) 11 (5) 12 (4) 12 (4) 13 (3) 0.653
Monounsaturated fat (g) 31 (14) 28 (18) 30 (12) 32 (14) 0.578
Monounsaturated fat (% of total E) 14 (4) 13 (3) 13 (2) 14 (3) 0.388
Polyunsaturated fat (%) 14 (6) 13 (7) 13 (8) 13 (7) 0.514
Carbohydrate (g) 234 (138) 199 (117) 236 (85) 172 (98) 0.478
Carbohydrate (% of total E) 43 (7) 40 (7) 42 (8) 38 (16) 0.666
Starch (g) 135 (97) 111 (69) 125 (39) 101 (50) 0.085
Sugars (g) 94 (46) 73 (54) 84 (52) 86 (57) 0.533
NSP (g) 12 (11)a,b 12 (11)a 15 (6)a 17 (10)b 0.014
Total fibre (AOAC) (g) 18 (13)a,b 16 (16)a 19 (10)a,b 22 (15)b 0.032
Values are median (interquartile range). Groups were compared using Kruskal-Wallis test with pairwise comparisons and Bonferroni correction for multiple comparisons.
Columns without superscript letters in common are significantly different at the 0.05 level. FGS, functional gastrointestinal symptoms; NSP, non-starch polysaccharide;
AOAC, Association of Analytical Chemists
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Table 2.7 Micronutrient intakes across the four study groups
Active IBD (n=21) Inactive IBD with FGS (n=52) Inactive IBD without FGS (n=38) Healthy controls (n=36) P-value
Sodium (mg) 2194.7 (1080.5) 2186.9 (1048.5) 2424.7 (665.8) 2040.6 (925.4) 0.285
Potassium (mg) 2912.8 (1055.8)a,b 3059.0 (1444.7)a 3077.0 (968.2)a,b 3482.0 (2040.3)b 0.048
Calcium (mg) 947.7 (562.9) 801.4 (638.4) 947.3 (379.3) 858.9 (279.1) 0.433
Magnesium (mg) 324.2 (168.1) 297.2 (219.1) 328.4 (103.6) 332.8 (168.2) 0.055
Phosphorous (mg) 1369.1 (791.3) 1219.9 (846.7) 1343.1 (378.3) 1315.1 (578.2) 0.401
Iron (mg) 11.2 (5.8) 11.0 (7.1) 11.1 (3.4) 13.0 (7.3) 0.095
Copper (mg) 1.5 (1.2)a,b 1.5 (0.9)a 1.4 (0.5)a,b 1.9 (2.0)b 0.006
Zinc (mg) 8.1 (6.1) 8.5 (6.0) 9.0 (2.4) 9.6 (11.4) 0.447
Chloride (mg) 3531.0 (1839.3) 3297.3 (1695.2) 3310.4 (1310.2) 3140.5 (1247.0) 0.415
Manganese (mg) 3.9 (3.5)a,b 3.2 (2.6)a 3.6 (1.7)a,b 4.3 (4.4)b 0.006
Selenium (μg) 48.7 (19.9) 52.5 (27.7) 56.6 (21.5) 61.6 (31.7) 0.557
Iodine (μg) 85.2 (119.4) 115.8 (85.5) 134.5 (65.5) 114.9 (54.2) 0.493
Vitamin A (μg) 869.8 (621.4) 1085.8 (1969.1) 721.4 (604.4) 1167.5 (609.6) 0.647
Vitamin D (μg) 3.8 (2.2) 3.3 (3.0) 3.0 (1.3) 2.3 (3.1) 0.131
Vitamin E (mg) 10.1 (7.3) 11.8 (7.3) 9.5 (5.4) 11.4 (6.5) 0.121
Vitamin C (mg) 78.9 (92.8)a,b 84.5 (75.6)a 116.5 (66.8)a,b 137.0 (55.1)b 0.012
Vitamin K1 (μg) 56.0 (90.6) 53.4 (80.8) 69.4 (83.9) 102.1 (98.7) 0.394
Thiamin (vitamin B1) (mg) 1.7 (0.7) 1.5 (0.7) 1.4 (0.7) 1.6 (0.9) 0.500
Riboflavin (vitamin B2) (mg) 1.5 (0.8) 1.6 (1.1) 1.6 (0.8) 1.7 (0.7) 0.265
Niacin (vitamin B3) (mg) 33.8 (19.8) 39.8 (26.1) 36.5 (9.4) 35.2 (17.3) 0.568
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Active IBD (n=21) Inactive IBD with FGS (n=52) Inactive IBD without FGS (n=38) Healthy controls (n=36) P-value
Pantothenate (vitamin B5) (mg) 5.1 (2.5) 6.0 (2.5) 5.7 (1.7) 6.0 (3.4) 0.908
Pyridoxine (vitamin B6) (mg) 2.3 (1.2) 2.0 (1.1) 1.9 (0.5) 1.8 (0.8) 0.416
Biotin (vitamin B7) (μg) 36.9 (29.5)a,b 36.2 (19.0)a 36.3 (13.6)a,b 46.5 (20.7)b 0.024
Folate (μg) 268.4 (162.9) 203.4 (121.1) 202.7 (141.8) 266.6 (79.4) 0.079
Cobalamin (vitamin B12) (μg) 5.5 (2.1) 5.3 (3.2) 4.4 (2.8) 3.7 (4.2) 0.416
Values are median (interquartile range). Groups were compared using Kruskal-Wallis test with pairwise comparisons and Bonferroni correction for multiple comparisons.
Columns without superscript letters in common are significantly different at the 0.05 level. FGS, functional gastrointestinal symptoms
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2.5.6 Nutritional adequacy
Table 2.8 shows the proportions of participants in the study groups meeting recommendations
for macronutrient and micronutrient intakes. Across groups, there was a significant difference
in the proportion of participants meeting recommendations for fibre (AOAC) (P=0.047), calcium
(P<0.001), riboflavin (vitamin B2) (P=0.025) and folate (P=0.018). Upon pairwise comparisons, no
differences in the proportion of participants meeting fibre or riboflavin recommendations were
observed between any of the study groups. The proportion of participants meeting calcium
recommendations was lower in all the IBD groups compared to the healthy control group, while
the proportion meeting the folate recommendation was lower in patients with inactive IBD with
FGS compared to healthy controls. When a calcium requirement of 700 mg/d was assumed for
all study groups, there was no difference across the study groups in the proportion of patients
meeting the requirement. This suggests that the difference across groups was driven by different
requirements assumed for IBD groups (1000 mg/d) and healthy controls (700 mg/d).
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Table 2.8 The proportion of participants achieving recommendations for macronutrients, fibre and micronutrients across the four study groups
Active IBD (n=21) Inactive IBD with FGS (n=52) Inactive IBD without FGS (n=38) Healthy controls (n=36) P-value
Protein (0.75 g/kg weight) 20 (95) 47 (90) 37 (97) 34 (94) 0.573
Fat (≤30% energy) 6 (29) 18 (35) 17 (45) 13 (36) 0.625
Saturated fat (≤11% energy) 7 (33) 15 (29) 15 (40) 13 (36) 0.753
Carbohydrate (≥50% energy) 2 (10) 9 (17) 7 (18) 5 (14) 0.799
Free sugars (≤5% energy) 5 (24) 15 (29) 9 (24) 11 (31) 0.888
Fibre (AOAC) (30 g/day) 2 (10) 8 (15) 2 (5) 10 (28) 0.047
Potassium 6 (29) 12 (23) 11 (29) 17 (47) 0.109
Calcium (all 700 mg/d) 14 (67) 29 (56) 30 (79) 26 (72) 0.117
Calcium (1000 and 700 mg/d) 4 (19)a,b 12 (23)a,b 13 (34)a 26 (72)b <0.001
Magnesium 11 (52) 27 (52) 25 (66) 28 (78) 0.069
Phosphorous 21 (100) 52 (100) 38 (100) 36 (97) 0.376
Iron 14 (67) 18 (35) 17 (45) 16 (44) 0.101
Zinc 14 (67) 31 (60) 26 (68) 30 (83) 0.131
Selenium 5 (24) 12 (23) 13 (34) 16 (44) 0.156
Iodine 6 (29) 14 (27) 11 (29) 11 (31) 0.986
Vitamin A 14 (67) 33 (64) 26 (68) 27 (75) 0.724
Vitamin D 1 (5) 1 (2) 0 (0) 1 (3) 0.643
Vitamin E 21 (100) 52 (100) 38 (100) 36 (100) NA
Vitamin C 18 (86) 41 (79) 33 (87) 33 (92) 0.405
Vitamin K 7 (33) 17 (33) 17 (45) 19 (53) 0.233
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Active IBD (n=21) Inactive IBD with FGS (n=52) Inactive IBD without FGS (n=38) Healthy controls (n=36) P-value
Thiamin (vitamin B1) 21 (100) 47 (90) 38 (100) 34 (95) 0.127
Riboflavin (vitamin B2) 17 (81) 37 (71) 35 (92) 33 (92) 0.025
Niacin (vitamin B3) 21 (100) 52 (100) 38 (100) 35 (97) 0.376
Pyridoxine (vitamin B6) 20 (95) 47 (90) 35 (92) 32 (89) 0.863
Folate 13 (62)a,b 30 (42)a 26 (68)a,b 26 (72)b 0.018
Cobalamin (vitamin B12) 21 (100) 49 (94) 37 (97) 35 (97) 0.629
All values are number of participants (percent of group). Groups were compared using a Chi-squared test. Columns without superscript letters in common are significantly different
at the 0.05 level
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2.5.7 IBD-control
The total IBD-control score was significantly different across the IBD groups (P<0.001). Pairwise
comparisons revealed that patients with active IBD (45.5 IQR 50.0) and inactive IBD with FGS
(75.5 IQR 35.0) both had significantly lower perceived IBD control than inactive IBD without FGS
(116.0 IQR 19.0) (P<0.001 and P<0.001) (Figure 2.2).
Figure 2.2 Box and whisker plot depicting IBD control score in active IBD, inactive IBD with FGS and
inactive IBD without FGS (P<0.001 across the groups; P<0.001 active IBD and inactive IBD with FGS vs.
inactive IBD without FGS)
2.5.8 Food-related quality of life
There was a significant difference in total FR-QOL score across the four study groups (P<0.001).
Pairwise comparisons showed a significantly lower FR-QOL score in patients with active IBD
compared  to  healthy  controls  (64.0  IQR  24.0  vs.  119.0  IQR  26.0,  P<0.001),  in  patients  with
inactive IBD with FGS compared to healthy controls (74.0 IQR 26.0 vs. 119.0 IQR 26.0, P<0.001),
in patients with active IBD compared to inactive IBD without FGS (65.0 IQR 24.0 vs. 108 IQR 58.0,
P<0.001) and in patients with inactive IBD with FGS compared to without FGS (74.0 IQR 26.0 vs.
108.0 IQR 58.0, P<0.001) (Figure 2.3). A Pearson correlation was conducted and showed a strong
positive correlation between IBD-control score and FR-QOL score (r=0.670, P<0.001).
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Figure 2.3 Box and whisker plot depicting total FR-QOL score in the four study groups (P<0.001 across the groups; P<0.001 for all IBD groups compared to healthy controls)
2.6 Discussion
2.6.1 FODMAP intake
In this case-control study, FODMAP and nutrient intakes and FR-QOL were explored in patients
with active IBD (inflammatory GI symptoms), inactive IBD with FGS (functional GI symptoms),
inactive IBD without FGS (no GI symptoms), and healthy controls (no GI symptoms). Total
fermentable carbohydrate intakes were similar across the study groups, while intakes of GOS,
total polyols and sorbitol were significantly lower in IBD compared to healthy controls. When
interpreting the findings of this study, it is important to note that the target sample size was not
achieved for any of the groups, and the number of patients with active IBD included in the
analysis is approximately half that of the other groups. Therefore, when the target sample size
is reached, final conclusions regarding accepting or rejecting the hypothesis can be made.
Fructan intake were similar across the four study groups. Fructans are found in foods commonly
eaten in the UK, including bread, pasta, onion and garlic, and unsurprisingly fructans therefore
make the greatest contribution to total FODMAP intakes in the UK diet (Staudacher et al., 2017b,
Staudacher et al., 2012). Fructan intakes were comparable to those observed in a case-control
study of patients with active CD (median 2.6 g/day here vs. 2.9 g/day in previous study), inactive
CD (median 2.8 g/day here vs. 3.6 g/day in the previous study) and healthy controls (median 3.0
g/day here vs. 3.9 g/day in the previous study) (Anderson et al., 2015). Although there was no
statistical difference in fructan intake across groups in the current study, the numerically lowest
intake was in active IBD, followed by inactive IBD with and without FGS, followed by healthy
controls; the expected pattern according to the previous study (Anderson et al., 2015). However,
these values are not statistically significantly different between groups, perhaps a result of a
type II error resulting from inadequate power at this stage of recruitment.
The lack of difference between study groups in this study compared to the previous study
(Anderson et al., 2015)  may relate to the different methods of assessing fructan intakes, with
the previous study using a fructan-specific food frequency questionnaire (FFQ) (Dunn et al.,
2011), as opposed to 7-day food diaries in the current study, with some food frequency
questionnaires over-estimating intakes (Fallaize et al., 2014, Flood et al., 2004, Barclay et al.,
2008). On the other hand, the FFQ clearly does not include all the fructan-containing foods that
exist and this could result in underestimation of fructan intakes. Furthermore, the current study
included patients with UC as well as CD and dietary differences may exist between the
conditions. Similar to the other analyses for this study, the small number of participants in the
active  IBD  group  compared  to  the  other  groups  may  have  limited  the  power  to  detect  a
difference between groups. A possible explanation for similar fructan intakes across groups may
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relate to the fact that fructans are derived from a wider range of foods than, say, GOS, which
are generally limited to pulses and nuts. Therefore, it may be less likely that fructan restriction
will occur unintentionally from exclusion of specific foods. For example, white bread contains
fructans  and  consumption  is  greater  than  other  cereal  products  in  the  UK  (Pot  et  al.,  2015,
Whelan  et  al.,  2011).  Even  if  a  patient  were  restricting  fibre  during  active  IBD  or  for  the
management of GI symptoms, white bread would be permitted. On the other hand, fibre-rich
(and GOS-containing) pulses and nuts would be limited. Therefore, it is possible that fructan
intake is maintained despite dietary restrictions for IBD or GI symptoms.
Regression analysis revealed that lower fructan intakes in patients with IBD were associated with
the presence of colonic disease.
There  was  a  lower  GOS  intake  in  patients  with  inactive  IBD  with  FGS  compared  to  healthy
controls. Intakes of GOS in the healthy control group in this study were comparable to those
observed in the control group of the RCT described in Chapters 4-6. These were in line with the
GOS intakes of patients with IBS in the placebo-control group of a recent RCT of the low FODMAP
diet  (Staudacher  et  al.,  2017b).  Meanwhile,  GOS  intake  in  inactive  IBD  with  FGS  were
comparable to those observed in the low FODMAP diet groups of previous trials (Staudacher et
al., 2017b, Bohn et al., 2015). This is unlikely to relate to lower energy intake in inactive IBD with
FGS because energy intake was not different across the groups and GOS intake remained
significantly lower when expressed per 1000 kcal/d. The most likely explanation for lower GOS
intake in this group relates to the effect of GOS on GI symptoms. Several cross-sectional studies
indicate that pulses and nuts, the major dietary sources of GOS, are perceived symptom triggers
in a proportion of patients with IBD (Vagianos et al., 2016, Holt et al., 2017) and also in patients
with IBS  (Bohn et  al.,  2013b).  A  trial  of  GOS supplementation in  IBS  showed a  better  clinical
response to a low dose than high dose GOS, and this may be a consequence of increased GI
symptoms (such as bloating) following the high dose GOS (Silk et al., 2009). However, the B-GOS
(or trans-galactooligosaccharide) used in this trial is distinct from the α-GOS found naturally in
pulses and nuts. The lower GOS intake in patients with inactive IBD with FGS may be a result of
excluding foods noted to worsen GI symptoms and may represent a long-term dietary
modification, but were not the result of following a clinician-advised low FODMAP diet since
these  patients  were  known  to  be  naïve  to  the  low  FODMAP  diet.  Galacto-oligosaccharides
stimulate a range of GI bacteria, including immune-modulatory bacteria such as F. prausnitzii
(Fernando  et  al.,  2010)  (Vulevic  et  al.,  2004),  and  the  effects  of  long-term  restriction  on
immunology and IBD activity are unknown.
Lactose intake was not significantly different across the study groups. This is surprising in view
of multiple reports of dairy restriction in IBD (Limdi et al., 2016, Cohen et al., 2013). One study
Chapter 2: Case-control study of dietary intake in IBD
103
revealed 37% of patients with IBD perceived milk to worsen GI symptoms (Prince et al., 2011),
while another found 12% of patients always avoid milk and milk products (Vagianos et al., 2016).
Lactose intakes were lowest in active IBD and highest in the healthy control group, while inactive
IBD with FGS had an intermediate intake and inactive IBD without FGS had a similar intake to
healthy controls. Given that there is clearly a difference in lactose intake between the active IBD
and healthy control group, the lack of a statistically significant difference across groups may
again be explained by the small sample size in all groups but particularly in the active IBD group.
Lactose intakes in healthy controls in this study were similar to those in the control groups of
previous trials of the low FODMAP diet in IBS (Staudacher et al., 2017b, Staudacher et al., 2012,
Bohn et al., 2015), and only slightly lower than healthy Swedish individuals (Larsson et al., 2004),
suggesting realistic lactose intakes in this study.
Sorbitol intakes were lower in the active IBD, inactive IBD with FGS and inactive IBD without FGS
than in healthy controls. Sorbitol is a polyol present in stone fruits and added during
manufacturing to sweetened products and sugar-free chewing gum (Yao et al., 2014). As
discussed in section 1.4.2.5, polyols are osmotically active due to their small size and a mannitol
challenge increased small bowel water content in healthy controls and patients with IBD
(Marciani et al., 2010). Large doses of sorbitol can induce laxative effects in healthy individuals
(Skoog et al., 2006), and patients with active IBD may intentionally or unintentionally restrict
high sorbitol foods to reduce stool frequency and consistency. This may occur simply as a result
of restricted fruit and vegetable intake in IBD, which is conceivable given that 24% of patients
with IBD in a large cross-sectional study reported restricting fruits and vegetables in the belief
that they may induce relapse (Limdi et al., 2016) and another study revealed similar proportions
of patients reporting fruits and vegetables to worsen GI symptoms (23% and 26% of patients,
respectively) (Prince et al., 2011). Alternatively, lower sorbitol intake in IBD may relate to a lower
intake of sweetened products such as sugar-free chewing gum and low-calorie products. In
active  IBD  particularly,  a  more  plain  and  monotonous  diet  may  be  observed  as  a  result  of
significant GI symptoms. However, this is speculative and investigation into dietary patterns in
active IBD and inactive IBD compared to healthy controls is needed to clarify this.
There was no statistical difference in total FODMAP intakes across the groups, although the
difference approached significance. The numerically lowest total FODMAP intake was in active
IBD, followed by inactive IBD with FGS, inactive IBD without FGS and highest in healthy controls,
although again are not statistically significantly different at this stage of recruitment. This
pattern of intakes was maintained when expressed per 1000 kcal of energy intake, suggesting it
was not a consequence of reduced overall food intake in active IBD. If this represents habitual
intake in IBD, there could be ramifications of this. Firstly, fructans and GOS are considered
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prebiotic carbohydrates (Gibson et al., 2017) and it is clear from fructan and GOS
supplementation studies and low FODMAP diet studies that they have a profound impact upon
the GI microbiota composition (Staudacher et al., 2017b, Staudacher et al., 2012, Bennet et al.,
2017,  Ramirez-Farias  et  al.,  2009,  Fernando  et  al.,  2010,  Lomax  et  al.,  2012,  Ramnani  et  al.,
2015). In view of the numerous proposed positive GI and non-GI health implications of prebiotic
consumption (Roberfroid et al., 2010), it is reasonable to suspect that chronic dietary restriction
could have an adverse effect on health. Secondly, there may be implications of a lower FODMAP
intake on the possible efficacy of the low FODMAP diet in IBD. If a subset of patients already
have  low  FODMAP  intakes,  response  to  a  further  FODMAP  reduction  may  be  less  likely.
However, it is unlikely that in clinical practice a patient with low FODMAP intakes at baseline
would  be  advised  to  attempt  a  low  FODMAP  diet  since  the  expected  clinical  benefit  is  low
(Whelan et al., 2018)
2.6.2 Nutrient intake
Patients with inactive IBD with and without FGS had significantly lower NSP intakes, and patients
with  inactive  IBD  with  FGS  had  lower  total  fibre  intakes  compared  to  healthy  controls.  In
addition, patients with inactive IBD with FGS had lower intakes of potassium, copper,
manganese, biotin and vitamin C compared to healthy controls.
Lower fibre intake in patients with inactive IBD with FGS compared to healthy controls in this
study may reflect an attempt to manage functional GI symptoms. Many of the foods that
patients with IBD commonly exclude are fibre-rich, for example fruits and vegetables and
legumes (Limdi et al., 2016, Vagianos et al., 2016, Cohen et al., 2013, Prince et al., 2011, Holt et
al., 2017), and many patients report that dietary exclusions relate specifically to GI symptoms
(Prince et al., 2011, Vagianos et al., 2016). The IBS guidelines also encompass modifying fibre
intake where appropriate, to control GI symptoms (McKenzie et al., 2016). Since around a third
of patients with FGS fulfilled the criteria for diarrhoea-predominant IBS, it is conceivable that
reduced fibre intakes may reflect an attempt to reduce stool frequency and consistency. Lower
total fibre intake in patients with inactive IBD with FGS was mirrored by lower fibre intakes per
1000 kcal of energy intake, suggesting that the differences in fibre intake were not merely the
result of lower overall food intake. Total fibre intake in the healthy controls was slightly higher
than the general population (PHE, 2018), and this may have increased the difference between
the study groups.
A reduced fibre intake in inactive IBD could bear clinical relevance. In a longitudinal survey of
patients with inactive IBD, patients with CD in the highest quintile of fibre intake were less likely
to experience a CD relapse, although the same association was not observed in UC (Brotherton
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et al., 2016). It is possible that patients with low fibre intakes were those with more complicated
IBD and therefore more likely to relapse (irrespective of fibre intake), especially since patients
with prior surgery, longer duration of disease and past hospitalisation ate less fibre. However,
considering the numerous other positive health implications of fibre, adequate fibre intakes
should be encouraged in patients with inactive IBD unless contraindicated (for example, in
patients with fibrotic strictures).
It is interesting that fibre intakes were not significantly different in patients with active IBD
compared to healthy controls. Patients are often advised to reduce fibre intake during active
IBD  either  to  reduce  the  risk  of  GI  obstruction  in  stricturing  CD  or  simply  to  reduce  stool
frequency and GI symptoms, although there is little evidence supporting the use of a low-fibre
or low-residue diet in active IBD (Lee et al., 2014a).
Alternatively, the patients with active IBD and healthy controls in this study may indeed have
similar fibre intakes. Evidence for compromised fibre intake in active IBD is lacking. A cross-
sectional study utilising 7-day food diaries observed no significant difference in fibre intakes
between patients with active (15 g/day) and inactive IBD (18 g/day), although there was a trend
towards lower fibre intake in active IBD (Aghdassi et al., 2007). A further study revealed a lower
fibre intake in patients with IBD assessed to be malnourished (Lim et al., 2014), however this
likely relates to the significantly lower energy intake in the malnourished group, Lower fibre
intake has been observed in patients with CD receiving immunomodulating therapy (Sousa
Guerreiro et al., 2007), although again a lower total energy intake in the CD group suggests the
reduced fibre intake was a consequence of reduced overall food intake. In the current study
energy intakes were similar across groups, and fibre intakes remained similar even when
calculated per 1000 kcal/d, suggesting that differences seen here were not merely the result of
lower food intake. Limiting dietary fibre is specifically clinically indicated in stricturing CD, which
constitutes only a small proportion of all patients with IBD in this study, which might explain
similar fibre intakes to healthy controls. Moreover, significantly fewer patients with active IBD
had CD compared to those with inactive IBD with FGS. Another consideration is that the severity
of active IBD in this study was mild to moderate (Falvey et al., 2015) and dietary alterations in
the active IBD group may therefore have been minimal.
Several nutrients were lower in patients with inactive IBD with FGS compared to healthy
controls, which may again relate to dietary restrictions implemented to control functional GI
symptoms. This is the first study to investigate nutrient intakes specifically in patients with IBD
with FGS, but previous studies have established inadequate micronutrient intakes in inactive IBD
compared to either the intake of healthy controls or compared to national recommendations.
Inadequate micronutrients may include zinc (Filippi et al., 2006), B vitamins (Filippi et al., 2006),
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calcium (Geerling et al., 2000, Vagianos et al., 2007), vitamin C (Geerling et al., 2000), vitamin D
(Vidarsdottir et al., 2016, Vagianos et al., 2007). That said, the GI symptoms in this group are
assumed to be functional, rather than relating to active GI inflammation. Nutrient intakes in IBS
appear to be similar to, or even greater than, the general population (Bohn et al., 2013a,
Williams et al., 2011), despite evidence from cross-sectional studies that patients with IBS make
dietary modifications (Ligaarden et al., 2012). Interestingly, an assessment of nutrient intakes in
outpatients with IBD, IBS, dyspepsia and gastro-oesophageal reflux disease revealed a lower
intake of  several  micronutrients  in  the non-IBD patients  compared to  IBD (Gee et  al.,  1985).
Dietary intake was measured using only a 24-hour dietary recall and it is difficult to establish
whether this represented long-term dietary intake, however this may provide evidence of
poorer nutritional adequacy in IBS. Otherwise, there is little evidence to date that dietary
restrictions relating to GI symptoms in functional bowel disorders adversely affects nutrient
intakes. It is surprising that patients with active IBD did not display inadequate intakes of
micronutrients. Again, this may relate to an insufficient sample size or to the mild severity of IBD
in this study, or may simply indicate that not all patients with active IBD modify their diets or are
able to do so without compromising nutrient intakes.
There were minor differences in the proportion of participants meeting national dietary
recommendations across the groups. A notable finding was that only 19-34% of IBD patients met
calcium recommendations from dietary intake compared to 72% of healthy controls. The
proportion meeting calcium requirements was particularly low in patients with active IBD, and
this may relate to dairy restriction, which is implemented by as many as 65% of patients with
IBD, more likely in patients with active disease and with extensive UC (Holt et al., 2017, Cohen
et al., 2013, Limdi et al., 2016, Prince et al., 2011, Brasil Lopes et al., 2014). Lactose intolerance
is higher in IBD than the general population (Szilagyi et al., 2016) and this may be particularly
prevalent in CD due to reduced lactose digestion and resulting malabsorption. When calcium
requirements were set at 700 mg/d for all participants (as opposed to 1000 mg/d in IBD and 700
mg/d in healthy controls), there was no difference across groups in the proportion meeting
requirements, suggesting that the higher calcium requirement in IBD (1000 mg/d) is achieved
by few patients. Calcium supplements were taken by some patients and would significantly
elevate dietary intake but these were not analysed since the aim was to examine nutrient intakes
from food. Nonetheless, poor intestinal calcium absorption, steroid use and greater risk of
osteoporosis drive the greater calcium requirements in IBD and future analyses in larger groups
of patients should address the proportion of patients achieving these intakes.
Body weight and BMI were significantly higher in patients with inactive IBD with FGS compared
to healthy controls, which is somewhat unexpected considering that a lower BMI has been
Chapter 2: Case-control study of dietary intake in IBD
107
observed in patients with IBD (Mijac et al., 2010, Geerling et al., 2000) and patients with IBD are
regarded at risk of malnutrition (Gerasimidis et al., 2011). That said, several studies have shown
similar BMI in patients with IBD and healthy controls (Filippi et al., 2006, Aghdassi et al., 2007,
Vagianos et al., 2007) and one study observed that the average BMI in patients with IBD was in
the overweight range (≥25 kg/m2) (Vidarsdottir et al., 2016). However, several studies have
demonstrated altered body composition in IBD compared to healthy controls (Bryant et al.,
2013), indicating that malnutrition may not be apparent from BMI alone. The difference in BMI
between patients with IBD with FGS compared to healthy controls may also be explained by a
lower BMI in healthy controls resulting from the recruitment methods used to identify them.
2.6.3 Food-related quality of life
Food-related  quality  of  life  was  significantly  lower  in  active  IBD  and  inactive  IBD  with  FGS
compared to healthy controls, while FR-QOL in inactive IBD without FGS was similar to that of
healthy controls. Food-related quality of life has been shown to be lower in IBD than healthy
controls and patients with asthma, but no distinction was made between active and inactive IBD
(Hughes et al., 2016). This is therefore the first study to demonstrate lower FR-QOL in IBD and
GI symptoms (active IBD and inactive IBD with FGS) compared to those without (inactive IBD
without FGS) and compared to healthy controls. There were similar scores in patients with active
IBD and inactive IBD with FGS, suggesting that the origin of GI symptoms makes little difference
to FR-QOL. Although periods of active IBD will likely be short-lived, FGS can persist for months
or years and the individual burden of poor FR-QOL is substantial. Furthermore, certain questions
in the FR-QOL questionnaire pertain to difficulty in deriving sufficient nutrients from food and
mealtime interruptions by GI symptoms, therefore low FR-QOL could imply compromised
nutritional intake.
Average FR-QOL score in patients with active IBD and inactive IBD with FGS in this study were
comparable to those observed in the validation cohort for the FR-QOL questionnaire (64-74 vs.
90) (Hughes et al., 2016). Previous studies indicate that patients with IBD manipulate their diet
to manage the condition and such dietary restrictions impact upon social interactions involving
food (Jamieson et al., 2007, Daniel, 2002). Control over food intake as a means of coping with
GI symptoms is also reported by patients with IBS (Fletcher and Schneider, 2006, Jamieson et
al., 2007), therefore it is unsurprising that FR-QOL scores were low in patients with IBD with GI
symptoms in this study.
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2.6.4 Strengths and limitations
This is the first study to assess dietary intake in patients with inactive IBD with FGS compared to
patients without FGS and healthy controls and is the first study to characterise habitual FODMAP
intakes in active and inactive IBD compared to healthy controls. Once the target sample size is
achieved, it may make an important contribution to the current literature regarding dietary
intake in IBD, which is currently limited to small studies with major methodological limitations.
A major strength of this study is the thorough prospective assessment of dietary intake using 7-
day food diaries. Most of the previous assessments of dietary intake in IBD have utilised either
FFQ or 3-4 day food diaries, the former being associated with recall bias and overestimation of
nutrient intakes and the latter potentially failing to capture sufficient day-to-day variation in
dietary intake (Barclay et al., 2008, Fallaize et al., 2014, Flood et al., 2004). One study that did
use a 7-day food diary to estimate nutrient intakes did not include patients with UC (Aghdassi et
al., 2007). However, although participants in the current study were encouraged to record
dietary intake contemporaneously, it is entirely possible that at least some participants recorded
dietary intake sometime after eating due to work or other commitments. Therefore, dietary data
gathered from prospective food diaries may still be susceptible to some degree of recall bias,
representing a possible limitation of the dietary assessment in this study.
Furthermore, food diaries were only completed on one occasion, therefore failing to capture
fluctuations in dietary intake over time and alongside changes in IBD activity. It was therefore
not the aim of this study to establish whether differences in dietary intake between groups are
a possible cause or consequence of the current IBD activity. A prospective longitudinal study of
dietary intake in IBD would help establish dietary patterns associated with a likelihood of IBD
remission or relapse, and such a study design has been used to establish an association between
fibre  intake  and  CD  relapse  (Brotherton  et  al.,  2016).  Moreover,  participants  were  urged  to
complete the diary in a week representative of their normal routine and were encouraged not
to change their habitual diet during the study, but it is possible that the dietary intake recorded
does not represent normal intake in some individuals due to conscious or unconscious change
in dietary intake during dietary assessment.
Weighed food diaries would enable greater accuracy of food intake than the estimated or
unweighed food diaries that were used in the current study. Unfortunately, it was not feasible
to provide all participants with weighing scales for this 7-day food diary and it was also
anticipated that this additional participant burden would significantly hinder compliance and
diary return and impact habitual intake. A comparison of weighed and unweighed food diaries
revealed  similar  nutrient  intakes  with  the  two  methods,  in  contrast  to  an  overestimation  of
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nutrient intakes with an FFQ (Bingham et al., 2007, Bingham et al., 1995). A major issue with
unweighed food diaries is the requirement for participants to estimate portion sizes, which can
lead to inaccuracies in nutrient intake data. This was addressed in this study through thorough
instructions provided by an experienced dietitian, and provision of food portion size
photographs and other portion size aids. Food portion size photographs have been shown to
improve the accuracy of portion size estimation (Turconi et al., 2005, Nelson et al., 1996).
There are a number of methods for identifying individuals misreporting dietary intake, each with
strengths and limitations (Banna et al., 2017). One of the simplest methods is to exclude
participants at the extremes of nutrient intake, but this fails to individualise the assessment of
misreporting and is thus likely to exclude individuals with plausible intakes while including true
misreporters. An alternative method, that was used in the current study, is to calculate the ratio
of reported energy intake to estimated energy requirement (EI:EER) and apply cut-offs to define
plausible and implausible ratios (Huang et al., 2005). This is a simple method that is specific to
weight and age (since EER estimation is based upon the Henry Oxford equation for BMR (Henry,
2005) and has been shown to agree with the doubly-labelled water energy expenditure
calculation  when  certain  cut-offs  are  applied  (Huang  et  al.,  2005).  A  major  limitation  of  this
method is that the applied PAL may be incorrect, which could under or overestimate EER and
incorrectly define an individual as an under-reporter or over-reporter. In this study, the same
PAL was applied to all participants as information was not available regarding occupational
activity levels and physical activity levels. Therefore, the estimated proportion of under-
reporters, plausible reporters and over-reporters may not be accurate for all individuals.
However, the proportion of under-reporters, plausible reporters and over-reporters was not
significantly different across the study groups and therefore it was not anticipated that there
would be a bias associated with greater misreporting in any of the study groups and, in light of
this, the analysis was not adjusted for misreporting.
A major limitation of this study is the small group sample sizes, none of which reached the target
number of participants (80 per group) within the time frame for the submission of this thesis.
Just over a third of enrolled participants with IBD (excluding patients with IBD with FGS who had
been recruited in the RCT) returned a food diary and hence a longer time is required to recruit
sufficient participants to ensure food diary numbers reach the target of 80 per group. The
inadequate group sizes likely limited the ability to detect differences across the groups.
The rate of food diary return in patients with IBD (excluding patients with IBD with FGS who had
been recruited in the RCT) was around 35%, compared to 67% of healthy controls. This
difference in return rates probably relates to the methods of recruitment. Patients with IBD
were approached by the researcher in an outpatient clinic and asked to consider participating
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in the survey. The vast majority of patients expressed a willingness to participate, in line with
previous studies (Gehrmann et al., 2016, Ravikoff et al., 2012). However, a 7-day food diary is
time-consuming, can be inconvenient and may be challenging for patients not familiar with
recording dietary intake, and these factors probably compromised food diary return.
In contrast to the patients with IBD, healthy controls approached the researcher following study
advertisement and are therefore likely to represent motivated and willing individuals, who are
inherently more likely to return the diary. Furthermore, healthy controls were staff and students
from a University and a hospital, and overall represented individuals with a higher educational
level than patients with IBD, as evidenced by the greater proportion of healthy controls with a
Masters-level degree. Although there is no evidence that a higher educational level enhances
food diary completion, previous studies indicate that demographic and socioeconomic factors
can predict response or non-response to surveys (Mannetje et al., 2011, Boshuizen et al., 2006).
However, the predictors of patients with IBD completing and returning a food diary are
unknown. Survey response rates may be improved by using monetary incentives, recorded
delivery, pre-notification and shortening survey length (Edwards et al., 2009). These strategies
were not possible or not relevant in the current study and whether they would improve return
of a food diary, as opposed to a questionnaire survey, is unknown. However, several other
strategies that were used in the current study, such as follow-up contact, unconditional
incentives (the offer of a nutritional report following dietary analysis), and the use of stamped
rather than franked return envelopes may have contributed to diary return (Edwards et al.,
2009).
The assessment of IBD activity could be viewed as both a strength and limitation of this study.
Disease activity was defined using both objective (inflammatory markers, endoscopy or imaging)
and subjective (clinical disease activity indices) criteria in active IBD and inactive IBD without
FGS. Some patients had only recent serum CRP concentrations available and were included in
the appropriate group based upon this value. This is a potential limitation of the trial since serum
CRP is not specific for GI inflammation and thus, some patients in the active group may not have
had GI inflammation. Furthermore, not all patients with GI inflammation have a raised CRP,
meaning that some suitable patients may have been excluded, or categorised as having inactive
IBD, although the measurement of clinical disease activity indices would hopefully have avoided
this.
The  required  cut-off  for  faecal  calprotectin  was  <250  μg/g  for  inactive  IBD,  based  upon  a
previous meta-analysis (Lin et al., 2014). A more recent meta-analysis suggests this cut-off may
include participants with mild disease activity, with the optimal cut-off shown to be much lower
at 50 μg/g (Mosli et al., 2015). However, this is not anticipated to significantly impact the study
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results since the majority of participants were enrolled based upon a recent blood CRP, which is
regularly monitored in clinical practice.
This  was  the  first  study  to  investigate  FODMAP  intakes  in  patients  with  IBD,  representing  a
strength of this study. However, the analysis is not without limitations. Firstly, although the
FODMAP database is comprehensive, it is not close to containing all foods that participants
consume and FODMAP composition of speciality and ethnic foods is particularly limited. This
means that some foods, which may be sources of FODMAPs, are omitted from the analysis and
FODMAP intakes may therefore be underestimated. Secondly, the database is based upon the
analysis of Australian foods, although some have been imported from other countries for
analysis, such as plant-based milks. The FODMAP content of UK fruits, vegetables and grains may
vary due to different growth environments, meaning the FODMAP analysis may not be accurate
for UK diets. Additionally, and related to the prior point, some foods are available in Australia
and not the UK, meaning the database is not representative of a UK diet. An additional source
of error is the effect food processing techniques such as pickling and canning have on FODMAP
content (Tuck et al., 2018); unfortunately, the database does not contain exhaustive processing
options for individual foods. Finally, the FODMAP analysis is subject to the aforementioned
limitations associated with collecting food diaries, namely under or selectively reporting dietary
intake.
2.6.5 Conclusion
This study is the first to investigate intakes of all FODMAPs in IBD compared to healthy controls
and nutrient intakes in inactive IBD with FGS. Using a robust dietary assessment method,
differences in the intakes of GOS and sorbitol were observed between patients with inactive IBD
with FGS and healthy controls. Total FODMAP and fructan intakes were not significantly
different across the groups, although total FODMAP intake approached statistical significance.
Intakes of a number of micronutrients (e.g. potassium, copper and manganese) and fibre were
significantly lower in patients with inactive IBD with FGS compared to healthy controls. These
findings indicate a possible relationship between FODMAPs and FGS that requires exploration
to establish whether FODMAPs directly influence GI symptoms in inactive IBD. They also suggest
that patients with inactive IBD with FGS may be nutritionally vulnerable and this should be
considered when implementing dietary management. Food-related quality of life was impaired
in  patients  with  IBD  with  GI  symptoms  (active  IBD  and  inactive  IBD  with  FGS)  compared  to
patients without GI symptoms (inactive IBD without FGS) and healthy controls. The small sample
size may have limited the power to detect differences between groups. Continued recruitment
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and future analysis following attainment of the target sample size may reveal further differences
in FODMAP and nutrient intakes between groups.
3 A double-blind, placebo-controlled, randomised, cross-over, re-
challenge trial to investigate the effects of fermentable
carbohydrates on functional gastrointestinal symptoms in
inactive IBD
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3.1 Introduction
Functional gastrointestinal symptoms (FGS) are common in patients with inactive IBD (Halpin
and Ford, 2012), despite minimal evidence of intestinal inflammation. These common FGS are
associated with anxiety, depression and poor health-related quality of life (Simrén et al., 2002,
Berrill  et  al.,  2013,  Bryant  et  al.,  2011,  Jonefjäll  et  al.,  2016),  although  the  direction  of  this
relationship has not been established. Clinicians treating patients with FGS are faced with a
treatment dilemma, since escalating IBD therapy would be ineffective in this context and
potentially associated with unpleasant side effects. The aetiology of FGS in IBD may differ from
that of GI symptoms in IBS (without IBD) given the background of an organic inflammatory
disease (Quigley, 2016). Therefore, while there is evidence that dietary fibre manipulation,
antispasmodics, antidepressants and fermentable carbohydrate restriction may be effective in
IBS (McKenzie et al., 2016), it is unclear whether these treatment options demonstrate equal
efficacy in inactive IBD.
The case-control study presented in Chapter 2 of this thesis revealed that patients with active
IBD and inactive IBD with FGS have lower intakes of GOS and polyols than healthy controls,
suggesting that patients with GI symptoms may modify their diets to intentionally or
unintentionally reduce high FODMAP foods. Although this case-control study does not establish
a direct relationship between FODMAPs and GI symptoms in IBD, it suggests that investigation
is warranted to establish the effect of FODMAPs on FGS.
Trials of dietary interventions pose unique challenges compared to pharmaceutical trials. Foods
are a heterogeneous mixture of nutrients and bioactive components and multicollinearity for
nutrients and food components results in difficulty in interpreting the effect of dietary factors
or interventions on outcomes of interest (Freudenheim, 1999, Jacobs and Steffen, 2003). This
difficulty in dietary research is relevant to trials in functional bowel disorders, and is illustrated
by the case of non-coeliac gluten sensitivity (NCGS). Gluten and fructans co-exist in wheat and
have both been hypothesised to influence FGS (Biesiekierski and Iven, 2015). An initial trial
concluded that gluten re-challenge induced symptoms in patients with NCGS following symptom
control on a gluten-free diet (Biesiekierski et al., 2011a), while a subsequent RCT demonstrated
that gluten alone did not induce symptoms in self-reported NCGS on the background of a low
FODMAP diet (Biesiekierski et al., 2013). Indeed, a randomised placebo-controlled crossover re-
challenge trial recently established that fructans, and not gluten, were responsible for GI
symptoms in patients with NCGS (Skodje et al., 2017).
An additional challenge posed by trials of dietary interventions pertains to blinding both
participants and study investigators to treatment allocation. A meta-analysis of irritable bowel
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syndrome (IBS) treatment trials showed a pooled placebo response rate of 37.5% (Ford and
Moayyedi, 2010), emphasising the importance of blinding participants in trials of functional
bowel disorders. In contrast to drug trials, in which a placebo pill that appears identical to the
active treatment is relatively simple to produce, it is much more challenging to design a placebo
or control diet that participants cannot identify as such (Yao et al., 2013).
Therefore, improvements in GI symptoms following dietary treatments could reflect a placebo
response or a response to the restriction of another food component. While randomised,
placebo-controlled trials would control for the placebo response to the low FODMAP diet, it is
still possible that the diet leads to changes in food components other than fermentable
carbohydrates that may influence FGS. Regarding the low FODMAP diet, it is also impossible to
separate effects of different fermentable carbohydrates when implementing restriction of all
FODMAPs. Restriction of FODMAPs followed by isolated re-challenge with a series of pure
fermentable carbohydrates and glucose (placebo) established that FODMAPs are indeed
responsible for GI symptoms in IBS (Shepherd et al., 2008). Elimination and re-challenge has also
established adverse effects of food components in NCGS (Biesiekierski et al., 2013, Skodje et al.,
2017), chronic constipation (Carroccio and Iacono, 2006) and asthma (Baker et al., 2000). Pure
forms of the food component can be used as challenges to overcome the issues relating to the
complexity of whole foods and simplifies participant blinding.
Although fructans and fructose challenges have been shown to exacerbate FGS in IBS following
a low FODMAP diet (Shepherd et al., 2008), and fructan supplementation exacerbated GI
symptoms in active CD on the background of a habitual diet (Benjamin et al., 2011b), the effect
of blinded fermentable carbohydrate challenges following symptom control with a low FODMAP
diet has not thus far been investigated in IBD. A randomised, placebo-controlled, double-blinded
crossover re-challenge trial was therefore designed to establish whether fermentable
carbohydrates exacerbate FGS in patients with IBD in remission.
3.2 Aims of the re-challenge trial
The aim of this study was to conduct a randomised, double-blinded, placebo-controlled,
crossover, re-challenge trial to determine whether individual fermentable carbohydrates
exacerbate FGS in patients with inactive IBD.
3.3 Hypotheses
Null hypothesis: In patients with inactive IBD who have reported adequate relief of FGS following
a low FODMAP diet, re-challenge with individual fermentable dietary carbohydrates (fructans,
GOS and sorbitol), will not exacerbate FGS compared with a placebo (glucose).
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Alternative hypothesis: In patients with inactive IBD who have reported adequate relief of FGS
following a low FODMAP diet, re-challenge with individual fermentable carbohydrates (fructans,
GOS and sorbitol), will exacerbate FGS compared with a placebo (glucose).
3.4 Methodology
3.4.1 Trial design
This was a randomised, placebo-controlled, double-blind, crossover re-challenge trial
investigating the effect of a series of individual fermentable carbohydrate challenges on FGS in
patients with inactive IBD on the background of a low FODMAP diet.
3.4.2 Trial sites
Trial recruitment took place at Guy’s and St Thomas’ Foundation Trust and Barts Health NHS
Trust, London, UK. Participants were recruited from gastroenterology and dietetic outpatient
clinics and trial visits took place in either the hospital clinic or at King’s College London (KCL),
Department of Nutritional Sciences.
3.4.3 Patient selection, inclusion and exclusion criteria
Potentially eligible participants were identified by screening medical notes and clinic lists and by
approaching potentially suitable patients for screening after clinic appointments.
Inclusion criteria:
· Patients aged 18 years or over;
· Diagnosed with Crohn’s disease (CD) or ulcerative colitis (UC) at least six months’ prior;
· Inactive IBD as defined by Physician Global Assessment, CRP <10 mg/L and faecal
calprotectin <250 µg/g in the past four weeks. This faecal calprotectin cut-off was
chosen as having been shown to perform optimally in distinguishing active from inactive
IBD in terms of sensitivity and specificity in a meta-analysis (Lin et al., 2014);
· Current FGS fulfilling the Rome III criteria for IBS, functional bloating or functional
diarrhoea;
· A marked improvement in FGS following the low FODMAP diet. A ‘marked response’ to
the low FODMAP diet was defined as an affirmative answer to the Global Symptom
Question (GSQ) “Do you currently have adequate relief of your gut symptoms?”, which
patients were asked after at least two weeks on the diet.
Exclusion criteria:
· Other significant comorbidities including diabetes, cardiovascular disease and renal
failure, due to the possible impact upon diet and ability to follow a dietary intervention;
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· Patients with recent changes in IBD medications, currently taking steroids or antibiotics,
probiotics or prebiotics in the preceding four weeks, due to the possible confounding on
GI symptom responses;
· Current stricturing CD, previous proctocolectomy or current stoma, as altered
physiology may alter GI symptom responses.
3.4.4 Interventions
Participants were allocated to a random order of three fermentable carbohydrates and one
placebo challenge. The fermentable carbohydrate challenges were fructans, GOS and sorbitol
(Table 3.1). Glucose was chosen as the placebo as it is efficiently absorbed in the proximal small
intestine, thus does not generate a breath hydrogen rise or an increase in small intestinal water
or colonic gas, and therefore should not induce GI symptoms (Major et al., 2017, Murray et al.,
2014).  The  FODMAPs  were  chosen  as  these  had  not  previously  been  investigated  in  FGS
induction (GOS, sorbitol) or had not been investigated in FGS in IBD specifically (fructans,
sorbitol). Although fructose has not been investigated as an inducer of FGS in IBD specifically, it
is well established that fructose malabsorption and intolerance is present in a significant
proportion of patients with functional bowel disorders (Gibson et al., 2007). Therefore, since
this trial already included four carbohydrate challenges, fructose was omitted in the interest of
minimising participant burden (i.e. the trial would become larger) and maximising participant
retention (particularly crucial in a crossover trial).
Table 3.1 Carbohydrate challenges and daily dose in the re-challenge trial
The aim was to challenge patients with the highest possible dose of fermentable carbohydrate
that could realistically be achieved in a normal UK diet and therefore demonstrate the effects of
the carbohydrates when consumed within a diet (Table 3.2). The challenges were the upper end
of the quantities likely to be consumed in a normal diet as participants were also following a
strict low FODMAP diet during the 4-week re-challenge trial. Low FODMAP dietary advice has
previously resulted in a reduction of total FODMAP intake of around 12 g/day (Staudacher et al.,
Challenge Dose/day Composition, molecular weight Product, manufacturer,
country
Fructans 12 g 95% oligofructose, average DP 4, 666.58 g/mol Orafti P95, Beneo,
Germany
Alpha-GOS 6 g Stachyose ≥55-65%, raffinose ≥14-18%,









12 g 100% dextrose monohydrate, 180.16 g/mol Dextrose, Thornton and
Ross, UK
GOS, galacto-oligosaccharides
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2012). Therefore, the addition of 12 or 6 g/d of fermentable carbohydrate in the form of pure
challenges is likely to return the total FODMAP intake to an average daily UK intake.
Table 3.2 Estimated typical daily intakes of fermentable carbohydrates included in re-challenge trial
The fermentable carbohydrate doses capable of inducing GI symptoms were also chosen based
upon previous GI symptom provocation and supplementation studies in patients with functional
bowel disorders or IBD (Table 3.3). Although the sorbitol dose for this trial is greater than the
average UK intake, previous symptom provocation studies have mainly used doses of 5-10 g,
and a previous study has demonstrated tolerance to a much higher dose of sorbitol, albeit in
healthy volunteers (Skoog et al., 2006).
Carbohydrate Estimated intake, g/day Country Reference
Fructans Median 2.6 (range 1.04-4.46) USA (Moshfegh
et al., 1999)
Mean 3.6 (95% CI 2.9-4.2) UK (IBS) (Staudacher
et al., 2012)
Mean 4.0 (SD 1.3) UK (Dunn et
al., 2011)
Median 3.9 (IQR 2.1) UK (Anderson
et al., 2015)
GOS Mean 2.0 (95% CI 1.4-2.5) UK (IBS) (Staudacher
et al., 2012)
Sorbitol Mean 0.4 (95% CI 0.2-0.5) UK (IBS) (Staudacher
et al., 2012)
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Table 3.3 Mechanistic or prebiotic supplementation studies in functional bowel disorders or IBD using the fermentable carbohydrates included in re-challenge trial
Carbohydrate Outcomes assessed Participants Daily dose(s) Reference
Fructans Fructose and inulin on small intestinal water and colonic gas volume Healthy volunteers 40 (Murray et al., 2014)
Fructose and inulin on small intestinal water and colonic gas volume Healthy volunteers and
IBS
40 (Major et al., 2017)
Fructose and fructan challenges on GI symptoms following FODMAP restriction IBS 7, 14, 19 (Shepherd et al., 2008)
Short-chain fructo-oligosaccharides on rectal hypersensitivity IBS 5 (Azpiroz et al., 2017)
Oligofructose on GI symptoms, stool weight, transit time and breath hydrogen IBS 6 (Hunter et al., 1999)
Fructo-oligosaccharides on GI symptoms IBS 20 (Olesen and Gudmand-
Hoyer, 2000)
Short-chain fructo-oligosaccharides on GI symptoms and quality of life Functional bowel
disorders
5 (Paineau et al., 2008)
Oligofructose-enriched inulin on disease activity, FCP and GI symptoms Active UC 12 (Casellas et al., 2007)
Fructo-oligosaccharides on clinical disease activity, GI microbiota and immunology Active CD 15 (Lindsay et al., 2006)
Fructo-oligosaccharides on clinical disease activity, GI microbiota and immunology Active CD 15 (Benjamin et al., 2011b)
Oligofructose-enriched inulin on disease activity and faecal metabolite profile Active CD 20 (De Preter et al., 2013)
GOS Effect of trans-GOS on GI symptoms, stool output and faecal microbiota IBS 3.5 or 7 (Silk et al., 2009)
Sorbitol Sorbitol and mannitol on GI symptoms and breath hydrogen Healthy volunteers and
IBS
10 (Yao et al., 2014)
Fructose, sorbitol and fructose-sorbitol mixture on GI symptoms IBS, functional diarrhoea
or excessive
flatulence/bloating
5 (Rumessen and Gudmand-
Hoyer, 1988)
Lactose, fructose and sorbitol on GI symptoms Functional bowel
disorders
5 (Fernández-Bañares et al.,
1993)
Presence of sugar malabsorption and dietary restriction of malabsorbed sugar Functional bloating 3.5 (Fernandez-Banares et al.,
2006)
GOS, galacto-oligosaccharides; GI, gastrointestinal; FCP, faecal calprotectin; IBS, irritable bowel syndrome; UC, ulcerative colitis; CD, Crohn’s disease
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At the baseline visit (visit 1; prior to challenge phase), participants were given three containers
for each of the three days of the challenges, each of which contained the relevant carbohydrate
in powder form (i.e. 12 containers in total) (Figure 3.1). Each container was labelled with the
relevant randomisation ID and the week in which it was to be consumed (for example: ‘FM01,
week 1’). Participants were instructed to reconstitute the powder with 200 ml cold water and
consume it with or without food before 11:00 on days 1-3 of each of the four challenge weeks
(each week included the 3-day challenge and 4-day washout).
Figure 3.1 The containers containing the carbohydrate challenge powders given to participants. Each
was labelled with the week of the trial in which it was to be consumed (week 1-4) and the participant
ID. Since there was 3 challenge days for each carbohydrate, there were three containers per week.
3.4.5 Randomisation
Crossover trials carry the advantage that each participant receives all treatments or challenges,
which mitigates inter-individual variability, thus increasing the statistical power of the study and
allowing smaller sample sizes (Louis  et al., 1984). However, crossover trials are susceptible to
order and carryover effects which can render the results difficult to interpret. This design is
suited  to  conditions  that  are  relatively  stable  over  time  (van  Zanten  et  al.,  1999).  Although
functional bowel disorders fluctuate over time, a crossover design was most appropriate in this
trial given the expected inter-individual variability in symptom responses and the infeasibly large
sample size  that  would be required for  a  four-arm parallel  trial.  Patients  were allocated to  a
random order of challenges to neutralise possible carryover effects. There was the potential for
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a greater placebo (or ‘nocebo’) response during the first challenge, which could ultimately
inflate (if a FODMAP is the first challenge) or suppress (if the placebo is the first challenge) the
effect of the FODMAPs compared to the placebo challenge. Additionally, order effects may be
large in crossover trials with shorter treatment periods (Spiller, 1999), such as in this trial.
The random order in which each participant was to consume the four challenges (fructans, GOS,
sorbitol and glucose placebo) was generated using an online random number generator
(http://www.randomization.com) by a member of the research team not involved in trial
recruitment. Since there are only twenty-four possible permutations of the four challenges, an
additional block of eight random orders was generated to maintain balance in the allocations.
3.4.6 Blinding
Maximum possible blinding of participants and researchers to treatment allocation is
recommended in IBS and IBD trials to mitigate the substantial expectancy effects (placebo and
nocebo) characteristic of these disorders, and to minimise conscious and unconscious bias
introduced by researchers (Irvine et al., 2016, Elsenbruch and Enck, 2015). Open challenges are
problematic in establishing adverse reactions due to potentially significant ‘nocebo’ responses
(Niec et al., 1998), defined as the adverse effects experienced after an inert treatment due to
negative expectations and negative experiences of previous treatments (Elsenbruch and Enck,
2015). For example, adverse reactions to glucose placebo challenges have been noted in 30-63%
of patients in the context of food allergy and intolerance (Pastorello et al., 1989, Farah et al.,
1985).
Although participants were aware that the purpose of this trial was to investigate the effects of
fermentable carbohydrate challenges on FGS, the specific types of carbohydrates included in the
challenges was not disclosed until all data had been collected and the trial had concluded.
Blinding of participants was further facilitated by using opaque sealed containers for the
carbohydrate challenges, thus obscuring the view of the colour or quantity of the carbohydrate
powder.
Fermentable carbohydrates were weighed into the opaque containers, labelled and arranged
into opaque bags for each participant by a researcher not involved in recruitment. This allowed
the recruiting researchers to collect the appropriate bag upon enrolment of a new participant,
thus remaining blinded to the order of challenges for each participant.
3.4.7 Compliance
Adherence to a dietary intervention clearly has a major influence over its perceived
effectiveness. In this trial, participants were instructed to follow a strict low FODMAP diet but
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were not provided with low FODMAP foods or meals. While controlled feeding studies (in which
participants are provided with all foods to be consumed) maximise participant adherence, this
design does not reflect clinical practice and is often infeasible. Additionally, the provided study
diet is likely to differ substantially from the participants’ usual diet, which may heighten anxiety
and stress related to perceived symptom triggers that the experimental diet may contain,
potentially impacting upon symptom responses (Colagiuri, 2010).
In this study, detailed and tailored low FODMAP diet education was provided by the research
dietitians. In addition, participants were contacted once weekly by the research dietitians to
address any questions or concerns and to encourage compliance to both the low FODMAP diet
and to the FODMAP challenges.
In the absence of biomarkers to measure adherence to the low FODMAP diet, non-validated
patient-reported compliance has mainly been assessed in trials investigating this diet (Halmos
et  al.,  2014b,  Staudacher  et  al.,  2012).  In  this  trial,  adherence  to  the  low  FODMAP  diet  was
assessed  on  days  1-3  of  each  challenge  week  (i.e.  on  the  days  that  challenge  drinks  were
consumed) with the question “How much of the time today did you follow the low FODMAP
diet?” with five possible responses: “never”, “a quarter of the time”, “half of the time”, “three
quarters of the time”, or “always”. Participants also recorded intake of challenge drinks on days
1-3 of each challenge period by answering the question “How much of the test drink did you
consume?” with five possible responses: “none”, “less than half”, “half of it”, “more than half
but not all” or “all”. The above written compliance questions were recorded in a paper diary
provided to participants at visit 1 (prior to challenges).
3.4.8 Adverse events and withdrawals
Researchers enquired about adverse events during weekly telephone contacts conducted during
the trial. The nature, duration, severity and relation of any adverse events to the challenge drinks
were recorded consistently on a pre-designed form.
3.4.9 Ethics approval
All participants provided informed consent prior to providing stool samples or before any trial
procedures. The study was approved by London - Camberwell St Giles Research Ethics
Committee (reference number 15/LO/1878). The study was approved by the respective research
and development offices prior to patient recruitment.
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3.4.10 Trial protocol and procedures
The trial protocol and procedures are illustrated in Figure 3.2.
3.4.10.1 Screening
There were two potential streams of participants:
a) Retrospective participants: patients who had previously received low FODMAP dietary
advice as part of routine clinical care, with a resulting GI symptom improvement
b) Prospective participants: patients referred to the dietetic department or directly to the
research dietitians  for  dietary  advice  for  FGS were given low FODMAP advice by the
researchers and monitored for a response
All researchers actively recruiting patients (SC, thesis author; Alexis Prince, MRes Student; Clio
Myers, MRes Student) were specialised and experienced in delivering low FODMAP dietary
advice in clinical practice. Prospective participants met with the researchers at either the
hospital clinic or King’s College London for a dietetic consultation lasting 45-60 minutes, during
which the low FODMAP diet was discussed in detail and appropriate written resources were
provided. Patients were asked to restrict all fermentable carbohydrates, including fructans, GOS,
sorbitol, mannitol, lactose and excess fructose. Patients were contacted once a week to assess
response to the diet. Patients achieving adequate relief of GI symptoms within four weeks on
the low FODMAP diet, and continuing to meet all other inclusion criteria, underwent further
screening for eligibility in the study by providing a blood and stool sample for CRP and faecal
calprotectin (section 3.4.3), respectively, prior to enrolment in the re-challenge trial.
Retrospective participants were identified through retrospective screening of gastroenterology
and dietetic outpatient clinic lists at the hospital sites. Patients with IBD who had received low
FODMAP  dietary  advice  for  FGS  and  reportedly  experienced  a  marked  improvement  in  GI
symptoms were approached via telephone to discuss the re-challenge trial. Patients meeting all
inclusion criteria and none of the exclusion criteria and expressing an interest in participating
attended a screening visit with the researchers. During this visit, they were instructed to
recommence a strict low FODMAP diet until adequate relief of FGS was achieved. Patients then
provided a blood sample for CRP and a stool sample for faecal calprotectin screening. Figure 3.2
depicts the trial procedures and visits.
3.4.10.2 Visit 1
Patients with acceptable concentrations of CRP and faecal calprotectin (section 3.4.3) and
reporting adequate relief of GI symptoms following a low FODMAP diet returned to the hospital
clinic or King’s College London for a trial baseline visit, during which they were consecutively
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assigned a unique randomisation code from FM01-FM32 corresponding to a random order of a
series of fermentable carbohydrate challenges (section 3.4.6 for randomisation; section 3.4.4
for interventions). Participants completed the GSQ, Gastrointestinal Symptom Rating Scale
(GSRS) and the Bristol Stool Form Scale (BSFS), with reference to the preceding 7 days (section
3.4.12). Participants were provided with an opaque bag containing the challenge carbohydrates
(section 3.4.7), and a stool, symptom and compliance diary for the 4-week re-challenge trial,
along with detailed instructions regarding when and how to complete the challenges.
Participants were instructed to continue a strict low FODMAP diet throughout the re-challenge
trial.
3.4.10.3 Weekly monitoring
Participants were contacted once per week during the challenge phase the day before
commencing each challenge (day 0) to ensure they had adequate relief, to address any questions
or concerns and to monitor adverse events (section 3.4.9).
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Figure 3.2 Flow diagram showing the re-challenge trial procedure. FCP, faecal calprotectin
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Stool and blood samples collected
to check FCP and CRP
Low FODMAP diet trial explained
Baseline visit (visit 1)
Randomisation to sequence of
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Intervention phase
Week 1: random allocation to
challenge (3 days), washout (≥ 4
days)
Week 2: random allocation to
challenge (3 days), washout (≥ 4
days)
Week 3: random allocation to
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days)
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challenge (3 days), washout (≥ 4
days)
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3.4.10.4 Visit 2
Following completion of all four challenges and the final washout period, participants returned
to  the  hospital  clinic  or  King’s  College  London  for  an  end  of  trial  visit  with  the  researchers.
Symptom, stool and adherence diaries were checked for completeness and participants
repeated the GSQ, GSRS and BSFS. Participants provided a stool and blood sample for faecal
calprotectin and CRP determination. Prospective participants were provided with FODMAP
reintroduction advice as part of routine clinical care.
3.4.11 Outcome measures and rationale
3.4.11.1 Gastrointestinal symptoms
The primary outcome was adequate relief of FGS on the final day of the 3-day challenges
measured using the GSQ, “Do you currently have adequate relief of your gut symptoms?”
The concept of ‘adequate relief’ was proposed as an outcome in IBS drug trials to overcome the
difficulties posed by the heterogeneity of IBS symptoms. This measure was believed to be
clinically relevant and to represent the overall experience of GI symptoms and well-being
(Mangel  et  al.,  1998).  At  the  time  of  planning  the  current  trial,  the  Rome  III  guidelines
recommended binary end-points as outcome measures in FGID trials (Irvine et al.,  2006) and
therefore the GSQ was chosen as the primary outcome.
Functional GI symptoms are extremely heterogeneous between patients and therefore it is
advised that in addition to a subjective global assessment of symptoms (e.g. GSQ), a scale which
measures individual symptom incidence and severity should also be administered (Irvine et al.,
2006). Individual symptom incidence and severity was assessed in this study using the GSRS,
composed of 12 symptoms including abdominal pain, bloating, and flatulence. This is a
reproducible four-point Likert scale (0 none/absent; 1 mild, 2 moderate, 3 severe) that has been
validated for use in IBS (Svedlund et al., 1988).
3.4.11.2 Stool output
The BSFS was completed prospectively on the day prior to each challenge (day 0) and on each
of the three challenge days (days 1-3) of each of the four challenge periods. This simple measure
rates stool form on a scale from type 1 (hardest stool form) to 7 (softest stool form) and is widely
used in research and clinical practice. The Rome Foundation recommends the use of the BSFS in
the diagnosis of functional bowel disorders and IBS subtype classification (Mearin et al., 2016).
Changes in stool form as measured by the BSFS correlate well with changes in whole-gut transit
time (Lewis  and Heaton,  1997b)  and with stool  water  content  (Blake et  al.,  2016).  The scale
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demonstrates substantial validity and reliability and is able to detect differences in stool form
between healthy individuals and patients with IBS-D (Blake et al., 2016).
3.4.11.3 Biomarkers
The aim of this trial was to investigate the effect of fermentable carbohydrate challenges on FGS
in patients with inactive IBD, and therefore it was essential to establish that GI symptoms were
not related to active GI inflammation. Although endoscopy and/or imaging are preferable for
establishing IBD activity, these procedures are invasive and costly. Serum and stool biomarkers
provide non-invasive, yet objective, measures of GI inflammation and can therefore facilitate
assessment of patients for clinical trial recruitment where endoscopy and imaging may not be
feasible or appropriate (Peyrin-Biroulet et al., 2015).
Faecal calprotectin correlates with endoscopic disease activity in both CD and UC, suggesting it
to  be  a  surrogate  marker  of  GI  inflammation  (Arai  et  al.,  2017,  Schoepfer  et  al.,  2013).  It  is
therefore increasingly used to monitor disease activity in established IBD (Lehmann et al., 2015).
Although faecal calprotectin thresholds for defining IBD activity are unclear, a ≤250 µg/g cut-off
provided optimal sensitivity (80%) and specificity (82%) for detecting endoscopically inactive IBD
in a meta-analysis of diagnostic accuracy studies (Lin et al., 2014). Lower cut-offs (50 µg/g and
100 µg/g) compromised specificity (60% and 66%, respectively), which in practice would
increase the risk of obtaining false positives (i.e. inactive IBD incorrectly classified as active IBD
and therefore unnecessarily  excluded from the trial).  A  faecal  calprotectin  of  <250 µg/g was
therefore required for inclusion in this trial.
Patients provided stool samples prior to randomisation (at screening, to determine eligibility for
inclusion) and at end of trial (visit 2). For convenience, patients were permitted to collect stool
samples  and  store  them  in  a  refrigerator  for  up  to  6  days  in  advance  of  providing  them  to
researcher, as per the manufacturers’ instructions. Faecal calprotectin concentration was
quantified by trained researchers using the Bühlmann Quantum Blue® lower range quantitative
immuno-chromatographic assay.
This test is a lateral flow immunoassay followed by calprotectin quantitation by a reader
designed to analyse colorimetric tests, with an upper limit of 300 µg/g. Lateral flow assays have
numerous diagnostic uses within healthcare, particularly where a rapid and simple test is
required (Koczula and Gallotta, 2016).
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Figure 3.3 Components of a lateral flow assay test cassette (Koczula and Gallotta, 2016)
This technique permitted calprotectin quantification by the researchers shortly after the
screening visit, thus enabling efficient recruitment. In contrast, calprotectin ELISA requires at
least 3 hours to complete, is more technically demanding, and the microplate layout and cost
makes it suited to analysing samples in batch (e.g. upon completion of a trial) rather than on an
individual basis (Labaere et al., 2014). Although the rapid technique does not replace ELISA for
quantification of calprotectin, it reduces processing time significantly and performs comparably
in the investigation of suspected or known IBD (Labaere et al., 2014), particularly at lower faecal
calprotectin concentrations (Kolho et al., 2012).
The lateral flow immunoassay is based upon the movement of a liquid sample (containing the
analyte of interest; in this case, calprotectin) via capillary force along a membrane, containing
various regions to which molecules able to interact with the analyte are attached (Posthuma-
Trumpie et al., 2009, Koczula and Gallotta, 2016) (Figure 3.3). The diluted faecal sample is loaded
onto the sample pad (depicted by ‘S’ in Figure 3.4B) and migrates to the conjugate release pad
which is coated with monoclonal anti-calprotectin antibodies conjugated to a
coloured/fluorescent label. These antibodies bind to calprotectin in the sample and the new
calprotectin-antibody conjugates migrate towards the test line. This porous membrane contains
monoclonal antibodies to the calprotectin-antibody conjugates, and colour is generated upon
binding. The signal intensity of the test line is measured by the POC reader to determine
calprotectin concentration in the sample.
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Figure 3.4 A) Faecal calprotectin extraction device (Schebo QuickPrep), B) test cassette after sample
analysis. The faecal calprotectin concentration indicated from this sample was < 30 µg/g. C=control line,
T=test line, S=sample pad
The calprotectin extraction and assay were carried out as per the manufacturers’ instructions
(Alpha Laboratories):
1. The dosing tip of the extraction device was removed (figure 3.4A) and inserted into the
stool sample. This was repeated 3-5 times until all grooves were filled with stool. The
dosing tip was inserted back into tube containing buffer.
2. The sample was homogenised by vortexing the extraction device for 30 seconds. The
sample was then incubated upright at room temperature for 10 minutes. This was
repeated as necessary to remove all stool from dosing tip.
3. 300  µl  buffer  was  transferred  into  a  test  tube,  along  with  20  µl  diluted  stool  from
extraction device. This mixture was vortexed briefly.
4. The sample was incubated upright at room temperature for 10 minutes.
5. 60 µl diluted faecal extract was transferred onto the sample loading port of the test
cassette (figure 3.4B)
6. The test cassette was incubated for 12 minutes at room temperature.
7. The test cassette was placed into the test cassette drawer of the Quantum Blue® reader
and the sample was read as per the manufacturer’s instructions.
Blood samples were also collected by nurses or the lead researcher at baseline and end of trial
for CRP quantification. As patients were identified from gastroenterology clinics and required
this test as part of routine clinical care, this was carried out in the respective hospital pathology
laboratories using a standard assay.
BA
S
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Patients  were  required  to  have  a  CRP  <10  mg/L  for  inclusion  in  the  study  (section  3.4.3).
Although 5 mg/L is more commonly used as a cut-off for defining IBD activity (Walsh et al., 2016),
a mildly raised CRP is not specific to GI inflammation, and 0-10 mg/L is the normal reference
range for CRP in the local hospital laboratories. The slightly higher threshold was used to avoid
unnecessary patient exclusions resulting from a mildly raised CRP (5-10 mg/L), which could be
unrelated to GI inflammation.
3.4.12 Sample size calculation
The sample size calculation was based on the primary outcome, which was the proportion of
patients reporting adequate relief of GI symptoms on the final day of each challenge. The
estimation of the effect size of the challenges was based on the only trial of this nature, in which
patients with IBS consumed a series of pure fermentable carbohydrate challenges on the
background of a strict low FODMAP diet (Shepherd et al., 2008). During the 19 g/d fructan
challenge, 77% of participants reported that their symptoms were not adequately controlled,
compared to 14% during the glucose (placebo) challenge. Since the doses of fructans chosen for
the current study (12 g/d) were lower than those in the IBS re-challenge trial (19 g/d), it was
anticipated that the effect size would be lower. Therefore, it was estimated that in the current
study, 50% of participants would not have adequate relief of GI symptoms during the fructan
challenge, compared to 14% during the placebo challenge.
Assuming a power of 80% and a 2-sided significance of 5%, an estimated 26 participants would
be required to detect a difference in the primary outcome. The sample size calculation can be
seen below, calculated by hand using a formula for a primary comparison of proportions:
Calculating the standardised difference ∆ = ௉భି௉మ
ඥ௣̅ × (ଵି௣̅) where ݌̅ = (௉భା௉మ)ଶ
∆= 0.50 − 0.14
√0.32 × (1 − 0.32)
∆ = 0.7717436331
Using values for a significance level of 5%, ݖ ቀ1 − ఈ
ଶ
ቁ = 1.96, and a power of 80%, ݖ(1 − ߚ) =0.8416 then:
݉ = 2 × [1.96 + 0.8416]ଶ
∆ଶ
݉ = 15.69790.7717436331 × 0.7717436331
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݉ = 26.35696791
= 26 participants per treatment group
Based on the previous study of this nature (Shepherd et al., 2008), an attrition rate of 15% was
assumed and an additional five participants would be required to ensure that the study was
adequately powered at 80%. Therefore, the aim was to recruit 32 participants in total.
3.4.13 Statistical analysis
Following data collection for all 32 participants, data was entered into an excel spreadsheet by
the author of this thesis (SC). All statistical analysis was performed using IBM SPSS Statistics for
Windows Version 22.0. Un-blinding of the challenge order allocation was performed after
analysis of the primary endpoint.
All continuous data was examined for normality prior to choosing statistical tests. Any non-
normally distributed data were analysed using non-parametric tests. For demographic data,
continuous variables were compared between participants with CD and UC using independent
t-tests or a Mann-Whitney U test, while categorical variables were compared using a Chi-
squared test.
When comparing continuous variables across the carbohydrate challenges, a one-way repeated-
measures analysis of variance (ANOVA) was used, or a Friedman’s test for non-parametric data.
Following a significant difference across groups, a paired t-test or Wilcoxon Signed-Rank test
was used to compare between two challenges. A chi-squared test or Friedman’s test was used
to compare categorical variables across the challenges. A paired t-test or Wilcoxon Signed-Rank
test was used to compare continuous variables between the start and end of the trial (CRP and
faecal calprotectin concentrations). A Chi-squared test was used to compare categorical
variables between two challenges. A Bonferroni correction was applied where multiple
challenges were compared.
3.4.14 Roles and responsibilities
Patients were recruited by AP (n=10), CM (n=14) and SC (n=8). Each researcher organised CRP
and faecal calprotectin quantification and conducted all trial visits for each patient
screened/recruited. All researchers promoted the trial through increasing awareness among
gastroenterologists and dietitians and encouraging referrals to the trial. This was achieved
through attendance and oral communication at gastroenterology research meetings and weekly
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outpatient clinics and liaising regularly with gastroenterology dietitians. Data entry, analysis and
interpretation, writing of the paper (Cox et al., 2017) and thesis chapter was undertaken by SC.
3.5 Results: the effect of fermentable carbohydrate challenges on gastrointestinal
symptoms and inflammatory markers in inflammatory bowel disease
The following section describes the results of a randomised, placebo-controlled, double-blind,
crossover re-challenge trial, designed to investigate whether individual fermentable
carbohydrates exacerbate FGS in patients with inactive IBD.
3.5.1 Patient recruitment, characteristics, compliance and adverse events
3.5.1.1 Patient recruitment and progress
The randomised controlled trial opened for recruitment in March 2014 and was completed in
September 2015, recruiting thirty-two participants in 18 months.
Between March 2014 and October 2015, 293 patients were screened for eligibility. Thirty-two
patients  were  recruited  (CD,  n=14;  UC,  n=18).  The  main  reasons  for  screening  failures  were
evidence of active IBD, a current stricture in patients with CD and significant comorbidities,
including diabetes and cardiovascular disease. Trial data in accordance with CONSORT
requirements are shown in Figure 3.5. Twenty-six participants were recruited from Guy’s and St
Thomas’ NHS Foundation Trust and six from Barts Health NHS Trust.
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Figure 3.5 CONSORT diagram for the re-challenge trial. FCP, faecal calprotectin; FGS, functional
gastrointestinal symptoms; CD, Crohn’s disease; UC, ulcerative colitis
Assessed for eligibility (n=293)
Invited for tests (n=167)
Screening tests and baseline diet
(n=122)
Randomised (n=32)
UC, n=18; CD, n=14
Analysis (n=29)
CD 12; UC 17
Excluded during preliminary screening (n=126)




Active IBD or stricturing CD (n=59)
Comorbidities (n=37)
Prescribed nutrition support (n=8)
Left service/emigrated (n=8)
Pregnancy (n=3)
Changes in medication (n=3)
Declined to participate (n=45)
Lack of time (n=23)
Unwilling to trial low FODMAP diet (n=8)
Other (n=14)
Withdrawn (n=3)
Lost to follow up (n=1)
 Prescribed antibiotics (n=1)
CRP >10 mg/L (n=1)
Excluded (n=90)
FCP >250 µg/g (n=5)
CRP >10 mg/L (n=2)
Poor adherence to low FODMAP diet (n=32)
No response to low FODMAP diet (n=51)
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Three participants exited the trial prematurely. Two were withdrawn after randomisation but
prior to consuming the first challenge; one due to personal commitments, and one had a second
blood test revealing a CRP exceeding 10 mg/L. One participant was withdrawn prior to
commencing the final challenge due to developing pneumonia and commencing a course of
antibiotics. Trial data were not available for these participants. Trial data for all challenge arms
were available for all remaining 29 participants (CD, n=12; UC, n=17). Baseline demographic
characteristics and disease phenotype for these participants are provided in Table 3.4.
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Male, n (%) 11 (34.4) 4 (33.3) 7 (41.2) 0.668a
Age (y), median (IQR) 39.0 (19.5) 40.5 (25.0) 32.0 (19.5) 0.661b
Disease duration (y),
mean (SD)
12.8 (13.0) 15.6 (15.8) 10.9 (10.6) 0.346b
Time since last flare, n (%) 0.060a
≤ 1 year 15 (46.9) 3 (25.0) 12 (70.6)
1-5 years 8 (25.0) 6 (50.0) 2 (11.8)
6-10 years 3 (9.4) 1 (8.3) 2 (11.8)




L1, ileal: 3 (25)
L2, colonic: 5 (42)





B2, stricturing: 0 (0)
B3, penetrating: 2
(17)
P, perianal disease: 2
(17)
Extent
E1, proctitis: 9 (53)
E2, left-sided: 3 (18)
E3: pancolitis: 5 (29)
-
CRP (mg/L), mean (SD) 2.4 (1.7) 2.3 (1.3) 2.5 (2.0) 0.741b
FCP (µg/g), mean (SD) 30.2 (29.9) 19.8 (12.2) 37.6 (36.3) 0.116b
Disease activity score,
mean (SD)
HBI score 2.3 (3.3) SCCAI score 1.8 (1.9) -
FBD category, n (%) 0.596a
IBS 12 4 8
Functional bloating 12 5 7
Functional diarrhoea 5 3 2
Previous surgery, n (%) 2 (6.3) 2 (16.7) 0 (0) -
Medications, n (%)
5-ASA 18 (56.3) 3 (25.0) 15 (88.2) 0.002a
Thiopurines 10 (31.3) 6 (50.0) 4 (23.5) 0.280
Biologics 3 (9.4) 3 (25.0) 0 (0) 0.119
a Chi-squared test; b Unpaired t-test; c CD vs. UC
FCP, faecal calprotectin; FBD, functional bowel disorder; IBS, irritable bowel syndrome; 5-ASA, 5-
aminosalicylates
3.5.1.2 Baseline patient demographic and clinical characteristics
Participants were aged 22-69 years (median 39 years, IQR 19.5), and 11 (34.4%) were male. All
participants  met  Rome  III  criteria  for  either  IBS  (12/29,  41.4%),  functional  bloating  (12/29,
41.4%) or functional diarrhoea (5/29, 17.2%). Mean CRP was 2.4 (1.7) mg/L and faecal
calprotectin  was 30.2  (29.9)  µg/g at  baseline.  Except  for  a  significantly  greater  proportion of
patients with UC taking 5-ASA (15/17, 88.2% vs. 3/12, 25.0%, p=0.002), patients with CD and UC
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were similar in baseline characteristics (Table 3.4). There were no significant differences in
symptom incidence and severity at baseline (measured at visit 1) between CD and UC (Table
3.5). The most commonly experienced symptoms prior to randomisation were abdominal
bloating (13/29, 45%), flatulence (16/29, 55%), incomplete evacuation (13/29, 45%) and
tiredness (24/29, 83%).
Table 3.5 Gastrointestinal Symptom Rating Scale scores at randomisation








Pain 0.38 (0.50) 0.42 (0.52) 0.35 (0.50) 0.739
Bloating 0.45 (0.51) 0.42 (0.51) 0.47 (0.51) 0.783
Flatulence 0.59 (0.57) 0.67 (0.65) 0.53 (0.51) 0.531
Belching 0.24 (0.58) 0.42 (0.79) 0.12 (0.33) 0.239
Gurgling 0.41 (0.50) 0.33 (0.49) 0.47 (0.51) 0.478
Urgency 0.52 (0.69) 0.42 (0.67) 0.59 (0.71) 0.518
Incomplete evacuation 0.52 (0.63) 0.58 (0.52) 0.47 (0.72) 0.645
Nausea 0.24 (0.51) 0.25 (0.62) 0.24 (0.44) 0.941
Heartburn 0.07 (0.37) 0.17 (0.58) 0.00 (0.00) 0.339
Acid regurgitation 0.10 (0.41) 0.17 (0.58) 0.06 (0.24) 0.495
Lethargy 1.21 (0.82) 1.33 (0.65) 1.12 (0.93) 0.495
Overall 0.55 (0.51) 0.67 (0.49) 0.47 (0.51) 0.313
a 0=absent, 1=mild, 2=moderate, 3=severe; b CD vs UC; unpaired t-test
3.5.1.3 Compliance
Data on adherence to the low FODMAP diet and the challenge drinks were available for all 29
participants throughout all challenges and data were included in the analysis for all patients
completing the trial irrespective of compliance to the low FODMAP diet and the challenge drinks.
One participant reported consuming less than half of the drink on the first two days of the GOS
challenge, and half of the drink on the remaining day. One participant did not consume any of
the drink on day 3 of the glucose challenge due to experiencing “unbearable symptoms”.  The
numbers of participants consuming all of the carbohydrate drink on all three days of the
challenge was high during the fructan (97%),  GOS (93%),  sorbitol  (100%),  and glucose (97%)
challenges (P=0.392).
All participants reported good adherence to the low FODMAP diet during all of the challenge
periods (defined as ≥75% adherence on all three challenge days). There was no significant
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difference in the proportion of participants reporting full adherence to the low FODMAP diet
across the challenges, assessed using a Friedman’s test (P=0.065).
3.5.1.4 Adverse events
Two adverse events were reported during the trial. One participant reported dizziness and
severe faecal incontinence during the fructan challenge, which resolved on the same day. This
was not thought to require further investigation and the participant chose to continue the trial.
One patient developed pneumonia following the GOS challenge, not thought relate to the
challenge drinks, and was withdrawn due to having a course of antibiotics.
3.5.2 Gastrointestinal symptoms
Across the challenges, there was a significant difference in the proportion of participants
reporting adequate relief of GI symptoms on the final day (‘day 3’) of the challenges (P=0.033)
(Table 3.6). Post hoc correction comparing differences between each FODMAP challenge and
glucose (placebo) revealed significantly fewer participants reported adequate relief on the final
day of the fructan challenge (18/29, 62.1%) than the glucose challenge (26/29, 89.7%) (P=0.033)
but no significant differences were found between GOS (22/29, 75.9%, P=0.306) or sorbitol
(23/29, 79.3%, P=0.771) compared to glucose. The difference in the incidence (number of days)
of adequate relief across the challenges approached significance (P=0.057), with the lowest
incidence being for fructans (Table 3.6).
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Table 3.6 Adequate relief during and on the final day of the challenges
Fructan GOS Sorbitol Glucose  P value
P value for challenge vs
glucosec




On final day of
challenge
18 (62.1) 22 (75.9) 23 (79.3) 26 (89.7) 0.033a 0.033 0.306 0.771
On all three days
of challenge
15 (51.7) 20 (69.0) 21 (72.4) 23 (79.3) 0.070a - - -




2.1 (1.2) 2.4 (1.0) 2.5 (1.0) 2.7 (0.8) 0.057b - - -
a Friedman’s test across the challenges; b Repeated-measures ANOVA across the challenges; c Each
challenge compared with placebo (glucose) using Wilcoxon Signed Rank test with Bonferroni correction
for multiple comparisons
GOS, galacto-oligosaccharides; SORB, sorbitol
There were significant differences in the incidence (number of days) of moderate or severe pain
(P=0.006), bloating (P <0.001), flatulence (P=0.001) and overall symptoms (P=0.021) across the
challenges (Table 3.7). Following post hoc correction, there was a significantly greater incidence
of moderate or severe pain (P=0.014), bloating (P=0.017) and flatulence (P=0.034) during the
fructan challenge compared to the glucose, but not for any of the other challenges (Table 3.7).
There were significant differences in the average (3-day) severity of pain (P=0.004), bloating
(P<0.001), flatulence (P <0.001), incomplete evacuation (P=0.013) and lethargy (P=0.012) across
the challenges. Following post hoc correction, there was a significantly greater severity of pain
(P=0.004), bloating (P=0.013) and flatulence (P=0.006) during the fructan challenge compared
to glucose, but not for any of the other challenges (Figure 3.6).
In addition, on the final day of the challenges, there were significant differences in the severity
of pain (P=0.006), bloating (P <0.001), flatulence (P <0.001), borborygmi (P=0.036), faecal
urgency (P=0.011), incomplete evacuation (P=0.026) and overall symptoms (P=0.006) across the
challenges (Table 3.7). Following post hoc correction, there was a significantly greater severity
of pain (P=0.004), bloating (P=0.002), flatulence (P=0.004) and faecal urgency (P=0.014) on the
final day of the fructan challenge compared to glucose, but not for any of the other challenges.
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Figure 3.6 Severity of gastrointestinal symptoms as measured by the GSRS during the challenges
(0=absent, 1=mild, 2=moderate, 3=severe). Symptom severity was measured on each challenge day and
a 3-day average was calculated. * P < 0.05 for the fructan challenge compared to glucose (placebo)
challenge
The average severity of all 12 GI symptoms measured using the GSRS (absent=0, mild=1,
moderate=2, severe=3) across the three challenge days was summed and divided by 36 (12
symptoms measured across three days) to obtain an average composite symptom severity score
for each challenge. There was a significant difference in the composite score across the
challenges (P<0.001), with post hoc correction revealing a significantly greater composite score
during the fructan challenge (0.64, SD 0.45) compared to glucose (placebo) (0.38, SD 0.33)
(P=0.004). There was no significant difference in any of the individual scores or in the composite
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Table 3.7 Incidence of moderate or severe GI symptoms and severity of GI symptoms on the final day of the challenges
Incidence (number of days) of moderate or severe symptoms
during three-day challenge, mean (SD)
Severity of symptoms on the final day of challenges, mean (SD)b
Fructan GOS Sorbitol Glucose P valuea Fructan GOS Sorbitol Glucose P valuea
Abdominal pain 0.9 (1.1)* 0.4 (0.8) 0.6 (0.9) 0.2 (0.6) 0.006 1.1 (0.8)* 0.8 (0.9) 0.7 (0.9) 0.5 (0.6) 0.006
Bloating 1.0 (1.0)* 0.2 (0.6) 0.6 (1.1) 0.3 (0.7) <0.001 1.3 (0.9)* 0.6 (0.7) 0.8 (0.8) 0.6 (0.7) <0.001
Flatulence 1.2 (1.2)* 0.6 (1.0) 0.2 (0.5) 0.4 (0.7) 0.001 1.5 (0.8)* 0.9 (1.0) 0.7 (0.6) 0.7 (0.7) <0.001
Belching 0.3 (0.7) 0.1 (0.4) 0.1 (0.4) 0.1 (0.4) 0.095 0.3 (0.7) 0.3 (0.7) 0.3 (0.6) 0.2 (0.4) 0.751
Borborygmi 0.3 (0.9) 0.2 (0.6) 0.0 (0.2) 0.2 (0.7) 0.239 0.7 (0.9) 0.4 (0.8) 0.3 (0.5) 0.3 (0.5) 0.036
Faecal urgency 0.7 (1.1) 0.4 (0.9) 0.4 (0.9) 0.2 (0.7) 0.055 0.9 (1.1)* 0.7 (1.0) 0.5 (0.7) 0.4 (0.6) 0.011
Incomplete evacuation 0.4 (0.9) 0.1 (0.3) 0.1 (0.4) 0.1 (0.4) 0.158 0.6 (0.7) 0.3 (0.5) 0.2 (0.6) 0.2 (0.5) 0.026
Nausea 0.1 (0.4) 0.0 (0.2) 0.1 (0.6) 0.1 (0.3) 0.699 0.2 (0.5) 0.2 (0.5) 0.2 (0.5) 0.2 (0.4) 0.987
Heartburn 0.1 (0.4) 0.0 (0.2) 0.0 (0.0) 0.0 (0.2) 0.179 0.2 (0.5) 0.2 (0.5) 0.1 (0.3) 0.0 (0.2) 0.273
Acid regurgitation 0.0 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.0) 0.596 0.1 (0.4) 0.1 (0.3) 0.1 (0.3) 0.1 (0.4) 0.505
Lethargy 0.6 (1.1) 0.3 (0.8) 0.4 (0.9) 0.4 (0.9) 0.159 1.0 (1.0) 0.6 (0.8) 0.8 (0.9) 0.8 (1.0) 0.068
Overall 0.8 (1.1) 0.3 (0.6) 0.3 (0.6) 0.3 (0.6) 0.021 1.1 (0.9) 0.7 (0.8) 0.6 (0.7) 0.7 (0.6) 0.006
a Repeated-measures ANOVA across the challenges; b Severity scoring system: 0 = absent, 1 = mild, 2 = moderate, 3 = severe
* Significantly different from placebo (glucose) on Wilcoxon Signed Rank test with Bonferroni correction for multiple comparisons
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3.5.3 Stool output
Stool frequency and consistency were assessed using the BSFS on each day of the challenges
(Table 3.8). There was a significant difference in stool frequency during the challenges when
compared across the challenges (P=0.026), although following post hoc correction this did not
reach significance between any of the fermentable carbohydrate challenges alone compared to
glucose (placebo) (Table 3.8). There was no significant difference in stool frequency on the final
day of each challenge when compared across the challenges (P=0.412).
There was a significant difference in stool consistency across the challenges (p=0.010) and post
hoc correction revealed softer stools (a higher score on BSFS) during the fructan (P=0.007) and
GOS (P=0.033) challenges compared to glucose (Table 3.8). There was also a significant
difference in stool consistency of the final day of the challenge across the challenges (P=0.017),
although following post hoc correction this did not reach significance between any of the
fermentable carbohydrate challenges alone compared to glucose.
Across the challenges, there was no significant difference in the proportion of stools that were
of  normal  consistency  (BSFS  type  3,  4  or  5)  (P=0.273),  hard  consistency  (BSFS  type  1  or  2)
(P=0.051), or loose consistency (BSFS type 6 or 7) (P=0.269) during the challenges (Figure 3.7).
There was no significant difference in the proportion of stools that were of normal consistency
on the final day of the challenges (P=0.141).
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Table 3.8 Stool frequency and consistency during and on the final day of the challenges
Mean (SD) Fructan GOS Sorbitol Glucose P valuea P value challenge vs. glucoseb
Fructan GOS Sorbitol
Stool frequency (per day) 2.4 (1.4) 2.1 (1.2) 2.1 (1.5) 1.9 (1.2) 0.026 0.067 1.000 0.986
Stool frequency (final day of challenge) 2.3 (1.8) 2.1 (1.4) 2.1 (1.6) 1.9 (1.3) 0.412 - - -
Stool consistency (BSFS) during challengesc 4.2 (1.3) 4.0 (1.0) 3.8 (1.2) 3.5 (1.0) 0.010 0.007 0.033 0.247
Stool consistency during challenges
Normal (type 3, 4 or 5) 71.0 (33.5) 78.5 (30.0) 74.3 (34.5) 66.6 (32.6) 0.273 - - -
Hard (type 1 or 2) 11.8 (26.5) 12.1 (24.3) 15.3 (31.5) 24.7 (29.5) 0.051 - - -
Loose (type 6 or 7) 17.2 (28.2) 9.4 (18.0) 10.4 (23.0) 8.7 (19.0) 0.269 - - -
a Repeated-measures ANOVA across the challenges; bEach challenge compared with placebo (glucose) using Wilcoxon Signed Rank test with Bonferroni correction for multiple
comparisons; c Hard stools, BSFS type 1 or 2; normal stools, BSFS type 3, 4 or 5; loose stools, BSFS type 6 or 7
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Figure 3.7 Proportion of hard (BSFS type 1 or 2), normal (BSFS type 3, 4, or 5) and loose (BSFS type 6 or
7) stools during the challenges
3.5.4 Biomarkers
Start and end of trial CRP concentrations were available for 27 participants (10 CD, 17 UC), and
faecal calprotectin concentrations for 24 participants (10 CD, 14 UC) (Table 3.9). There was no
significant difference in CRP between the start and end of trial (P=0.797). However, faecal
calprotectin increased significantly between baseline (29.5 µg/g, SD 31.0) and end of trial (72.9
µg/g, SD 82.1) (P=0.018). However, only two participants (8%) had a faecal calprotectin >250
µg/g at end of trial, and the difference in end of trial faecal calprotectin between baseline and
end of trial appears to be driven by large increases in five individuals (Figure 3.8). When sub-
group analyses were performed individually for CD and UC, the difference in faecal calprotectin
was significant only for CD between baseline (16.8 µg/g, SD 5.7) and end of trial (46.4 µg/g, SD
32.8) (P=0.026).
Table 3.9 Biomarkers at baseline (prior to challenge phase) and end of trial (after last washout period)
Mean (SD) Baseline End of trial P value a
CRP (mg/L)
All participants (n=27) 2.3 (1.8) 2.4 (1.7) 0.797
CD (n=10) 2.1 (1.3) 2.6 (2.2) 0.487
UC (n=17) 2.5 (2.0) 2.3 (1.3) 0.624
Faecal calprotectin (µg/g)
All participants (n=24) 29.5 (31.0) 72.9 (82.1) 0.018
CD (n=10) 16.8 (5.7) 46.4 (32.8) 0.026
UC (n=14) 38.6 (38.3) 91.9 (101.3) 0.083
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Figure 3.8 Baseline and end of trial faecal calprotectin concentrations




The aim of this chapter was to report the results of a randomised, double-blinded, placebo-
controlled, crossover, re-challenge trial designed to determine whether individual fermentable
carbohydrates exacerbate FGS in patients with IBD in remission. The null hypothesis that
fermentable carbohydrate challenges do not exacerbate FGS can be rejected since there was a
significant difference in the proportion of participants reporting adequate relief on the final day
(the primary outcome) and in individual GI symptom incidence and severity across the
challenges compared to the placebo. This was particularly the case when analysed for the
fructan challenge compared to placebo.
Fewer participants reported adequate relief on the final day of the fructan challenge compared
to the placebo (glucose), reflecting a worsening of GI symptoms. This was supported by
increased incidence and severity of abdominal pain, bloating and flatulence and is consistent
with the proposed mechanisms of fermentable carbohydrates in FGS exacerbation. Fructans are
a heterogeneous group of linear or branched fructose oligosaccharides and undergo minimal
digestion in the human small intestine due to a lack of the β-fructofuranosidase enzyme required
to hydrolyse the β-(2-1) fructosyl-fructose glycosidic bonds. Studies using ileostomy models and
aspiration of distal ileal contents demonstrate that 87-89% of ingested fructans are recovered
from the small intestine (Knudsen and Hessov, 1995, Molis et al., 1996, Ellegard et al., 1997),
indicating that the majority are available for colonic bacterial fermentation with associated
production of hydrogen, carbon dioxide and methane.
The mechanisms of fermentable carbohydrates in FGS induction or exacerbation have been
examined in studies using functional MRI. A blinded fructan challenge compared to a placebo
(glucose) significantly increased colonic gas volume in healthy volunteers (Murray et al., 2014,
Major  et  al.,  2017)  and  patients  with  IBS  (Major  et  al.,  2017).  However,  GI  symptoms  were
significantly exacerbated only in the patients with IBS but not in healthy volunteers. Therefore,
symptom exacerbation following the fructan challenge observed in this trial is supported
mechanistically.
Although significantly fewer patients reported adequate relief of FGS on the final day of the
fructan challenge compared to placebo (glucose), there was no significant differences in the
proportion of participants reporting adequate relief on all three days of the challenges or in the
mean number of days of adequate relief during the challenges. One possible explanation for this
discrepancy is a cumulative effect of fermentable carbohydrates, with FGS becoming
progressively worse with prolonged intake. The lack of symptom exacerbation when analysing
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all three challenge days, but a significant difference when analysing just the final day of the
challenge may indicate a symptom peak on the final day of the fructan challenge compared to
the first two days of the challenge. A cumulative effect of on-going fermentable carbohydrate
intake on GI symptoms is yet to be established in other studies.
Although fructans at a dose of 12 g/d induced GI symptoms compared to placebo (glucose), the
same effects were not observed during the GOS or sorbitol challenges (6 g/d). A soybean-derived
α-GOS (including raffinose, stachyose and verbascose) was chosen in this study to mimic GOS
found in the diet (e.g. pulses, grains and nuts). Mammals lack the α-galactosidase enzyme
required for monosaccharide liberation by hydrolysis of α-1,6 linkages within α-GOS, therefore
dietary α-GOS is assumed to reach the colon intact and become susceptible to bacterial
fermentation. Mechanistic studies investigating the digestion of α-GOS in humans are limited to
raffinose, with 88% passing through the small intestine undigested in a small study of patients
with ileostomies (Saunders and Wiggins, 1981).
The gas-forming capacity of legumes has been known for some time, with several studies in
healthy human volunteers establishing increased flatulence following consumption of different
types of legumes (Steggerda et al., 1966, Calloway et al., 1971, Suarez et al., 1999). Although
these studies were not conducted in patients with IBD or IBS, they indicate that α-GOS-
containing foods increase colonic gas production and therefore have the potential to exacerbate
FGS through luminal distension. The gas-forming properties of legumes relate to colonic
bacterial fermentation of α-GOS contained within them (Singh et al., 2017), supported by an
animal study demonstrating greater gas production following α-GOS-containing soy milk
compared to α-GOS-depleted soy milk (LeBlanc et al., 2008).
Interestingly, the case-control study described in Chapter 2 revealed significantly lower GOS
intake in inactive IBD with FGS compared to healthy controls. This indicated a possible
relationship between GOS and GI symptoms in inactive IBD, which seems discordant with the
lack of GI symptoms following GOS challenge in this trial. However, the effect of GOS in food
form may differ to that in pure form.
The lack of symptom exacerbation observed during the GOS challenge could be explained in
several ways. Firstly, it could be that α-GOS do not induce FGS in patients with IBD. This could
relate to the metabolism and interactions of the complex bacterial community in the GI tract,
which is known to be altered in patients with IBD compared to healthy controls (Sartor and
Mazmanian, 2012). Hydrogen produced via fermentation of dietary α-GOS may be consumed by
other microbes. Methanogens (e.g. Methanobrevibacter smithii) and sulphate-reducing bacteria
(e.g. Desulfovibrio spp.) consume hydrogen and carbon dioxide, reducing the gas molar volume
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of the GI lumen (Blaut, 1994, Gibson et al., 1993). Therefore, individuals harbouring high
numbers of these species may experience fewer symptoms attributable to colonic gas
accumulation (e.g. bloating, flatulence) upon consumption of fermentable carbohydrates. If this
were the case, however, fructans would be expected to be similarly tolerated in these
individuals, which given the significant increase in symptoms following the fructan challenge,
was not the case.
Secondly, the daily dose of GOS (6 g/d) may have been insufficient to significantly exacerbate
FGS,  compared  to  the  fructan  dose  (12  g/d).  The  doses  were  chosen  to  reflect  the  highest
achievable daily intake of GOS in the UK, based on limited dietary intake data that suggested an
average GOS intake of 2 g/d in patients with IBS (Staudacher et al., 2012). In contrast, fructan
intakes in the UK are greater than GOS, at 3.6-4.0 g/d in healthy individuals (Table 3.2), patients
with IBS and patients with inactive CD (Dunn et al., 2011, Staudacher et al., 2012, Anderson et
al., 2015). It was therefore deemed inappropriate to administer equal doses of fructans and GOS
in the current study. Regardless of the different doses of GOS and fructans used in the current
study, the GOS dose was high compared to the average GOS intake of patients with IBS in the
UK (2 g/d), and therefore the lack of significant symptom induction during this challenge is
surprising.
Thirdly, different varieties of beans and pulses contain variable quantities and combinations of
α-GOS and these are altered to differing degrees during processing methods such as soaking and
boiling (Brummer et al., 2015). Different species of pulses have been identified as containing
variable proportions of raffinose, stachyose and verbascose (Guillon and Champ, 2002). It is
therefore likely that α-GOS from different pulse varieties are fermented to differing degrees by
different bacteria and the use of α-GOS derived from another variety in this study may have
rendered different effects on FGS. Additionally, other carbohydrate fractions of pulses such as
resistant starch are fermented by certain GI bacteria and therefore their effects on FGS in IBD
should be investigated (Yang et al., 2013a).
Sorbitol is a polyol found naturally within various fruits and vegetables (Yao et al., 2014) and,
owing to poor intestinal absorption and reduced caloric value compared to sugar, is frequently
added to low calorie products (Zumbe et al., 2001). Mannitol, another common polyol,
significantly increased small bowel water content in healthy volunteers when given as a pure
carbohydrate  challenge  of  17.5  g  (Marciani  et  al.,  2010).  Osmotic  effects  upon  ingestion  of
polyols likely result from their incomplete intestinal absorption, which has been demonstrated
in  an  ileostomy  study  (Langkilde  et  al.,  1994).  Complete  absorption  of  a  10  g  pure  sorbitol
challenge, determined using breath hydrogen concentration following the challenge, was
observed in 40% of patients with IBS and 33% of healthy volunteers (Yao et al., 2014). In that
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study, GI symptoms significantly increased following the sorbitol challenge in patients with IBS,
although malabsorption of the polyols was not required for symptom generation. Other studies
have demonstrated increased GI symptoms following a 10 g dose of sorbitol in > 30% of healthy
subjects (Corazza et al., 1988, Jain et al., 1987).
The lack of symptom induction following the sorbitol challenge in the current study, in contrast
to the aforementioned studies, may relate to differences in the dose of polyol administered (10
g in previous studies vs. 6 g in the current study). Furthermore, patients in the aforementioned
studies took the polyol challenges after an 8-hour fast, in contrast to the current study in which
patients were permitted to take the challenge drink alongside normal diet. Gastric emptying of
liquid sorbitol was slower when ingested with a solid meal than when taken alone in healthy
volunteers (Skoog et al.,  2006), therefore sorbitol may reach the small intestine more rapidly
under fasted conditions and thus induce more noticeable luminal distension and symptom
exacerbation.
Finally, it has been demonstrated that doses of sorbitol much in excess of those used in the
current study (27-30 g) can be well tolerated in healthy volunteers, with just an increase in
flatulence  compared  to  glucose  (Skoog  et  al.,  2006,  Beaugerie  et  al.,  1990).  Although  these
studies were conducted in people without GI symptoms, they again indicate that the lack of
symptom exacerbation following the sorbitol challenge in the current study may be explained
by the relatively small dose used.
It could be argued that since the fructan dose (12 g/d) was double that of the GOS and sorbitol
doses (6 g/d), the symptom exacerbation following fructans may simply reflect a greater load of
fermentable carbohydrate and may not be a fructan-specific effect. Although there was sound
rationale for using different doses of different FODMAPs, further research would be required to
elucidate whether GOS and sorbitol in doses of 12 g induce FGS in patients with IBD.
Despite the seemingly high fructan dose of 12 g/d used in this study, a total habitual FODMAP
intake of 29.6 g/d has been observed in patients with IBS in the UK, with low FODMAP dietary
advice  resulting  in  an  11.9  g/d  reduction  in  total  FODMAP  intake  (Staudacher  et  al.,  2012).
Therefore the 12 g daily dose of fructans likely still represents a relatively typical dietary
FODMAP intake. Furthermore, the only previous study of this nature administered 19 g/d of
fructans, a larger dose than that used in the current study (Shepherd et al., 2008).
3.6.2 Stool output
During the fructan and GOS challenges there was significantly softer stool consistency compared
to placebo. There were no significant differences in stool frequency or the proportion of stools
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classified as normal, loose or hard during any of the fermentable carbohydrate challenges
compared to placebo.
Fructans and GOS are types of dietary fibre (Flamm et al., 2001). Fibre is generally accepted to
accelerate whole-gut transit time through bulking of luminal contents (Brownlee, 2011, Chaplin,
2003). Although fructans and GOS are rapidly and completely fermented by the colonic
microbiota and thus do not have a high water-binding capacity, these highly fermentable fibres
may influence stool frequency and consistency through increased biomass, short-chain fatty
acid production and reduced pH (Blackwood et al., 2000, Flamm et al., 2001).
Fructan supplementation significantly reduced defaecation difficulties in elderly patients
(Marteau  et  al.,  2011),  a  finding  that  has  been  replicated  for  GOS  (Surakka  et  al.,  2009).
Furthermore, a recent randomised, placebo-controlled trial in children demonstrated a
softening of stool form following inulin supplementation compared to placebo (Closa-
Monasterolo et al., 2016), and chicory inulin supplementation increased stool frequency and
reduced the proportion of participants with hard stools in adults with constipation (Micka et al.,
2017).
These previous studies demonstrate the capacity of fructans to influence stool form, as observed
in the current study. However, the above studies were conducted in patients with constipation,
in contrast to the current study in which patients met the criteria for either IBS, functional
bloating or functional diarrhoea. Additionally, some studies have demonstrated no effect of
inulin on stool frequency or consistency in healthy volunteers and patients with constipation
(Slavin and Feirtag, 2011) (Linetzky Waitzberg et al., 2012). Furthermore, a meta-analysis of fibre
supplementation in patients with chronic constipation showed that psyllium, a soluble fibre that
is slowly and partially fermented (Kaur et al., 2011), exerted a greater effect on stool frequency
and consistency than inulin and GOS (Christodoulides et al., 2016). However, unsurprisingly,
inulin and GOS did increase faecal Bifidobacteria counts.
Interestingly, no significant differences in stool frequency or consistency were observed during
the sorbitol challenge compared to placebo. Sorbitol has long been thought to have laxative
effects (Peters and Lock, 1958), owing to an increase in luminal water resulting from incomplete
absorption and low molecular weight (Yao et al., 2014). Sorbitol is therefore used under certain
circumstances for the relief of chronic constipation (Lederle et al.,  1990), although there is a
paucity of RCT evidence to support this (Ramkumar and Rao, 2005). A study in healthy
volunteers demonstrated accelerated colonic transit, but no effect on stool frequency or
consistency, following a 27g dose of sorbitol (Skoog et al., 2006). Although this study was not
performed in patients with IBD or IBS, it demonstrates that doses of sorbitol more than 4 times
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that used in the current study can be tolerated by some individuals. The dose of sorbitol used in
the current study therefore may be insufficient, or a longer period of consumption may be
required, to exert effects on stool output.
3.6.3 Biomarkers
Faecal calprotectin increased significantly between baseline (prior to randomisation) and end of
trial, and sub-group analyses of CD and UC revealed that this effect was specifically observed in
patients with CD only. In any IBD trial, there lies the potential for a natural fluctuation in disease
activity, irrespective of the intervention under investigation. A significant increase in FCP during
the trial may not necessarily indicate an increase in disease activity in patients with CD, but may
represent subtle changes in intestinal inflammation.
While it has been demonstrated that faecal calprotectin concentration in patients with active
UC is reproducible in different aliquots of the same stool sample, it may fluctuate significantly
in different stools passed over a single day and over two consecutive days in the same individual
and faecal calprotectin concentrations increased with length of time between bowel
movements (Lasson et al., 2015). Conversely, faecal calprotectin concentrations on three
consecutive days were similar in patients with inactive CD, suggesting that faecal calprotectin
may be more stable in inactive IBD (Naismith et al., 2013). Whether the rise in faecal calprotectin
observed in this study in an individual sample in patients with CD represents an increase in GI
inflammation or a natural fluctuation is unclear.
A prebiotic is defined as a substrate that is selectively utilised by host microorganisms conferring
a health benefit (Gibson et al., 2017). Numerous studies have demonstrated that fructans and
GOS selectively stimulate Bifidobacteria and Lactobacilli in healthy human subjects (Roberfroid
et al., 2010). The distinction should be made between α-GOS, derived from beans and pulses
(e.g. raffinose, stachyose, verbascose), and β-GOS, which have a terminal β-linked glucose unit
and are commercially synthesised from lactose. These differing types of GOS likely have different
prebiotic  potential  (Vulevic  et  al.,  2004,  Bouhnik  et  al.,  2004)  and  the  majority  of  studies
assessing the prebiotic activity of GOS to date have focussed on β-GOS.
The GI microbiota can interact directly (through interaction of microbial associated molecular
patterns with pattern recognition receptors on immune cells) and indirectly (via, for example,
bacterial metabolites such as butyrate) with the host immune system (Kamada and Kao, 2013).
Certain GI bacteria, including Bifidobacteria, Lactobacilli and Faecalibacterium prausntizii,
exhibit anti-inflammatory or immune-modulatory effects in vitro and in vivo (Breyner  et  al.,
2017, Fanning et al., 2012, Kelly et al., 2005). The GI microbiota are altered in IBD compared to
healthy individuals, most notably characterised by a reduction in the abundance of F. prausnitzii,
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particularly in CD (Pascal et al., 2017). Furthermore, 15 g/d fructan supplementation in patients
with active CD significantly reduced the proportion of mucosal IL-6 positive dendritic cells (DC)
and increased IL-10 staining in DC, indicating that fructans may influence mucosal immune
function in CD (Benjamin et al., 2011b). This occurred in the absence of alterations to
Bifidobacteria or F. prausnitzii, indicating potentially direct effects of prebiotics on the GI
immune system.
The low FODMAP diet requires a restricted intake of dietary prebiotic carbohydrates (fructans
and α-GOS). Unsurprisingly, several RCTs have demonstrated alterations to the gut microbiota
following the diet (Staudacher et al., 2012, Halmos et al., 2014a, McIntosh et al., 2016), including
reduced Bifidobacteria and F. prausnitzii. It is possible that these changes could impact upon
host immune function, although the length of FODMAP restriction required for immunological
changes to occur is yet to be elucidated. In this trial, participants followed a strict low FODMAP
diet prior to and during the re-challenge trial. Whether the rise in faecal calprotectin observed
between the start  and end of  the trial  is  related to  GI  microbiota  changes related to  dietary
prebiotic restriction is unclear, given the lack of GI microbiota assessment in this trial. This issue
is further complicated by the pure FODMAP challenges that overlaid the FODMAP restriction,
which could be seen as a replacement of the restricted dietary prebiotic. Further research is
required to clarify the effect of dietary fermentable carbohydrate restriction and challenge on
biomarkers of intestinal inflammation in IBD.
3.6.4 Significance of results
This is the first trial to establish that fermentable carbohydrates exacerbate GI symptoms in
patients with inactive IBD. The symptom exacerbation observed following the fructan challenge
is supported mechanistically and demonstrates the ability of FODMAPs to exacerbate FGS in
inactive IBD.
The lack of symptom exacerbation following the GOS and sorbitol challenges, in doses at least
three times the average dietary UK intake, could be interpreted to suggest that the low FODMAP
diet, as implemented to date, is excessively restrictive. It could be argued that if patients can
tolerate doses of GOS and sorbitol much in excess of average intake, the diet could be made
more flexible and thus more acceptable to patients. However, caution should be applied in
extrapolating the results of a proof-of-concept study of this nature directly to clinical practice.
Participants were given GOS and sorbitol in pure form and were permitted to take them with or
without food. The physiological responses to the carbohydrate challenges may differ to those
taken within foods. Additionally, the effects of different doses of GOS and sorbitol require
further investigation in the context of FGS in inactive IBD. Although this study does not
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demonstrate  efficacy  of  the  low  FODMAP  diet  in  this  patient  group,  it  suggests  that  a
randomised, placebo-controlled trial of the low FODMAP diet in IBD in remission is warranted.
3.6.5 Strengths and limitations
This is the first randomised, placebo-controlled, double-blinded crossover re-challenge trial to
investigate the effects of fermentable carbohydrate challenges on FGS in patients with inactive
IBD. The study was designed to identify whether fermentable carbohydrates exacerbate FGS in
IBD while overcoming the inherent methodological difficulties associated with establishing
adverse food reactions through restriction of dietary components, namely the potentially large
placebo responses and the possibility of altering dietary components other than those under
investigation.
It was vital that this trial included a placebo challenge, since significant symptom responses to
placebo challenges such as potato starch, sucrose and glucose have been observed in food
elimination and re-challenge studies (Yao et al., 2013). Around 10% of participants reported that
they did not have adequate relief following the glucose challenge, which is comparable to 14%
of patients with IBS in the only other trial of this nature (Shepherd et al., 2008).
The observed effect size of the fructan challenge in the current trial was lower than predicted
from the previous  IBS  trial  (Shepherd et  al.,  2008).  It  was  expected that  50% of  participants
would report inadequate relief of GI symptoms following the fructan challenge, compared to
14% during the glucose placebo (section 3.4.12). However, 38% of participants reported
inadequate relief following the fructan challenge compared to 10% following the glucose. A post
hoc sample size estimation indicates that 38 participants would be required to detect a
difference between groups based upon these findings, suggesting that the trial may have been
under-powered to detect differences between the groups with this smaller effect size.
Open challenges have been demonstrated to be of little value in establishing adverse food
reactions due to the large ‘nocebo’ response, as described above (Yao et al.,  2013). Maximal
blinding of participants and researchers reduces ascertainment bias and is particularly important
in FBD trials (Irvine et al., 2016). Although participants in this trial were aware that the objective
was to assess the effect of fermentable carbohydrates on GI symptoms, they were not informed
of the carbohydrates under study and therefore remained blinded. Although the fructan and
glucose challenge were double the dose of the GOS and sorbitol challenges and would have
appeared to be a larger quantity of powder, this did not appear to increase the symptom
responses since around 90% of participants reported adequate relief following the glucose
challenge. Researchers involved in trial recruitment were blinded to the order of carbohydrate
challenges received by each participant.
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Crossover study designs have been frequently used in functional bowel disorder trials
(AKEHURST  and  KALTENTHALER,  2001).  The  overarching  advantage  of  this  trial  design  is  the
possibility of a smaller sample size, since each individual serves as their own control (Miller,
2014). This is particularly relevant to trials with several treatment arms, where parallel trials may
become infeasibly large. Despite this, the possibility of carryover effects has cast debate over
the suitability of crossover trials for FBDs. Nonetheless, a crossover design was judged most
appropriate for this trial since there were four treatment arms, the challenges were of short
duration, and it was anticipated that the physiological effects of the challenges (GI symptoms)
would be short-lived and therefore unlikely to continue into the following challenge (Miller,
2014). Furthermore, participants were not permitted to commence a challenge until adequate
relief of GI symptoms was achieved, thus reducing the chance of carryover effects.
Adherence  to  the  low  FODMAP  diet  during  the  trial  was  crucial  in  order  to  conclude  with
confidence that the challenges were responsible for any symptom responses observed.
Currently, a validated tool for measuring compliance to this dietary intervention does not exist.
Although participants reported good adherence (defined as ≥75% adherence on all three
challenge days) to the low FODMAP diet, dietary intake was not recorded in a food diary, and
therefore it is impossible to assess for accidental or deliberate FODMAP exposure. Subjective
ratings of compliance are prone to error, since participants may report the level of compliance
that they perceive to be desirable to the researcher. However, completing food diaries can be
burdensome and as a result can alter dietary intake (Lewis et al., 2017). In this trial, dietary
intake would need to be recorded for at least 12 days (4 x 3-day challenges). It was felt that this
would compromise participant retention in the trial, and that the accuracy of recording could
decline as the participant fatigues.
The doses of the carbohydrate challenges were chosen based on previous provocation studies
and upon typical dietary intakes of the carbohydrates. Since typical UK intakes of fructans
exceed those of GOS and sorbitol, a higher dose was chosen for this carbohydrate (12 g/d vs. 6
g/d). This could be viewed as both a strength and limitation of this trial. Providing doses that
reflect the higher end of typical intake potentially makes the findings more clinically relevant,
demonstrating the effects of the carbohydrates as consumed within a normal diet. Providing 12
g/d of all of the challenges would be equal to providing c. 1kg chickpeas for GOS or eight plums
for sorbitol (Muir et al., 2007, Muir et al., 2009). On the other hand, challenging with different
doses of carbohydrates renders the findings difficult to interpret; whether the increase in GI
symptoms observed during the fructan challenge is specific to fructans or simply due to the
greater dose administered requires clarification in future studies.
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3.7 Conclusion
This trial established that a pure fructan challenge exacerbates FGS in patients with IBD in
remission following FGS control with a low FODMAP diet. This may appear to suggest the need
for dietary fructan restriction for the control of FGS in IBD remission, as opposed to a broader
fermentable carbohydrate restriction (the low FODMAP diet). However, the limitations
associated with this trial (namely, the varying doses of fermentable carbohydrates used) and the
difficulties in extrapolating the results to clinical efficacy of dietary carbohydrate restriction are
such that the results of this trial can only be interpreted as an indication that fermentable
carbohydrate restriction diet may be of benefit in IBD.
A recent trial demonstrated that compared to patients with IBD in remission following their
habitual diet, patients randomised to the low FODMAP diet experienced an improvement in FGS
and health-related quality of life (Pedersen et al., 2017). This, together with the evidence from
the  current  re-challenge  trial  that  fermentable  carbohydrates  may  have  a  role  in  FGS
exacerbation in IBD, confirms the need for a randomised, placebo-controlled trial of the low
FODMAP diet in IBD in remission.
4 Design and methods of a randomised controlled trial to
investigate the effect of fermentable carbohydrate restriction
on functional gastrointestinal symptoms, gut microbiota and
blood immunology in patients with inactive IBD
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4.1 Introduction
The evidence that dietary fermentable carbohydrate restriction in IBD is effective is growing.
Uncontrolled studies have suggested an improvement of GI symptoms in patients with inactive
IBD following the low FODMAP diet in clinical practice (Gearry et al., 2009a, Prince et al., 2016)
Furthermore, compared to patients following their habitual diet, the low FODMAP diet resulted
in improved GI symptom severity in a randomised controlled trial (RCT) of patients with inactive
or  mildly  to  moderately  active  IBD (Pedersen et  al.,  2017).  This  was the first  RCT of  the low
FODMAP diet in IBD, however this trial was not placebo-controlled.
Studies of dietary advice for GI symptoms are fraught with issues including the choice of control
treatment. Allocating the control group to a habitual diet renders the trial unblinded and unable
to control for the potentially substantial placebo response in functional bowel disorders such as
IBS (Elsenbruch and Enck, 2015), while the gold standard placebo ‘sham’ diet is extremely
challenging to design. Comparing the treatment of interest to a standard treatment allows
superiority or inferiority of the new treatment to be established, however both treatments may
produce a placebo response which is unaccounted for. Furthermore, blinding can be difficult
since the standard treatment may be commonly known. Another issue faced by researchers
investigating dietary interventions is that posed by the complexity of whole foods, with the
possible inadvertent manipulation of dietary components that may influence the study
outcomes independent of the component under investigation (Yao et al., 2013). The lack of a
placebo control diet in the aforementioned trial of the low FODMAP diet in functional
gastrointestinal symptoms (FGS) in inactive IBD (Pedersen et al., 2017) is a major limitation given
the substantial placebo responses that have been observed in both IBS and IBD (Elsenbruch and
Enck, 2015, Su et al., 2004, Jairath et al., 2016). Detailed dietary advice provided by a healthcare
professional can induce a powerful placebo response and comparing to a control group not
provided with any advice results in uncertainty around the degree of placebo response induced.
This study also lacked an assessment of the GI microbiota before and after the diets, and several
previous trials in IBS have revealed a profound effect of the low FODMAP diet on the
composition of the GI microbiota (Staudacher et al., 2012, Staudacher et al., 2017b). This may
be particularly relevant in patients with IBD given the divergence of the microbiota from that of
healthy controls that likely already exists in a large proportion of patients (Halfvarson et al.,
2017, Pascal et al., 2017). A reduction in immune-regulatory Bifidobacteria, such as has been
observed in several studies of the low FODMAP diet in IBS, has the potential alter GI immune
function (Sarkar and Mandal, 2016). Furthermore, the products of degradation of complex
polysaccharides by Bifidobacteria (e.g. acetate) are substrates for other members of the GI
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microbiota (Turroni et al., 2016). Such cross-feeding reactions mean that a depletion in
Bifidobacteria has the potential to influence other beneficial bacteria, such as Faecalibacterium
prausnitzii (Moens et al., 2016), which has in vitro and in vivo anti-inflammatory actions (Miquel
et  al.,  2013).  Therefore,  through effects  on the GI  microbiota,  the low FODMAP diet  has  the
potential to impact upon the inflammatory process in IBD, although previous studies of the low
FODMAP diet in IBD have failed to measure immunological sequelae.
Additionally, studies assessing the GI microbiota in IBS following a low FODMAP diet have used
quantification methods such as fluorescence in situ hybridisation (FISH) (Staudacher et al., 2012)
and quantitative polymerase chain reaction (qPCR) (Halmos et al., 2014a, Staudacher et al.,
2017b), and two studies have used a 16S rRNA sequencing approach (McIntosh et al., 2016). The
former methods (qPCR and FISH) allow quantification of only a selection of bacteria, while 16S
rRNA sequencing characterises the composition of the GI microbiota but provides no
information on the potential functions of the microbiota.
Therefore, the aim of this RCT was to address the aforementioned issues in design of low
FODMAP diet trials and the lack of randomised, placebo-controlled evidence for the low
FODMAP diet in IBD. The RCT was designed to investigate the effect of low FODMAP dietary
advice compared to placebo sham dietary advice on GI symptoms, GI microbiota composition
and function, blood immunology and inflammatory markers in patients with inactive IBD.
4.1.1 Aims of the RCT
The aim of this RCT was to investigate the effect of low FODMAP dietary advice compared to
placebo ‘sham’ dietary advice on FGS, GI microbiota, circulating T-cell gut-homing phenotype
and markers of intestinal inflammation in patients with inactive IBD with FGS.
Primary objective: to investigate the change in symptom severity score (IBS-SSS) following low
FODMAP dietary advice compared to placebo ‘sham’ dietary advice in patients with inactive IBD
with FGS.
Secondary objectives:
To investigate the effect  of  low FODMAP dietary  advice  compared to  placebo ‘sham’  dietary
advice on the following outcomes in patients with inactive IBD with FGS:
1. GI symptoms and stool output:
a. Adequate relief of GI symptoms (global symptom question)
b. Individual GI symptom incidence and severity (gastrointestinal symptom rating
scale)
c. Stool frequency and consistency (Bristol stool form scale)
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2. Clinical disease activity (Harvey Bradshaw Index for CD and Partial Mayo Score for UC)
3. Patient perceived control of IBD (IBD control questionnaire)
4. Health-related quality of life (UK inflammatory bowel disease questionnaire, IBDQ)
5. Food-related quality of life (Food-related quality of life questionnaire)
6. Biomarkers of intestinal inflammation:
a. Faecal calprotectin
b. Serum C-reactive protein
7. GI luminal environment:
a. Faecal microbiota composition and function
b. Faecal SCFA concentration
c. Faecal pH
d. Faecal volatile organic compounds





There is no difference in the change in symptom severity score (IBS-SSS) at four weeks following
low FODMAP dietary advice compared to placebo sham dietary advice in patients with inactive
IBD with FGS.
Alternative hypothesis:
There is a difference in the change in symptom severity score (IBS-SSS) at four weeks following
low FODMAP dietary advice compared to placebo sham dietary advice in patients with inactive
IBD with FGS.
4.2 Interventions, trial design and approvals
4.2.1.1 Trial design
The major objectives of treatment trials for functional bowel disorders (FBD) are to ascertain
whether the intervention of interest relieves symptoms, improves health-related quality of life,
improves ability to cope with the symptoms and decreases the use of healthcare resources,
while avoiding harm (Irvine et al., 2016).  The randomised, double-blind, placebo-controlled
parallel group trial reduces major sources of bias and confounding and therefore remains the
gold standard method to investigate efficacy of a new treatment (Kramer and Shapiro, 1984,
Irvine et al., 2016). Trials in FBD pose unique challenges including the high placebo response
characteristic of these conditions (Elsenbruch and Enck, 2015), the lack of biomarkers and
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subjectivity of symptom reporting, fluctuation of symptoms, heterogeneous symptom aetiology,
difficulty in blinding participants and investigators in trials of behavioural interventions, and a
lack of appropriate and validated endpoints for some types of FBD (Irvine et al., 2016).
Furthermore, the background of inactive IBD in the current trial may influence GI symptoms and
introduces potential confounding factors including medications, prior dietary restrictions, prior
GI surgery and heterogeneous IBD phenotype.
As outlined above, dietary intervention trials pose challenges not encountered in
pharmacological treatment trials. One complexity of dietary trials is the choice of an appropriate
control or comparator group, since designing placebo dietary advice is extremely challenging.
Blinding participants and investigators to the treatment allocation is also problematic compared
with drug trials, since a dietary intervention is clearly easier to identify than a pill (Yao et al.,
2013). Finally, with no recognised reporting guidelines for dietary intervention trials, the quality
of trials and papers reporting dietary interventions is highly variable.
This study was a multi-centre, single-blinded, randomised, parallel placebo-controlled trial
conducted in line with CONSORT recommendations. The trial protocol and procedures are
illustrated in Figure 4.1. Although participant blinding was made possible through using placebo
dietary advice, it was not possible to blind the investigator providing the advice since dietary
counselling was required. Dietary counselling was used to mimic clinical practice (except for an
explanation of the proposed mechanisms of the diet) and to maximise participant compliance
to the dietary interventions.
The duration of the dietary intervention was four weeks, based upon previous studies of 3-4
weeks duration demonstrating efficacy of the low FODMAP diet in IBS (Staudacher et al., 2012,
Halmos et al., 2014b, McIntosh et al., 2016, Eswaran et al., 2016, Bohn et al., 2015, Staudacher
et al., 2017b). Furthermore, although not all women have a 28-day menstrual cycle, a 4-week
trial may reduce the potential confounding effect of menstruation on GI symptoms in a
proportion of female subjects, which may be enhanced in patients with IBD, particularly CD
(Bernstein et al., 2012), and in IBS (Heitkemper et al., 2003).
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Figure 4.1 The RCT protocol and procedures; PGA, Physician Global Assessment; CRP, C-reactive protein; FCP, faecal calprotectin; GI, gastrointestinal; QoL, quality of life; SCFA,
short-chain fatty acids
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4.2.1.2 Trial sites
Trial recruitment took place at Guy’s and St Thomas’ NHS Foundation Trust and Barts Health
NHS Trust, London, UK. All participants were recruited by the thesis author from
gastroenterology and dietetic outpatient clinics and trial visits took place in the hospital clinic or
in the Department of Nutritional Sciences, King’s College London.
4.2.1.3 Patient selection
Patients were recruited between February 2016 and April 2017. Enrolled patients were those
that met the following criteria:
4.2.1.3.1 Inclusion criteria
· Men and women aged ≥18 years
· Diagnosis of IBD, as defined by:
o Standard clinical, histological and radiological criteria
o Diagnosis at least 6 months prior to screening
· Inactive disease, as defined by:
o Physician Global Assessment
o Faecal calprotectin <250 μg/g
o Serum CRP <10 mg/L
o Stable medications (see exclusion criteria)
o No GI surgery in the 6 months preceding screening
o No IBD flare in the 6 months preceding screening
· GI symptoms fulfilling the following criteria:
o Have been assessed with objective investigations and thought not to be a
result of active inflammation, and which do not require escalation of IBD
medications
o Meet the Rome III criteria for IBS-D, IBS-M, IBS-U, functional bloating or
functional diarrhoea
o Meet the required threshold:
§ Lack of adequate relief of symptoms during the screening week
§ Mild, moderate or severe abdominal pain, bloating or diarrhoea on at
least 2 days during the screening week
· Have not been exposed to a low FODMAP diet in the past
· Individuals able to give informed consent
· A willingness to participate
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4.2.1.3.2 Exclusion criteria
· Any evidence of active disease, defined as:
o Requiring escalation in medications as assessed by the treating physician
o Currently taking steroids
o GI surgery is thought to be imminent
· Changes in dose of azathioprine, 6-mercaptopurine, methotrexate or anti-TNF-α
agents in the preceding 12 weeks, or oral 5-ASA in the preceding four weeks
· Constipation-predominant symptoms (either meeting criteria for IBS-C or functional
constipation)
· Use of antibiotics, probiotics or prebiotics in the preceding eight weeks or non-
steroidal anti-inflammatory drugs in the preceding week
· Pure perianal disease
· Current stoma
· Other factors likely to be the cause of gut symptoms:
o Extensive colonic or small intestinal resection
o Symptoms thought to relate to a current stricture
o Taking any medications with the potential to influence GI symptoms, e.g.
lactulose, loperamide or senna, unless taking long-term stable dose that is
unlikely to change or stop during the trial
o Individuals with established bile acid malabsorption
· Comorbidities:
o Sepsis or fever
o Diabetes or coeliac disease
o Other concomitant serious comorbidity e.g. significant hepatic, renal,
endocrine, respiratory, neurological or cardiovascular disease
· Seen by a dietitian in the preceding 6 months for advice regarding nutrition support
· Pregnancy or lactation
· Full bowel preparation for a diagnostic or monitoring procedure in preceding 4 weeks
4.2.1.4 Intervention
The principles and practical aspects of the low FODMAP diet are described in section 1.4. Briefly,
this diet requires exclusion of foods high in fructans, galacto-oligosaccharides, lactose, fructose
and polyols (including sorbitol and mannitol). This was achieved through provision of food lists
to participants, which clearly stated foods that were permitted (low in fermentable
carbohydrates) and foods that were to be avoided (high in fermentable carbohydrates).
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As discussed in section 4.1, use of a placebo group is particularly desirable in trials of functional
bowel disorders given the considerable placebo response in these conditions (Elsenbruch and
Enck, 2015). Placebo responses of 10-33% have also been observed in maintenance and
treatment trials in IBD (Jairath et al.,  2016, Su et al.,  2004). To overcome the lack of placebo
dietary advice for use in comparison to the low FODMAP diet, placebo ‘sham’ dietary advice had
been developed previously by our group (Staudacher et al., 2017b). Three previous trials have
utilised  sham  dietary  advice  effectively  in  patients  with  CD,  two  of  which  investigated  an
exclusion diet based upon IgG-specific responses (Bentz et al., 2010, Gunasekera et al.) and one
that investigated a low microparticle diet (Lomer et al., 2005).
The aims of the sham dietary advice were as follows:
1. To provoke dietary modifications in patients in the control group, while masking diet
allocation, such that a placebo response may be generated
2. To maintain an intake of macronutrients and micronutrients comparable to baseline
3. To maintain an intake of fermentable carbohydrates comparable to baseline
Development of the sham diet began with a review of suitable and unsuitable foods on the low
FODMAP diet. Foods likely to contribute significantly to UK FODMAP intake (e.g. wheat, onion,
garlic, apples, pears) were allocated to the ‘suitable’ foods list, since restricting these would
likely restrict overall FODMAP intake. Meanwhile, foods less likely to make a significant
contribution to FODMAP intake, such as rye and millet, were allocated to the ‘restricted’ list.
There was also consideration of foods that, when restricted, may influence intake of other foods
that  are  typically  eaten  alongside  them.  For  example,  tomatoes  are  often  eaten  in  dishes
containing onion and garlic, and therefore tomatoes were allocated to the ‘suitable’ food list.
Certain principles of the low FODMAP diet were consistent within the sham diet; for example,
while meat and meat products were generally on the ‘suitable’ list, those containing unsuitable
ingredients, such as chives, were unsuitable. The sham diet was shown to be successful in a large
RCT of patients with IBS, where nutrient and FODMAP intake were not changed by the diet
(Staudacher et al., 2017b)
All patients randomised to the trial (in both groups) completed a 7-day food diary prior to
randomisation, which was assessed at the baseline visit. The relevant dietary advice was then
provided, consisting of counselling on the foods permitted and excluded without an explanation
of the proposed mechanisms of the diet, a process which took approximately 20 minutes for all
participants. Written dietary resources were provided to all participants.
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4.2.1.5 Sample size calculation
The sample size calculation was based on the primary endpoint, the change in symptom severity
score (IBS-SSS) between baseline and end of trial in the low FODMAP diet compared to the
placebo sham diet groups.
The estimate of the effect size of the low FODMAP diet was based on the findings of an RCT
assessing the effects of a low FODMAP diet compared to a placebo sham diet in patients with
IBS (Staudacher et al., 2017b). Design of the current trial was similar in its use of the same
placebo sham diet although the patient groups were different (IBD vs. IBS). However, in the
absence of any published RCTs of the low FODMAP diet in IBD at the time of calculating the
sample size, this trial was the most similar on which to base the sample size. Furthermore, the
aim of the current RCT was to examine the effect of the low FODMAP diet in patients meeting
the criteria for functional bowel disorders with a background of IBD, therefore it could be
expected that the effect size would be similar to that in patients with IBS.
In the previous trial, the mean change in IBS-SSS score between baseline and week four in the
low FODMAP diet group and sham diet group was -118 (SD 86) and -44 (SD 72), respectively. The
sample size calculation was performed by hand using a formula for the comparison of two
sample means (Bland, 2000):
݊ = ݂(ߙ,ܲ)ߪଶ2(ߤଵ − ߤଶ)ଶ
݊ = 7.9 ݔ 86ଶ ݔ 2(118 − 44)ଶ
݊ = 1168565329
݊ = 22 per group
Where:
f = significance level multiplied by power
α = significance level
β = power
σ = standard deviation of mean of low FODMAP diet group in previous trial
μ1 = mean of the low FODMAP diet group in previous trial
μ2 = mean of the sham diet group in previous trial
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Assuming a power of 80% and overall 2-sided significance of 5%, 44 participants would be
required across both groups to detect a difference between the diets. Based on previous work
by our group (Staudacher et al., 2012, Staudacher et al., 2017b), 15% attrition was assumed,
leading to an overall sample size of 52 participants across both groups (26 per group).
4.2.1.6 Recruitment
All patients were recruited by the thesis author (SC) from Guy’s and St Thomas’ NHS Foundation
Trust (n=23) and Barts Health NHS Trust (n=29) and were mainly identified via two routes.
Firstly, doctors, specialist nurses and pharmacists identified potentially suitable and interested
patients and referred them to the investigator in weekly gastroenterology outpatient and
infusion clinics at the included hospitals. Furthermore, potentially suitable patients were
identified in virtual clinics and multi-disciplinary meetings.
Secondly, gastroenterology specialist dietitians at Guy’s and St Thomas’ NHS Trust vetted
dietetic referrals for patients with inactive IBD requiring advice for GI symptoms and these were
regularly viewed by the investigator. Patients who appeared to meet the main inclusion criteria
upon preliminary medical note screening were contacted by the investigator.
4.2.1.7 Randomisation
This was a randomised trial. Randomisation reduces selection bias and ensures balance of
characteristics, which may influence study outcomes, across the study groups.  Allocation bias
can occur in treatment trials through allocating individuals with particular known and unknown
characteristics to particular groups, via selectively enrolling participants into a trial based upon
the next treatment allocation (Kahan et al., 2015). This can lead to biased estimates of the effect
size of interventions.
Randomisation was stratified based upon diagnosis (CD or UC) and faecal calprotectin at
screening (≤100 μg/g and >100 μg/g), resulting in four strata (CD, ≤100 μg/g; CD, >100 μg/g; UC,
≤100 μg/g; UC, >100 μg/g). Stratified randomisation ensures that certain participant
characteristics, that may have an influence on treatment effect, are balanced across study
groups (Doig and Simpson, 2005). Patients with CD and UC may respond differently to a dietary
intervention given their distinct pathophysiologies, as illustrated by a systematic review
demonstrating different effects of fibre supplementation in patients with CD and UC (Wedlake
et al., 2014). Additionally, IBD activity could affect response to dietary interventions, as
demonstrated in which children with CD entering remission following enteral nutrition had a
lower clinical disease activity score at baseline than those who did not (Sigall-Boneh et al., 2014).
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Randomisation occurred in blocks of eight participants. Block randomisation is commonly used
to ensure equal numbers of participants are allocated to each group within a trial. In contrast to
simple randomisation, this method reduces the chance that the groups contain unbalanced
numbers of participants should the trial cease earlier than expected. However, a drawback of
block randomisation in single-blinded trials is that it is easier for investigators to correctly guess
the next group allocation, therefore compromising allocation concealment (Doig and Simpson,
2005). Larger block sizes mitigate this issue to some extent.
A random allocation sequence was prepared by a researcher not involved in trial recruitment
(Dr Megan Rossi, Research Associate, King’s College London) using an online program
(www.sealedenvelope.com),  with  a  1:1  ratio  of  low FODMAP to sham diet  allocation.  Group
allocation for each trial ID was sealed in an opaque envelope, with separate envelopes for each
stratum. Envelopes were stored in a locked filing cabinet at King’s College London and the next
envelope was opened only after baseline data had been collected.
4.2.1.8 Blinding
Maximum blinding of participants and investigators is advisable in any treatment trial,
particularly in trials of FGS which often involve behavioural interventions and use subjective end-
points (Irvine et al., 2016). Blinding participants and investigators reduces conscious and
unconscious bias associated with knowledge of treatment allocation. For example, ineffective
blinding can alter expectation bias in participants in different treatment groups of a trial
(Staudacher et al., 2017a). Blinding of dietary interventions is notoriously more challenging than
that of pharmacological treatments.
Placebo ‘sham’ dietary advice was used in the control group in this trial. During screening,
participants were informed that the purpose of the trial was to investigate a type of dietary
intervention that may improve GI symptoms. For ethical reasons, patients were informed that
they would be randomly allocated to either the ‘intervention’ diet group (described as the
dietary advice under investigation) or the ‘placebo’ diet group (described as the control or
comparison dietary advice). The appearance of the written resources for both the diet groups
were similar, with the exception of the foods listed as ‘suitable’ and ‘unsuitable’. The terms
‘fermentable carbohydrates’, ‘the low FODMAP diet’ or mechanisms of the intervention were
not mentioned in the study information, written resources or verbally by the investigator. In
accordance with the use of the low FODMAP diet in clinical practice, both booklets provided a
list of low and high fibre foods to ensure that participants maintained their habitual fibre intake.
The dietary advice was provided in the same style for both groups and the same amount of time
was taken to deliver it. To ensure similar efficacy of the diet to that seen in clinical practice, the
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dietary advice was provided by the same registered dietitian trained in the low FODMAP diet
(SC), who could therefore not be blinded to the allocation.
4.2.1.9 Compliance
Compliance to an intervention during a treatment trial can have a major impact upon its
measured effectiveness (Yao et al., 2013) and may be influenced by prior patient beliefs and
behaviours, socioeconomic issues, knowledge or suspicion of the treatment allocation, and side
effects of the treatment. Trials involving whole diet interventions, such as the low FODMAP diet,
require adherence to many dietary modifications in free-living individuals, which could limit
compliance compared to pharmacological or nutrient trials that simply require taking a
pill/supplement. Previous studies have demonstrated variable compliance to dietary
interventions for functional bowel disorders, which likely reflects variable patient characteristics
and measures of compliance (Osicka et al., 2015).
Measuring compliance to dietary interventions is usually via subjective participant ratings, which
can be influenced by the participant’s perception of the desired response and by their
perception of compliance, which may differ from that of the investigator. Nutritional biomarkers
have been used as measures of compliance in, for example, fatty acid supplementation
(Patterson et al., 2015) and whole diet interventions (Le Marchand et al., 1994), and reduce bias
associated with subjective measures. However, to date there are no biomarkers for compliance
to the low FODMAP diet. Therefore, in previous trials of the low FODMAP diet, compliance with
the dietary intervention has been measured using food records and participant-reported ratings
of compliance (Staudacher et al., 2012).
In this trial, overall participant-reported compliance was assessed with a question at the end of
trial visit relating to compliance throughout the whole 4-week diet. Participants were asked to
rate overall compliance to the trial diet in the previous week as: “never/rarely” (0-25% of the
time), “Sometimes” (25-50% of the time), frequently (50-75% of the time) or “always” (75-100%
of the time). For defining the patients to be included in the per protocol analysis, compliance
with the diet was defined as reporting to have followed the diet ≥ 75% of the time throughout
the trial.
To monitor and encourage optimal compliance, participants were also asked about compliance
on a weekly basis during telephone contact with the investigator using the aforementioned
responses. Additionally, participants were asked to recall dietary intake in the preceding 24
hours and this was also used to determine the correct compliance rating. Weekly compliance
ratings were not used in the end of trial overall compliance assessment.
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4.2.1.10 Adverse events and withdrawals
Adverse events were monitored by the investigator during weekly telephone contact with the
participant throughout the 4-week trial, and at the end of trial visit. For each reported adverse
event, onset, duration, frequency, intensity, management and possible relationship with the
trial diet was recorded. Where the relationship with the trial diet was unclear, the principle
investigator for the appropriate trial site was contacted for clarification.
Participants were free to withdraw at any time during the trial, and could do so without
providing a reason (classified as having ‘withdrawn consent’). Where participants were not
contactable for several consecutive weeks despite multiple attempts from the investigator, they
were deemed ‘lost to follow up’ and were withdrawn from the trial. Additionally, participants
meeting an exclusion criterion during the trial (for example commencing antibiotics, changing
IBD medications or becoming pregnant) were withdrawn.
4.2.1.11 Ethics approval
Ethical approval for the trial was granted by the London – Dulwich Research Ethics Committee
on 22nd October 2015 (15/LO/1684) and the RCT was registered on the ISRCTN registry on 21st
January 2016 (ISRCTN17061468). No patients were recruited until ethical approval and trial
registration were in place.
4.3 Trial protocol and procedures
The trial protocol and procedures are illustrated in Figure 4.1.
4.3.1.1 Screening 1
Patients expressing interest in the trial were screened against inclusion and exclusion criteria
and, if eligible, were provided with a participant information sheet. They were invited to arrange
a screening visit once they had read and understood the participant information sheet.
At the screening visit, informed consent was taken and patients were provided with a 7-day food
and symptom diary and a whole stool collection kit for the subsequent baseline visit. The patient
provided a stool sample for faecal calprotectin screening (analysed by the author of this thesis
(SC), using the technique described in section 3.4.11.3) and a blood sample for CRP screening
(analysed in the hospital pathology department). The food and symptom diary was completed
for 7 days preceding the baseline visit.
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4.3.1.2 Screening 2
On the final day of the 7-day food and symptom diary, patients were contacted to determine
whether symptoms reported during the screening week met the threshold required for inclusion
in the trial (not reporting adequate relief of GI symptoms, as well as abdominal pain, bloating or
diarrhoea on at least two of seven days) (section 4.2.1.3). Patients reaching the symptom
threshold were invited to return for a trial baseline visit the following day.
4.3.1.3 Baseline visit
Food and symptom diaries were checked for completeness and accuracy and data regarding
smoking history, current medications and previous flares of IBD were collected and participants
completed five questionnaires measuring various clinical outcomes (section 4.4). Body weight
and height were measured.
Participants provided a whole stool sample as well as blood samples for immunology analysis
and serum storage.
Following measurement of all baseline outcomes, the randomisation envelope was opened and
the trial diet allocated to the patient was explained in detail by the thesis author (SC) with
reference to the patient’s habitual diet as outlined in the 7-day screening diary.
4.3.1.4 Weekly monitoring
Participants were contacted weekly during the 4-week trial to address concerns and to monitor
compliance and any changes in medication and smoking status.
4.3.1.5 End of trial visit
Participants provided a further 7-day food and symptom diary which had been completed during
the fourth and final week of the trial diet. This diary was checked for completeness by the thesis
author (SC) and dietary intake was reviewed. Any changes in medications or smoking history
were documented and participants were asked whether they were aware of their diet allocation
(intervention or placebo). Participants completed six questionnaires to measure various clinical
outcomes and diet acceptability (section 4.9) and body weight was measured.
Participants provided a whole stool sample and blood samples were collected as in the baseline
visit, with an extra vacutainer of blood collected for CRP measurement.
Following measurement of all outcomes, diet allocation was revealed to the participant and
participants allocated to the low FODMAP diet group during the trial were provided with
FODMAP reintroduction advice, in line with standard clinical practice. Participants allocated to
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the sham diet group were provided with the low FODMAP dietary advice if they wished and a
follow-up appointment was arranged with the investigator to discuss FODMAP reintroduction.
4.4 Outcome measures and rationale: clinical efficacy
4.4.1 Gastrointestinal symptoms and stool output
Gastrointestinal symptoms in patients with IBD and functional bowel disorders are extremely
heterogeneous within and between individuals, and thus the accurate and meaningful
measurement of these symptoms is challenging (Klein, 1988).
Irritable bowel syndrome is a disorder diagnosed and monitored through GI symptoms alone,
and therefore a symptom measure used in clinical practice and research must accurately reflect
patient’s symptoms and have the ability to detect clinically meaningful symptom responses
(Irvine et al., 2006). Symptom measures in IBS are broadly classified as ‘global’ measures (e.g.
Adequate Relief), individual symptom measures or composite symptom measures (Bijkerk et al.,
2003). Ideally, symptom measures in IBS should span relevant elements of the operational
definition (Klein, 1988), which according to the Rome IV diagnostic criteria are abdominal pain
and an altered bowel habit (Mearin et al., 2016).
The concept of an overlap between FGS and IBD is relatively new, with the traditional view that
the conditions are pathophysiologically and clinically distinct (Barbara et al., 2014). While there
are clear similarities in GI symptoms experienced by patients with IBS and IBD (Quigley, 2016),
there are likely fundamental differences in illness experiences and symptom perception in
patients with IBD. The use of tools validated in patients with ‘true’ IBS in patients with IBD may
therefore  be  problematic.  However,  to  date  there  are  no  GI  symptom  measures  validated
specifically for use in patients with FGS in IBD. Although it is debatable whether patients with
IBD can meet the Rome criteria for a functional bowel disorder (given the presence of an organic
abnormality) (Quigley, 2016), in the absence of specific tools for this patient group IBS validated
tools continue to be utilised (Halpin and Ford, 2012, Prince et al., 2016).
4.4.1.1 Rationale for choice of method: IBS Severity Scoring System (IBS-SSS)
The IBS Severity Scoring System (IBS-SSS) was used as a composite scoring system in the current
study (Francis et al., 1997). The IBS-SSS is composed of four visual analogue scales (VAS),
assessing the frequency and severity of abdominal pain, severity of bloating, satisfaction with
bowel habits and interference of symptoms with life in general. Each question is scored out of
100, with a maximum total score of 500. Scores of 75-175 are deemed ‘mild’ IBS, 175-300 are
‘moderate’ and >300 are ‘severe’ (Francis et al., 1997). This scoring system has been validated
across a combination of secondary and tertiary care patients and demonstrated reproducibility
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and sensitivity to a clinically meaningful change in symptoms following hypnotherapy (Francis
et al., 1997). In a study comparing different functional symptom measures, the IBS-SSS
performed well in parameters such as responsiveness, face validity, content validity and
construct validity, although the practical utility was questioned given the difficulty in using VAS
experienced by some patients (Bijkerk et al., 2003).
The  IBS-SSS  has  several  merits  which  made  it  appealing  for  use  in  this  trial.  It  includes  an
assessment of both abdominal pain and bowel habits, the diagnostic criteria for IBS, and
therefore the measure demonstrates content validity. Furthermore, it specifically measures
abdominal pain rather than discomfort, in contrast to other IBS symptom questionnaires
(Svedlund et al., 1988). The IBS-SSS includes an assessment of both abdominal pain severity and
incidence. Severity of irritable bowel syndrome is considered by the Rome Foundation an
important factor in determining patients’ illness experience and behaviour, and in guiding
diagnostic decisions and treatment planning (Drossman et al., 2011).  The IBS-SSS also includes
a measure of the impact of symptoms on life in general, an important consideration in IBS
treatment given the significant impact of IBS symptoms on quality of life (Chang, 2004). Finally,
given that this measure provides an absolute score, a minimally clinically important difference
(MCID)  can  be  detected  following  treatment.  A  fall  in  absolute  score  of  ≥50  points  was
determined to perform with optimal sensitivity and specificity to detect this MCID (Francis et al.,
1997).
The attention given to abdominal pain in the IBS-SSS could be seen as both a strength and a
limitation of this measure. Although pain is a cardinal symptom of IBS, other common symptoms
such as flatulence and belching are omitted from the IBS-SSS. These symptoms can be equally
or more debilitating for some patients than abdominal pain (Spiegel et al., 2010, Lembo et al.,
1999).
4.4.1.2 Rationale for choice of method: Adequate relief
The global symptom measure of adequate relief was used in this trial. Global measures of GI
symptoms are attractive for use in functional bowel disorders given the heterogeneous
symptom profile experienced by patients and because they are simple to administer and
interpret (Naliboff et al., 1999). Adequate relief, measured using the Global Symptom Question
(GSQ), has traditionally been considered acceptable as the primary endpoint in functional bowel
disorder trials (Irvine et al., 2006), and hence many pharmaceutical IBS trials have used this
measure as the primary endpoint (AKEHURST and KALTENTHALER, 2001). A Rome Foundation
working party showed equivalent construct validity of the GSQ when compared to a 50%
improvement in pain, and both outcome measures were able to detect MCID (Spiegel et al.,
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2009). Adequate relief has demonstrated efficacy of various drugs for IBS such as alosetron and
cilansetron, where this measure performed equivalently to symptom-specific measures
(Camilleri et al., 2007).
However, this type of outcome measure has faced criticism in recent years. Baseline symptom
severity may confound a clinical response determined using this measure (Whitehead et al.,
2006), and it is not sensitive to changes in individual symptoms or different symptom responses
in different IBS subtypes. Furthermore, since it is a dichotomous outcome, it may not always be
capable of detecting a deterioration in symptoms (Camilleri et al., 2007). These concerns have
led the US Food and Drug Administration (FDA) to discourage the use of global symptom
measures as primary end-points in clinical trials of FBD (Irvine et al., 2016).
Nonetheless, based on the merits of this measure described above, many IBS trials continue to
use it and it arguably reflects an improvement in overall symptoms important to the individual
patient (Camilleri et al., 2007), therefore it was used in this trial.
4.4.1.3 Rationale for choice of method: Gastrointestinal Symptom Rating Scale (GSRS)
The gastrointestinal symptom rating scale (GSRS) was used to measure individual symptoms in
the current trial. While the IBS-SSS provides a measure of some GI symptoms, several potentially
relevant symptoms are omitted, such as faecal urgency, flatulence, fatigue and specific changes
in stool output (Spiegel et al.,  2010). The GI symptom rating scale (GSRS) is a modified Likert
scale (Svedlund et al., 1988, Revicki et al., 1998, Wiklund et al., 2003). A study comparing the
psychometric and methodological characteristics of IBS symptom measures concluded that the
GSRS demonstrates internal consistency, face validity, content validity and construct validity
(Bijkerk et al., 2003). In a trial of 234 patients with IBS, the GSRS demonstrated test-retest
reliability, was able to discriminate different symptom clusters and was responsive to changes
in symptoms (Wiklund et al., 2003).
The GSRS includes categorical responses for symptom severity, with the variation used in this
trial including ‘absent’, ‘mild’, ‘moderate’ and ‘severe’. This carries the inherent limitation that,
in  contrast  to  VAS,  patients  are  forced to  choose from limited responses,  when in  fact  their
answer may lie between the possible responses. This may therefore compromise sensitivity and
poses potential challenges in statistical analysis in converting categorical responses to numerical
scores (Naliboff et al., 1999).
4.4.1.4 Rationale for choice of method: Bristol Stool Form Scale
Stool frequency and consistency was measured using the Bristol Stool Form Scale. Stool
consistency is an important component of stool output and refers to viscosity and rheology of
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stool. Stool consistency is mainly determined by water content, with the ratio of faecal water to
solids remaining within a narrow range in healthy individuals despite variation in stool volume
(Wenzl et al., 1995). Furthermore, stool consistency correlates with the proportion of stool
water in patients with chronic diarrhoea (Wenzl et al., 1995). An evaluation of stool output in
healthy individuals showed that 33% of women and 40% of men regularly pass stool once a day
(Heaton et al., 1992). Dietary habits can influence stool frequency and consistency. For example,
more frequent and softer stools are passed by healthy individuals following a vegan diet
compared  to  those  following  an  omnivorous  diet  (Davies  et  al.,  1986).  It  was  especially
important in this trial, given that altered stool output is required for a diagnosis of IBS (Mearin
et al., 2016) and is a common feature of IBD (Mowat et al., 2011).
Stool water content, viscosity and rheology can be measured directly using lyophilisation, a
viscometer and a penetrometer, respectively (Bliss et al., 1999, Wenzl et al., 1995, Davies et al.,
1986).  However,  this  poses  clear  logistical  challenges  in  treatment  trials,  in  which  it  may  be
desirable to assess stool consistency prospectively over several days or weeks. In these
circumstances, stool shape and texture may instead be assessed visually and recorded by
participants (Bliss et al., 1999).  Stool form scales have been developed for this purpose, and the
most commonly used in the UK is the Bristol Stool Form Scale (BSFS) (O'Donnell et al., 1990).
This scale has been utilised for a number of years in research and clinical practice, and has been
adapted for use in children (Lane et al., 2011) and translated into a number of languages (Chira
and Dumitrascu, 2015, Pares et al., 2009, Martinez and de Azevedo, 2012). However, despite its
widespread use and recommendation for use by the Rome Foundation (Mearin et al., 2016), the
BSFS has only recently undergone extensive validation (Blake et al., 2016).
Discrepancy between recalled and recorded stool frequency and consistency has been observed
in patients with IBS (Coletta et al., 2010). Furthermore, poor concordance in stool output was
observed when measured with a 4-week diary compared to a retrospective questionnaire in
healthy adults (Bellini et al.). Therefore in this trial, the form of each stool passed during the
week  prior  to  the  baseline  visit  and  the  week  prior  to  the  end  of  trial  visit  was  recorded
prospectively (and therefore stool frequency was also measured) to minimise recall bias.
4.4.2 Clinical disease activity
The goal of therapy in IBD is to manage inflammation effectively in order to improve quality of
life and reduce the risk of long-term complications, while minimising the risks associated with
therapy. There are three main factors that must be considered in the assessment of IBD activity:
the overall impact of current symptoms on the patient, the extent and severity of inflammation
and any damage that inflammation has inflicted on the GI tract (Peyrin-Biroulet et al.).
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Assessment of IBD activity can include clinical, biochemical, endoscopic, radiologic and histologic
measures (Walsh et al., 2016).
Clinical activity indices are based exclusively or partially on GI and extra-intestinal symptoms.
The first clinical disease activity index for Crohn’s Disease was developed in 1976 to enable
consistent assessment of disease activity in Crohn’s disease clinical trials (Best et al., 1976) and
several alternatives have subsequently been developed, in addition to UC disease activity indices
(Walsh et al., 2016).
4.4.2.1 Rationale for choice of method: Harvey-Bradshaw Index (HBI)
The Harvey Bradshaw Index (HBI) was used to assess clinical activity of CD in this trial. The HBI
is a short disease activity index for CD and comprises five questions, assessing general well-
being, abdominal pain, liquid stools, abdominal mass and extra-intestinal symptoms in the
preceding 24 hours (Harvey and Bradshaw, 1980). This is simple to administer and is suited to
clinical trials. The Crohn’s Disease Activity Index (CDAI) is based upon the number of liquid stools,
abdominal pain and overall well-being measured across 7 days. The CDAI continues to be the
most widely used instrument for the assessment of CD activity in clinical trials, however it is
rarely used in clinical practice due to the logistical challenges and complexity associated with
completing and scoring the instrument (Walsh et al., 2016). Furthermore, significant inter-
observer variability has been noted in the use of the CDAI (Sands and Ooi, 2005). Although the
HBI omits several components included in the CDAI, results of the two instruments display a
strong positive correlation (Harvey and Bradshaw, 1980, Vermeire et al., 2010). Furthermore,
results of the HBI appear to display less variability than the CDAI (Jorgensen et al., 2005).
Although a 7-day GI symptom diary was completed prior to enrolment in the current trial, it was
felt that certain components of the CDAI would be difficult for the investigator to obtain (e.g.
recent haematocrit may not be available since patients were in remission). Therefore, given the
aforementioned strong correlation between the CDAI and the HBI, the HBI was used for
assessing CD activity at the baseline and end of trial visits.
4.4.2.2 Rationale for choice of method: Partial Mayo Score
The Partial Mayo Score was chosen to measure UC disease activity in the current trial since it is
simple to administer and is derived from the Mayo Score, the most widely used invasive disease
activity index (Su et al.). This is in contrast to the case-control study described in Chapter 2 of
this thesis (section 2.4.3), where a Physician Global Assessment (PGA) was not always possible
due to the recruitment methods (for example, from virtual gastroenterology clinics). Thus, in the
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case-control study the Partial Mayo score was deemed unfeasible and the SCCAI was used to
assess UC activity.
There are 13 clinical disease activity indices for UC, eight of which are based purely upon GI and
extra-intestinal  symptoms  (Walsh  et  al.,  2016).  The  Partial  Mayo  Score,  comprising  the  non-
endoscopic  components  of  the Mayo Score (Lewis  et  al.,  2008),  is  the most  commonly  used
clinical disease activity index in clinical trials of UC. This instrument includes an assessment of
stool frequency and rectal bleeding and a Physician Global Assessment of disease activity.
Although the Partial Mayo Score has not been extensively validated, it has been shown to
optimally differentiate patients with active and inactive UC compared to other UC disease
activity indices and displayed construct validity and responsiveness to change. However, the
instrument did not shown sufficient test-retest reliability (Turner et al.).
4.4.3 Patient-reported outcome measures
Patient-reported outcomes measures (PROMs) assess patients’ experiences with a disease and
are increasingly used to assess the effectiveness of interventions in research and clinical settings
(El-Matary, 2014). The use of PROMs is advocated by the Medical Research Council, although a
workshop in 2009 identified on-going research gaps surrounding them, including the content of
PROMs, gaps in the current repertoire of PROMs and the need to develop guidelines for the use
of  PROMs  (MRC,  2009).   Debate  around  the  value  of  PROMs  in  determining  disease
improvement continues  and some healthcare professionals remain opposed to them as the
predominant indicator of improvement, due to a lack of objectivity and a host of confounding
factors that may influence scores  (El-Matary, 2014). In contrast, many healthcare professionals
recognise the potential advantages of the routine use of PROMs, such as the positive effects
that may be gained by involving a patient in their own care, and the elimination of observer bias
(Black and Jenkinson, 2009).
4.4.3.1 Rationale for choice of method: IBD control questionnaire
The IBD control questionnaire was used as PROM in this trial (Bodger et al., 2013). Development
of this instrument included a literature search of existing PROMs and a qualitative study
consisting of patient focus groups. The resulting instrument was validated in patients with IBD
and demonstrated good internal consistency, test-retest reliability, construct validity, ability to
discriminate between mild, moderate and severe IBD, and responsiveness to change in IBD
activity (Bodger et al., 2013). Patients with IBD had lower scores in each of the PROMIS domains
than the general population.
This trial aimed to assess the effect of the low FODMAP diet in inactive IBD and was therefore
not targeted at improving disease activity. Nonetheless, it was of interest to measure patient-
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perceived IBD control before and after the intervention, with the hypothesis that an
improvement  in  GI  symptoms  may  lead  to  a  greater  patient-perceived  control  of  IBD.  Since
symptoms of active IBD and IBS-like symptoms overlap, it may be difficult for some patients to
distinguish between them.
4.4.4 Health-related quality of life
Both IBD and IBS substantially impact upon health-related quality of life (HR-QOL) (Akehurst et
al., 2002, Rubin et al., 2004). Some studies have demonstrated differences in HR-QOL between
IBD and IBS (Blagden et al., 2015, Tkalcic et al., 2010), while others have shown similar HR-QOL
between the conditions (Pace et al., 2003). The impact of IBD on HR-QOL may be influenced by
disease activity (Graff et al., 2006), gender, psychological distress, frequency of relapses and
frequency of hospitalisations (Moradkhani et al., 2013).
It is unsurprising that HR-QOL is consistently shown to be poorer in patients with IBS-like
symptoms in inactive IBD compared to patients without IBS-like symptoms (Simrén et al., 2002,
Jonefjall et al., 2013, Abdalla et al., 2017, Farrokhyar et al., 2006, Ansari et al., 2008), and may
be impaired to a similar degree as in active IBD (Jonefjäll et al., 2016, Ansari et al., 2008). The
impairment in HR-QOL and increased anxiety and depression associated with IBS-like symptoms
in inactive IBD have been shown to associate with the number of GI symptoms (Bryant et al.,
2011). Impaired HR-QOL may also be associated with disease type (CD vs. UC), annual income
and smoking status (Farrokhyar et al., 2006). The cross-sectional nature of the majority of
studies to date precludes any firm conclusions regarding the direction of association between
IBS-like symptoms and HR-QOL in IBD. However, an improvement in certain domains of HR-QOL
has been demonstrated in patients with IBS following low FODMAP dietary advice (Staudacher
et  al.,  2017b),  therefore  this  diet  may  improve  HR-QOL  in  inactive  IBD  and  is  an  important
outcome for assessment.
4.4.4.1 Rationale for choice of method: UK IBD Questionnaire (UK IBDQ)
The UK inflammatory bowel disease questionnaire (IBDQ) was used to assess HR-QOL in this trial
(Cheung et al., 2000). Some HR-QOL assessment tools are generic measures, purported to be
suitable across a range of diseases, populations and treatments (Patrick and Deyo, 1989).
Generic instruments allow a comparison of HR-QOL across different disease states; for example,
the Sickness Impact Profile produces different scores for a range of chronic diseases including
IBD (Patrick and Deyo, 1989). However, they lack content validity when used in specific diseases,
since there are few or no items related specifically to the major domains of HR-QOL that may be
specifically impaired in different diseases (Patrick and Deyo, 1989). Instruments have therefore
been developed to include factors relevant and important to patients with specific diseases,
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including chronic obstructive pulmonary disease and rheumatoid arthritis (Weldam et al., 2013,
Lee et al., 2014b). Generic and disease-specific HR-QOL instruments likely measure different
aspects of HR-QOL, as demonstrated by a study showing a lack of correlation in HR-QOL scores
on generic and disease-specific measures completed contemporaneously by patients with lung
disease (Assari et al., 2009).
At least ten IBD-specific HR-QOL instruments currently exist (Alrubaiy et al., 2015). The
McMaster IBDQ is the most widely used instrument and meets all of the criteria for desirable
measurement properties, some of which are lacking in other instruments (Alrubaiy et al., 2015).
The IBDQ assesses bowel, social and emotional function and systemic symptoms and
demonstrates validity, internal consistency, reliability and responsiveness to change (Guyatt et
al., 1989, Irvine, 1999). The IBDQ has been translated into several different languages (Ren et
al.,  2007, Janke et al.,  2005) and has been adapted and validated for use in a UK population
(Cheung et al., 2000). This adaptation was initiated by investigators planning a UK RCT, with a
consensus that the wording of the McMaster IBDQ was ambiguous in places and the responses
too complex.
4.5 Outcome measures and rationale: microbiota and markers of fermentation
4.5.1 Sample collection
An important outcome in this RCT was the impact of the low FODMAP diet on the GI microbiota.
There are differences in microbiota composition between the luminal and mucosal microbiota
in healthy controls and patients with IBD (Ringel et al., 2015, Chen et al., 2014) . Although the
majority of studies have examined the faecal microbiota in response to treatment due to
obvious logistical challenges associated with obtaining biopsies, the mucosa-associated
microbiota are in closer proximity to host epithelial and immune cells and could therefore have
a greater interaction with the host. However, the bowel preparation required for endoscopic
procedures such as colonoscopy and flexible sigmoidoscopy is known to impact significantly
upon the mucosal microbiota in healthy controls and patients with IBD (Shobar et al., 2016). The
luminal  microbiota  may  also  be  more  susceptible  to  alterations  in  dietary  intake  than  the
mucosal microbiota, which receives a more consistent nutrient balance (Donaldson et al., 2016).
Faecal samples were collected at baseline and end of trial to examine the luminal microbiota.
The descending and sigmoid colon are predominantly anaerobic and a gradient of microbes
associated with oxygen distribution has been observed in mice and humans (Albenberg et al.,
2014). Therefore, exposure of faecal samples to the external environment after voiding has the
potential to alter the microbiota composition and/or function. In vivo sampling would overcome
this issue but is extremely logistically challenging. Furthermore, a strong correlation has been
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observed in diversity and abundance of the luminal microbiota between faeces obtained directly
from the sigmoid colon lumen and that passed by patients (Couch et al., 2013), although stool
samples were stored with a substance to maintain an anaerobic atmosphere after voiding and
prior to freezing. The impact of exposure to the external environment and the length of time
required for changes to occur in other luminal parameters such as SCFA and pH are unclear.
Stool sample collection was carried out by all participants as per the International Human
Microbiome Standards standard operating procedure 2 (V2) (IHMS, 2015a), in order to comply
with standards for studies performing metagenomic sequencing. Stool samples were collected
by patients at the baseline and end of trial visits using the stool collection kit provided and
explained by the investigator (Appendix 8.19). A thick stomacher bag was used to line an opaque
plastic container, into which a whole stool was passed. The bag was then folded on top of the
sample and the container was sealed with a secure plastic lid. Participants were asked to avoid
urinating while passing the sample. Participants were permitted to collect the sample within two
hours prior to the baseline visit, at which point it was placed on ice until processing. Temporary
refrigeration of faecal samples has been shown to maintain microbiota composition similarly to
freezing at -80°C (Choo et al., 2015), therefore if the sample was being transported from home
or work to the research site, the participant was asked to place the sample on ice during
transport. Alternatively, the sample was collected during the visit and placed on ice until
processing.
Following the trial visit, the stool sample was processed by the investigator. Bacteria in stool are
structured and spatially organised and random samples taken from different areas of un-
homogenised stool samples leads to intra-individual variation in microbiota (Hsieh et al., 2016,
Gorzelak et al., 2015). This intra-individual variation is significantly reduced by homogenisation
prior to analysis, therefore stool samples were homogenised for 2 minutes on each side prior to
further processing (Steward Laboratory Blender Stomacher 400).
Immediately after processing, faecal aliquots were frozen at -80°C, since this has been shown to
preserve taxonomic composition compared to DNA extraction on fresh stool (Fouhy et al., 2015)
and is therefore recommended for faecal sample storage (Thomas et al., 2015).
4.5.2 Metagenomic sequencing
Stool sample preparation prior to storage was performed by the author of this thesis (SC), while
DNA extraction and metagenomic sequencing was performed at Institut National de la
Recherche Agronomique (INRA) (Jouy-En-Josas, Paris, France), in the laboratory of and led by
Professor Dusko Ehrlich. Regular contact with SC and Professor Kevin Whelan was maintained
during laboratory analysis and SC visited INRA for one week to learn about and be trained in the
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techniques used and to guide the bioinformatics analysis. The pipeline used for metagenomic
sequencing and taxonomic assignment on these samples is illustrated in Figure 4.2. For the
purpose of this thesis, functional annotation of the microbiome is not included.
4.5.2.1 Rationale for choice of method
The characterisation of the compositionally and functionally complex GI microbiota began with
culture-dependent techniques that are limited to cultivable bacterial species, dependent upon
pH, redox state, temperature and nutrient availability of the growth media, and estimated to
represent  <20%  of  the  environmental  microbial  consortia  (Ward  et  al.,  1990).  These  studies
therefore had the inherent limitation that the majority of the GI microbial community remained
uncharacterised. Initial cultivation studies of GI bacteria failed to detect obligate anaerobes,
which have since been determined to constitute a large proportion of the GI microbiota.
Although anaerobic culture techniques have since been developed, the complexity and varied
growth requirements of the GI microbiota is such that culture-dependent techniques continue
to limit the proportion of species that can be characterised (Rajilić-Stojanović and de Vos, 2014).
The development of molecular techniques such as quantitative polymerase chain reaction
(qPCR) and fluorescence in situ hybridisation (FISH) have progressed the field of GI microbiota
characterisation. The majority of these methods utilise the small subunit (16S) ribosomal RNA,
which has highly conserved regions and regions that vary with evolutionary time (Tringe and
Hugenholtz, 2008). This can therefore be used as a marker of all bacteria and can identify
individual bacterial species based upon the hypervariable regions of the 16S rRNA gene. These
techniques are however limited to species for which hypervariable 16S rRNA sequences are
known for the development of primers (qPCR) or probes (FISH). PCR bias is a further limitation
of qPCR. Furthermore, even if the 16S sequences were known for all GI bacteria, qPCR and FISH
would be prohibitively time and labour intensive for an exhaustive assessment of the GI
microbiota.
The development of next-generation sequencing techniques has proven revolutionary for the
characterisation of the GI microbiota. 16S rRNA gene sequencing and mapping to databases of
known sequences permits comprehensive taxonomic assessment of the GI microbiota.
However, results may vary depending upon the 16S region sequenced (Rintala et al., 2017) and
PCR bias remains a problem. Furthermore, an individual bacterium can possess copies of the 16S
rRNA gene with different sequences which can thus over-estimate bacterial diversity.
Additionally, sequencing only one or two hypervariable 16S rRNA regions makes it challenging
to distinguish species, and different regions sequenced in different studies introduces challenges
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in  comparing  studies  (Thomas  et  al.,  2015).  Finally,  16S  rRNA  sequencing  does  not  allow
identification of strains within a species that may vary considerably in terms of function.
Shotgun metagenomic sequencing is a powerful method of characterising microbiome
composition, in which all DNA is sheared into fragments and then sequenced. In contrast to 16S
sequencing, this technique does not require extensive DNA amplification and thus minimises
PCR  bias.  It  does  not  rely  on  a  single  target  gene  to  assign  taxonomy  and  therefore  more
accurately captures microbiome composition than 16S sequencing (Thomas et al., 2015).
Furthermore, the full genetic potential of the GI microbiome can be characterised, allowing an
assessment of not only composition but also potential functions of the GI microbiome. For
example, genes involved in carbohydrate metabolism may already be altered in IBD (Erickson et
al., 2012) and could feasibly be impacted by dietary carbohydrate manipulation. Metagenomic
sequencing does not, however, measure gene expression. Additionally, the DNA extraction
protocol has a significant influence on metagenomic analyses, greater than variations in sample
storage and library preparation (Costea et al.,  2017). The cost of metagenomic sequencing is
greater per sample than the aforementioned methods, although this is declining due to greater
efficiency of newer sequencing platforms. Metagenomic sequencing generates vast quantities
of complex data that requires specialist bioinformatics pipelines to produce meaningful
conclusions, therefore in this trial metagenomic sequencing was performed by experts in the
technique and bioinformatic analysis at INRA.
4.5.2.2 Sample preparation and storage
Stool sample preparation for metagenomic sequencing analysis was performed in line with the
International Human Microbiome Standards (IHMS) standard operating procedures for
metagenomic sequencing studies (IHMS, 2015b). These guidelines aim to maintain consistency
in sample preparation, DNA extraction and sequencing, thus providing optimal comparability
between metagenomics studies conducted in different research centres.
Within  2  hours  of  stool  collection,  0.2-0.5  g  aliquots  of  fresh,  homogenised  stool  were
transferred in triplicate to sterile screw-cap 2 ml micro-tubes (Sarstedt AG and Co, Nϋmbrecht,
Germany).  The  aliquots  were  stored  at  -80°C  for  1-14  months,  as  this  has  been  shown  to
preserve DNA of certain bacterial species (Fouhy et al., 2015). Samples were then shipped on
dry ice to INRA on 31st May 2017 for DNA extraction and shotgun metagenomic sequencing.
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Figure 4.2 The metagenomic sequencing pipeline used in this trial. Fresh faecal samples were collected
and stored at -80°C (1). Following thawing, DNA was extracted using the Sambo platform (2) and DNA
fragment libraries were constructed (3). These were sequenced using the MetaQuant platform (4). After
mapping to the reference gene catalogue, gene frequency tables were obtained (5) and taxonomic
assignment is performed using 50 marker genes per species (6). Data analysis was then performed (7).
4.5.2.3 DNA extraction protocol
The Sambo platform was used for DNA extraction from the stool samples prior to metagenomic
sequencing using a standardised protocol published by IHMS (SOP 07 V2). This was carried out
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Day 1
1. 250 μL Guanidine Thiocyanate, 40 μL of 10% N-lauroyl sarcosine and 500 μL 5% of N-
lauroyl sarcosine were added to each tube containing ~ 200 mg faeces
2. Tubes were vortexed until fully homogenised, followed by a 60 minute incubation at
70°C in a dry bath
3. Each tube was vortexed on high speed with 750 mg of 0.1 mm glass beads and shaken
to mechanically disrupt the cells with a Bead BeaterTM for 10 minutes total
4. Each tube and was vortexed with 15 mg of polyvinylpolypyrrolidone (PVPP) powder and
then centrifuged at 14,000 rpm (18,000 g) for 5 minutes at 4°C.
5. The supernatant was transferred to a sterile, graduated 2 ml tube and set aside
6. The remaining pellet was vortexed with 500 μL of TENP (containing Tris, EDTA, NaCl,
PVPP) and centrifuged at 14,000 rpm (18,000 g) for 5 minutes at 4°C. The supernatant
was added to that obtained in step 5 and two more washes with TENP were performed.
7. The supernatant  was centrifuged at  14,000 rpm (18,000 g)  for  5  minutes  at  4°C and
dispensed into two 2 ml Eppendorf tubes, producing two tubes per sample, to which 1
ml of isopropanol (propanol-2) was added and mixed gently.
8. Tubes were incubated for 15 minutes at room temperature, centrifuged at 14,000 rpm
(18,000 g) for 5 minutes at 4°C and the supernatant removed from the tubes, retaining
the pellet inside.
9. 450 μL of phosphate buffer and 50 μL of potassium acetate were added to one of the
tubes, and the pellet and solution was added into the second tube and dissolved through
gentle aspirations with a P200 pipette.
10. Samples  were  left  on  ice  for  at  least  90  minutes,  before  centrifuging  at  14,000  rpm
(18,000 g) for 5 minutes at 4°C
11. The supernatant, containing DNA, was transferred to a 2 ml Eppendorf tube and 2 μL of
RNase (10 mg/ml) was added and then vortexed briefly.
12. Tubes were incubated for 30 minutes at 37 oC after which 50 μL sodium acetate and 1
ml 100% ethanol was added.
13. Tubes were mixed gently and stored overnight at -20oC.
Day 2
1. The samples were centrifuged at 14,000 rpm (18,000 g) for 5 minutes at 4°C and 1 ml
70% ethanol was added, followed by a further 5 minute centrifuge and removal of the
ethanol.
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2. The samples were centrifuged with 500 μL 70% ethanol at 14,000 rpm (18,000 g) for 5
minutes at 4°C and then the ethanol was removed.
3. The DNA pellet was dried for 10 minutes under a laminar flow hood and then dissolved
in 200 μl of TE (containing Tris.HCl and EDTA)
Quality control was performed following DNA extraction and prior to library construction.
Adequate quality of the DNA, defined as being 20 kilo base pairs, was determined using 1%
agarose gel. At least 3 μg DNA was required for subsequent fragmentation and this was
determined using NanoDrop.
4.5.2.4 Library construction and shotgun metagenomic sequencing
Metagenomic sequencing was performed via the MetaQuant platform in the laboratory of
Professor Dusko Ehrlich at INRA (Jouy-En-Josas, Paris, France).
DNA of adequate quality and quantity was sheared into fragments of approximately 150 base
pairs (BP) using the Covaris E220 system, which utilises Adaptive Focussed Acoustics ™ (AFA)
technology. Agencourt beads (Beckman Coulter) were then used to purify fragments by
removing residual nucleotides, salts and impurities.
A quality control step followed DNA fragmentation and consisted of determining fragment size,
which was required to be approximately 150 bp for optimal sequencing with the Ion Proton
technology. The size of DNA fragments was analysed using a size profile Fragment AnalyserTM
(Advanced Analytical), which is based upon parallel capillary electrophoresis and utilises
fluorescent intercalating dyes to detect the quantity of different sized DNA fragments. DNA was
quantified again using fluorescence emission using the Invitrogen QubitTM Fluorometer
(ThermoFisher Scientific). This is an efficient, highly sensitive and accurate assay suitable for use
with very small or dilute samples. The assay utilises dyes that are specific for DNA and emit
fluorescence only when bound to DNA. This is in contrast to measuring UV absorbance (the
method utilised with the NanoDrop technology), which has lower sensitivity for discriminating
between RNA and DNA. This method of DNA quantification is considered useful for next-
generation sequencing since it quantifies intact double-stranded DNA.
A fragment library was then constructed for each sample. This was performed using the 5500
SOLID 48 Fragment Library Amplification Module and Ion Plus Fragment Library Adapters (Life
Technologies). Following end-repair of the DNA fragments, adapters containing one of 96 single
barcodes (Life Technologies) were ligated to each fragment. The constructed library was then
amplified using PCR to ensure an adequate signal for the detection of all reads, followed by a
further purification step and quantification using the 2100 Bioanalyzer System (Agilent). This
Chapter 4: RCT design and methods
184
quantification step ensured that the library contained the target quantity of 90 pM DNA. The
size of the DNA fragments was again assessed, aiming for 250 bp including adaptors.
For sequencing, purified and amplified DNA fragment libraries were loaded onto the Ion Proton
sequencer (Life Technologies) and a minimum of 20 million high-quality reads were generated
for each library. This technology utilises a chip containing 165 million wells, into which one bead
is placed. To this bead, one DNA fragment should be ligated via the adaptors added during library
construction. Free nucleotides are added sequentially to the wells (e.g. first adenosine, then
thymine,  etc).  When  DNA  polymerase  incorporates  a  nucleotide  into  a  strand  of  DNA,  a
hydrogen  ion  is  released.  This  hydrogen  ion  carries  a  charge  that  is  detected  by  the  Proton
System, essentially a sensitive, small-scale pH meter. This allows each incorporated base to be
detected, thus producing a DNA sequence. In contrast to Illumina sequencing technology, Ion
Proton  technology  is  quicker  and  permits  the  detection  of  errors  at  an  earlier  stage,  thus
reducing costly losses.
4.5.2.5 Bioinformatics and statistical analysis
Following sequencing of the microbial DNA fragment libraries, bioinformatics analysis was
performed by Sébastien Fromentin (Biostatistics Analyst) and Dr Nicolas Maziers (Data Analyst)
at INRA (Jouy-En-Josas, Paris, France).
First, sequencing reads were trimmed, cleaned and filtered for human DNA. Subsequently, the
following bioinformatics steps were performed prior to data analysis:
1. Sequencing reads of varying length were mapped using the METEOR pipeline to the
Integrated Gene Catalogue (IGC), which contains 9.9 million non-redundant genes
including those derived from the microbiome of patients with IBD (Li et al., 2014b).
Mapping was performed with a >95% identity threshold to account for gene variability.
This mapping procedure resulted in a table of gene frequencies per sample.
2. Sequencing reads were normalised for varying lengths of genes using reads per kilobase
of transcript per million mapped reads (RPKM). The number of reads uniquely mapping
to a gene in the catalogue was divided by its nucleotide length, and the resulting
normalised gene abundance was then divided by the total number of uniquely mapped
reads for that sample. The resulting gene abundances were used as the microbiome
profile for that individual.
3. Following mapping to the IGC, mapped read counts were plotted for each sample.
Downsizing of the data was performed to adjust for varying sequencing depths among
the samples. This was performed by setting an optimum threshold according to the
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plotted curve, which equated to 14 million randomly-selected reads per sample. This
read count was used for each sample in the subsequent analysis.
Upon completion of the above pre-analysis steps, metagenomic species (MGS) were identified
within each sample. These are groups of >500 genes that have been shown to identify a
microbial species due to co-varying abundance across samples (Nielsen et al., 2014). Relative
abundance of each MGS was calculated as the mean abundance of the 50 most representative
marker genes per species with correlating normalised abundance (Nielson et al 2014). These
known marker genes were mapped to the gene frequency tables produced during the catalogue
mapping described above. To estimate the abundance of each gene within a species, it was
assigned a relative abundance, with total gene abundance equating to a value of 1. Within a
sample, the relative abundance of each species was calculated as the average abundance of the
50 marker genes for that species.
The gene richness of each sample was determined as the number of uniquely mapped reads,
described above. Species alpha diversity was calculated using the Shannon Index, which
accounts for both abundance and evenness of the species within a sample.
For statistical analysis, only participants with an available sample at baseline and end of trial
were included. Gene richness, alpha and beta diversity and relative species abundance were
compared between diet groups at end of trial using a likelihood ratio test (described in section
4.10). Paired analyses were also performed to assess the change in the above parameters
between baseline and end of trial in each group. Sub-group analyses for each variable was
performed for CD and UC. Exploratory analyses, including correlation analysis and principle
component analysis (PCA), were performed to assess the gene and species richness and
composition of responders and non-responders to the low FODMAP diet at baseline and end of
trial, as well as according to faecal calprotectin concentrations.
4.5.3 Stool SCFA
Sample preparation was performed by the thesis author (SC) and GLC was conducted by the
thesis author (SC) at King’s College London together with Robert Gray (Analytical Chemist) and
supervised by Professor Kevin Whelan.
4.5.3.1 Rationale for choice of method
Short-chain fatty acids are a major product of bacterial fermentation in the human GI tract. Total
SCFA concentrations rise rapidly in the caecum, where undigested carbohydrates are abundantly
available for bacterial fermentation, and then progressively decline throughout the colon due
to  depletion of carbohydrates and rapid absorption by colonocytes (Cummings et al., 1987).
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Several approaches have been used to directly measure in vivo SCFA concentration, including
extraction of GI contents from sudden death victims (Cummings et al., 1987), measurement of
SCFA concentrations in portal venous blood during surgery (Peters et al., 1992) and SCFA
measurement in transverse or sigmoid colostomy effluent (Mitchell et al., 1985). In vivo SCFA
production can also be determined by directly measuring the quantity of undigested
carbohydrate entering the colon and the SCFA concentration in the colon. Furthermore, the
difference between portal and venous blood SCFA concentration would indicate SCFA
production  (Millet  et  al.,  2010).  Access  to  the  proximal  colon  is  challenging  and  all  of  the
aforementioned methods of in vivo SCFA measurement are invasive and technically challenging
to perform, making them infeasible in the majority of RCTs.
The majority of SCFA are absorbed along the length of the colon, therefore faecal concentrations
do not accurately represent SCFA production in the caecum. Furthermore, SCFA concentrations
in faeces can be influenced by whole gut transit time (Lewis and Heaton, 1997a). Nonetheless,
measurement of SCFA concentrations in faeces is less invasive than in vivo measurement and
SCFA excretion can indicate changes in SCFA balance in the GI tract (production-absorption).
Gas liquid chromatography was used to quantify faecal SCFA in this trial. Other methods for
quantifying SCFA include high performance liquid chromatography, nuclear magnetic resonance
and capillary electrophoresis. Gas liquid chromatography is the most commonly used method
for SCFA quantification and is based upon compound separation, relying on a carrier gas which
transports the compounds within the sample towards a detector. Depending on properties such
as size, different compounds have different retention times and thus elute from the oven
column and reach the detector at different times, allowing assessment of the compounds within
the sample (Primec et al., 2017). Gas liquid chromatography is quick, inexpensive and
concentration of SCFA in the sample can be determined by calculating the area under the
detection peak for each SCFA.
4.5.3.2 SCFA analysis protocol
Following homogenisation, duplicate aliquots of 3-5g of fresh stool were stored in sterile
containers at -80oC for SCFA analysis. Extraction of SCFA was performed for all samples as
follows:
1. Glass beads were placed into a 15 ml falcon tube together with 2-3 g of thawed faeces and
SCFA extraction buffer was added in a 1 in 5 dilution (e.g. 2g of faeces to 8ml buffer).
SCFA extraction buffer (made up to 100 ml with distilled water):
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· 0.1g mercury chloride (Sigma, UK) to inhibit bacterial fermentation within the
sample (which would elevate SCFA concentrations)
· 1g phosphoric acid (Merck, Germany)
· 4.5 mg 2,2-dimethylbutyric acid (internal standard; Sigma, UK). The internal
standard is not a product of the GI microbiota but exits the column within the same
time as the SCFA’s of interest.
2. The faeces and buffer were vortexed for 2 minutes or until the slurry appeared fully
homogenised, and the slurry was centrifuged at 5000 g (Beckman J2-HS, USA) at 4°C for 45
minutes.
3. Approximately  1  ml  of  the supernatant  was passed through a  sterile  0.2  µm filter  into a
Micro-vial Snap Ring Vial and stored at -20°C until gas liquid chromatography (GLC) analysis.
Prior to GLC analysis, extracted SCFA samples were defrosted at room temperature. A 9890A
series GLC system (Agilent Technologies, US) was then used for SCFA analysis. This system is
equipped with a flame ionisation detector and a 220 µm internal diameter, 25 m fused silica
capillary column with a film thickness of 0.25 µm (ID-BP21, SGE, Australia). The system uses
nitrogen as a carrier gas. The oven temperature began at 80°C, then increased 10oC per minute
until 145°C, and 200°C at 100°C per minute. A total of 0.2 µl of sample was injected, with 1.2%
formic acid cleaning solution (Merck, Germany) injected between samples to minimise carry
over from the previous sample.
Gas liquid chromatographer calibration was performed with a blend of pure SCFA solutions at
six different concentration, producing calibration curves (area vs concentration). The
concentrations of acetate, propionate, butyrate, valerate, isobutyrate and isovalerate were read
in  duplicate  for  each  sample.  Mean  concentration  for  each  SCFA,  for  each  patient,  at  each
timepoint was then calculated (µmol/g wet weight). The individual SCFA concentrations were
summed to give total SCFA concentration in each sample. Data analysis was performed using
the Agilent Chromatogram database (Agilent Technologies, US).
4.5.4 Stool pH
Sample preparation and measurement of stool pH was performed by the investigator (SC)
contemporaneously with stool processing.
4.5.4.1 Rationale for choice of method
The pH of the colonic lumen is determined by bacterial fermentation of undigested
carbohydrates, proteins and amino acids, producing lactate, SCFA and alkaline compounds such
as ammonia. Direct measurement of luminal GI pH using a radiotelemetry capsule in healthy
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volunteers revealed a sharp drop in luminal pH from 7.5 in the ileum to 6.4 upon entering the
caecum, due to a peak in bacterial fermentation in the caecum. This was then followed by a
gradual rise in pH along the distal colon as SCFA are absorbed (Evans et al., 1988). The relevance
of colonic pH to GI health remains unclear but potential roles in colon cancer risk have been
suggested (Newmark and Lupton, 1990).
In this trial, faecal pH was measured directly using a solids pH probe. The measurement of faecal
pH is non-invasive and represents differences in net excretion of acidic compounds between the
two diets. The limitation of this is that net absorption of acidic and alkaline components
produced by the microbiota along the GI tract, and the possible impact of transit time, renders
faecal pH non-representative of the pH of luminal contents. While, direct measurement of
luminal pH in the GI tract using radiotelemetric capsules or pH sensitive electrodes passed into
the GI tract orally give an accurate measure of intraluminal pH, these methods are invasive,
expensive and technically or logistically challenging.
4.5.4.2 pH measurement protocol
Stool samples were homogenised prior to direct measurement of stool pH. This was completed
prior to any further stool processing.
The solids pH probe (InLab®, Mettler Toledo) was used for pH analysis. The probe was calibrated
in stock pH 4.01 and 7.0 calibration buffer prior to each use. It was then immersed in the sample
to a depth of approximately 1.5 cm or at least until the glass tip of the probe was fully immersed.
The probe was held in the sample until a pH value was read and confirmed (FE20 FiveEasyTM
Benchtop pH Meter).
4.6 Outcome measures and rationale: immunology
4.6.1 Biomarkers of intestinal inflammation
A thorough assessment of disease activity in IBD includes clinical, biochemical, endoscopic and
radiologic measures (Peyrin-Biroulet et al.). Although disease activity indices such as the HBI
include important GI symptoms for distinguishing active from inactive IBD, they do not correlate
perfectly with endoscopic disease activity and symptoms may relate to non-inflammatory
factors such as bile acid malabsorption (Yang et al.,  2013b, Falvey et al.,  2015). Furthermore,
these measures are clearly of limited use as inclusion criteria in trials recruiting patients with
suspected IBS-like symptoms, which are likely to elevate scores despite a lack of active
inflammation. Endoscopy with histology is generally the preferred objective method for
establishing disease activity (Magro et al., 2017, Gomollon et al., 2017). However, the invasive
nature of these investigations in patients with inactive IBD would likely limit recruitment to a
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clinical trial (Denters et al., 2013), particularly involving a dietary intervention not targeted at
improving disease activity. Biomarkers, such as CRP, erythrocyte sedimentation rate, faecal
calprotectin and faecal lactoferrin are non-invasive measures of inflammation and may be used
as adjuncts to GI symptom assessment in the monitoring of IBD activity (Walsh et al., 2016).
Some of these correlate with endoscopic and histologic IBD activity thus reducing unnecessary
use of invasive, potentially unpleasant and costly investigations such as endoscopy and imaging
(Schoepfer et al., 2013, Langhorst et al., 2008, Lehmann et al., 2015).
4.6.1.1 Faecal calprotectin
Calprotectin is a small, calcium-binding protein found in abundance in the cytoplasm of
neutrophils and to a lesser extent, monocytes and macrophages (Steinbakk et al., 1990). During
active IBD, neutrophils migrate from the circulation to the GI mucosa as part of the inflammatory
cascade and are then shed into the lumen, where calprotectin is released due to cell disruption
or death and can be measured in faeces (Brazil et al., 2013, Voganatsi et al., 2001). Faecal
calprotectin has been used as a diagnostic aid in IBD (van Rheenen et al., 2010), to monitor GI
inflammation in established IBD (D'Haens et al., 2012), as a predictor of mucosal healing (Røseth
et al., 2004) and as a prognostic aid to predict IBD relapse (Mao et al., 2012). Faecal calprotectin
is superior to serum CRP, blood leukocytes and clinical disease activity scores in differentiating
endoscopically mild, moderate and severe disease in both CD and UC (Schoepfer et al., 2010,
Schoepfer et al., 2013).
Appropriate faecal calprotectin cut-offs to define active and inactive IBD are controversial and
ill-defined. Although a 250 µg/g cut-off predicted endoscopic IBD activity with optimal sensitivity
and specificity (Lin et al., 2014), a more recent meta-analysis, published after the protocol for
this study had been written, demonstrated a much lower 50 µg/g optimal cut-off through
receiver operating characteristic curve analysis (Mosli et al., 2015). This discrepancy is likely
partly explained by differences in study inclusion criteria.  Although the use of a lower cut-off
would increase sensitivity for detecting inactive IBD, this would result in exclusion of patients
with inactive disease despite a slightly elevated faecal calprotectin. Therefore, patients had to
have a screening faecal calprotectin of <250 µg/g to be enrolled.
Calprotectin concentrations in faeces can be quantified using ELISA or point-of-care (POC) test
kits. There are a range of ELISA kits available, using different monoclonal and polyclonal
antibodies to calprotectin (Ikhtaire et al., 2016). The CALPRO ELISA kit was shown to be superior
to the EK-CAL and HK325 ELISA kits in identifying patients with IBD and in distinguishing between
clinically active and inactive IBD (Mirsepasi-Lauridsen et al., 2016) and was chosen to quantify
faecal calprotectin concentrations at baseline and end of trial.
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4.6.1.1.1 Screening faecal calprotectin
Stool samples were collected following informed consent and faecal calprotectin was measured
using the Bühlmann Quantum Blue® lower range quantitative immuno-chromatographic assay
described in section 3.4.11.3, using an identical protocol. Patients with a screening faecal
calprotectin  of  <250  µg/g  were  invited  to  complete  a  7-day  food  and  symptom  diary  as  the
second stage of screening.
4.6.1.1.2 Faecal calprotectin ELISA
Enzyme-linked immunosorbent assay (ELISA) allows quantification of peptides, proteins,
antibodies and hormones. ELISA is based upon the immobilisation of an antigen of interest and
detection through the assessment of enzyme activity, determined through colour changes. A
standard curve is constructed from the absorbance of wells containing a standard concentration
of the antigen of interest, thus allowing quantification of the substance in the test samples.
The calprotectin ELISA kit used in the current study (Calpro AS) uses a rabbit anti-calprotectin
antibody and the enzyme is alkaline phosphatase.
4.6.1.1.3 Calprotectin extraction and ELISA protocol
At the baseline and end of trial visits, patients provided a whole stool sample to the investigator.
An aliquot of 3-5g was reserved and frozen at -80oC for the ELISA.
Stool aliquots were thawed fully at room temperature prior to calprotectin extraction.
Calprotectin extraction was carried out according to the manufacturer’s instructions and all
reagents were provided with the kit unless otherwise stated (Calpro AS, Lysaker, Norway):
1. Faeces was loaded into the extraction device (Figure 4.3), avoiding trapping air bubbles
and undigested solid materials. The sample was weighed (aiming for approximately 100
mg) and the exact weight documented.
2. The cap was fixed to the extraction device and extraction buffer was added in a 1:50
dilution.
3. The extraction device containing sample and buffer was vortexed for 3 minutes or until
the sample was completely homogenised in the buffer, which was longer.
4. 500 μl of the faecal suspension was transferred to a sterile microtube and stored at 2-
8°C until analysis the following day.
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Figure 4.3 Faecal calprotectin extraction device used to extract calprotectin from faecal samples prior
to quantification with the ELISA
Calprotectin ELISA was carried out according to the manufacturer’s instructions and all reagents
were provided with the kit unless otherwise stated (Calpro AS, Lysaker, Norway):
1. Faecal extracts were further diluted using the sample diluent solution. To ensure that
all the test samples fell within the linear section of the standard curve, the dilution factor
was adapted depending on the screening faecal calprotectin concentration for each
patient. In patients whose screening faecal calprotectin of < 100 μg/g, a dilution of 1:25
was used. In patients with a screening faecal calprotectin of > 100 μg/g, a dilution of
1:50 was used.
2. Samples, standards, and the control solution were added to duplicate wells on the plate
in 50 μl aliquots. Two wells were left blank, i.e. contained no test solution but received
all other reagents for the ELISA. The baseline and end of trial samples for the same
participant were included on the same plate, and each plate had a combination of CD
and UC patients to avoid differences between these groups occurring as an artefact
resulting from plate differences and variations in experimental conditions.
3. The plate was incubated at room temperature on a plate shaker for 45±5 minutes at
500-700 rpm, after which the wells were washed five times
4. 50 μl of the enzyme conjugate was added to each well using a multi-channel pipette.
5. The plate was incubated at room temperature on a plate shaker for 45±5 minutes at
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6. 100  μl  of  the  enzyme  substrate  solution  was  added  to  each  well.  The  plate  was
incubated for 30 minutes in a dark drawer at room temperature.
7. The optical density (OD) of the wells were read at 405 nm using a microplate reader.
8. The OD of the controls was plotted to create a standard curve. The optional highest
standard (1000 μg/g) was not included in the ELISA since screening calprotectin had
been performed 1-2 weeks prior to enrolment and had to be <250 μg/g for enrolment
in the trial, therefore it was not expected that any samples would have a faecal
calprotectin concentration greater than 250 μg/g. The highest included standard (500
μg/g) displayed very little difference in OD compared to the 250 μg/g standard for all
three plates and was removed from the curve to retain the optimal fit of the line to the
standards.
9. A logarithmic line was fitted as the standard curve, since this produced a line closest to
all the standards. Therefore, a quadratic equation was used to calculate the calprotectin
concentrations of the samples.
4.6.1.1.4 Advantages and limitations of ELISA
Enzyme-linked immunosorbent assay for faecal calprotectin permits a quantitative assessment
of multiple samples at once and is therefore suited to batch sample analysis following a trial. It
is the most commonly used method of faecal calprotectin quantification (Ikhtaire et al., 2016).
However, despite being efficient and cost-effective batch sample analysis, ELISA is more labour
intensive and requires greater laboratory expertise than POC test kits. Furthermore, samples
with a higher calprotectin concentration can exceed the upper limit of the ELISA and the
concentration of these samples cannot be calculated with accuracy. However, this was not an
issue in this trial since the participants were recruited on the basis that their screening faecal
calprotectin was <250 μg/g.
Calprotectin is resistant to heat and bacterial degradation, is stable in faeces for 3-7 days at
room temperature (Røseth et al., 1992, Lasson et al., 2015) and has a homogeneous distribution
in stool (Lasson et al., 2015). Excretion of faecal calprotectin in stools was shown to have low
intra-individual variability on 3 consecutive days in a large cohort of patients with inactive CD
(Naismith et al., 2013). Conversely, some studies have shown considerable day-to-day or within-
day variation in faecal calprotectin, which may be more substantial in patients with IBD
compared to healthy controls and may be greater in patients with active IBD and in patients with
UC compared to CD (Husebye et al., 2001, Dobrzanski et al., 2014, Lasson et al., 2015, Naismith
et al., 2013).
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The rabbit-derived polyclonal anti-calprotectin antibody and the enzyme-conjugated antibody
in the Calpro ELISA bind to several different epitopes on calprotectin, meaning the ELISA can
detect calprotectin even if some epitopes are damaged or hidden due to complex formation
with other components of stool.
4.6.1.2 C-reactive protein
C-reactive protein was measured in the current trial at screening and end of trial in the hospital
pathology department. Active inflammation in IBD is associated with an acute phase reaction
and therefore acute phase proteins such as CRP may be elevated in serum. Several studies have
demonstrated that active IBD can be differentiated from functional bowel disorders based upon
elevated serum CRP (Poullis et al., 2002, Shine et al., 1985). C-reactive protein may be used to
predict endoscopic disease activity, albeit with only a modest correlation between them (Mosli
et  al.,  2015).  Blood  tests  are  routinely  performed  in  patients  with  IBD  and  the  CRP  assay  is
relatively cheap, making this an accessible method for monitoring IBD.
However, the correlation between serum CRP and endoscopic IBD activity is generally poorer
than for faecal biomarkers such as faecal calprotectin and CRP may be a less sensitive marker of
endoscopic activity in UC compared to CD (Lewis, 2011). Therefore, CRP in isolation is unlikely
to be sufficient to define IBD activity but may be a useful adjunct to other biomarkers such as
faecal calprotectin.
4.6.2 Peripheral T-cell gut-homing phenotype
Whole blood samples were collected by the author of this thesis at the baseline and end of trial.
Whole-blood labelling and all flow cytometry analysis were performed on all samples by the
author of this thesis at the Blizard Institute, Queen Mary University of London. Prior to the
analysis of any participant samples, training in the required techniques and supervision of flow
cytometry was provided by Dr Andrew Stagg (Reader in Immunology, Queen Mary University of
London), Dr Neil McCarthy (Post-doctoral Research Fellow, Queen Mary University of London)
and Inva Hoti (PhD student, Queen Mary University of London).
4.6.2.1 Principles of flow cytometry
Flow cytometry measures multiple physical and chemical characteristics of particles in a sample
as they pass through one or several lasers and is used to investigate cell morphology and
intracellular gene expression and to enumerate cell subsets. For example, it is commonly used
to identify and quantify immune cell subsets within blood (Fischer et al., 2015, Globig et al.,
2014, Hedin et al., 2014).
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Flow cytometry measures size, granularity, internal complexity and emitted fluorescence of
cells. To analyse cell subsets, fluorescent-labelled antibodies to cell surface markers specific to
the subsets of interest are added and the cells are passed within a fluid in single-file through a
laser intercept, allowing each cell to be assessed individually. Laser light hitting the cell is
scattered and any fluorescent molecules present on the cell fluoresce. Via a collection filters,
scattered and fluorescent light is directed to the appropriate wavelength-specific detectors, and
finally electronic signals are produced. Different fluorophores are detected by different
detectors, and can therefore be differentiated (Jahan-Tigh et al., 2012).
There is evidence of systemic inflammation in patients with IBD, for example serum cytokine
concentrations  may  differ  in  IBD  compared  to  healthy  controls  (Kleiner  et  al.,  2015).
Furthermore, serum concentrations of IL-6 and IL-8 been shown to change following a low
FODMAP diet in IBS (Hustoft et al., 2017). However, serum cytokines may reflect inflammation
outside the GI tract, and the aim of analysing immunology outcomes in this study was to
establish whether the low FODMAP diet impacts upon GI inflammation specifically. The α4β7
integrin is a heterodimeric adhesion molecule expressed on the surface of leukocytes,
facilitating entry of leukocytes into the intestine upon contact with mucosal addressin cell
adhesion molecule-1 (MAdCAM-1) on venules of the mesenteric lymph nodes and Peyer’s
patches  (Berlin  et  al.,  1993).  Expression  of  α4β7  on  circulating  T-cells  could  therefore  be
considered a marker of their propensity to home to the GI tract and altered proportions of T-
cell subsets expressing α4β7 have been observed in both CD and UC (Hedin et al., 2014, Fischer
et al., 2015). Changes in the proportion of circulating T-cells expressing α4β7 could result from
changes in GI inflammation, due to a greater number of T-cells primed to traffic to the GI tract,
and therefore circulating T-cell phenotype could change according to disease activity. Therefore,
flow  cytometry  was  used  to  assess  circulating  T-cell  phenotype  as  a  proxy  for  GI  immune
function.
The whole blood labelling protocol was designed to permit enumeration of T-cell subsets,
identified through the CD3 T-cell co-receptor. T-cells that have not yet been exposed to antigen
are referred to as ‘naïve’ and express the longer CD45RA isoform. In contrast, effector/memory
(or ‘antigen experienced’) T-cells typically express the shorter CD45RO isoform (Altin and Sloan,
1997). Therefore, CD45RA was used to identify naïve T-cells and effector/memory (cells negative
for CD45RA).
Gut homing potential of T-cell subsets was assessed by labelling for α4β7. The beta subunit is
also present at low concentrations in blood bound to αE (CD103). Labelling whole blood with an
antibody to the β7 unit would detect both α4β7 and αEβ7, therefore antibodies specific to αE
were included in the labelling panel to enable isolation of α4β7.
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A small proportion express the γδ rather than the αβ T-cell receptor (typically <5%). These cells
can rapidly expand during bacterial and parasitic infections and are activated by phosphoantigen
released by the GI microbiota (Eberl et al., 2003). The majority of Vδ2 T-cells express α4β7 and
promote inflammation in the GI mucosa (McCarthy et al., 2013), therefore an antibody to the
Vδ2 complex was included in the labelling panel.
4.6.2.2 Antibodies
Anti-CD3  PB  (clone  SK7,  Biolegend,  San  Diego,  CA,  USA),  anti-CD8  PerCPCy5.5  (clone  HIT8a,
Biolegend), anti-CD45RA PE-Cy7 (clone HI100, Biolegend), anti-β7 PE (clone FIB504, Biolegend),
anti-CD103 Alexafluor-647 (clone Ber-ACT8, Biolegend) and anti-Vδ2 FITC (clone B6, Biolegend)
conjugated antibodies were used for the staining protocol (Table 4.1).
To determine gating for positive and negative populations of T-cell subsets, isotype-matched
controls were used as follows: FITC mouse IgG1 (clone MOPC-21, Biolegend), PE rat IgG2a (clone
RTK2758, Biolegend), PE-Cy7 mouse IgG1 (clone MOPC-21, Biolegend) and Alexafluor-647
mouse IgG1 (clone MOPC-21, Biolegend).
Single-colour controls were used to compensate for spectral overlap of fluorophores. Anti-CD8
FITC (clone SK1, Biolegend), anti-CD8 PE (clone SK1, Biolegend), anti-CD8 PerCPCy5.5 (clone
HIT8a, Biolegend), anti-CD45RA PE-Cy7 (clone HI100, Biolegend), Anti-CD3 PB (clone SK7,
Biolegend), and anti-CD8 Alexafluor-647 (clone SK1, Biolegend) were used as single-colour
controls.
4.6.2.3 Sample collection and labelling
Blood samples were collected from participants at the baseline visit and the end of trial visit.
Whole blood was collected into 4 ml lithium heparin vacutainers and stored at room
temperature for labelling within 4 hours of collection.
Whole blood was antibody-labelled as follows:
1. Fluorescently labelled antibodies were added to 100μl whole blood according to the
protocol in Table 4.1 and were incubated in the dark at room temperature for 15
minutes.
2. To each tube, 500 μl Optilyse C solution (Beckman Coulter, UK) was added to lyse red
blood cells. These were vortexed and incubated in the dark at room temperature for 15
minutes.
3. Fluorescence activated cell sorting (FACS) buffer was added to each tube before
centrifuging at 1700 rpm for 5 minutes.
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4. The supernatant was discarded and cells were re-suspended in FACS buffer and
centrifuged as per step 3.
5. The supernatant was discarded and the cells re-suspended in 300 μl 1%
paraformaldehyde.
6. To the experimental tube only, 20 μl fluorescently-labelled beads (Flow-count
fluorospheres, Beckman Coulter, UK) were added immediately prior to acquisition to
determine absolute cell counts.
Table 4.1 Protocol for antibody labelling of whole blood for flow cytometry












8 Vδ2 Β7 CD8 CD45RA CD3 CD103
9 Vδ2 rIgG2a CD8 CD45RA CD3 CD103
10 mIgG1 Β7 CD8 CD45RA CD3 CD103
11 Vδ2 Β7 CD8 CD45RA CD3 mIgG1
12 Vδ2 Β7 CD8 mIgG1 CD3 CD103
FITC, Fluoroscein isothiocyanate; PE, phycoerythrin; PerCPCy5.5, peridinin chlorophyll protein-
cyanine 5.5; PE-Cy7, phycoerythrin-cyanine 7; PB, pacific blue; AF647, alexafluor 647
4.6.2.4 Data acquisition
Following fixation of the cells, flow cytometry data was acquired using the BD FACSCanto II flow
cytometer and the FACS DIVA software version 6.1.3 was used to collect data (BD Bioscience).
The BD FACSCanto II contains the following lasers: blue (488-nm, air-cooled, 20-mW solid state),
red (633-nm, 17-mW HeNe) and violet (405-nm, 30-mW solid state). For all compensation tubes
and the blank tube, 20,000 events were recorded, while for the test and isotype control tubes
100,000 events were recorded.
4.6.2.5 Data analysis
Flow cytometry data was analysed contemporaneously using the Winlist software programme
version 6.0 (Verity, Topsham, ME, USA).
First, compensation was performed for spectral overlap. Lymphocytes stained with single-colour
monoclonal antibodies were used as the compensation standards (Table 4.1). A light scatter plot
was constructed of forward scatter (relating to cell size) against side scatter (relating to cellular
granularity) and a gate was drawn around the lymphocyte population (Figure 4.4).
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Figure 4.4 Compensation of spectral overlap. The left-hand histogram displays the fluorescence in the
PE and PE-Cy7 channels for the PE single-colour control. There is fluorescence in the PE-Cy7 channel
despite a lack of PE-Cy7 staining in the tube. Compensation assesses the geometric mean of the
fluorescence in the y-axis and adjusts fluorescence to eliminate this overlap (right-hand histogram).
The degree of overlapping fluorescence between fluorophores was assessed by constructing
two-parameter plots containing each possible permutation of the fluorophores used in the
protocol (Table 4.1) and then activating the software-generated compensation (Figure 4.4). Plots
were visually inspected and any remaining overlap was manually adjusted by assessing and
adjusting  the  geometric  mean  of  fluorescence  on  the  y  axis  of  the  two-parameter  plot.  The
compensation protocol was saved once all fluorophores had been compensated.
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4.6.2.6 Analysis of flow cytometry data
The file corresponding to the experimental tubes was analysed with the compensation protocol
applied. Again, using a light scatter plot, lymphocytes were gated (Figure 4.7).
Figure 4.5 Gating of the CD45RA-positive population with reference to the isotype control. In the left-
hand plot, CD4+ T-cells were stained with PE-Cy7 conjugated anti-mIgG1 antibodies (isotype control).
The CD45RA-positive and negative populations were then defined with reference to the peak of this
isotype control (with the positive population presumably lying to the right of isotype control peak). The
right-hand plot shows the same gates applied to the test tube file (containing CD4+ T-cells stained with
PE-Cy7 conjugated anti-CD45RA antibodies)
As isotype-matched control antibodies were not included for CD3 and CD8, these populations
were gated by eye. For all other populations, the isotype-matched control tube was used to set
the gating for the positive and negative populations, as illustrated in Figures 4.5 and 4.6.
Within the analysis protocol, the flow count beads added to the experimental tube were
identified by gating the highest peak on an ungated, one-parameter FITC plot. Absolute cell
counts for each population of interest were calculated using the following equation:




N = number of events per ml of blood analysed
c = concentration of beads in the bead solution (beads/μl)
r = number of events in the gate of interest
b = number of events in the bead gate
Isotype (PE-Cy7) CD45RA (PE-Cy7)
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4.6.2.7 Flow cytometry gating strategies to investigate α4β7 expression on T-cell subsets
The same gating strategy for enumerating α4β7+ naïve and effector/memory CD4+ and CD8+ T-
cells was used for all samples in the trial and is illustrated for the CD4+ population in Figure 4.7.
From the lymphocyte population (derived from a light scatter plot), the Vδ2 T-cell population
were identified by plotting CD3-PB against Vδ2-FITC. The population positive for only CD3-PB
was assumed to contain CD4+ and CD8+ T-cells. A one-parameter histogram of CD8-PerCPCy5.5
was then plotted and the negative population was assumed to be CD4+ T-cells. Within the CD4+
and CD8+ populations, a one-parameter plot of CD45RA-PE-Cy7 was then used to determine the
naïve and effector/memory populations using the PE-Cy7-conjugated anti-mIgG1 isotype
control.  Two-parameter  plots  of  β7  against  CD103  were  constructed  for  the  naïve  and
effector/memory CD4+ and CD8+ T-cells. Using the PE-conjugated anti-rIgG2a and AF647-
conjugated anti-mIgG1 isotype controls, the populations positive for only β7 were assumed to
be the α4β7-positive populations, while the populations positive for both PE conjugated anti-β7
and AF647 conjugated anti-CD103 antibodies were assumed to be αEβ7-positive T-cells (Figure
4.7).  A  one-parameter  plot  of  the  Vδ2  T-cells  was  constructed  to  determine  the  proportion
expressing α4β7.
Figure 4.6 Gating strategy for defining α4β7-positive αEβ7-negative populations. The left panel shows
the CD4+ T-cells stained with PE conjugated anti-rIgG2a antibodies (isotype control). The vertical cross-
hair was set to define the PE positive and negative populations. The middle plot shows the CD4+ T-cells
stained with AF647 conjugated anti-mIgG1 antibodies (isotype control). The horizontal cross-hair was
set to define the AF647 positive and negative populations. The right-hand plot shows the same gates
applied to the test tube file (containing CD4+ T-cells stained with PE conjugated anti-β7 and AF647
conjugated anti-CD103 antibodies).
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Figure 4.7 Strategy used to determine a4B7-positive populations within naive and memory CD4+ and
CD8+ T-cell populations. A light scatter plot was constructed and lymphocytes gated. From this “live”
gate, a two-parameter plot of CD3 against delta-2 was constructed. The ‘double-positive’ population
was gated, assumed to the Vδ2+ T-cell population (R2) and the single-positive CD3+ population was
gated (containing the CD4+ and CD8+ T-cells; R3). From the single-positive CD3+ population, a one-
parameter plot of CD8 was plotted. The negative population was assumed to represent the CD4+ T-cell
population. From the CD8+ and CD4+ T-cell populations (R4 and R5), a one-parameter plot of CD45RA
was used to define the naïve (CD45RA+) and effector/memory (CD45RA-) populations (R8 and R9
display this for CD4+ T-cells only). From the naïve and memory populations, two-parameter plots of β7
vs. CD103 were used to define the α4β7-positive populations (R18 and R22 show the α4β7-positive
naïve and memory CD4+ T-cell population) with reference to the isotype control, Figure 3.4.
The number of events in each gated region was used to determine the proportions and absolute
numbers  of  T-cells  subsets.  For  example,  to  calculate  the  proportion  of  naïve  CD4+  T-cells
expressing α4β7, the number of events in that region was divided by the number of events in
the naïve CD4+ T-cell region and multiplied by 100.
Chapter 4: RCT design and methods
201
4.6.2.8 Advantages and limitations of flow cytometry
Flow cytometry is a highly efficient technique allowing identification and characterisation of up
to 20 parameters of cell phenotype simultaneously. It is highly specific and can be used to
identify rare cells within a sample since each cell is examined individually (Jahan-Tigh et al.,
2012). This contrasts with transcriptional profiling, immunoblotting and PCR that provide no
information on individual cells. In this trial, flow cytometry permitted the investigation of
peripheral T-cell subsets without the need for the more laborious and technical methods
required to extract T-cells from other tissues.
The focus of the flow cytometry experiments in this study was the expression of α4β7 on T-cell
subsets. The labelling protocol allowed differentiation between α4β7 and αEβ7-positive T-cells,
thus being more specific for α4β7-positive T-cells.
There remains a lack of standardisation in flow cytometry experiments and analysis, limiting
comparisons of results between studies. Additionally, gating relies purely on the person
performing the analysis and is therefore subject to inter-observer bias. However, all analysis was
performed by one investigator (SC) in this study and therefore gating was consistent throughout.
There is some debate over the specificity of some markers to detect cell subsets. Naïve T-cells
are typically identified through CD45RA expression, however CD45RA can also be expressed by
senescent and terminally differentiated CD8 effector T-cells (Henson et al., 2014, Hoflich et al.,
1998), and can be re-expressed by CD4 memory T-cells (Arlettaz et al., 1999). Therefore, a small
proportion of CD45RA+ T-cells may not be truly naïve.
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4.7 Outcome measures and rationale: Nutrient intake
4.8 Food diaries, diary administration, data input and analysis
Prospective 7-day unweighed food diaries were completed prior to enrolment and in the final
week of the diet to examine energy, nutrient and fermentable carbohydrate intakes. The
rationale for this method of dietary assessment is described in section 2.4.8.1. The diaries were
identical to those used in the case-control study in Chapter 2 and were administered in an
identical fashion (section 2.4.8.2). Food diaries were checked for completeness at the baseline
and end of trial visits and additional information was requested if required. All food diaries were
entered into Nutritics by Charlotte Howard (student dietitian, King’s College London) using the
same protocol described in section 2.4.8.1. Data were analysed by the author of this thesis (SC)
as described in section 2.4.8.5.
4.8.1.1 FODMAP intake analysis
Food diary data were analysed for FODMAP intakes at baseline and end of trial by the author of
this thesis using identical methods to those described in section 2.4.8.4.
4.8.2 Food-related quality of life
The rationale for measuring FR-QOL has been discussed in section 2.4.9.2. The same validated
questionnaire was used to assess FR-QOL at baseline and end of trial in this trial as that described
in section 2.4.9.2.
4.9 Outcome measures and rationale: diet acceptability
Patient acceptability of an intervention is likely determined by factors such as like or dislike for
the treatment modality, perceived benefit of the treatment and a lack of knowledge, at least in
IBS (Harris and Roberts, 2008). Acceptability clearly has the potential to impact upon compliance
and is therefore an important outcome in trials of treatments that could undergo widespread
dissemination and use in clinical practice.
Acceptability questionnaires for dietary interventions assess factors such as palatability, ease of
food purchase and preparation, effort required to follow the diet, convenience of the diet and
satisfaction with meals during the diet (Barnard et al., 2009, Moore et al., 2015)
There are no validated acceptability questionnaires for the low FODMAP diet. However, a
previous PhD student developed a questionnaire for measuring acceptability of the low
FODMAP diet in a trial of patients with IBS with a similar design to the current trial.  The answers
were based on a Likert scale and included questions regarding palatability, ease of meal
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preparation and time spent shopping and cooking, ease of locating suitable foods, cost and
convenience of the diet. This questionnaire was also used to assess long-term acceptability of
the low FODMAP diet in IBS (O'Keeffe et al., 2018).
4.10 Statistical analysis
Data collection, entry and statistical analysis, with the exception of microbiome data, was
conducted by the author of this thesis with guidance from the Statistical Consultancy Service at
King’s College London. Statistical analysis was performed after the last participant’s end of trial
data had been collected, using IBM SPSS Statistics for Windows Version 24.0.
Prior to running statistical tests, continuous data were explored for normality via visual
inspection of histograms. Demographic data were analysed between the diet groups at baseline
using an independent t-test for continuous variables and a Chi-squared test for categorical
variables.
Normally-distributed continuous variables were compared between groups at baseline using
independent t-tests. End of trial values were compared using analysis of covariance (ANCOVA)
with the baseline value as a covariate. Non-normally distributed variables were transformed
prior to performing ANCOVA. Categorical variables were compared using the Chi-squared test
or Fisher’s Exact Test where expected counts in contingency tables were below five.
Logistic regression was used to determine the degree to which diet allocation predicted
categorical variables and multiple linear regression was used to investigate the degree to which
diet allocation predicted continuous variables. Pearson or Spearman correlation analyses were
used to investigate correlations between continuous variables.
Metagenomic bioinformatics analysis was performed by Sébastien Fromentin (Bio-analyst,
INRA).  Microbiome data  were compared between diet  groups at  end of  trial  (accounting for
baseline microbial abundance) and between baseline and end of trial in each of the diet groups
using a likelihood ratio test. This test compares the goodness of fit of two nested statistical
models;  the null  model  and the alternative  model.  If  the value of  the likelihood ratio  is  very
small, then it is likely to reach statistical significance, thus concluding a difference between the
compared data sets.
Data are presented as mean (SD), plus mean difference and 95% confidence intervals (CI’s).
Categorical variables are presented as number (%). Data were considered significant when P
≤0.05.
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4.10.1 Analysis sets
The intention to treat (ITT) dataset included all participants enrolled in the trial, regardless of
compliance to the intervention and whether the trial was completed. Intention to treat analysis
provides a more conservative estimate of the effect size of an intervention and represents the
likely effectiveness in clinical practice, where patients may not complete or adhere to prescribed
interventions. This eliminates bias that could be introduced through excluding participants who
may systematically differ from those completing the trial, thus to some extent nullifying
randomisation (Ranganathan et al., 2016, Gupta, 2011). The Rome committee recommends the
use  of  ITT  analysis,  however  acknowledging  that  per  protocol  (PP)  analysis  has  its  place  for
demonstrating the efficacy of the treatment under optimal conditions (Irvine et al., 2016).
Furthermore, similar results in the ITT and PP analysis provides further confidence in the
findings. A PP analysis, excluding participants who withdrew from the trial prematurely along
with  those  failing  to  comply  with  the  allocated  diet  ≥75%  of  the  time,  was  therefore  also
conducted for all outcomes in this trial.
4.10.2 Missing and ambiguous data
To avoid missing data, all questionnaires and diaries were checked by the author of this thesis
during trial visits. Participants were then encouraged to complete any missing fields.
There are several methods for handling missing data, including modelling techniques and simple
and multiple imputation methods (Powney et al., 2014). Multiple imputation accounts for
uncertainty regarding missing data by creating a combination of different plausible imputed data
sets (Sterne et al., 2009). This reduces bias associated with the assumption that outcomes were
the  same  at  baseline  and  at  the  point  of  withdrawal  from  the  trial  for  patients  who  were
prematurely withdrawn.
However, multiple imputation is most effective where there are reliable predictors of outcome
(Vickers and Altman, 2013). In this trial it was not expected that baseline values would correlate
with values throughout the trial, therefore multiple imputation was not appropriate. Missing
data was instead imputed using Last Observation Carried Forward to allow an ITT analysis.
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5 Results: the effect of fermentable carbohydrate restriction on
clinical and diet outcomes in patients with inactive
inflammatory bowel disease
Chapter 5: RCT clinical and dietary intake results
206
5.1 Introduction
This thesis has thus far demonstrated that a proportion of patients with IBD restrict dietary
FODMAP intake (Chapter 2), and that FODMAPs, particularly fructans, induce functional
gastrointestinal  symptoms  (FGS)  in  patients  with  inactive  IBD  on  the  background  of  a  low
FODMAP diet (Chapter 3). Although Chapter 3 demonstrated that a pure fructan challenge
induces  FGS,  it  cannot  confirm  that  the  low  FODMAP  diet  (restricting  the  dietary  intake  of
several fermentable carbohydrates) is effective for reducing FGS in patients with inactive IBD.
A recent randomised, placebo-controlled trial indicated that a low FODMAP diet is effective for
the management of gastrointestinal (GI) symptoms in IBS (Staudacher et al., 2017b). However,
to date, evidence of the clinical effectiveness of the diet in patients with inactive IBD with FGS
is limited to retrospective and prospective uncontrolled studies and a non-blinded RCT (Prince
et al.,  2016, Gearry et al.,  2009b, Pedersen et al.,  2017). In the non-blinded RCT, significantly
more patients in the low FODMAP diet group responded to the diet compared to patients
continuing their habitual diets (Pedersen et al., 2017). However, 46% of participants in the
habitual diet group were also classified as responders, representing a significant placebo
response as a result of simply taking part in research (Sedgwick and Greenwood, 2015). This
reinforces the need for a placebo-controlled trial of the low FODMAP diet in IBD.
Therefore, a RCT was designed to investigate the effect of low FODMAP dietary advice compared
to placebo ‘sham’ dietary advice on FGS, the GI microbiome and markers of intestinal
inflammation in patients with inactive IBD, the methods for which are described in Chapter 4.
This chapter reports the effects of the low FODMAP diet on GI symptoms, stool output, clinical
disease activity, health-related quality of life (HR-QOL), food-related quality of life (FR-QOL),
patient-perceived control of IBD, nutrient and FODMAP intakes, and diet acceptability.
CONSORT guidelines were followed in reporting outcomes of this RCT (Schulz et al., 2010).
5.2 Patient recruitment and progress, characteristics, compliance and adverse events
5.2.1 Patient recruitment and progress
Trial screening began in December 2015, the first participant was recruited on 25th February
2016  and  the  last  participant  completed  the  trial  on  16th May  2017.  Figure  5.1  shows  the
CONSORT diagram for the trial.
Of 155 patients screened, 98 were excluded during initial screening because they met exclusion
criteria (Figure 5.1). Following completion of the 7-day baseline food and symptom diary, five
patients were excluded due to not experiencing symptoms with sufficient incidence and severity
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(at least one of: abdominal pain, bloating or diarrhoea at least two days per week during the
screening week) (section 4.2.1.3). Therefore, a total of 52 patients were enrolled in the trial, 27
to the low FODMAP diet and 25 to the sham diet. Twenty-three participants were recruited from
Guy’s and St Thomas’ NHS Foundation Trust and 29 from Barts Health NHS Trust.
Forty-six patients completed the trial and six were withdrawn; two withdrew consent during the
trial (one in each group), one became pregnant (sham diet group), two commenced steroids due
to the onset of symptoms of active IBD (one in each group), and one commenced antibiotics for
an infection unrelated to IBD (low FODMAP diet group). Of the 46 patients completing the trial,
three were deemed non-compliant to the diet (defined as following the diet ≤75% of the time
overall during the trial, assessed at the end of trial visit) and were excluded from the per protocol
(PP) analysis, therefore leaving 43 participants (21 in the low FODMAP diet group and 22 in the
sham diet group).
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Symptoms failed to meet
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5.2.2 Baseline patient demographic and clinical characteristics
Baseline demographic data are presented in Table 5.1. Patients in the low FODMAP diet group
were significantly younger than those in the sham diet group (33 SD 11 years vs. 40 SD 13 years,
P=0.031). Furthermore, significantly more patients in the low FODMAP diet group were white
compared  to  the  sham  diet  group  (25/27,  93%  vs.  19/25,  76%,  P=0.029).  There  were  no
significant differences in any other baseline demographics between the groups.
Table 5.1 Baseline demographic characteristics of the ITT population (n=52)
Variable Low FODMAP diet (n=27) Sham diet (n=25) P
Age (years) 33 (11) 40 (13) 0.031
Male, n (%) 10 (37) 13 (52) 0.278
Current smokers, n (%) 2 (7) 3 (12) 0.391
Weight (kg)
BMI (kg/m2) 24 (3) 25 (4) 0.526
Ethnicity, white, n (%) 25 (92) 19 (76) 0.029
Rome III criteria, n (%) 0.150
IBS-D 10 (37) 5 (20)
IBS-M 2 (7) 2 (8)
IBS-U 0 (0) 1 (4)
Functional bloating 15 (56) 13 (52)
Functional diarrhoea 0 (0 4 (16)
Values are mean (SD) unless otherwise stated.
BMI, body mass index; IBS-D, IBS diarrhoea subtype; IBS-M, IBS mixed subtype; IBS-U, IBS unsubtyped
Baseline clinical variables relating to IBD are displayed in Table 5.2. Twenty-six participants each
with CD and UC were recruited. There were no significant differences in any clinical
characteristics between the diet groups.
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Table 5.2 Baseline IBD characteristics of the ITT population (n=52)
Low FODMAP diet (n=27) Sham diet (n=25) P
Crohn’s disease, n (%) 14 (52) 12 (48) 0.781
Time since diagnosis, years 7 (8) 11 (11) 0.187
Time since last flare, years 2 (1) 4 (8) 0.193
Montreal classification
Crohn’s disease location, n (% of CD) 0.773
Ileal 4 (29) 2 (17)
Colonic 4 (29) 4 (33)
Ileocolonic 6 (42) 6 (50)
Crohn’s disease behaviour, n (% of CD) 0.949
Non-stricturing, non-penetrating 9 (64) 8 (66)
Stricturing 3 (21) 2 (17)
Penetrating 2 (14) 2 (17)
Perianal disease, n (% of CD) 4 (29) 3 (25) 1.000
Ulcerative colitis extent, n (% of UC) 0.403
Proctitis 6 (46) 3 (23)
Left-sided 4 (31) 7 (54)
Extensive 3 (23) 3 (23)
Clinical disease activity
Crohn’s disease (HBI) 4 (2) 5 (2) 0.427
Ulcerative colitis (Partial Mayo) 0.8 (0.9) 0.4 (0.7) 0.233
Surgery, n (%)
Small intestinal resection 1 (4) 1 (4) 1.000
Right hemicolectomy 3 (12) 2 (7) 0.662
Medication, n (%)
5-ASA 12 (44) 11 (44) 0.974
Thiopurine 9 (33) 12 (48) 0.282
Infliximab 10 (37) 4 (16) 0.087
Adalimumab 2 (7) 4 (16) 0.411
Vedolizumab 0 (0) 1 (4) 0.481
Methotrexate 2 (7) 1 (4) 1.000
Values are mean (SD) unless otherwise stated.
HBI, Harvey-Bradshaw Index
5.2.3 Compliance
During weekly telephone calls with the researcher, participants were asked about their diet
adherence over the preceding week. Most of the participants (42/52, 81%) reported following
the diet >75% of the time on all three phone calls for both diets. When asked at the end of trial
visit about overall adherence during the entire four-week trial, 24/27 (88%) of participants in
the low FODMAP diet group and 25/25 (100%) in the sham diet group reported following the
diet >75% of the time (P=0.230). Of the remaining patients in the low FODMAP diet group, 2/27
(8%) reported following the diet 50-75% of the time and 1/27 (4%) reported following the diet
25-50% of the time overall. There was no significant difference in the proportion of patients with
CD and UC adhering to the diet >75% of the time (24/26, 91% CD vs. 25/26, 96% UC, P=0.570).
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5.2.4 Adverse events
There were six adverse events during the trial. Two participants had an IBD relapse (one with CD
and one with UC; one in the low FODMAP group and one in sham group), both requiring a course
of steroids. One participant in the low FODMAP diet group commenced antibiotics for a
nasolabial cyst, unrelated to the diet. All three participants were withdrawn from the trial due
to meeting exclusion criteria. One participant in the sham diet group reported a worsening of
abdominal pain in the second week of the trial lasting two days. Upon discussion with the
referring consultant, it was not thought to relate to the diet and the participant completed the
trial. One participant in the low FODMAP diet group reported flu-like symptoms and one in the
sham diet group experienced sinusitis, both of which were unrelated to the diet and the patients
completed the trial. All patients were included in the ITT analysis.
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5.3 Gastrointestinal symptoms and stool output
5.3.1.1 IBS-SSS
5.3.1.1.1 All participants
The IBS Severity Scoring System (IBS-SSS) outcomes at end of trial for the ITT and PP populations
are presented in Table 5.3. There was no significant difference in the primary outcome (change
in IBS-SSS score between baseline and end of trial) between the low FODMAP diet (-67, SD 78)
and the sham diet group (-34, SD 50) (P=0.075) (also see Figure 5.2).
In terms of other IBS-SSS outcomes, there was no difference between the diet groups in the total
end of trial score or in any of the subscores except for bloating severity (question 2), which was
significantly lower in the low FODMAP diet (23 SD 16) than the sham diet group (34 SD 15) at
end of trial (P=0.021) (Table 5.3). The PP analysis showed similar results to the ITT analysis for
the end of trial IBS-SSS score and subscores (Table 5.3). Linear regression showed diet allocation
and diagnosis were not associated with end of trial IBS-SSS score F(2, 49)=1.82 (P=0.173). There
was no difference between the groups in the proportion of patients reaching the MCID of a 50-
point reduction in IBS-SSS score between baseline and end of trial. However, significantly more
participants achieved a 50% reduction in total IBS-SSS score between baseline and end of trial
in the low FODMAP diet (9/27, 33%) than in the sham diet group (1/25, 4%; P=0.012) (Table 5.3).
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Table 5.3 IBS-SSS change, total score, sub-scores and proportion of patients achieving the minimally clinically important difference at end of trial














Change in IBS-SSS score -67 (78) -34 (50) -33 (-68, 3) 0.075 -73 (64) -38 (66) -35 (-74, 4) 0.078
Total IBS-SSS score 157 (68) 190 (65) 33 (-3, 69) 0.075 153 (64) 188 (66) 35 (-4, 74) 0.078
    Pain severity 22 (16) 30 (15) 8 (-1, 17) 0.098 23 (18) 31 (19) 8 (-2, 19) 0.106
    Days of pain (days) 36 (26) 38 (25) 2 (-12, 16) 0.781 37 (23) 37 (24) 0 (-14, 16) 0.922
    Bloating severity 23 (16) 34 (15) 11 (2, 20) 0.021 21 (18) 34 (19) 12 (2, 23) 0.023
    Satisfaction with bowels 39 (16) 47 (20) 8 (2, 19) 0.103 36 (18) 46 (19) 10 (-3, 22) 0.121
    Impact on life 38 (16) 41 (15) 3 (-7, 13) 0.521 37 (18) 40 (19) 3 (-8, 15) 0.574
IBS-SSS 50-point reductiona, n (%) 15 (56) 9 (36) - 0.158 14 (67) 9 (41) - 0.091
IBS-SSS 50-percent reductionb, n (%) 9 (33) 1 (4) - 0.012 8 (38) 1 (5) - 0.009
All values are mean (SD) adjusted for baseline values using ANCOVA, unless otherwise stated. Estimated mean differences and 95% CI’s are presented for continuous outcomes.
IBS-SSS, Irritable bowel syndrome severity scoring system
a Patients achieving at least a 50-point reduction and  b a 50-percent reduction in total IBS-SSS score between baseline and end of trial
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5.3.1.1.2 Crohn’s disease and ulcerative colitis
Sub-group analyses of the primary outcome were performed in CD and UC. In patients with CD
(n=26), there was no difference in the change in IBS-SSS score during the trial between the low
FODMAP diet (-60 SD 90) and sham diet group (-39 SD 52) (P=0.515) (Figure 5.2). There was no
significant difference in the total end of trial IBS-SSS score between the diets or any of the IBS-
SSS sub-scores between the diets (data not shown). There was also no difference between the
low FODMAP and sham diet groups in the proportion of patients reaching the MCID (50-point
reduction) (7/14, 50% vs. 5/12, 42%, P=0.671) or a 50% reduction in score in the IBS-SSS score
(5/14, 36% vs. 1/12, 8%, P=0.170).
Figure 5.2 Change in IBS-SSS score between baseline and end of trial in all participants (n=52) (left
panel), and patients with CD (n=26) (middle panel) and UC (n=26) (right panel). Values are mean (SEM)
adjusted for baseline using ANCOVA. IBS-SSS, irritable bowel syndrome severity scoring system
In patients with UC (n=26), there was a significantly greater reduction in IBS-SSS score between
baseline and end of trial in the low FODMAP diet (-77 SD 54) compared with the sham diet group
(-29 SD 50) (P=0.031) (Figure 5.2), in addition to a significantly lower total IBS-SSS score at end
of trial (135 SD 69 vs. 184 SD 69, P=0.031). There was no significant difference in any of the IBS-
SSS sub-scores between the diet groups (data not shown) or in the proportion of patients
reaching the MCID (50-point reduction) (8/13, 62% vs. 4/13, 31%, P=0.116) or a 50% reduction
in the IBS-SSS score (4/13, 31% vs. 0/13, 0%, P=0.096).
Considering that a greater reduction in IBS-SSS during the trial was observed in patients with UC
following the low FODMAP diet, a linear regression analysis was performed with the change in
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IBS-SSS score between baseline and end of trial as the dependent variable and diet allocation
and diagnosis as independent variables. The regression model was not associated with change
in IBS-SSS score F(2, 49) = 1.49 (P=0.236).
5.3.1.1.3 Factors associated with response to the low FODMAP diet
Given that the mechanisms of a low FODMAP diet on GI symptoms are largely hypothesised to
involve bacterial fermentation and colonic gas production, it was important to determine the
effect of the diet on patients with and without colonic disease. There were six patients in the
trial with purely ileal CD (i.e. lacking colonic disease); four in the low FODMAP diet group and
two in the sham diet group. In a sensitivity analysis excluding these participants, the reduction
in IBS-SSS score during the trial became significantly greater in the low FODMAP diet group (-76
SD  68)  compared  to  the  sham  diet  group  (-36  SD  46)  (P=0.033).  Furthermore,  ANCOVA  was
performed with all participants included but controlling for the presence of colonic disease as a
covariate. Here, the difference between the groups failed to reach significance (-66 SD 81 vs. -
35 SD 46, P=0.050).
In the only other previous RCT of low FODMAP dietary advice in IBD, the diet appeared to be
less efficacious in patients with high faecal calprotectin at baseline (Pedersen et al., 2017).
Therefore, a possible correlation between baseline faecal calprotectin with change in IBS-SSS
score during the trial was examined. This showed a moderate positive correlation, suggesting a
lower baseline faecal calprotectin to be associated with a greater decrease in IBS-SSS score
during the trial (r=0.425, P=0.002). It was not possible to perform sub-group analysis according
to baseline faecal calprotectin since only 9 patients had faecal calprotectin above 100 μg/g.
5.3.1.2 Adequate relief
Significantly more participants reported adequate relief of GI symptoms at end of trial in the low
FODMAP diet (14/27, 52%) compared with the sham diet group (4/25, 16%) (P=0.007) in the ITT
population (Figure 5.3). Likewise, significantly more patients reported adequate relief at end of
trial  in  the  low  FODMAP  diet  (13/21,  62%)  compared  with  the  sham  diet  group  (4/22,  18%)
(P=0.003) in the PP population.
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Figure 5.3 Adequate relief in the intention to treat population (n=52) (left panel), and in patients with
CD (n=26) (middle panel) and UC (n=26) (right panel)
There was no difference in the proportion of participants reporting adequate relief at end of
trial between the low FODMAP diet and sham diet groups in patients with CD (7/14 vs. 2/12,
P=0.110) or UC (7/13 vs. 2/13, P=0.097).
A logistic regression analysis including all participants revealed that a model including diet
allocation and diagnosis as independent variables was significantly associated with the
likelihood of reporting adequate relief ꭓ2(2)=7.72 (P=0.021). The model predicted 19% of the
variance in adequate relief and correctly classified 67% of cases. The odds of reporting adequate
relief were 5.67 times greater in the low FODMAP diet than the sham diet group (95% CI 1.53,
20.93; P=0.009), but diagnosis was not significantly associated with reporting adequate relief
(OR 1.07, 95% CI 0.31, 3.69; P=0.910).
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5.3.1.3  Gastrointestinal Symptom Rating Scale
The end of trial incidence (number of days on which each symptom was reported during the
final week of the diet) and severity (7-day average symptom severity) of 15 individual symptoms
and overall symptoms on the Gastrointestinal Symptom Rating Scale (GSRS) are reported for the
ITT population in Table 5.4. There were no differences in the end of trial incidence or severity of
any of the symptoms assessed, except for lower severity of flatulence in the low FODMAP diet
(0.9  SD  0.5)  compared  to  the  sham  diet  group  (1.2  SD  0.5)  (P=0.035).  Analysis  of  the  PP
population also revealed no differences in the incidence of moderate or severe symptoms
between groups, or the severity of any symptoms except for a significantly lower severity of
flatulence at end of trial in the low FODMAP diet (0.8 SD 0.4) compared to the sham diet group
(1.1  SD  0.4)  (P=0.028).  There  was  no  difference  in  the  incidence  or  severity  of  any  GSRS
symptoms between the diet groups at end of trial in CD or UC (data not shown).
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Table 5.4 Incidence and severity of GI symptoms as measured by the Gastrointestinal Symptom Rating Scale at end of trial in the ITT population (n=52)
Incidencea of moderate or severe symptoms Severityb of symptoms













Pain 1.5 (1.3) 1.1 (1.3) 0.5 (-0.3, 1.2) 0.220 0.9 (0.5) 0.7 (4.5) 0.1 (-0.1, 0.4) 0.243
Heartburn 0.3 (0.5) 0.2 (0.5) 0.1 (-0.2, 0.4) 0.514 0.2 (0.5) 0.1 (0.3) 0.0 (-0.1, 0.1) 0.344
Acid regurgitation 0.3 (0.5) 0.2 (0.5) 0.1 (-0.2, 0.4) 0.359 0.2 (0.5) 0.2 (0.5) 0.0 (-0.1, 0.2) 0.504
Nausea 0.5 (0.6) 0.3 (0.6) 0.1 (-0.2, 0.5) 0.283 0.3 (0.5) 0.3 (0.5) 0.1 (-0.1, 0.2) 0.335
Gurgling 0.7 (1.0) 0.8 (1.0) -0.1 (-0.6, 0.5) 0.858 0.6 (0.5) 0.6 (0.5) 0.0 (-0.2, 0.2) 0.995
Bloating 1.4 (1.7) 1.7 (1.7) -0.2 (-1.2, 0.7) 0.595 0.9 (0.5) 0.9 (0.5) -0.1 (-0.3, 0.2) 0.628
Belching 0.2 (0.6) 0.5 (0.6) -0.3 (-0.6, 0.1) 0.141 0.4 (0.5) 0.5 (0.5) -0.1 (-0.3, 0.1) 0.312
Flatulence 1.4 (1.8) 2.1 (1.8) -0.7 (-1.7, 0.3) 0.152 0.9 (0.5) 1.2 (0.5) -0.2 (-0.5, 0.0) 0.035
Constipation 0.5 (1.1) 0.6 (1.1) -0.1 (-0.7, 0.5) 0.768 0.3 (0.5) 0.3 (0.5) 0.0 (-0.1, 0.2) 0.513
Diarrhoea 0.4 (0.7) 0.5 (0.7) -0.1 (-0.5, 0.3) 0.507 0.2 (0.5) 0.3 (0.5) -0.1 (-0.2, 0.0) 0.214
Loose stools 0.9 (1.0) 0.9 (1.0) -0.0 (-0.6, 0.5) 0.914 0.5 (0.5) 0.5 (0.5) 0.0 (-0.2, 0.2) 0.981
Hard stools 0.1 (0.7) 0.3 (0.7) -0.2 (-0.6, 0.2) 0.293 0.2 (0.4) 0.2 (0.5) 0.0 (-0.2, 0.1) 0.656
Urgency 0.9 (1.1) 0.8 (1.1) 0.1 (-0.5, 0.7) 0.756 0.6 (0.5) 0.5 (0.5) 0.0 (-0.2, 0.2) 0.635
Incomplete evacuation 0.7 (1.2) 0.5 (1.2) 0.2 (-0.5, 0.9) 0.592 0.5 (0.5) 0.4 (0.5) 0.1 (-0.1, 0.3) 0.166
Tiredness 2.3 (1.8) 2.1 (1.8) 0.2 (-0.8, 1.2) 0.692 1.1 (0.5) 1.0 (0.5) 0.0 (-0.2, 0.3) 0.694
Overall symptoms 1.0 (0.5) 1.1 (0.5) -0.1 (-0.2, 0.1) 0.493
All values are mean (SD) adjusted for baseline using ANCOVA. Estimated mean differences and 95% CI’s are also presented.
a Number of days on which each symptom was reported at moderate or severe during the final week of the diet; b Average severity across 7 days; 0=absent, 1=mild, 2=moderate,
3=severe
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5.3.2 Stool output
Stool frequency and consistency at end of trial in the ITT population are displayed in Table 5.5.








Daily stool frequency 1.7 (0.5) 2.1 (0.5) -0.3 (-0.6, -0.1) 0.012
Bristol Stool Form Scale 4.3 (0.5) 4.4 (1.0) -0.1 (-0.5, 0.3) 0.606
Proportion normal stools a, % 64.8 (22.9) 69.1 (22.5) -4.5 (-17.0, 8.1) 0.478
Proportion loose stools a, % 22.4 (19.2) 21.4 (19.0) 1.3 (-9.3, 11.8) 0.807
Proportion hard stools a, % 12.8 (18.2) 9.5 (18.5) 3.3 (-6.9, 13.5) 0.518
All values are mean (SD) adjusted for baseline using ANCOVA. Estimated mean differences and 95% CI’s
are also presented
a Normal (Bristol Stool Type 3, 4 or 5); loose (Bristol Stool Type 6 or 7); Hard (Bristol Stool Type 1 or 2)
There was significantly lower daily stool frequency at end of trial in the low FODMAP diet (1.7
SD  0.5)  compared  with  the  sham  diet  group  (2.1  SD  0.5)  (P=0.012),  however  there  were  no
differences in stool consistency or the proportion of stools that were normal, loose or hard at
end of trial. Similarly, significantly lower daily stool frequency was observed in the low FODMAP
diet (1.8 SD 0.8) compared to the sham diet group (2.1 SD 1.1) (P=0.022) at end of trial in the PP
analysis.
There was a significantly lower daily stool frequency at end of trial in the low FODMAP diet (1.7
SD 1.0) compared to the sham diet group (2.1 SD 1.1) (P=0.019) in patients with CD but not in
UC (1.8 SD 0.6 vs. 2.0 SD 0.9, P=0.501). There was no difference in stool consistency between
the diet groups in CD or UC at end of trial (data not shown).
5.4 Clinical disease activity
There was no difference in clinical disease activity between the low FODMAP diet and sham diet
groups at baseline (Table 5.2) or at the end of trial for CD (mean HBI score 3.2 SD 1.9 vs. 3.4 SD
1.9, P=0.814) or UC (mean Partial Mayo Score 0.2 SD 0.4 vs. 0.2 SD 0.7, P=0.951). There were no
differences in scores on the individual questions of the HBI or Partial Mayo score between the
groups at baseline or end of trial (data not shown).
5.5 Health-related quality of life and food-related quality of life
There was a significantly higher end of trial IBDQ score (implying greater quality of life) in the
low FODMAP diet group (81.9 SD 8.3) compared to the sham diet group (78.3 SD 7.5) (P=0.042)
(Table 5.6). Specifically, there was a significantly higher score in the bowel II domain of the IBDQ
in the low FODMAP diet group (76.5 SD 13.0) compared to the sham diet group (70.0 SD 9.5)
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(P=0.031), however no other IBDQ domains (emotional, social, bowel I, systemic) were different
between the diet groups (Table 5.6).
There was a higher total IBDQ score in the low FODMAP diet (83.0 SD 6.1) compared to the sham
diet group (77.9 SD 6.1) (P=0.010) in the PP population, as well as a significantly higher score in
the bowel I (87.3 SD 11.4 vs. 81.8 SD 10.9, P=0.029) and bowel II (79.4 SD 13.2 vs 70.3 SD 9.0,
P=0.007) domains. There was no significant difference between the diet groups in total IBDQ
score or sub-scores in CD and UC (data not shown).
It was hypothesised that an improvement in GI symptom severity may predict an improvement
in HR-QOL. Univariate linear regression revealed that end of trial IBS-SSS score did indeed
predict end of trial IBDQ score F(1,50) = 56.1 (P<0.001). The model accounted for 51% of the
explained variability in end of trial IBDQ score. For each one-point decrease in the IBS-SSS, there
was a predicted 0.08-point increase in IBDQ score.
Table 5.6 UK IBDQ total score and domain scores at end of trial in the ITT population (n=52)
At end of trial, there was no significant difference in FR-QOL score between the low FODMAP
diet (77.3 SD 15.6) and sham diet (82.8, SD 18.5) (P=0.164). The results were similar in the PP
population. Sub-group analyses showed no significant different between diet groups in CD or
UC (data not shown).
5.6 IBD-control questionnaire
There was a significantly greater IBD-control score at end of trial in the low FODMAP diet (88.3
SD 22.3) compared to the sham diet (74.3 SD 25.0) (P=0.028). Sub-group analysis revealed that
this was specific to patients with UC (94.2 SD 21.3 vs. 71.3 SD 25.6, P=0.022) and was not evident
in CD (81.4 SD 24.0 vs. 79.1 SD 22.5, P=0.768). The results were similar in the PP population.
It was hypothesised that the IBS-SSS score at end of trial may be associated with the IBD-control








Total score 81.9 (8.3) 78.3 (7.5) 3.6 (0.1, 7.0) 0.042
    Emotional 81.7 (9.4) 79.8 (9.0) 1.9 (-2.2, 2.2) 0.352
    Bowel I 86.1 (12.0) 81.8 (10.5) 4.3 (-0.2, 8.9) 0.061
    Social 93.8 (9.4) 90.6 (10.5) 3.2 (-1.3, 7.6) 0.157
    Bowel II 76.5 (13.0) 70.0 (9.5) 6.5 (0.6, 12.4) 0.031
    Systemic 62.3 (16.6) 58.0 (13.0) 4.3 (-2.0, 10.7) 0.176
All values are mean (SD) adjusted for baseline using ANCOVA. Estimated mean differences and 95% CI’s
are also presented
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inflammation. A linear regression showed that the IBS-SSS score was significantly associated
with end of trial IBD-control score F(1, 50) = 49.7, P<0.001, accounting for 48.9% of the explained
variability in IBD-control score.
5.7 Nutrient intake
Seven-day food records were obtained from all 52 participants at baseline and from 45
participants at end of trial (6 withdrawn from the trial, 1 failed to return food record). All dietary
data were analysed ITT. Since one coder entered all 97 food diaries, it was not necessary to check
inter-observer agreement. This section describes the effect of the low FODMAP and sham
dietary advice on nutrient intakes.
Table 5.7 displays nutrient intakes at the end of trial (adjusted for baseline intakes). End of trial
daily energy intake was significantly lower in the low FODMAP diet (1697 SD 514) than the sham
diet group (1918 SD 624) (P=0.002). There was significantly lower protein and fat intake in the
low FODMAP diet compared to the sham diet group. However, there was no difference between
the low FODMAP diet and sham diet groups in the proportion of energy derived from
carbohydrate (42% SD 6% vs. 41% SD 7%, P=0.687), protein (18% SD 4% vs. 18% SD 4%, P=0.442)
or  fat  (36%  SD  6%  vs.  37%  SD  6%,  P=0.442).  There  was  significantly  lower  sugar,  calcium,
phosphorous and iodine intake in the low FODMAP diet compared to the sham diet at end of
trial.
To specifically investigate the effect of the low FODMAP diet on nutrient intake, baseline and
end of trial nutrient intakes were compared in this group. The intake of energy (1640 SD 514
kcal/d vs. 1867 SD 593 kcal/d, P=0.001), protein (74 SD 18 g/d vs. SD 28 g/d, P=0.024), fat (66 SD
26g/d vs.  75 SD 27 g/d,  P=0.018),  carbohydrate (170 SD 60 g/d vs.  195 SD 69 g/d,  P=0.001),
calcium (664 SD 279 mg/d vs. 801 SD 308 mg/d, P=0.006), sodium (1469 SD 531 mg/d vs. 2095
SD 860 mg/d, P <0.001) and phosphorous (1131 SD 309 mg/d vs. 1277 SD 401 mg/d, P=0.005)
significantly declined between baseline and end of trial.
The proportion of participants meeting national macronutrient, micronutrient and fibre
recommendations was not different between the diet groups at end of trial (DoH, 1991), or
between baseline and end of trial in the low FODMAP diet and sham diet groups (compared
using a McNemar’s test) (data not shown).
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Table 5.7 Seven-day average nutrient intakes in the low FODMAP and sham diet groups at end of trial








Energy (kcal) 1697 (514) 1918 (624) -220 (-357, -85) 0.002
Protein (g) 74 (18) 83 (25) -9 (-16, -2) 0.008
Fat (g) 68 (26) 80 (36) -11 (-22, -1) 0.035
Saturated fat (g) 24 (12) 27 (15) -4 (-8, 1) 0.102
Carbohydrate (g) 180 (60) 197 (72) -17 (-34, 1) 0.058
Starch (g) 116 (36) 118 (50) -1 (-15, 12) 0.841
Sugars (g) 63 (30) 76 (33) -13 (-24, -2) 0.022
Fibre (g) 18 (6) 19 (8) -1 (-4, 1) 0.249
Calcium (mg) 692 (279) 911 (361) -219 (-332, -106) <0.001
Iron (mg) 11 (5) 12 (4) -1 (-3, 1) 0.170
Zinc (mg) 9 (6) 10 (4) -1 (-4, 2) 0.470
Sodium (mg) 1533 (531) 2196 (896) -663 (-910, -415) <0.001
Potassium (mg) 2939 (1106) 3034 (937) -95 (-526, 335) 0.658
Phosphorous (mg) 1140 (310) 1313 (402) -173 (-276, -69) 0.002
Magnesium (mg) 290 (97) 297 (109) -7 (-44, 30) 0.709
Iodine (μg) 124 (59) 176 (372) -51 (-95, -8) 0.022
Selenium (μg) 59 (29) 57 (22) 1 (-11, 13) 0.823
Vitamin A (μg) 1358 (1005) 1328 (3599) 30 (-573, 632) 0.921
Vitamin C (mg) 90 (54) 75 (48) 15 (-6, 36) 0.166
Vitamin D (μg) 6 (2) 6 (23) 0 (-1, 1) 0.818
Vitamin B1 (thiamin) (mg) 2 (1) 1 (0) 0 (-0, 0) 0.963
Vitamin B2 (riboflavin) (mg) 2 (1) 2 (1) 0 (-0, 0) 0.182
Vitamin B3 (niacin) (mg) 20 (6) 20 (7) -1 (-4, 3) 0.672
Vitamin B6 (pyridoxine) (mg) 2 (1) 2 (1) 0 (-0, 0) 0.634
Vitamin B7 (biotin) (μg) 36 (18) 36 (15) 0 (-7, 7) 0.993
Vitamin B9 (folate) (μg) 229 (85) 257 (108) -28 (-62, 7) 0.110
Vitamin B12 (cobalamin) (μg) 6 (7) 6 (2) 0 (-2, 3) 0.782
All values are mean (SD) adjusted for baseline using ANCOVA
5.7.1 Body weight
There was a significantly lower body weight in the low FODMAP (71 SD 14 kg) compared to the
sham diet group at end of trial (73 SD 12 kg) (P <0.001). In the sham diet group, end of trial body
weight (74.8 SD 12.1 kg) was significantly higher than baseline (74 SD 12 kg) (P=0.015), while in
the low FODMAP diet group end of trial body weight (70.0 SD 14.4 kg) was significantly lower
than baseline (70.7 SD 15.0 kg) (P=0.015).
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5.8 FODMAP intake
Fermentable carbohydrate intakes at end of trial were analysed ITT and are presented in Table
5.8. Total FODMAP intake was calculated as the sum of fructans, GOS, lactose, fructose in excess
of glucose and polyols (sorbitol and mannitol). Total and individual FODMAP intakes were
significantly lower in the low FODMAP diet than in the sham diet group at end of trial.











Total 8.1 (7.5) 17.9 (10.3) -9.8 (-13.2, -6.4) <0.001
Change in total FODMAPsa
from baselineb
-7.9 (8.6) 2.3 (4.8) -9.8 (-13.2, -6.3) <0.001
    Fructans 1.3 (0.9) 2.9 (1.3) -1.6 (-2.2, -1.0) <0.001
    GOS 0.4 (0.3) 0.9 (0.6) -0.4 (-0.7, -0.2) <0.001
    Lactose 5.8 (7.1) 10.7 (9.9) -5.3 (-8.3, -2.3) 0.001
    Excess fructose 0.5 (0.5) 1.3 (1.3) -0.9 (-1.4, -0.4) 0.001
    Sorbitol 0.2 (0.3) 0.6 (0.8) -0.5 (0.2, 0.8) 0.001
    Mannitol 0.1 (0.2) 0.3 (0.3) -0.2 (-0.3, -0.1) 0.002
Values are mean (SD) grams per day adjusted for baseline using ANCOVA
a Change in total FODMAP intake between baseline and end of trial
Total and individual FODMAPs were significantly lower at end of trial compared to baseline in
the low FODMAP diet group (Figure 5.4) while in the sham diet group there was no difference
between baseline and end of trial (data not shown).
Figure 5.4 Fermentable carbohydrate intakes at baseline and end of trial in the low FODMAP diet group.
Baseline and end of trial  intakes were compared using the Wilcoxon Signed Rank test.  All  P<0.05 for
baseline vs. end of trial. Fructose in excess of glucose is presented
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5.9 Acceptability
For most of the diet acceptability questions, significantly more patients in the low FODMAP diet
group answered the question negatively compared to the sham diet group, except for meal
preparation and understanding the written material provided during the trial (Table 5.9). Most
of the participants in both groups reported that the benefits of being involved in the research
outweighed the burden of taking part (84% low FODMAP diet vs. 64% in the sham diet group,
P=0.180).






Meal preparation was more difficult 18 (72) 10 (36) 0.081
Longer time spent shopping for food 20 (80) 8 (36) 0.003
Longer time spent preparing and cooking meals 14 (56) 5 (23) 0.036
Finding suitable foods when eating out was more difficult 23 (92) 13 (59) 0.014
The flavour of meals and snacks was less appealing 15 (60) 2 (9) 0.001
More money spent on shopping and eating out 20 (80) 1 (5) <0.001
The written information was difficult to understand 0 (0) 1 (5) 0.468
The diet was less convenient 20 (80) 15 (32) 0.001
The diet was more difficult 22 (88) 8 (36) <0.001
Lots of dietary changes were made 22 (88) 11 (50) 0.004
Values are number of participants (% of group) with a negative response
Groups were compared using a Chi-squared test
5.10 Blinding
At end of trial, participants were asked whether they were able to identify which diet group they
had been allocated to (‘intervention diet’, ‘placebo diet’ or ‘not sure’). Of all the patients
completing the trial, 34/46 (74%) correctly identified their diet allocation. In the low FODMAP
diet group, 14/24 (58%) correctly identified diet allocation compared to 20/22 (91%) in the sham
diet group (P=0.034). Two patients in the low FODMAP diet group (8%) and one patient in the
sham diet group (5%) were ‘not sure’ of their diet allocation (P>0.05).
To determine the level of agreement between participants’ actual diet allocation and perceived
diet allocation, Cohen’s κ was computed between diet allocation and perceived diet allocation.
For the purpose of this analysis, participants who answered ‘not sure’ (3/52, 6%) of their diet
allocation were classified as guessing incorrectly. There was moderate agreement between the
actual and perceived diet allocation, κ = 0.485 (95% CI 0.25, 0.72), P < 0.001 (Landis and Koch,
1977).
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5.11 Discussion and conclusion
5.11.1 Gastrointestinal symptoms
The null hypothesis of this trial was that there is no difference in the change in symptom severity
score (IBS-SSS) at four weeks following low FODMAP dietary advice compared to placebo sham
dietary advice in patients with inactive IBD with FGS. This hypothesis must be accepted since
there was no significant difference between the groups. However, the difference between
groups approached statistical significance (P=0.075) with a greater reduction in score in the low
FODMAP diet group. Additionally, there were numerous findings suggestive of an improvement
in GI symptoms following the low FODMAP diet, including more patients with adequate relief of
GI symptoms, lower bloating and flatulence severity, and greater patient-perceived control of
IBD following the low FODMAP diet compared to the sham diet.
An improvement in global GI symptoms (adequate relief) and specifically bloating and flatulence
following the low FODMAP diet is supported mechanistically. Fructan challenges increase
colonic gas volume and fructose and polyols increase small intestinal water content in healthy
individuals and patients with IBS, with resulting GI symptoms experienced by patients with IBS
(Major et al., 2017, Murray et al., 2004, Marciani et al., 2010). Although colonic gas generation
following  α-GOS  ingestion  has  not  been  directly  studied  using,  for  example,  MRI,  α-GOS  are
capable of increasing flatulence in healthy volunteers (Steggerda et al., 1966, Suarez et al.,
1999).  As  explained  in  Chapter  1  of  this  thesis,  colonic  gas  generation  following  FODMAP
consumption is hypothesised to occur through colonic bacterial fermentation of FODMAPs,
which likely varies considerably among different FODMAPs and even different degrees of
polymerisation of fructans and GOS (Hernot et al., 2009).
It is therefore unsurprising that pure fructan and fructose challenges increased global GI
symptoms and fructans increased bloating and flatulence following a low FODMAP diet in
patients with IBS (Shepherd et al., 2008). Similarly, the re-challenge trial described in Chapter 3
of this thesis demonstrated for the first time that fructan challenge increased abdominal pain,
bloating and flatulence in patients with inactive IBD following FODMAP restriction, indicating
similar effects of FODMAPs in patients with FGS on the background of inactive IBD (Cox et al.,
2017). Furthermore, numerous studies have observed improved GI symptoms including
abdominal bloating and flatulence following the low FODMAP diet in IBS (Staudacher et al.,
2012, Staudacher et al., 2017b, Halmos et al., 2014b, Bohn et al., 2015, Eswaran et al., 2016) and
uncontrolled studies have suggested a similar response in IBD (Gearry et al., 2009b, Prince et al.,
2016). Indeed, abdominal bloating and flatulence demonstrated the greatest improvement
following  low  FODMAP  dietary  advice  in  the  latter  prospective  study.  Furthermore,  a  large
proportion (54%) of patients in the current trial fulfilled the criteria for functional bloating at
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enrolment and an improvement in bloating was therefore possible and may have resulted in
adequate relief at end of trial.
It  is  promising  that  more  patients  reported  adequate  relief  following  the  low  FODMAP  diet
compared to the sham diet. This outcome permits a global assessment of GI symptoms that can
be extremely heterogeneous in IBS and IBD and, since it reflects the overall  tolerability of GI
symptoms, is arguably of great clinical significance. Adequate relief has therefore been widely
utilised in IBS trials (Mangel et al., 1998) and continues to be recommended by the Rome
committee for the assessment of GI symptoms in FGID because it demonstrates excellent
construct validity (Irvine et al., 2016, Spiegel et al., 2009).
Adequate relief permits comparison of trial results since it overcomes the heterogeneity in GI
symptom responses to treatments. This has has been demonstrated in trials of linaclotide for
constipation-predominant constipation (Camilleri et al., 2015). The previous placebo-controlled
trial of the low FODMAP diet in IBS revealed similar proportions of patients reporting adequate
relief in the low FODMAP diet group (57% vs. 52% in the current trial), but a greater proportion
of patients in the sham diet group reported adequate relief in the previous trial (38% vs. 16% in
the current trial) (Staudacher et al., 2017b). This may reflect differences in GI symptom
perception and validity of the adequate relief outcomes between IBS and IBD. Indeed, adequate
relief has not been validated in patients with IBD, although it has been recently used to
demonstrate  an  improvement  in  GI  symptoms  following  low  FODMAP  dietary  advice  and  a
worsening of GI symptoms following fructan challenge in patients with inactive IBD (Prince et
al., 2016, Cox et al., 2017).
Meanwhile, the difference in the change in IBS-SSS between baseline and end of trial failed to
reach significance between the diet groups. This is discordant with recent trials in both IBD
(Pedersen et al., 2017) and IBS (Staudacher et al., 2017b) and may be explained in several ways.
The recent trial in patients with FGS in IBD (Pedersen et al., 2017) was unblinded and thus
achieved a greater difference between the diet groups as a result of a placebo response in the
low FODMAP diet group that was not present in the control group. Moreover, a full explanation
of the mechanisms and theory of the low FODMAP diet was provided to patients in the
intervention group, which may have inflated the placebo response. These differences in trial
design could explain the more modest difference observed between the low FODMAP diet and
sham diet in the current study, in which sham dietary advice was provided to patients in the
control group and in which patients simply received a list of foods permitted, without an
explanation of the mechanisms.
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There was no difference in abdominal pain incidence or severity between the diet groups in this
trial. Luminal distension associated with bacterial gas production would be expected to result in
abdominal pain as well as bloating and flatulence. Indeed, previous studies of the low FODMAP
diet in IBS and IBD observed an improvement in abdominal pain (Halmos et al., 2014b,
Staudacher et al., 2017b, McIntosh et al., 2016, Bohn et al., 2015, Eswaran et al., 2016, Pedersen
et al., 2017) and fructan challenge increased abdominal pain (in addition to bloating and
flatulence) in patients with IBD in the second chapter of this thesis. A lack of improvement in
abdominal pain in this trial may reflect alternative mechanisms of pain induction not related to
luminal distension, such as low-grade inflammation (Vivinus-Nébot et al., 2014), nerve receptor
sensitisation (Lapointe et al., 2015) and on-going undetected small bowel complications such as
strictures in CD. Secondly, and likely most importantly, 38% of participants met the criteria for
IBS at baseline, while the remainder met the criteria for functional bloating (54%) and functional
diarrhoea (8%). Up to 62% of participants may therefore have had no abdominal pain at
baseline, which of course would preclude an improvement in this symptom. Finally, as previously
discussed, prior experience of severe recurrent abdominal pain during IBD relapses may result
in differing perceptions of abdominal pain compared to patients with IBS and may influence
abdominal pain ratings in patients with a background of IBD.
While  the most  recently  published trial  of  the low FODMAP diet  in  IBS  used the same sham
dietary advice as the current study (Staudacher et al., 2017b), the discordant IBS-SSS findings
compared to the current trial could reflect differences in IBS and IBD pathophysiology or
differing ability of the IBS-SSS to accurately represent symptoms in IBD, a population in which
this questionnaire has not been validated. Interestingly, the IBS trial failed to show a significant
difference in adequate relief, in contrast to the current trial. This further supports differing
validity  of  GI  symptom  outcome  measures  in  IBS  and  IBD.  Prior  experience  of  GI  symptoms
during IBD relapses may shape the likelihood of reporting adequate relief, although this is yet to
be formally evaluated (Prince et al., 2016, Cox et al., 2017).
Although there was no significant difference between the diet groups in the proportion of
patients achieving the MCID (50-point reduction) in the IBS-SSS, more patients in the low
FODMAP diet group achieved at least a 50% reduction in IBS-SSS score during the trial. This could
reflect a placebo response in the sham diet group narrowing the difference between the groups
for the MCID; i.e. lots of patients achieved a small reduction in score in both groups (50 points)
but few patients achieved a drastic reduction (≥50%). The proportion of patients achieving the
MCID  in  the  sham  diet  group  in  this  trial  (36%)  is  similar  to  the  previous  trial  in  IBS  (42%)
(Staudacher et al., 2017b). However, the proportion achieving the MCID in the low FODMAP diet
group in  this  trial  (56%) was lower  than in  the previous  trial  in  IBS  (73%) (Staudacher  et  al.,
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2017b) and in IBD (81%) . These differences could relate to differences in GI symptom responses
in IBS and IBD and the lack of blinding in the previous IBD trial.
There was also discrepancy between the same GI symptoms measured using the IBS-SSS and the
GSRS within this trial. Bloating was significantly lower following the low FODMAP diet when
measured using the IBS-SSS but not the GSRS. There was however lower severity of flatulence
on the GSRS in the low FODMAP diet group. While neither of these outcome measures have
been validated in patients with IBD specifically, they have been used to demonstrate GI
symptom improvements following low FODMAP dietary advice and to evaluate the prevalence
of  GI  symptoms  in  patients  with  inactive  IBD  (Prince  et  al.,  2016,  Simrén  et  al.,  2002).  The
observed differences in GI symptoms measured using these outcome measures could reflect
questionable validity in detecting symptom changes in IBD, different measurement scales, or a
difficulty in separating bloating and flatulence. In support of this, cognitive interviews have
demonstrated that patients with IBS struggle to differentiate pain and discomfort, and that
bloating involves both the sensation and the visual appearance (Spiegel et al., 2010).
5.11.2 Gastrointestinal symptoms according to diagnosis, disease location and baseline GI
inflammation
Based upon the adequate relief outcome, 48% of patients did not respond to the low FODMAP
diet in this trial. The ability to predict which patients are most likely to respond to low FODMAP
dietary advice is attractive in clinical practice since it would reduce the number of patients
unnecessarily attempting this diet, which can be challenging to execute.
Sub-group analyses revealed a significantly greater reduction in IBS-SSS score during the trial
and a significantly lower end of trial IBS-SSS score in the low FODMAP diet compared to the
sham diet group in patients with UC but not CD. Although this trial was not powered to detect
differential  effects  of  the low FODMAP diet  in  patients  with  CD and UC,  the lack  of  effect  in
patients with CD is interesting and there are several possible explanations for this. Firstly, the
pathophysiology of CD and UC differ substantially and it is therefore unsurprising that both drug
treatments (Cholapranee et al., 2017) and dietary treatments (Derwa et al., 2017, Narula et al.,
2018)  have demonstrated differing efficacy  in  CD and UC.  Secondly,  the low FODMAP diet  is
hypothesised to improve GI symptoms through reducing luminal distension associated with gas
generated through colonic bacterial fermentation (Staudacher and Whelan, 2017). Animal
models have shown that alterations in neurophysiology and GI motility can persist following
resolution of inflammation (Lapointe et al., 2015, Krauter et al., 2007) and the reduced
distension in the colon following the low FODMAP diet may therefore have a greater potential
to benefit patients with UC. That said, a large proportion of patients with CD in the low FODMAP
diet group in this trial had some degree of colonic involvement (71% with either ileocolonic or
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colonic CD). In line with this hypothesis, sensitivity analysis revealed a significantly greater
reduction in IBS-SSS score during the trial upon exclusion of patients with isolated ileal CD
(leaving only patients with either UC and colonic or ileocolonic CD).
Thirdly, patients were defined as in remission and therefore suitable for enrolment in the trial
based upon faecal calprotectin concentration. There are studies supporting and opposing the
ability of faecal calprotectin to detect isolated small intestinal inflammation (Sipponen et al.,
2012, Arai et al., 2017) and the small intestine is less accessible and more challenging to assess
through endoscopy. Therefore some patients with CD may have had on-going small intestinal
inflammation not detected through faecal calprotectin, which, as discussed above, could have
abrogated GI symptom responses to the diet in the patients with CD. Finally, fibrotic strictures
can result from prior transmural GI inflammation in CD and can cause GI symptoms even in the
absence of active inflammation (Van Assche et al., 2010). A recent endoscopy or MRI was not
required prior to trial enrolment and some patients with CD may have had strictures that could
confound GI symptom responses, although patients with known strictures were excluded.
Although there was no difference in the change in the IBS-SSS score between the low FODMAP
and sham diet groups at end of trial, a sensitivity analysis including only patients with IBD with
colonic involvement (i.e. UC, colonic CD, ileocolonic CD) resulted in a significantly larger
reduction in IBS-SSS in the low FODMAP diet group. This suggests the presence or absence of
colonic  disease  may  influence  GI  symptom  responses  to  the  low  FODMAP  diet.  A  possible
explanation may be lasting effects of prior colonic inflammation that may influence the
likelihood of GI symptoms following bacterial fermentation and colonic distension. It could be
that patients with colonic disease are more likely to respond to dietary fermentable
carbohydrate restriction and a reduction in colonic distension. For the same reason, these
patients may habitually avoid or reduce the intake of high FODMAP foods, supported by lower
GOS and polyol intakes in inactive IBD with FGS in the case-control study in Chapter 2. This may
also explain the observed association between a lower fructan intake with the presence of
colonic disease observed in the case-control study, but this requires further investigation in
larger studies.
Change in IBS-SSS score between baseline and end of trial was positively correlated with baseline
faecal calprotectin. This suggests that a lower degree of intestinal inflammation was associated
with a greater reduction in IBS-SSS score (and thus, an improvement in GI symptoms) during the
trial. This finding is congruent with the aforementioned IBD trial in which there was no difference
in change in IBS-SSS score between low FODMAP diet and habitual diet in patients with elevated
faecal calprotectin at baseline (>100 μg/g in UC and >200 μg/g in CD) (Pedersen et al., 2017),
although acknowledging that only 23% of participants had elevated faecal calprotectin at
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baseline. Unfortunately, the small numbers of participants with faecal calprotectin above 50
μg/g and 100 μg/g in the current trial prevented meaningful sub-group analyses of symptom
responses according to baseline faecal calprotectin. The aetiology of GI symptoms in the
presence of even subtle active intestinal inflammation may differ from truly ‘functional’
symptoms; for example, abdominal pain during inflammation is likely the result of primary
afferent neuron sensitisation by inflammatory cytokines and mediators (Farrell et al., 2014) and
whether patients with mildly active IBD could benefit from the low FODMAP diet requires
further investigation.
5.11.3 Stool output
There was a lower stool frequency following the low FODMAP diet compared to the sham diet
in this trial, however there was no difference in stool consistency. The difference in stool
frequency following the low FODMAP diet was somewhat expected on the basis that certain
fermentable carbohydrates, primarily fructose and polyols, increase small bowel water (Major
et  al.,  2017,  Murray  et  al.,  2014,  Marciani  et  al.,  2010).  Furthermore,  certain  fermentable
carbohydrates may influence GI motility. For example, a 30 g fructose-sorbitol mixture increased
GI  motility  in  healthy  volunteers  (Madsen  et  al.,  2006).  Finally,  inulin  and  GOS  are  types  of
dietary fibre and have been shown to influence stool output (Brownlee, 2011, Holscher et al.,
2014,  Micka  et  al.,  2017,  Silk  et  al.,  2009),  albeit  in  healthy  volunteers  with  and  without
constipation and patients with IBS in whom GI physiology may differ to patients with IBD. The
low  FODMAP  diet  has  also  been  shown  to  alter  stool  frequency  (Halmos  et  al.,  2014b)  and
consistency (Staudacher et al., 2012, Staudacher et al., 2017b) in some trials in patients with IBS.
The lack of effect on stool consistency following the low FODMAP diet in this trial is discordant
with the re-challenge trial described in Chapter 3 of this thesis that demonstrated softer stool
consistency following fructan and GOS challenges. There are several possible explanations for
this. Firstly, the GI tract may be able to accommodate additional luminal water in excess of that
likely to be introduced through osmotically active carbohydrates (Kamath et al., 1990).
Furthermore, short and long-chain fructans have differential effects on whole gut transit time in
healthy volunteers, indicating that the degree of polymerisation of the fermentable
carbohydrate challenges in the re-challenge trial may produce discrepancies compared to a low
FODMAP diet trial (Rumessen and Gudmand-Hoyer, 1998). Similarly, fermentable carbohydrate
challenge or supplementation does not mimic the effect of broad restriction of fermentable
carbohydrates within whole foods.
A further consideration is the small proportion of abnormal stools at baseline (35% of stools
were classified as ‘loose’ or ‘hard’ during the screening week) in the current trial and the fact
that 16% of the sham diet group fulfilled the criteria for functional diarrhoea compared to 0% in
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the low FODMAP diet group. This group of patients were experiencing regular persistent
diarrhoea and were confined to the sham diet group, which may have limited the ability to
detect an effect of the low FODMAP diet on stool consistency.
5.11.4 Clinical disease activity
There was no significant difference in clinical disease activity between the diets at the end of
trial. Given that much of the HBI is based upon GI symptoms (loose stools and abdominal pain)
and general well-being, it is unsurprising that the mean baseline scores in this trial exceeded the
typical threshold for disease in remission (a total score of ≤4 is often cited as an appropriate cut-
off for inactive CD since this corresponds to a CDAI ≤150 points (Vermeire et al., 2010)). This may
reflect  the fact  that  patients  were recruited to  this  trial  based upon the presence of  FGS.  In
contrast, mean baseline Partial Mayo scores in both diet groups were below the suggested ≤1
point cut-off for remission (Peyrin-Biroulet et al., 2015). This is likely because two of the three
questions in this measure relate to Physician Global Assessment and rectal bleeding, both of
which should have low scores in the context of patients in remission. Although sub-group
analyses revealed a greater reduction in GI symptom severity in patients with UC during the trial,
the end of trial Partial Mayo score is unlikely to reflect this since this score is less responsive to
GI symptom report than the HBI. In contrast, the Simple Clinical Colitis Activity Index (SCCAI)
assesses general well-being, stool frequency (daytime and nocturnal) and faecal urgency and
had it been used scores could be increased by the presence of FGS.
5.11.5 Health-related quality of life and food-related quality of life
There  was  a  significantly  higher  IBDQ  score  in  the  low  FODMAP  diet  group  at  end  of  trial,
suggesting greater HR-QOL in this group. As expected, end of trial symptom severity was
significantly associated with IBDQ score. These findings mirror those of a recent trial
demonstrating  a  significant  improvement  in  HR-QOL  following  the  low  FODMAP  diet  in  IBD
(Pedersen et  al.,  2017).  Furthermore,  HR-QOL score following exclusive enteral  nutrition has
been  shown  to  correlate  negatively  with  the  CDAI  score  in  active  CD  (Guo  et  al.,  2013).
Improvements  in  HR-QOL were also observed following medical  and surgical  treatments  in  a
large cohort of newly diagnosed European patients with IBD, suggesting that management of
inflammation and GI symptoms improves HR-QOL (Burisch et al., 2014b).
The Bowel II domain of the IBDQ scored significantly higher in the low FODMAP diet group at
end of trial. This is unsurprising given that this domain encompasses the effect of GI symptoms
(including abdominal pain, bloating, flatulence and nausea), which other GI symptoms measures
showed to be reduced following the diet, on HR-QOL. The lack of improvement in the emotional
and social function domains is interesting given that several previous studies have noted poorer
HR-QOL in these domains in patients with FGS in IBD compared to those without FGS (Gracie et
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al., 2017, Jelsness-Jorgensen et al., 2014). This may be explained by different coping styles
among different patients; a systematic review demonstrated varying coping styles among
patients with IBD, with some displaying a problem-focussed and others an emotion-focussed
coping style, the latter of which is generally associated with poorer outcomes (McCombie et al.,
2013). The lack of effect of the low FODMAP diet on emotional and social domains of the IBDQ
may relate to adaptive coping mechanisms in some patients with IBD (McCombie et al., 2016).
There are numerous IBD-specific HR-QOL instruments, including the IBDQ (Guyatt et al., 1989),
the short-IBDQ (Irvine et al., 1996) and the Rating Form of IBD Patient Concerns (Drossman et
al., 1991). A systematic review revealed that the IBDQ is the most widely used HR-QOL tool in
the literature and performs well in terms of measurement properties and methodological
quality, although certain other HR-QOL instruments were considered superior in terms of
construct validity and responsiveness (Chen et al., 2017). Although the FGS experienced by
patients enrolled in this trial are ‘IBS-like’, previous studies have generally utilised IBD-specific
measures (rather than IBS-specific measures) in patients with IBD and FGS since these reflect
domains of HR-QOL relevant to IBD (Pedersen et al., 2017, Abdalla et al., 2017, Bryant et al.,
2011).
Given that dietary restrictions were required during the dietary interventions in this trial, it was
important to investigate whether FR-QOL was affected. (Hughes et al., 2016). Interestingly,
there was no significant difference in end of trial FR-QOL score or change in score at baseline
and end of trial between the groups, despite dietary restrictions. This indicates that the low
FODMAP  diet  and  sham  diet  do  not  worsen  FR-QOL  in  patients  with  IBD  in  whom  this  may
already be lower than healthy individuals. This may be explained by an increase in perceived
control over diet and GI symptoms during the trial that counterbalanced the negative effects of
dietary restrictions on FR-QOL.
5.11.6 Patient-reported outcome (IBD-control questionnaire)
There was a significantly greater patient-perceived control of IBD in the low FODMAP diet group
at  end  of  trial,  particularly  in  those  with  UC,  where  a  reduced  symptom  severity  was  also
observed. The IBD-control questionnaire was developed using patient reports of domains
important  to  perceived control  of  IBD and therefore likely  captures  the aspects  of  IBD most
important to them.
The improved patient-perceived control of IBD occurred despite no observed difference in
clinical or biochemical disease activity between the groups, suggesting that this was a result of
reduced FGS following the low FODMAP diet in UC. This was supported by a positive correlation
between end of trial IBD control and IBS-SSS score.
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This finding raises the inevitable issue that patients with IBD are unable to differentiate FGS from
symptoms of active IBD, simply regarding these as symptoms of ‘IBD’. This reiterates both the
clinical dilemma of differentiating FGS from active IBD and a potential limitation of using PROMs
in patients with IBD and FGS. If clinical decisions were based entirely on PROMs, patients with
FGS and no GI inflammation could receive inappropriate escalation of anti-inflammatory
medication. Furthermore, a prospective study revealed that patients with more symptoms
attributable to IBD had a higher self-reported IBD disability and this was associated with greater
direct healthcare costs (van der Have et al., 2015).
5.11.7 Nutrient and FODMAP intake
Several previous studies have demonstrated that the low FODMAP diet influences nutrient
intakes in patients with IBS, however to date this had not been replicated in IBD. Total energy
intake was significantly lower following the low FODMAP diet in this trial, with no change in the
proportion of energy derived from each macronutrient. Additionally, calcium, phosphorous and
iodine intakes were lower following the low FODMAP diet compared to the sham diet.
Nonetheless, the proportion of patients meeting recommendations or requirements for
macronutrients, micronutrients and fibre was not different between the diet groups.
Reduced energy intake has previously been observed in patients with IBS in trials comparing the
low FODMAP diet to standard IBS advice (Bohn et al., 2015, Eswaran et al., 2016, Zahedi et al.,
2017). Other studies revealed no difference in energy intake following the low FODMAP diet
compared to a habitual diet (Staudacher et al., 2012) and sham dietary advice (Staudacher et
al., 2017b). Reduced energy intake likely relates to numerous dietary restrictions required during
the low FODMAP diet, which in IBD may be on the background of existing dietary restrictions
(Prince et al., 2011, Holt et al., 2017, Limdi et al., 2016). Patients with IBD are at increased risk
of malnutrition (Lomer, 2011) and further compromising energy and nutrient intake may
exacerbate existing malnutrition. Another important consideration is that human and murine
models have suggested an important role of energy intake on the GI microbiota (Cotillard et al.,
2013,  Griffin  et  al.,  2017).  It  is  therefore  possible  that  changes  in  energy  intake  in  the  low
FODMAP diet group could have a confounding effect on the microbiota alterations that were
observed (Chapter 6).
Reduced calcium intake has previously been observed following low FODMAP dietary advice in
IBS (Staudacher et al., 2012), the likely explanation for which being the restriction of calcium-
rich, lactose-containing dairy products. Although lactose-free cow’s milk and calcium-fortified
milk alternatives (such as soya, almond and rice milk) are encouraged during the low FODMAP
diet, clinical experience indicates that not all patients consume these products. This may relate
to cost, convenience and taste, and patients may choose instead to consume foods that do not
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require the addition of dairy products. For example, wheat-free toast or eggs may be chosen
instead of cereal and milk for breakfast. Patients are also encouraged to consume non-dairy
calcium-rich foods such as fish with bones and green, leafy vegetables, but these are unlikely to
be consumed in sufficient quantities in a normal diet to replace the calcium derived from dairy
foods. The full nutritional composition of some lactose-free specialty products is not available
in the Composition of Foods database used in this trial, and this could reduce observed calcium
intakes rather than actual intakes. Furthermore, the calcium intake in the sham diet group was
higher than in previous studies of IBD (Vernia et al., 2014, Lim et al., 2014, Vidarsdottir et al.,
2016), and this likely increased the difference in intake between the diet groups.
Nonetheless, the reduced calcium intake during the trial in the low FODMAP diet group may be
detrimental since patients with IBD are at greater risk of bone fractures than the general
population (Targownik et al., 2013, van Staa et al., 2003). These findings again suggest that
vigilant dietary counselling and monitoring is vital and reintroducing high FODMAP foods after
a maximum of 4 weeks is essential to correct reduced energy and calcium intakes (Whelan et
al., 2018).
The aim of this trial was to reduce dietary fermentable carbohydrate intake in the low FODMAP
diet group, while maintaining FODMAP intake in the sham diet group. The significantly lower
FODMAP intake in the low FODMAP diet group compared to the sham diet group at end of trial
and the reduced FODMAP intake between baseline and end of trial in the low FODMAP diet
group (but not the sham diet group) indicates that this aim was achieved. Total daily FODMAP
intake was 9.2 g lower in the low FODMAP diet group than the sham diet group at end of trial.
Several previous trials of the low FODMAP diet in IBS have estimated FODMAP intakes before
and after the diet. The 9.2 g/d difference in FODMAP intake between the diet groups in the
current trial is comparable to previous trials of low FODMAP dietary advice trials in the UK, which
reflects that the dietary advice was comparable and analysis was performed using the same
FODMAP database (Staudacher et al., 2017b, Staudacher et al., 2012). Interestingly, total
baseline FODMAP intake (15.9 g/d) was similar to that of the control groups in the previous trials
of the low FODMAP diet in IBS (17.4-17.7 g/d), suggesting that patients with IBD and FGS may
have similar dietary FODMAP intake to patients with IBS. Providing participants with all foods
during a trial facilitates much lower FODMAP intakes, as was demonstrated in an Australian trial
in which total daily FODMAP intake was 3.05 g on the low FODMAP diet when all meals were
provided (compared to 8.1 g/day in the current trial) (Halmos et al., 2014b). Some studies do
not report on all fermentable carbohydrates (Eswaran et al., 2016, Zahedi et al., 2017) or do not
assess dietary intake at all (McIntosh et al., 2016), which reduces the certainty that any observed
symptom responses relate to a reduction in FODMAP intake specifically. Others use different
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FODMAP composition databases to assess FODMAP intakes, limiting comparability between
studies (Bohn et al., 2015).
5.11.8 Acceptability
Diet acceptability is a predictor of adherence and thus, influences the success of the diet. In a
retrospective study of the low FODMAP diet in clinical practice in patients with IBD, GI symptom
improvement was associated with adherence to the diet, highlighting the need to assess
acceptability as a potential influencer of adherence (Gearry et al., 2009a). The low FODMAP diet
appeared to be less acceptable to patients than the sham diet. In addition, more patients in the
low FODMAP diet group reported making extensive dietary changes compared to the sham diet
group, which may explain the poorer diet acceptability observed in the low FODMAP diet group.
Nonetheless, the majority of patients in the low FODMAP diet group (84%) reported that the
benefit of taking part in the research outweighed the burden, suggesting that symptom
improvements and the positive impact of participating in research were sufficient to balance the
difficulties of the diet.
Acceptability of a dietary intervention is determined by the patient’s judgement of the
advantages and disadvantages of the intervention, in terms of perceived benefits, cost,
palatability and convenience (Berkow et al., 2010). Acceptability to vegan, vegetarian,
Mediterranean, and a web-based gluten-free diet have been measured using a variety of tools
(Moore et al., 2015, Lara et al., 2015, Sainsbury et al., 2015) but there is no validated tool to
measure the acceptability of the low FODMAP diet specifically and surprisingly few studies have
assessed the acceptability of the low FODMAP diet.
In clinical practice, more intensive dietary counselling on the low FODMAP diet is provided to
patients requiring it (Whelan et al., 2018). Acceptability of the low FODMAP diet may be poorer
in the research setting, particularly in a blinded trial, where a consistent period of time is spent
on dietary counselling for each participant. Furthermore, in the interest of blinding, mechanisms
of the diet were not explained to participants in this trial, and this may have reduced
acceptability since the perceived benefit of the diet is lessened. The differences in diet
acceptability between the low FODMAP diet and sham diet may relate to some of the permitted
foods being staple foods in the UK (such as wheat and dairy), that were permitted to ensure no
impact upon FODMAP or nutrient intakes. Unfortunately, this may have resulted in fewer dietary
changes in the sham diet group, as evidenced by only 50% reporting extensive dietary changes
(compared to 88% in the low FODMAP diet group). This may suggest that the sham diet may
need to be adapted for future studies to match the low FODMAP diet in terms of difficulty and
dietary changes.
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5.11.9 Blinding
The proportion of participants in the low FODMAP diet group who were able to correctly identify
their diet allocation (58%) is similar to what would be expected by chance, given that there are
two possible diet allocations (50%). In contrast, the proportion of participants in the sham diet
group able to correctly identify diet allocation was greater than would be expected by chance
(91%).  Many  patients  with  IBD  consider  diet  an  important  factor  in  terms  of  GI  symptom
induction and risk of relapse (Holt et al., 2017, Limdi et al., 2016, Prince et al., 2011).
Questionnaire surveys have revealed that 27% of patients believe a dairy free diet can improve
symptoms of active IBD, 73% had received dietary advice and 56% of patients modified their
diet after diagnosis (Limdi et al., 2016, Zallot et al., 2013). This suggests that patients with IBD
may have an enhanced awareness of the role of diet in IBD and GI symptom management and
there may be aspects of the sham diet that triggered suspicion of diet allocation. For example,
dairy products are a common perceived symptom trigger, yet were permitted on the sham diet.
A more effective sham diet, in terms of blinding, would perhaps exclude dairy products and
wheat. However, dairy is the source of the majority of lactose in the UK diet, and wheat is the
greatest contributor to fructan intakes. Therefore, by restricting dairy and wheat, the diet would
likely reduce FODMAP intakes, and would thus no longer be an effective placebo diet. A
prospective study of patients’ perceptions of the sham diet would be valuable to establish
predictors for correctly identifying diet allocation, including whether non-response of symptoms
is involved in assuming the sham diet is the placebo diet, and also to allow modification of the
sham diet to enhance blinding.
5.11.10 Significance of results
The low FODMAP diet has the potential to provide benefit to many patients with IBD, given the
success of the diet in IBS and the large proportion of patients with IBD in remission continuing
to experience functional GI symptoms (Staudacher and Whelan, 2017, Halpin and Ford, 2012).
This was the first ever placebo-controlled trial of the low FODMAP diet in IBD and demonstrates
that the diet improves GI symptoms compared to a placebo diet in patients with inactive IBD,
with 52% of patients reporting adequate relief. Although there was no difference between
groups in the proportion reaching the MCID in the IBS-SSS, 56% of patients in the low FODMAP
diet group reached the MCID, suggesting that the diet leads to clinically important
improvements in GI symptoms in more than half of patients with IBD in remission.
Abdominal bloating and flatulence severity were significantly lower following the low FODMAP
diet, which is clinically relevant given that 54% of participants had functional bloating. In contrast
to a previous placebo-controlled trial of the low FODMAP diet in IBS (Staudacher et al., 2017b),
this trial does not support an improvement in abdominal pain in IBD in remission following the
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low FODMAP diet, however this requires further investigation since only 38% of participants had
IBS (characterised by abdominal pain) at baseline.
This  trial  suggests  that  the  low  FODMAP  diet  may  be  more  effective  in  patients  with  UC
compared to CD. This may indicate future potential to direct the diet towards patients most
likely to respond to it, thus reducing the number of patients trialling the diet without success.
This trial was, however, not designed or powered to detect differences in these sub-groups,
therefore future trials are required to confirm these observations.
Several studies have established a relationship between the presence of IBS-like symptoms and
poor HR-QOL in patients with IBD in remission (Simrén et al., 2002, Abdalla et al., 2017, Jonefjäll
et  al.,  2016).  Patient-perceived  control  of  IBD  and  HR-QOL  were  greater  following  the  low
FODMAP diet, and FR-QOL was not different between the diets, suggesting that an improvement
in GI symptoms may improve HR-QOL without an impairment of FR-QOL. Therefore, the practical
challenges associated with following the diet do not appear to counterbalance the benefits of
the diet.
5.11.11 Strengths and limitations
This was the first randomised, placebo-controlled trial of the low FODMAP diet in patients with
inactive IBD. Patients were selected for this trial based upon stringent criteria and represented
a variety of IBD phenotypes, ranging from ileal CD to extensive UC. Furthermore, the inclusion
of patients meeting a selection of Rome III functional bowel disorders (IBS, functional bloating,
functional diarrhoea) renders the results generalizable to a wide variety of symptom profiles.
Meanwhile, the use of a variety of GI symptom measurement tools likely captures the
heterogeneous GI symptom profiles of the randomised patients.
Patients were required to fulfil a selection of criteria for inactive IBD for inclusion in the trial.
Objective measures of disease activity were used to define remission since the presence of FGS
would increase clinical disease activity index scores and would exclude suitable patients. In the
only other RCT of the low FODMAP diet in IBD, participants were selected for inclusion based
upon a SCCAI score <6 or a HBI score <12, while no objective markers of disease activity were
assessed during screening (Pedersen et al., 2017). Therefore, that trial likely included a
combination of active IBD and inactive IBD with FGS and it is unclear in which patient group the
diet is most likely to be effective.
One limitation of this trial was the measurement of faecal calprotectin during screening. A rapid
test was used to quantify faecal calprotectin during screening since this is suited to testing
individual samples. A further stool sample was collected at the baseline visit up to 2 weeks later
for future faecal calprotectin quantification using ELISA. Due to discrepancy between the rapid
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test and the ELISA and possibly the delay between screening and baseline in some patients, four
patients who had faecal calprotectin >250 μg/g at baseline (despite faecal calprotectin <250
μg/g during) were included in the trial. Discrepancy between the rapid tests and ELISA has been
observed previously, although it has been suggested that there is better agreement between
the tests at lower faecal calprotectin concentrations, such as was expected in this trial
(Vestergaard et al., 2008, Wassell et al., 2012, Coorevits et al., 2013).
Prior to this trial, no trials had compared the low FODMAP diet to placebo dietary advice in IBD
and  the  first  placebo-controlled  trial  of  the  low  FODMAP  diet  in  IBS  has  only  recently  been
published (Staudacher et al., 2017b). The sham dietary advice allows a placebo response to be
observed in the control group and permits blinding to diet allocation, in contrast to the only
other RCT of the low FODMAP diet in IBD (Pedersen et al., 2017). The sham dietary advice used
in the current trial has been piloted and shown to be effective in IBS (Staudacher et al., 2017a),
but not in IBD where there may be existing food restrictions and beliefs.
Blinding in the current trial was assessed at end of trial and showed that 74% of participants
were able to correctly guess their diet allocation, with more patients in the sham diet capable
of identifying diet allocation compared to the low FODMAP diet. This is comparable to previous
studies in the research group that have used the same sham dietary advice (unpublished data)
but may induce positive or negative expectation bias (Staudacher et al., 2017a). Despite the
large proportion of patients capable of identifying diet allocation, placebo response rates of 36%
were demonstrated (50-point reduction in the IBS-SSS score in the sham diet group), an
unexpected finding had blinding been ineffective. Nonetheless, a study of patient’s perceptions
of the sham diet may enable modifications to enhance the effectiveness of blinding in this group
particularly.
Since the lead researcher provided the dietary advice, it was not possible to be blinded to diet
allocation. Although every effort was made to provide dietary advice for both diets within the
same length of time and with the same conviction, it is possible that there may have been small,
unintentional differences in the delivery of the diets. To provide continuity to patients, the same
researcher collected all outcome measures. Non-blinded outcome assessment has been shown
to induce observer bias in the measurement of binary and scale outcomes (Hrobjartsson et al.,
2012, Hrobjartsson et al., 2013).
To date, there are no GI symptom measures validated specifically for use in patients with IBD
with FGS, mandating the use of measures that have not been validated in IBD, such as the IBS-
SSS, GSQ and GSRS (Francis et al., 1997). Nonetheless, the GSQ, IBS-SSS and GSRS were able to
demonstrate differences in GI symptoms between the groups and non-inflammatory GI
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symptoms in IBD are considered to be ‘functional’ and therefore IBS-specific measures would
likely be suitable for use in this patient group. On the other hand, the aforementioned
discrepancies between this trial and the previous similarly designed IBS trial may suggest a
difference in the validity of the outcome measures between the conditions, which may relate to
different symptom experiences and perceptions in IBS and IBD (Staudacher et al., 2017b). A
further limitation relating specifically to the IBS-SSS is that it has not been validated in patients
with functional bloating and functional diarrhoea, representing 62% of the patients in this trial.
Two of the five IBS-SSS questions pertain to abdominal pain, which may not be present in
functional bloating and functional diarrhoea and this may have limited the effect size observed
in the IBS-SSS.
A major strength of this trial was the measurement of a range of outcomes that may be altered
by the low FODMAP diet, including HR-QOL, FR-QOL and IBD-control (Bodger et al., 2013). The
IBD-control questionnaire was sensitive to changes in GI symptoms in the current trial, with an
improvement in IBD-control in the low FODMAP diet group, further supporting the effectiveness
of the diet in IBD.
5.11.12 Conclusion
In conclusion, this trial demonstrated that the low FODMAP diet improves FGS in patients with
inactive IBD, but not all GI symptom measures perform equally in reflecting this improvement.
Global GI symptoms (adequate relief), bloating, flatulence and stool frequency were lower
following the low FODMAP diet compared to the sham diet. In addition, an improvement in
perceived control of IBD was apparent following the low FODMAP diet. The impact of the diet
on the GI microbiome, immunology and inflammatory markers is unknown. These will be
discussed in Chapter 6.
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6 Results: the effect of fermentable carbohydrate restriction on
the gastrointestinal microbiome, markers of fermentation and
peripheral T-cell phenotype in patients with inactive
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6.1 Introduction
Chapter 5 of this thesis demonstrated that the low FODMAP diet improved GI symptoms, HR-
QOL and patient-perceived control of IBD, suggesting the low FODMAP diet to be a promising
strategy  for  the  management  of  common  FGS  in  IBD.  However,  previous  trials  of  the  low
FODMAP diet in IBS have established that it has a profound effect on the GI microbiome, the
most notable and consistent observation being a reduction in immune-modulatory
Bifidobacteria (Staudacher et al., 2017b, Staudacher et al., 2012). There is also some evidence
that the abundance of Faecalibacterium prausnitzii, a species with anti-inflammatory activity
that is often depleted in IBD (as discussed in Chapter 1), may be affected by the low FODMAP
diet (Halmos et al., 2014a, Hustoft et al., 2017). Changes in immune-modulatory bacteria may
influence GI inflammation, therefore an important outcome in this trial was whether the low
FODMAP diet exerts an effect on immunology in IBD.
6.2 Aim of this chapter
The aim of this chapter is to report the results of the GI microbiome, faecal short-chain fatty acid
(SCFA), faecal pH, inflammatory markers and peripheral T-cell analysis from the randomised,
placebo-controlled trial of the low FODMAP diet in patients with inactive IBD, described in
Chapter 4.
For all outcomes in this chapter, end of trial values were compared between groups adjusted
for baseline values. For metagenomic sequencing only participants providing a stool sample at
both baseline and end of trial were included in the analysis. The analysis of the ITT and PP
datasets are presented for SCFA and pH.
6.3 Gastrointestinal microbiome: metagenomic sequencing
Forty-two participants provided a stool sample for metagenomic sequencing analysis at both
baseline  and  end  of  trial  (low  FODMAP  diet,  21,  sham  diet,  21).  An  average  of  22,690,418
sequencing reads were obtained for each sample. An average of 14,310,652 reads mapped
uniquely to the gene catalogue, representing an average of 67% of the reads.
6.3.1 Microbiome composition between groups
6.3.1.1 End of trial comparisons between groups
This section will present the comparisons between the low FODMAP diet and sham diet groups
at end of trial, with all analyses adjusted for baseline values. Relative abundance of a given
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species is calculated as the average abundance of the 50 marker genes for that species,
described in section 4.5.2.5.
6.3.1.1.1 Alpha diversity and beta diversity
Table 6.1 displays the alpha diversity and beta diversity in the low FODMAP and sham diet
groups at end of trial. As can be seen, there was no difference between the low FODMAP diet
and  sham  diet  group  in  bacterial  gene  richness  (P=0.620),  species  richness  (P=0.520)  or  the
Shannon Index (P=0.580) or Simpson index (P=0.450).
Beta diversity was measured using the Bray-Curtis index, where a value of 0 indicates an
identical species composition between the samples (low beta-diversity) and a value of 1
indicates no overlap in species composition between the samples (high beta-diversity). The Bray-
Curtis index between samples in the low FODMAP diet group was not significantly different to
that between samples in the sham diet group (P=0.224).
Table 6.1 Alpha diversity and beta diversity in the diet groups at end of trial
Low FODMAP diet (n=21) Sham diet (n=21) P-value
Alpha diversity
Bacterial gene richnessa 498,771 (148,999) 524,660 (184,771) 0.620
Bacterial species richnessb 180 (65) 194 (70) 0.520
Shannon index 3.52 (0.55) 3.6 (0.7) 0.580
Simpson index 0.93 (0.05) 0.93 (0.05) 0.450
Beta diversity
Bray-Curtis index 0.74 (0.03) 0.72 (0.07) 0.224
All values are mean (SD). a Bacterial gene count; b Metagenomic species count
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6.3.1.1.2 Phylum
Figure 6.1 displays the phyla distribution in the diet groups at end of trial. There was no
difference in the proportion of the phyla between the diet groups at end of trial (data not
shown).
Figure 6.1 Phyla distribution (proportion of all bacteria) in the low FODMAP and sham diet groups at
end of trial
6.3.1.1.3 Species
Of the 616 species that were characterised by metagenomic sequencing, the abundance of 27
species was significantly different at end of trial between the low FODMAP diet and sham diet
groups. Figure 6.2 displays the fold difference between the diet groups in the species that were
significantly different at end of trial.
Sham LFD
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Figure 6.2 Fold difference between the low FODMAP diet and sham diet groups in abundance of species with significantly different (P<0.05) abundance at end of trial. Left panel,
species with lower abundance in low FODMAP diet group at end of trial; right panel, species with higher abundance in low FODMAP diet group at end of trial. Analysed using a
likelihood-ratio test taking into account the effect of diet allocation and baseline values.
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The end of trial abundance of bacterial species that have previously shown to be altered by the
low FODMAP diet (for example, Bifidobacterium longum and Bifidobacterium adolescentis,
Adlercreutzia equolifaciens) or have particular relevance in IBD (for example, F. prausnitzii,
Ruminococcus gnavus) are shown in Table 6.2.
After adjusting for baseline abundance, the relative abundance of Bifidobacteria at the genus
level was not significantly differently between the diet groups. The relative abundance of
Faecalibacterium prausnitzii (all strains), Bifidobacterium longum, Bifidobacterium adolescentis,
Dorea formicigenerans, Dorea longicatena 1, and unclassified Clostridiales, Prevotella,
Firmicutes and Blautia species were significantly lower at end of trial in the low FODMAP diet
group compared to the sham diet group (Figure 6.2 and Table 6.2). In contrast, the relative
abundance of Alistipes onderdonkii, Hungatella hathewayi, Bifidobacterium dentium,
Anerostipes hadrus, Adlercreutzia equolifaciens, Dorea longicatena 2, Faecalibacterium
prausnitzii SL3/3-M21/2 and unclassified Intestinimonas, Lachnospiraceae and Hungatella
species were significantly higher at end of trial in the low FODMAP diet group compared to the
sham diet group.
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Table 6.2 Relative abundance of species’ of interest (either holding importance in IBD or previously
shown to reduce following a low FODMAP diet in IBS) at end of trial
Genus or species Low FODMAP diet (n=21) Sham diet (n=21) P-valuea
Bifidobacteria 8.63-7 (4.41-7) 3.19-6 (3.59-6) 0.073
B. longum 1.24-7 (1.81-7) 6.95-7 (1.03-6) 0.006
B. adolescentis 1.99-7 (2.78-7) 2.55-6 (5.48-6) 0.005
F. prausnitzii 1.12-5 (1.42-5) 1.65-5 (1.35-5) 0.038
SL3/3-M21/2 1.52-6 (2.08-6) 1.35-6 (1.68-6) 0.002
A2-165 2.33-6 (1.93-6) 2.81-6 (2.81-6) 0.143
L2-6 3.61-6 (4.26-6) 1.30-6 (1.32-6) 0.763
KLE1255 2.68-6 (3.48-6) 3.41-6 (3.89-6) 0.404
Adlercreutzia equolifaciens 1.19-7 (1.85-7) 6.09-8 (6.75-8) 0.018
Roseburia hominis 4.10-6 (9.26-6) 8.48-7 (1.02-6) 0.472
Roseburia intestinalis 4.29-6 (7.78-6) 2.58-6 (6.06-6) 0.146
Eubacterium rectale 5.96-6 (7.22-6) 5.35-6 (6.28-6) 0.823
Dorea formicigenerans 2.26-7 (2.46-7) 2.72-7 (2.08-7) 0.021
Dorea longicatena 2.69-7 (4.34-7) 6.22-7 (7.42-7) 0.008
Blautia hansenii 3.84-9 (1.21-8) 9.49-9 (4.35-8) 0.663
Blautia hydrogenotrophica 1.97-9 (7.38-9) 5.75-9 (1.33-8) 0.376
Bacteroides fragilis 7.12-7 (1.46-6) 1.06-6 (3.19-6) 0.189
Bacteroides thetaiotaomicron 3.10-6 (4.20-6) 2.07-6 (3.21-6) 0.485
Ruminococcus bromii 2.35-6 (6.12-6) 1.21-6 (1.68-6) 0.765
Akkermansia muciniphila 6.62-7 (1.88-6) 2.09-6 (6.60-6) 0.933
All values are mean (SD) relative abundance. a Low FODMAP diet vs.  sham diet group at end of trial
compared using a likelihood-ratio test taking into account the effect of diet allocation and baseline
values
To establish whether the patients in the low FODMAP and sham diet groups could be
distinguished based upon end of trial microbiome composition, a principle component analysis
was performed based upon the ratio of the end of trial to baseline abundance of various species
(Figure 6.3). This plot shows a separation of the low FODMAP diet and sham diet participants
along the vertical axis and corroborates the abundance findings in Table 6.2 that the abundance
of certain species, including B. adolescentis, B. longum, Dorea longicatena and F. prausnitzii
SL3/3-M21/2 were associated with the sham diet, while other species, including Alistipes
onderdonkii and Hungatella hathewayi were associated with the low FODMAP diet.
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Figure 6.3 Principle component analysis of species that were significantly different between the low FODMAP diet and sham diet at end of trial. The fold-change of the log10
relative abundance of bacterial species was calculated as the ratio of end of trial to baseline abundance or scores. Blue circles indicate participants on the low FODMAP diet
while red circles are participants on the sham diet
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6.3.1.1.4 Bifidobacteria and Faecalibacterium prausnitzii
Bifidobacteria has been consistently shown to decline following a low FODMAP diet in IBS and
F. prausnitzii is consistently reduced in IBD with potentially clinical consequences (as described
in section 1.1.3.2). These were therefore species of particular interest in this trial.
As can be seen from Figure 6.4 and Table 6.2, the abundance of the Bifidobacteria genus was
lower in the low FODMAP diet group than the sham diet group at end of trial, although this did
not reach statistical significance (P=0.073). At the species level, the abundance of
Bifidobacterium longum and Bifidobacterium adolescentis were  significantly  lower,  and  the
abundance of Bifidobacterium dentium was significantly higher, in the low FODMAP diet group
compared to the sham diet group at end of trial. The abundance of total F. prausnitzii was
significantly lower in the low FODMAP diet group compared to the sham diet group at end of
trial (P=0.038). At the strain level, F. prausnitzii SL3/3-M21/2 was significantly higher in the low
FODMAP diet group at end of trial (see Table 6.2 for data).
Figure 6.4 The relative abundance of Bifidobacterium species and Faecalibacterium prausnitzii strains
at end of trial in the low FODMAP diet (dark blue bars) and the sham diet group (light blue bars). *P<0.05
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6.3.2 Microbiome composition within groups
Due to considerable variability in bacterial differences between diet groups and between
individuals, the change in bacterial abundance between baseline and end of trial was analysed
separately within the low FODMAP diet group and within the sham diet groups and is presented
in this section.
6.3.2.1.1 Alpha diversity and beta diversity
There were no differences in gene richness, species richness, Shannon index, Simpson index or
the Bray-Curtis index between baseline and end of trial in either the low FODMAP diet or sham
diet groups (data not shown).
6.3.2.1.2 Species
In the low FODMAP diet group, 27 species were significantly different between baseline and end
of trial. Species that decreased in abundance between baseline and end of trial included B.
longum (7.59-7 SD 9.57-7 vs. 1.24-7 SD 1.81-7, P<0.001), B. pseudocatenulatum (1.94-7 SD 4.47-7 vs.
3.55-8 SD 1.17-7, P=0.036), F. prausnitzii SL3/3-M21/2 (2.30-6 SD 2.69-6 vs. 1.52-6 SD 2.08-6,
P=0.029), F. prausnitzii KLE1255 (4.49-6 SD 3.33-6 vs. 2.68-6 SD 3.48-6, P=0.006) (see Figure 6.5 for
Bifidobacteria and F. prausnitzii at baseline and end of trial), Dorea longicatena 1 (3.83-7 SD 4.98-
7 vs. 2.69-7 SD 4.34-7, P=0.014), and Coprococcus comes (3.17-7 SD 3.58-7 vs. 2.18-7 SD 2.61-7, 0.028).
Among the species that increased between baseline and end of trial in the low FODMAP diet
group were Clostridium citroniae (4.32-8 SD 4.65-8 vs. 9.11-8 SD 1.01-7, P=0.007), Clostridium
asparagiforme (4.30-8 SD 4.88-8 vs. 8.31-8 SD 1.09-7, P=0.010), Hungatella hathewayi 2 (1.13-8 SD
1.64-8 vs. 2.52-8 SD 3.07-8, P=0.011), Anaerotruncus colihominis (1.59-8 SD 2.51-8 vs. 6.56-8 SD 1.70-
7, P=0.017), Alistipes onderdonkii (2.80-6 SD 8.50-6 vs. 5.48-6 SD 1.70-5, P=0.025), Roseburia
hominis (9.08-7 SD 1.49-6 vs. 4.10-6 SD 9.26-6, P=0.035) and Intestinimonas butyriciproducens (4.01-
8 SD 6.96-8 vs. 3.00-7 SD 9.03-7, P=0.012).
Only six species were altered between baseline and end of trial in the sham diet group. Species
that declined between baseline and end of trial were Coprobacter fastidiosus (2.34-7 SD 4.55-7 vs.
1.80-7 SD 3.53-7, P=0.022), Sutterella wadsworthenis 1 (6.38-6 SD 2.10-5 vs. 2.02-6 SD 3.49-6,
P=0.037), Parabacteroides distasonis (3.28-6 SD 4.36-6 vs. 2.25-6 SD 2.60-6 , P=0.045) and
Clostridium saccharolyticum (6.83-8 SD 1.02-7 vs. 4.63-8 SD 8.95-8, P=0.045), while an unclassified
Blautia (1.62-7 SD 1.56-7 vs. 2.16-7 SD 1.78-7, P=0.009) and an unclassified Clostridiales (3.92-9 SD
6.23-9 vs. 1.05-8 SD 1.81-8, P=0.044) increased.
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6.3.2.1.3 Bifidobacteria and Faecalibacterium prausnitzii
The abundance of Bifidobacteria species and F. prausnitzii strains at baseline and end of trial is
presented in Figure 6.5. As discussed in section 6.3.2.1.2, the abundance of B. longum, B.
pseudocatenulatum and F. prausnitzii KLE1255 significantly declined between baseline and end
of trial in the low FODMAP diet group. There were no differences in the other Bifidobacteria
species and F. prausnitzii strains  between  baseline  and  end  of  trial  in  the  low  FODMAP  diet
group, or any of them between baseline and end of trial in the sham diet group.




Figure 6.5 Relative abundance of Bifidobacteria species and Faecalibacterium prausnitzii strains at
baseline (dark blue bars) and end of trial (light blue/green bars) in (A) the low FODMAP diet group, (B)
the sham diet. *P<0.05
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6.3.3 Crohn’s disease and ulcerative colitis sub-group analysis
In line with the clinical outcome analysis, sub-group analyses of the GI microbiota in CD (n=19,
baseline and end of trial) and UC (n=23, baseline and end of trial) were performed.
At end of trial in patients with CD, there were no differences between the diet groups in gene
richness (495,484 SD 185,946 genes vs. 495,451 SD 213,084 genes; P=0.900), species richness
(181 SD 80 species vs. 180 SD 79 species; P=0.970), Shannon index (3.4 SD 0.8 vs. 3.5 SD 0.8;
P=0.770), Simpson index (0.9 SD 0.1 vs. 0.9 SD 0.1; P=0.446) or beta-diversity (Bray-Curtis Index)
(P=0.567). The relative abundance of a limited number of species was significantly different
between  the  low  FODMAP  diet  and  sham  diet  at  end  of  trial  in  patients  with  CD,  including
Adlercreutzia equolifaciens (2.75-8 SD 2.74-8 vs. 5.54-8 SD 6.39-8, P=0.003), Bacteroides
xylanisolvens (1.43-5 SD 2.43-5 vs. 2.58-6 SD 4.99-6, P=0.008), Eubacterium hallii (5.35-8 SD 6.15-8
vs. 1.73-7 SD 1.57-7, P=0.041), Dorea formicigenerans (1.00-7 SD 6.40-8 vs. 2.02-7 SD 1.86-7,
P=0.004), Dorea longicatena 1 (1.19-7 SD 7.84-8 vs. 5.72-7 SD 5.70-7, P=0.001), F. prausnitzii SL3/3-
M21/2 (1.87-6 SD 2.39-6 vs. 1.17-6 SD 1.90-6, P=0.033) and F. prausnitzii KLE1255 (1.13-6 SD 8.88-7
vs. 2.48-6 SD 2.89-6, P=0.023).
At  end  of  trial  in  patients  with  UC,  there  were  no  differences  in  gene  richness  (500,795  SD
129,693 genes vs. 556,789 SD 152,407 genes; 0.400), species richness (180 SD 58 species vs. 209
SD 60 species; P=0.310), Shannon index (3.6 SD 0.4 vs. 3.7 SD 0.6; P=0.640), Simpson index (0.9
SD  0.0  vs.  0.9  SD  0.1;  P=0.670)  or  beta-diversity  (Bray-Curtis  Index)  (P=0.594).  The  relative
abundance of several species was significantly different at end of trial in the low FODMAP group
compared to the sham diet group, including B. adolescentis (1.52-7 SD 2.65-7 vs. 1.72-6 SD 2.79-6,
P=0.014), B. bifidum (8.42-8 SD 1.62-7 vs. 2.50-7 SD 4.20-7, P=0.042), B. longum (1.60-7 SD 2.18-7 vs.
7.21-7 SD 1.13-6,P=0.001), Alistipes onderdonkii (9.11-7 SD 1.25-6 vs. 4.06-6 SD 1.06-6, P=0.018), F.
prausnitzii SL3/3-M21/2 (1.30-6 SD 1.93-6 vs. 1.55-6 SD 1.47-6, P=0.008) and Ruminococcus
bicirculans (8.78-7 SD 2.18-6 vs. 2.97-6 SD 5.15-6, P=0.005), Hungatella hathewayi 2 (2.50-8 SD 2.60-
8 vs. 3.83-9 SD 9.37 -9, P=0.034), Dorea longicatena 2 (2.61-7 SD 6.72-7 vs. 8.13-8 SD 1.16-7, P=0.036)
and Roseburia intestinalis (5.09-6 SD 8.80-6 vs. 4.71-6 SD 8.35-6, P=0.017).
Figure  6.6  and  6.7  show  PCA  plots  of  the  log  fold-change  in  abundance  (log  end  of  trial
abundance divided by baseline abundance) of species that were significantly different between
the diets at end of trial, in CD and UC. Figure 6.6 shows that in CD, several bacterial species were
associated with the sham diet, including Blautia obeum, Eubacterium hallii and Dorea
formicigenerans. Meanwhile, Parabacteroides distasonis and Clostridium citroniae were
associated with the low FODMAP diet group. In UC, B. bifidum, B. longum, Roseburia intestinalis
and F. prausnitzii SL3/3-M21/2 were associated with the sham diet.  Similar  to  the PCA in  all
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participants (Figure 6.3), Alistipes onderdonkii was  associated  with  the  low  FODMAP  diet  in
patients with UC.
Figure 6.6 Principle component analysis of species significantly different between the low FODMAP diet
and sham diet at end of trial in patients with CD only. The fold-change of the log10 relative abundance
of bacterial species was calculated as the ratio of end of trial to baseline abundance. Blue circles indicate
participants on the low FODMAP diet while red circles are participants on the sham diet.
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Figure 6.7 Principle component analysis of species significantly different between the low FODMAP diet
and sham diet at end of trial in patients with UC only. The fold-change of the log10 relative abundance
of bacterial species was calculated as the ratio of end of trial to baseline abundance. Blue circles indicate
participants on the low FODMAP diet while red circles are participants on the sham diet.
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6.4 Markers of fermentation
6.4.1 Faecal SCFA and pH
Faecal SCFA and pH results are presented in Table 6.3. There was no significant difference in
baseline pH or SCFA concentrations between the diet groups.
There was no significant difference in end of trial total faecal SCFA concentration or individual
SCFA concentrations in the ITT population. However, there was significantly lower end of trial
total SCFA concentration as well as significantly lower acetate concentration at end of trial in
the low FODMAP diet group compared to the sham diet group in the PP population only.
Sub-group  analysis  of  CD  (n=26;  14  low  FODMAP  diet,  12  sham  diet)  and  UC  (n=26;  13  low
FODMAP  diet,  13  sham  diet)  showed  significantly  lower  total  SCFA  in  the  low  FODMAP  diet
group than in the sham diet group (418.6 SD 177.8 mg/100g vs. 565.0 SD 177.8 mg/100g,
P=0.048) in UC only (Figure 6.8), as well as lower acetate (240.4 SD 101.4 mg/100g vs. 324.9 SD
101.4 mg/100g, P=0.045), butyrate (81.4 SD 26.6 mg/100g vs. 104.0 SD 26.6 mg/100g, P=0.043)
and valerate (7.1 SD 4.5 mg/100g vs. 11.4 SD 4.5 mg/100g, P=0.023) concentrations in UC only.
In CD, there was a significantly lower isobutyrate concentration in the low FODMAP diet than in
the sham diet group at end of trial only (7.9 SD 2.5 mg/100g vs. 10.3 SD 2.9, P=0.035).
There was no significant difference in end of trial faecal pH between the diet groups (Table 6.3),
nor was there any difference upon sub-group analyses of CD and UC (data not shown)
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Table 6.3 Faecal SCFA (mg per 100g faeces) concentrations and pH in the ITT (n=52) and PP populations (n=43)














Total SCFA 433.9 (164.9) 517.0 (165.1) -83.1 (-176.6, 10.4) 0.080 398.1 (170.8) 505.4 (170.7) -107.3 (-214.0, -0.6) 0.049
Acetate 251.1 (99.4) 302.4 (99.5) -51.3 (-107.6, 4.9) 0.073 230.5 (102.4) 296.3 (102.3) -65.9 (-129.8, -2.0) 0.044
Butyrate 71.2 (33.2) 86.7 (33.3) -15.4 (-34.1, 3.2) 0.102 64.7 (35.6) 83.4 (35.6) -18.7 (-40.7, 3.3) 0.094
Propionate 83.3 (44.8) 100.1 (44.9) -16.7 (-42.0, 8.6) 0.190 76.0 (46.9) 97.8 (46.9) -21.9 (-51.1, 7.4) 0.138
Valerate 8.2 (3.9) 9.8 (3.9) -1.5 (-3.8, 0.7) 0.165 7.7 (4.1) 9.4 (4.1) -1.8 (-4.3, 0.7) 0.161
Isobutyrate 7.2 (3.4) 8.6 (3.4) -1.4 (-3.3, 0.5) 0.145 6.8 (3.6) 8.7 (3.6) -2.0 (-4.2, 0.3) 0.086
Isovalerate 10.8 (4.9) 11.8 (4.9) -1.0 (-3.8, 1.8) 0.468 10.2 (5.3) 11.9 (5.3) -1.7 (-5.1, 1.6) 0.303
pH 6.53 (0.35) 6.46 (0.35) 0.07 (-0.13, 0.27) 0.494 6.57 (0.37) 6.48 (0.37) 0.09 (-0.14, 0.32) 0.430
All values are mean (SD) compared between groups using ANCOVA with baseline values as a covariate. Estimated mean differences and 95% CI are also presented
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Figure 6.8 SCFA concentrations in UC (left panel) and CD (right panel) at end of trial. *Low FODMAP diet
vs. sham diet at end of trial, P<0.05. All values are mean (standard error) compared between groups using
ANCOVA with baseline values as a covariate
To determine whether faecal pH is related to SCFA concentration, a Spearman correlation was
performed between end of trial faecal pH and total SCFA concentration. There was a moderate
negative  correlation  between  faecal  pH  and  SCFA  concentration  (r=-0.336,  P=0.015).
Furthermore, linear regression analysis showed that end of trial faecal pH was predicted by SCFA
concentration F(1,50)=29.0 (P < 0.001), accounting for 35% of the explained variability in pH.
Linear regression analysis showed that total end of trial SCFA concentration could be predicted
by diet allocation F(1,50)=6.73 (P=0.012), with diet accounting for 10% of the variability in SCFA
concentration. Diet allocation could also predict acetate concentration F(1,50)=6.69 (P=0.013),
propionate concentration F(1,50)=4.1 (P=0.048) and valerate concentration F(1,50)=4.75
(P=0.034). Acknowledging that GI transit can influence both SCFA concentrations and pH, end of
trial faecal total SCFA concentration and pH were analysed adjusted for end of trial Bristol Stool
Form Score in addition to baseline faecal concentrations. These analyses showed no significant
difference in SCFA concentration or pH between the diets (data not shown).








Faecal calprotectin was measured to determine eligibility during screening using a rapid point-
of-care kit (section 4.6.1.1.1). However, actual baseline and end of trial calprotectin was
measured using ELISA (section 4.6.1.1.2) since this is the gold standard method. A comparison
of the rapid and ELISA faecal calprotectin assessment can be found in section 7.2.
Stool aliquots were available for 52 participants at baseline and 41 at end of trial. There was no
difference in faecal calprotectin between the low FODMAP diet (60.0 SD 87.3) and sham diet
group  (59.6  SD  74.5)  at  end  of  trial  (P=0.976).  Sub-group  analyses  showed  no  differences  in
faecal calprotectin between the low FODMAP diet group and sham diet group in CD or UC.
6.5.2 C-reactive protein
At  screening  and  end  of  trial,  blood  samples  were  collected  for  CRP  analysis.  There  was  no
difference in CRP between the low FODMAP diet (2.0 SD 1.6) and sham diet groups (1.6 SD 1.6)
at end of trial (P=0.246).
6.6 Peripheral T cell phenotype
The ITT analysis for peripheral T-cell phenotype is presented below. One participant had no
blood sample available at baseline (due to difficulty collecting a blood sample), and for one
participant the analysis of the baseline sample was prevented by technical issues. These two
participants are not included in the T-cell analysis. Hence, there are 50 end of trial samples
included in  the ITT  analysis  (low FODMAP diet,  27,  sham diet,  23),  except  for  absolute T-cell
counts, for which there are 49 end of trial samples since count beads were omitted from the
experiment in error.
6.6.1 Total circulating T-cells
There was no significant difference in the absolute number of CD3+ T-cells at end of trial
between the low FODMAP diet and sham diet group (1,268,143 SD 7,798 vs. 1,268,000 SD 7,433
cells/ml-1; P=0.996) (Figure 6.9).
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Figure 6.9 Absolute CD3+ T-cells at end of trial in the low FODMAP diet group (n=27) and sham diet
group (n=22). All values are cell counts per ml-1 blood and were compared between groups using
ANCOVA with baseline values as a covariate
When sub-group analyses of CD and UC were performed, there was no significant difference in
absolute T-cell counts between the diet groups at end of trial (data not shown).
6.6.2 CD4+ and CD8+ T-cells
There was no significant difference in the proportion of total T-cells that were CD4+ between
the low FODMAP diet (66.5% SD 2.8%) and sham diet group (66.6% SD 2.8%) (P=0.893) (Figure
6.10). Likewise, there was no significant difference in the proportion of total T-cells that were
CD8+ between the low FODMAP diet (30.6% SD 2.5%) and the sham diet group (30.3% SD 2.5%)
(P=0.693). Sub-group analysis of CD and UC revealed no significant differences between the diet
groups in CD4+ or CD8+ T-cell proportions (data not shown). However, in patients with CD, there
were  significantly  more  CD8+  T-cells  in  the  low  FODMAP  diet  group  (520,414  SD  229,397
cells/ml-1) compared to the sham diet group (300,458 SD 244,959 cells/ml-1) (P=0.046).
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Figure 6.10 Proportion of CD3+ T-cells expressing CD4 at end of trial in the low FODMAP and sham diet
groups. Groups were compared using ANCOVA with baseline values as a covariate.
The  proportions  of  CD4+  and  CD8+  T-cells  that  were  naïve  (expressing  CD45RA)  and
effector/memory (not expressing CD45RA) were also quantified. Between the low FODMAP diet
group and sham diet group at end of trial there was no significant difference in the proportion
of CD4+ T-cells (49.6% SD 3.3% vs. 49.8% SD 3.3%, P=0.856) or CD8+ T-cells (68.1% SD 6.4% vs.
68.5% SD 6.4%, P=0.826) that were naïve.
There were no significant differences between the diets in absolute cell counts of naïve or
effector/memory CD4+ or CD8+ T-cells at end of trial (data not shown). In line with the increased
number  of  total  CD8+  T-cells  in  the  low  FODMAP  diet  group  in  CD  only,  there  was  also
significantly more naïve CD8+ T-cells in the low FODMAP diet (368,870 SD 6230 cells/ml-1)
compared to the sham diet group (182,223 SD 8870 cells/ml -1) (P=0.017). There was however no
difference in the number of effector/memory CD8+ T-cells in patients with CD (120,582 SD 2256
vs. 77,193 SD 3012 cells/ml-1; P=0.108). There was also significantly more naïve CD4+ T-cells in
the  low  FODMAP  diet  group  (573,507  SD  8747  cells/ml-1) compared to the sham diet group
(335,329 SD 12,435 cells/ml-1) (P=0.041) in patients with CD. There were no significant
differences in the proportions of naïve and effector/memory CD4+ and CD8+ T-cells in CD and
UC (data not shown).
6.6.3 Vδ2+ T-cells
There was no significant difference in the proportion of CD3+ T-cells expressing the Vδ2 receptor
between the low FODMAP diet (3.0% SD 1.2%) and sham diet group (3.2% vs. 1.2%) (P=0.489).
There were no significant differences between the diets in absolute counts of Vδ2+ T-cells at
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end of trial (data not shown). Sub-group analyses of CD and UC showed no significant differences
in the proportions of Vδ2+ T-cells at end of trial between the diet groups (data not shown).
6.6.4 T-cells expressing α4β7+ integrin
The proportions of different T-cell subsets expressing α4β7 integrin are displayed in Table 6.4.
There were no significant differences between the diet groups in the proportion of T-cell subsets
expressing α4β7, except for significantly fewer Vδ2+ T-cells expressing α4β7 at end of trial in the
low FODMAP diet group compared to the sham diet group. However, there were no differences
in the absolute counts of α4β7+ cells in any of the T-cell subsets between the diet groups at end
of trial (Table 6.4).
Table 6.4 Proportions and absolute cell counts of T-cell subsets expressing α4β7 integrin at end of trial
Low FODMAP diet
(n=27)





Proportion (%) 67.1 (15.1) 74.0 (15.1) -6.9 (-15.5, 1.8) 0.116




Proportion (%) 38.7 (6.1) 41.1 (6.1) -2.5 (-5.9, 1.0) 0.164
Absolute count 166,034 (84,941) 164,934 (85,426) 1100 (-49,498, 51,697) 0.965
Naïve CD8+
Proportion (%) 68.9 (13.1) 74.6 (13.1) -5.7 (-13.2, 1.8) 0.135




Proportion (%) 63.6 (11.3) 69.9 (11.3) -6.3 (-12.8, 0.1) 0.054
Absolute count 81,845 (45,788) 80,040 (45,890) 1805 (-25,264, 28,874) 0.894
Vδ2+
Proportion (%) 71.6 (10.5) 79.1 (10.9) -7.5 (-13.6, -1.4) 0.017
Absolute count 30,535 (20,249) 31,140 (20,726) -875 (-12,744, 10,933) 0.377
Data are expressed as mean % (SD) for cell proportions and mean cells per ml-1 blood (SD) for absolute
counts. Groups were compared using ANCOVA with baseline values as a covariate.
Two visible populations of α4β7+ cells were observed in the effector/memory CD4+ and CD8+
T-cell  scatter  plots,  one  at  a  lower  intensity  and  one  at  a  higher  fluorescence  intensity.  It  is
known that T-cells express α4β7 at an intermediate intensity prior to becoming dedicated to
gut-homing, therefore an additional gate was constructed around the α4β7+ population at the
higher intensity (‘α4β7+ high’), presumably reflecting the ‘true’ α4β7+ gut-tropic cells. There
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was no significant difference between the diet groups in the proportion of α4β7+ high CD4+ or
α4β7+ high CD8+ T-cells at end of trial (Figure 6.11).
Figure 6.11 Proportion of effector/memory CD4+ and CD8+ T-cells that were α4β7+ high at end of trial
Sub-group analyses of CD and UC showed that in the low FODMAP diet (compared to the sham
diet), fewer naïve CD4+ T-cells (58.2% SD 17.0% vs. 79.8% SD 17.0%; P=0.008), naïve CD8+ T-
cells (62.6% SD 14.8% vs. 76.4% SD 14.8%; P=0.042) and effector/memory CD8+ T-cells (59.5%
SD 11.2% vs. 70.3% SD 11.2%; P=0.036) expressed α4β7+ at end of trial in patients with CD only.
In patients with UC, there were significantly more α4β7+ high effector/memory CD4+ T-cells at
end of trial in the low FODMAP diet group compared to the sham diet group (21.4% SD 2.6% vs.
19.2% SD 2.6%; P=0.042). Upon analysis of absolute cell counts in the T-cell sub-sets, there were




In this trial, low FODMAP dietary advice induced significant alterations in GI microbiome
composition compared to sham dietary advice. This included a lower abundance of several
Bifidobacteria, Dorea and Blautia species, and a higher abundance of Adlercreutzia
equolifaciens, Alistipes onderdonkii and  Hungatella  species  at  the  end  of  the  trial  in  the  low
FODMAP diet group compared to the sham diet group. Some of these findings are in line with
previous trials of the low FODMAP diet in IBS, however some are unique findings and this is the
first trial revealing microbiome alterations resulting from the low FODMAP diet in IBD and the
first to use metagenomic sequencing to do so.
The significantly lower abundance of Bifidobacterium longum and Bifidobacterium adolescentis
following the low FODMAP diet in this trial is consistent with findings of several previous trials
of the low FODMAP diet in IBS (Staudacher et al., 2017b, Staudacher et al., 2012, Halmos et al.,
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2014a,  Bennet  et  al.,  2017,  Hustoft  et  al.,  2017).  This  likely  relates  to  the  reduced  intake  of
fructans and galacto-oligosaccharides (GOS) associated with the low FODMAP diet, which is
supported by the FODMAP intake analysis in Chapter 5. An increase in Bifidobacteria abundance
following fructan and GOS supplementation (the so-called prebiotic-effect) suggests that this
genus is capable of fermenting these carbohydrates in healthy (Ramirez-Farias et al., 2009,
Bouhnik et al., 2004, Holscher et al., 2015), IBS (Azpiroz et al., 2017, Silk et al., 2009) and IBD
(Lindsay et al., 2006). This is supported by in vitro analyses and relates to the expression of
fructofuranosidases and galactosidases by Bifidobacteria (McLaughlin et al., 2015, Watson et al.,
2013). However, variation in the hydrolysis of fructans of differing chain lengths is evident
among species and strains; for example, many species can proliferate on oligofructose but fewer
can do so on inulin (Rossi et al., 2005). Variations in substrate requirements among
Bifidobacterium species may explain why some were not affected by the low FODMAP diet in
this trial (including B. animalis and B. breve).
The reduction in Bifidobacteria alongside an improvement in GI symptoms seems paradoxical
considering that Bifidobacteria abundance has been shown to correlate negatively with pain
frequency (Parkes et al., 2008) and Bifidobacteria supplementation improves FGS in some
people  with  IBS  (Whorwell  et  al.,  2006).  Therefore,  a  possible  explanation  for  the  lack  of
response in some of the 48% of participants who did not respond to the diet may be the decline
in Bifidobacteria. However, in line with the findings of the current trial, a worsening of bacterial
‘dysbiosis’, defined using a ‘dysbiosis index’ that included Bifidobacteria abundance (Casen et
al., 2015), has been observed alongside an improvement in GI symptoms following the low
FODMAP diet in IBS (Bennet et al., 2017). These changes were seen in low FODMAP diet non-
responders as well as responders, suggesting this impact of the diet on Bifidobacteria did not
affect its ability to improve GI symptoms.
Anti-inflammatory effects of Bifidobacteria have been demonstrated in vitro and in vivo (Riedel
et al., 2006, You and Yaqoob, 2012, Dong et al., 2012). Furthermore, supplementation with a
Bifidobacteria-containing probiotic may be effective in inducing remission and may be equally
as effective as 5-aminosalicylates for maintaining remission in UC (Derwa et al., 2017). This
indicates that Bifidobacteria depletion could theoretically be detrimental in IBD. A large
randomised, placebo-controlled trial has established that a Bifidobacteria-containing probiotic
supplement maintained Bifidobacteria abundance when taken alongside a low FODMAP diet in
patients with IBS (Staudacher et al., 2017b). However, strategies to prevent Bifidobacteria
depletion during the low FODMAP diet have not been investigated in IBD specifically, but this
supports the need for such research.
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Although Faecalibacterium prausnitzii strains were not significantly different between the low
FODMAP and sham diet groups at end of trial, all strains were reduced between baseline and
end of trial in the low FODMAP diet group, with two reaching statistical significance, an effect
that  was  not  observed  in  the  sham  diet  group.  In  a  previous  trial  of  patients  with  IBS, F.
prausnitzii declined following a low FODMAP diet and increased following subsequent fructo-
oligosaccharide supplementation, indicating that F. prausnitzii is influenced by colonic fructan
availability (Hustoft et al., 2017). F. prausnitzii is  strictly  anaerobic  and  ferments  a  range  of
substrates including FODMAP and non-FODMAP carbohydrates (Lopez-Siles et al., 2017), thus it
would be expected that substrate utilisation would adapt to those available even during the low
FODMAP diet. However as described above, the significant decline in Bifidobacteria and other
acetate-producers, such as Blautia, following the low FODMAP diet could indirectly affect F.
prausnitzii abundance through deprivation of acetate (Heinken et al., 2014). In support of this,
difficulties have been reported in establishing an F. prausnitzii mono-associated murine model
and the need for another bacterium, such as Bacteroides thetaiotaomicron or Escherichia coli,
for successful colonisation, suggesting that F. prausnitzii is reliant on metabolic and substrate
cross-feeding reactions for growth (Wrzosek et al., 2013, Miquel et al., 2015).
F. prausnitzii is an immune-modulatory, butyrogenic bacterium with reduced abundance in IBD.
A protective effect of F. prausnitzii against experimental colitis has been demonstrated in murine
models (Martin et al., 2014, Sokol et al., 2008, Martin et al., 2015) and an inverse correlation
between F. prausnitzii abundance at surgical resection and recurrence 6 months later is
observed in patients with CD (Sokol et al., 2008). These effects are hypothesised to result from
the production of metabolites, with a peptide capable of blocking NF-κB recently identified in F.
prausnitzii supernatant (Quévrain et al., 2015, Miquel et al., 2015).
Therefore, it is feasible that a decline in F. prausnitzii could have detrimental clinical
ramifications especially on the background of existing depletion. However, in this trial there was
no  apparent  effect  of  the  low  FODMAP  diet  on  inflammatory  markers  or  gut-homing  T-cells
(discussed further later in discussion), suggesting that the decline in immune-modulatory
Bifidobacteria and F. prausnitzii were  not  harmful,  at  least  in  the  short-term.  The  decline  in
immune-regulatory bacteria (Bifidobacteria and F. prausnitzii) could be counterbalanced by a
maintenance of other species capable of regulating immune function. For example, Roseburia
intestinalis has anti-inflammatory effects in vitro and in vivo and was not reduced by the low
FODMAP diet (Shen et al., 2018). It may also relate to the short-term nature of the diet in this
trial. In clinical practice, it is common for patients to follow a low FODMAP diet for longer periods
of time, and the effect on the GI microbiota and immunology are undetermined and require
investigation.
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It is noteworthy that studies of the immune-modulatory effects of F. prausnitzii have
predominantly investigated the A2-165 strain (Martin et al., 2014, Martin et al., 2015, Miquel et
al., 2015), of which the decline during the low FODMAP diet did not reach significance in this
trial. The immunological implications of a decline in other F. prausnitzii strains (SL3/3-M21/2 and
KLE1255) are unclear. Supplementing F. prausnitzii to prevent the decline in this species during
a low FODMAP diet is not currently possible as the extreme oxygen-sensitivity of this species has
complicated efforts to develop an F. prausnitzii probiotic, although mechanisms involving
dietary vitamins may enable survival in the presence of oxygen (Khan et al., 2012a, Khan et al.,
2012b, Khan et al., 2014)
The effect of the low FODMAP diet on Bifidobacteria may have indirect effects on other GI
bacteria that are not capable of directly fermenting fructans and GOS. Co-culture experiments
have established that upon fermentation of fructans by Bifidobacteria, the resulting acetate,
shorter-chain oligo-saccharides and sugars are utilised by butyrogenic bacteria such as F.
prausnitzii, Eubacterium hallii, Anaerostipes caccae and Roseburia intestinalis to facilitate
fermentation of other substrates (El-Semman et al., 2014, Moens et al., 2016, Rios-Covian et al.,
2015,  Belenguer  et  al.,  2006,  Falony  et  al.,  2006).  Substrate  cross-feeding  reactions  render
growth of certain bacteria (e.g. F. prausnitzii) dependent upon the end-products of metabolism
of other bacteria (e.g. Bifidobacteria) and explains the ability of a low FODMAP diet to reduce
bacteria that are not primary degraders of FODMAPs. Other butyrate-producing bacteria, such
as Roseburia species and Eubacterium rectale,  were  not  affected  by  the  low  FODMAP  diet,
despite them preferentially fermenting FODMAPs such as oligofructose and inulin (Tamanai-
Shacoori et al., 2017). These species may be better equipped to adapt to changes in substrate
availability and a possible change in luminal pH than F. prausnitzii. Furthermore, species and
strain-specific substrate preferences have been observed for Roseburia, suggesting that some
strains may be compromised while others may thrive following dietary restrictions (Sheridan et
al., 2016).
Besides the observed Bifidobacteria depletion, several other genera and species were affected
by the low FODMAP diet in the current trial, including Blautia, Adlercreutzia, Alistipes and Dorea
spp. The mechanisms for these alterations are unclear but likely relate to altered colonic
substrate availability during the low FODMAP diet. Blautia are strict anaerobes that display
species-dependent fermentation of a range of substrates including fructose, mannitol and
raffinose and some, such as Blautia hydrogenotrophica, utilise hydrogen and carbon dioxide as
major energy sources, producing acetate (Liu et al., 2008). Dietary changes, such as wholegrain
consumption and resistant starch supplementation, have been shown to influence these genera
in healthy volunteers (Martinez et al., 2013), (Ordiz et al., 2015).
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Adlercreutzia equolifaciens is a hydrogen-consuming bacterium that was elevated following the
low FODMAP diet in the current trial, in line with a previous trial of the low FODMAP diet in IBS
(McIntosh et al., 2016). A possible emerging mechanism of the low FODMAP diet is an increased
abundance of hydrogen-consuming bacteria. This combination of reduced substrate and
increased bacteria that metabolise hydrogen could further reduce hydrogen concentrations in
the lumen, thus reducing distension. However, targeted investigations of the effect of increasing
or reducing the abundance of Adlercreutzia equolifaciens is required.
Alistipes onderdonkii is a bile-tolerant bacterium that was increased following the low FODMAP
diet compared to the sham diet in the current trial. Following a diet based on animal fat and
protein, Alistipes abundance increases (David et al., 2014). Since the low FODMAP diet requires
restriction of carbohydrate-rich foods such as grains, fruits and vegetables, the increase in a bile-
tolerant bacterium may reflect an increase in animal product consumption as alternative foods.
However, this is not supported by the RCT nutrient analysis, which revealed reduced protein and
fat intake following the low FODMAP diet (section 5.7). Alternatively, the reduction in
saccharolytic bacteria such as Bifidobacteria and F. prausnitzii, could simply reduce competition
for space and nutrients in the GI tract and therefore enable growth of other species.
Dorea species displayed divergent effects following the trial diets, likely relating to species and
strain-dependent carbohydrate utilisation. Dorea formicigenerans and Dorea longicatena 1
were significantly reduced following the low FODMAP diet while Dorea longicatena 2 was
increased. Dorea species metabolise a range of substrates including lactose, sorbitol, FOS and
inulin to produce hydrogen, carbon dioxide, acetate, lactate and formate (Taras et al., 2002).
Since Dorea utilise a range of FODMAP substrates, it is conceivable that some species are
susceptible to FODMAP deprivation, which may allow others to thrive.
In the current trial, alpha diversity (measured using the Shannon and Simpson indices) was not
different between the diets at end of trial, or between baseline and end of trial in either diet
group. This is consistent with a placebo-controlled trial in IBS where alpha diversity was not
affected  by  the  low  FODMAP  diet  (Staudacher  et  al.,  2017b).  Low  bacterial  diversity  is  a
consistent feature of the GI microbiota in IBD (Halfvarson et al., 2017), and the lack of effect of
the low FODMAP diet on diversity may be explained by different baseline diversity compared to
IBS. Alternatively, microbiota composition may shift without altering diversity following the low
FODMAP diet. Interestingly, patients classified as responders to the low FODMAP diet in this
trial had greater alpha diversity (Shannon Index) than non-responders, the possible explanations
for which will be discussed in the final discussion (Chapter 7).
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This is the first trial to investigate bacterial gene richness following the low FODMAP diet,
although species richness was higher following a low FODMAP diet compared to a high FODMAP
diet  in  patients  with  IBS  (McIntosh  et  al.,  2016).  This  may  relate  to  the  change  in  substrate
availability and subsequent reduction in abundance of the more dominant species’, which may
facilitate growth of the numerous less dominant species’. Clinical parameters have been
associated with bacterial richness, suggesting that this may be a clinically relevant, but often
overlooked, microbial parameter. In support of this, high bacterial gene richness was
characterised by a greater abundance of putatively anti-inflammatory bacteria, including F.
prausnitzii, in a study of lean and obese individuals, while low bacterial gene richness was
associated with putatively pro-inflammatory bacteria such as Bacteroides and Ruminococcus
gnavus (Le Chatelier et al., 2013).
There were divergent effects of the low FODMAP diet in CD and UC in this trial, albeit with a
reduced sample size upon sub-group analysis. A greater number of species were different
between the low FODMAP and sham diets in patients with UC than in patients with CD, which
mirrors the greater effect of the diet on GI symptoms (Chapter 5) and faecal SCFA concentration
in  UC (section 6.4.1).  The impact  of  the low FODMAP diet  on B. adolescentis and B. longum
abundance were specific to UC as these species were not different between the groups in CD,
although this could be the result of type II errors. This is interesting given that a Bifidobacteria-
containing probiotic supplement has been shown to be efficacious for inducing and maintaining
remission in UC, while there is limited efficacy in CD (Derwa et al., 2017). The UC-specific effect
on Bifidobacteria of the low FODMAP diet warrants further investigation.
The  lack  of  a  notable  effect  of  the  low  FODMAP  diet  in  CD  may  relate  to  different  baseline
microbiome compared to UC, which has been demonstrated in several studies. Crohn’s disease
is often characterised by reduced F. prausnitzii and increased Escherichia coli, and UC with
reduced Roseburia hominis and increased Clostridiaceae (Sokol et al., 2006, Pascal et al., 2017,
Machiels et al., 2013). Reduced F. prausnitzii abundance has also been observed in UC (Machiels
et al., 2013, Morgan et al., 2012), but dysbiosis may be more pronounced in CD than in UC (Pascal
et al., 2017).
The notion that baseline microbiome composition may influence response to treatments
targeting or influencing the GI microbiota is supported by a recent fructan supplementation trial
in which baseline dietary fibre intake was associated with the microbiome alterations following
prebiotic supplementation in healthy volunteers (Healey et al., 2018). Although this has not
been replicated in IBD, this provides evidence that GI microbiota composition prior to treatment
(in this case, possibly diet-induced) influences treatment-induced alterations in microbiota. The
lack of effect of the low FODMAP diet on faecal SCFA concentrations in CD despite a clear effect
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in UC lends further support to different microbiota abundance at baseline, perhaps constituting
bacteria of a lower SCFA-producing capacity, in line with a greater ‘dysbiosis’ (Pascal et al., 2017).
A distinct microbiota profile has also been observed in CD with ileal involvement compared to
colonic CD (Morgan et al.,  2012, Halfvarson et al.,  2017, Naftali  et al.,  2016), suggesting that
patients with ileal or ileocolonic CD (constituting 35% of the total patients in this trial) may also
display differential microbial alterations following the diets, thus contributing to the observed
differences between CD from UC.
6.7.2 Stool SCFA and pH
This trial showed no difference between diet groups in total or individual faecal SCFA at end of
trial, although there was a trend towards a lower total SCFA (P=0.080) and acetate (P=0.073)
concentration in the low FODMAP diet group, which reached statistical significance in the PP
population. Reduced faecal SCFA has not been consistently demonstrated in trials of the low
FODMAP diet in IBS (Staudacher et al., 2012, Halmos et al., 2014a). Previous trials in the research
group observed significantly lower faecal acetate and butyrate concentrations in patients with
IBS following a low FODMAP diet compared to the sham diet, similar to the PP population in the
current trial (Wilson et al., 2017).
Reduced faecal SCFA during the low FODMAP diet likely relates to the decline in dietary
fermentable substrate. Many GI bacteria generate acetate either through polysaccharide
fermentation or de novo from hydrogen and carbon dioxide (for example, Blautia
hydrogenotrophica) (Louis et al., 2014). The non-significantly lower acetate concentration
observed following the low FODMAP diet in this trial may relate, at least in part, to the decline
in acetate-producing Bifidobacteria. It may also be explained by changes in GI transit time in
patients with CD, in whom a reduced stool frequency was observed on the low FODMAP diet
(Lewis and Heaton, 1997a).
It is reassuring that faecal butyrate concentrations were unchanged on the low FODMAP diet
compared to the sham diet, since it has putative anti-inflammatory effects, such as promoting
differentiation  of  regulatory  T-cells  (Smith  et  al.,  2013,  Furusawa  et  al.,  2013).  Butyrate  is
generated predominantly by bacteria of the Firmicutes phylum via a range of metabolic
pathways. Some major butyrate producers significantly declined between baseline and end of
trial in the low FODMAP diet group including F. prausnitzii and Eubacterium whereas others,
such as Roseburia hominis and Intestimonas butyroproducens, significantly increased. This, as
well as the availability of two pathways for butyrate generation, may explain why butyrate
concentrations were maintained while acetate declined in the PP population (Louis et al., 2010).
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The significant reduction in total SCFA, and specifically acetate, butyrate and valerate following
the low FODMAP diet in patients with UC, but not CD, is interesting considering the differential
effects that were seen on the GI microbiome and GI symptoms in UC and CD. It is feasible that
previous colonic mucosal inflammation could result in a lasting impact upon SCFA absorption in
the colon. However, no difference in faecal SCFA concentrations was observed between CD and
UC at baseline. Furthermore, 77% of patients with CD in the trial had some colonic disease
(ileocolonic or colonic CD), and with this rationale SCFA absorption would be affected in colonic
CD in a similar manner to UC. Colonic transit time has an impact on faecal SCFA concentrations
and pH, as demonstrated by a reduced faecal SCFA concentration and higher pH following a
transit-delaying agent in healthy volunteers (Lewis and Heaton, 1997a). However, transit time
does not appear to explain the UC-specific differences in SCFA concentrations at end of trial
since the low FODMAP diet did not affect stool frequency or consistency in patients with UC; in
fact, there was significantly lower stool frequency following the low FODMAP diet in CD only,
where conversely no difference in SCFA was seen at end of trial between the groups.
The quantities of different SCFA produced in the caecum likely depends on the microbiome
composition. As discussed, microbiome differences are evident between CD and UC (Pascal et
al., 2017) and different species were altered by the low FODMAP diet in CD and UC in this trial.
In a previous RCT of the low FODMAP diet in children with IBS, responders to the low FODMAP
diet were enriched in bacteria with saccharolytic activity (and thus, SCFA-producing capacity)
such as Bacteroides and F. prausnitzii at baseline (Chumpitazi et al., 2015), suggesting that a
different baseline microbiome could explain the differential effects of the low FODMAP diet on
SCFA observed in UC.
There are potential implications of reduced SCFA in UC, particularly butyrate. Although minimal
clinical improvement has been observed following butyrate enema in UC (Hamer et al., 2010,
Steinhart et al., 1996), an increase in the IL-10 to IL-12 ratio and reduced nuclear translocation
of NF-κB in lamina propria macrophages from patients with UC treated with butyrate suggests
anti-inflammatory effects (Luhrs et al., 2002, Hamer et al., 2010). Furthermore, SCFA reduce pH
of the GI lumen and this limits pathogen colonisation (Blaut, 2002).
Given that SCFA concentrations were not significantly different between the diet groups at end
of trial in the analysis of all participants, it is unsurprising that faecal pH was not different. The
association between faecal SCFA concentration and pH was supported by a significant negative
correlation. Interestingly, no difference in faecal pH was observed between diet groups despite
lower SCFA concentrations in patients with UC on the low FODMAP diet. This may be explained
by the fact that colonic pH is determined by the concentration of alkaline metabolites such as
ammonia  as  well  as  acidic  SCFA  (Newmark  and  Lupton,  1990).  These  metabolites  were  not
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measured in this trial, but a concurrent reduction in alkaline metabolites during the low
FODMAP diet may have maintained faecal pH in UC.
6.7.3 Biomarkers
In active IBD, gastrointestinal symptom changes alone are insufficient to determine the impact
of therapeutic interventions on IBD activity and disease course, since GI symptoms do not
consistently correlate with GI inflammation (Peyrin-Biroulet et al., 2015). Biomarkers have
recently become central in IBD monitoring (Peyrin-Biroulet et al., 2015) and faecal calprotectin
and CRP were measured at baseline and end of trial as non-invasive markers of whether the low
FODMAP diet had unexpected effects on inflammation.
Reassuringly, there were no significant differences between the diet groups in faecal
calprotectin or CRP at end of trial. In the re-challenge trial described in Chapter 3 of this thesis,
faecal calprotectin concentration was significantly elevated between baseline and end of trial
(following all three FODMAP challenges and the placebo challenge) in patients with CD only. It
is  unclear  whether  this  was  a  result  of  the  background  low  FODMAP  diet,  the  FODMAP
challenges or a coincident fluctuation in GI inflammation, however it does indicate that changes
in fermentable carbohydrate intakes may influence GI inflammation. Although faecal
calprotectin was unchanged in the current trial, this may not reflect subtle alterations in mucosal
immune cell phenotypes. Dendritic cells (DC) may drive abnormal T cell responses to antigen in
patients with IBD, potentially through increased pro-inflammatory cytokine secretion (Mann et
al., 2014, Ng et al., 2011). The low FODMAP diet could alter mucosal DC and T cell phenotypes
via GI microbiome alterations, however obtaining mucosal biopsies was not feasible in this trial.
Future research should investigate any GI immune cell changes occurring following the low
FODMAP diet.
6.7.4 Peripheral T-cell phenotype
Immunology was assessed in this trial on the grounds that the low FODMAP diet has an impact
upon immune-regulatory bacteria such as Bifidobacteria in patients with IBS (Staudacher et al.,
2017b, Staudacher et al., 2012, Halmos et al., 2014a). Indeed, in this trial Bifidobacteria and F.
prausnitzii were reduced following the low FODMAP diet, as did potentially immune-modulatory
SCFA in UC. The proportion of T-cell subsets expressing the gut-homing integrin α4β7 was
measured as an indirect and non-invasive indicator of GI inflammation.
No differences were observed between the groups in total T-cells, the proportion of T-cells that
were CD4+ or  CD8+,  or  the proportion of  CD4+ and CD8+ T-cells  that  were antigen naïve or
differentiated effector/memory T-cells. There were also no significant differences in the
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proportion of T-cell subsets expressing the α4β7 integrin between the diets at end of trial,
except for a lower proportion of α4β7-expressing Vδ2 T-cells at end of trial in the low FODMAP
diet group.
The lack of effect of the low FODMAP diet on inflammation in this trial is incongruent with a
previous trial in which a low FODMAP diet resulted in reduced pro-inflammatory cytokines IL-6
and  IL-8  in  IBS  (Hustoft  et  al.,  2017).  However,  circulating  cytokine  concentrations  are  not
specific to the GI tract and could reflect changes in inflammation elsewhere in the body. The
inconsistency with the findings of the current trial could therefore relate to differences in overall
trial design and specifically immunology analysis.
Similar expression of α4β7 by circulating T-cells in the diet groups at end of trial suggests that,
reassuringly, there was no microbiota-induced or direct effect of the low FODMAP diet on gut-
homing  T-cells  during  the  4-week  trial.  However,  in  clinical  practice  an  8-12  week  FODMAP
restriction is commonplace, therefore future studies should establish whether a longer-term
FODMAP restriction leads to a detrimental impact upon gut-homing T-cells and GI inflammation.
Secondly, the reduction in immune-modulatory bacteria following the diet may be counter-
balanced by regulatory mechanisms in the gut designed to limit inflammation, such as an
increase in regulatory T-cell differentiation, which can be increased by certain bacteria in vitro
(Sun et al., 2015).
Thirdly, the measurement of circulating gut-homing T-cells may not reflect subtle immune
aberrations at the mucosal level. For example, probiotic consumption has been shown to alter
GI mucosal DC phenotype towards a more anti-inflammatory cytokine profile in UC (Ng et al.,
2010). Thus, changes in the GI microbiome following the low FODMAP diet may induce
alterations to the mucosal immune compartment, while the number of T-cells homing to the GI
tract remains unchanged. It was not possible to obtain mucosal biopsies in this trial, however,
future studies should address the immune effects of the low FODMAP diet at the mucosal level.
Fourthly, there are other molecules believed to be involved in T-cell homing to the gut, including
CCR9 and GPR15, and measuring these in addition to α4β7 may have afforded a more
comprehensive assessment of T-cell gut-homing. However, CCR9 appears to be involved
predominantly in T-cell homing to the small intestine, while the role of GPR15 in T-cell homing
to the GI tract remains uncertain (Adams and Eksteen, 2006, Fischer et al., 2015). In contrast,
α4β7 has a well-established role in T-cell homing to both the small intestine and colon (Berlin et
al., 1993). In support of the role of α4β7 for the assessment of changes in GI inflammation in
IBD, a shift of β7+ T-cells from the circulation to the mucosa has been observed in patients with
active IBD (Hart et al.,  2004b, Hart et al.,  2004a). Furthermore, a greater proportion of naïve
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CD4+ T-cells expressed α4β7 in patients with inactive CD compared to healthy controls (Hedin
et  al.,  2014),  and  elevated  expression  of  α4β7  has  also  been  observed  in  UC  compared  to
patients with CD or healthy controls (Fischer et al., 2015).
There was a significantly lower proportion of circulating α4β7+ Vδ2+ T-cells in the low FODMAP
diet group at end of trial. Typically, a large proportion of circulating Vδ2+ T-cells express α4β7
(>70%, in agreement with the current trial), and are activated by phosphoantigens that are
generated by GI  microbiome,  suggesting a  possible  role  in  GI  inflammation (McCarthy et  al.,
2013,  McCarthy  et  al.,  2015).  A  lower  proportion  of  α4β7+  Vδ2+  T-cells  following  the  low
FODMAP  diet  suggests  lower  homing  of  Vδ2+  T-cells  to  the  GI  tract.  However,  the  absolute
number of α4β7+ Vδ2+ T-cells was not different between the diets at end of trial and the lower
proportion of these cells may be explained by a higher number of total Vδ2+ T-cells in the low
FODMAP diet group, although this was not significantly different between the groups. A true
reduction in α4β7+ Vδ2+ T-cells following the low FODMAP diet could be explained by changes
in the GI microbiota, and thus in the levels of phosphoantigen exposure in the GI tract.
Phosphoantigens are produced by a wide spectrum of GI bacteria and therefore a shift in the
bacterial composition could impact upon Vδ2+ T-cells recruited to the GI tract (Eberl et al.,
2003).
A lower proportion of α4β7+ naïve CD4+ T-cells and α4β7+ naïve and effector/memory CD8+ T-
cells was observed on the low FODMAP diet in patients with CD. This occurred despite no
difference in absolute numbers of naïve or memory T-cells between the diets. A reduced
proportion  of  α4β7+  T-cells  on  the  low  FODMAP  diet  in  CD  suggests  that  fewer  cells  were
recruited  to  the  GI  tract.  Effector/memory  T-cells  are  primed  to  express  α4β7  in  the  gut-
associated lymphoid tissues (GALT) in response to antigen presentation by DC (Hart et al., 2010).
Therefore, a reduced proportion of these cells may suggest reduced bacterial antigen sampling
and presentation to T-cells in the GALT. In the context of the low FODMAP diet, this could reflect
reduced overall bacterial numbers (resulting from less fermentable substrate reaching the
colon) or the change in GI microbiome composition. The differences in α4β7+ T-cells in CD and
not UC could relate to the observed differential microbial effects of the low FODMAP diet in CD
and UC, differences in T-cell gut homing relating to varying disease location between CD and UC,
or low-grade GI inflammation in CD not detected by faecal calprotectin upon screening.
6.7.5 Significance of findings
This is the first RCT to establish the effects of low FODMAP dietary advice on the GI microbiota,
microbial metabolites and T-cell phenotype in patients with IBD. The diet influences GI
microbiota  composition  in  a  similar  pattern  to  that  seen  in  IBS,  namely  the  reduction  in
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Bifidobacteria and F. prausnitzii, but with some additional novel findings. A trend towards a
lower concentration of SCFA was observed following the low FODMAP diet, reaching significance
in the PP population and in patients with UC.
Despite the reduction in immune-modulatory bacteria following the low FODMAP diet, few
effects on circulating gut-homing T-cells were observed. Fewer Vδ2 T-cells expressed α4β7 and
in CD, fewer naïve CD4+ and CD8+ T-cells, effector/memory CD8+ T-cells expressed α4β7 at end
of  trial  in  the  low  FODMAP  diet  group.  While  this  may  be  a  chance  observation  owing  to
fluctuating immunological parameters in IBD, this may be a true consequence of the microbial
alterations or an unidentified effect of the low FODMAP diet. The relevance of these findings is
currently unclear and the cause of the reduction in gut-homing integrin expression requires
further elucidation.
Overall, although the low FODMAP diet reduced immune-modulatory bacteria and SCFA (in
patients with UC), alarming increases in inflammatory markers or gut-homing T-cells were not
observed. This suggests that the low FODMAP diet is likely safe in IBD when implemented for a
period of up to four weeks, as intended in clinical practice. The reality, however, is that due to
patient unwillingness to reintroduce FODMAPs or due to clinical demands, longer-term FODMAP
restriction is common (Whelan et al., 2018). It is essential that future research establishes the
potential immunological and clinical implications of a prolonged decline in immune-modulatory
bacteria, and indeed whether FODMAP reintroduction does recover the abundance of these
bacteria.
6.7.6 Strengths and limitations
A major strength of this trial pertains to the comprehensive analysis of the GI microbiome using
metagenomic sequencing, which is a first-ever in the low FODMAP diet. A detailed discussion of
methods for microbiome characterisation can be found in section 4.5.2.1. Next-generation
sequencing techniques are more time efficient than methods such as qPCR and FISH because
millions of nucleotide bases can be sequenced in a short period of time. Metagenomic
sequencing allows greater taxonomic resolution than 16S rRNA sequencing since multiple genes
are used to assign taxonomy. Furthermore, it allows identification of species for which 16S rRNA
sequences are not known and an assessment of the potential functions of the GI microbiome
(though due to time constraints, this was not presented in this thesis). The ion proton
sequencing technology used in the current study is more time-efficient than Illumina technology
and alerts users to errors early in the sequencing process, thus increasing cost efficiency.
Although metagenomic sequencing is a powerful method for the characterisation of the GI
microbiota, it is not without drawbacks. Bias can be introduced through variations in sample
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collection, storage, DNA extraction, library preparation and sequencing protocols and despite
efforts to standardise metagenomic studies, different research centres continue to use different
protocols and pipelines (Costea et al., 2017). Furthermore, although databases of known genes
are expanding, the function of many genes arising from metagenomic sequencing studies
remain unknown. A theoretical limitation of metagenomic sequencing over 16S sequencing is
that  more  data  must  be  generated  to  obtain  the  same  information.  This  is  because  16S
sequencing targets an individual gene that is amplified prior to sequencing, while in
metagenomic studies, genes of interest must be identified from a large pool of sequencing data
(Thomas et al., 2015). Estimates of species richness and alpha and beta-diversity can be affected
by sequencing depth, defined as the average number of times a particular nucleotide is
represented in a collection of raw sequences (Sims et al., 2014, Finotello et al., 2016). A greater
sequencing depth can also overcome the problem associated with sequencing errors (Sims et
al., 2014). Sequencing depth in this trial (20 million reads generated per sample) was comparable
to previous metagenomics studies (Cotillard et al., 2013, Le Chatelier et al., 2013). Finally,
determining absolute bacterial abundance within a sample is difficult using metagenomic
sequencing, rendering it difficult to make comparisons between studies or to identify whether
total bacterial abundance was altered by the diet.
An  intention  to  treat  analysis  was  not  performed  on  the  microbiome  data  in  this  trial.  This
decision was based upon the expected small effect size of the diet on the GI microbiome and
the relatively small sample size compared to other metagenomic studies (Cotillard et al., 2013,
Le Chatelier et al., 2013). This was felt to be justified since the microbiota was a secondary
outcome in this trial, however this does not reflect the impact the diet would have on the GI
microbiome under clinical conditions in which a proportion of patients discontinue or poorly
comply with the diet.
The ability to compare hundreds of species across the study groups facilitates a less biased
characterisation of the GI microbiome and is an advantage of metagenomic sequencing, but the
vast number of comparisons increases the likelihood of a significant difference occurring by
chance between groups (Bland and Altman, 1995). This can be accounted for by applying a
Bonferroni correction for multiple comparisons. In this trial, however, the number of statistical
tests performed for the microbiome analysis was around 500. Applying a Bonferroni correction
would therefore obscure any real effects of the diet on the microbiome since a p-value of 0.0001
would be required for significance. Indeed, a criticism of the Bonferroni correction is that it is
extremely conservative and increases the likelihood of type II error (albeit while reducing type I
error) (Streiner, 2015). Some of the observed effects of the diet, such as the reduction in several
species of Bifidobacteria and F. prausnitzii abundance, were expected based upon previous
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evidence and are unlikely to have occurred by chance. For these reasons, correction for multiple
comparisons was not performed and this should be acknowledged in interpreting the
microbiome data.
The collection of faecal samples is relatively straight-forward and non-invasive for participants,
and likely enhances trial retention. However, there is an inherent limitation that the time
between participants voiding the sample and sample processing may vary, as might sample
storage conditions. To minimise this variation in this trial, all participants were asked to pass the
sample less than two hours before providing to the researcher, and were provided with a
standardised stool collection kit. Despite these measures, it is likely that there was some
variation but this has recently been shown to have a lesser impact on microbiome composition
than variations in DNA extraction protocol (Costea et al., 2017).
Faecal bacterial analysis captures the luminal microbiota but does not provide any information
on the mucosa-associated microbiota (MAM). Intra-individual differences between the luminal
and mucosal microbiota have been observed in healthy individuals (Ringel et al., 2015, Zoetendal
et al., 2002) and patients with IBD (Lavelle et al., 2015) and there may be species that are specific
to the MAM and are not captured through faecal analysis. However, the bowel preparation
required for colonoscopy or flexible sigmoidoscopy is known to profoundly impact the MAM and
introduces bias into microbiota assessment in biopsies (Shobar et al., 2016). Furthermore,
colonoscopy is considerably more invasive than faecal sample collection and would have limited
recruitment  to  this  trial  (Denters  et  al.,  2013).  The  decision  to  omit  biopsies  was  therefore
justified, but effects of the diet on the MAM may have gone undetected.
Longitudinal gradients in the colonic microbiome have also been observed and certain genera
may dominate the proximal and distal colon (Lavelle et al., 2016). Thus, the faecal microbiome
is representative of the distal colon but not necessarily the proximal colon, although a small
study of patients with UC demonstrated greater variability in microbiota between the mucosa
and lumen than that observed longitudinally (Lavelle et al., 2016, Lavelle et al., 2015). Likewise,
fermentation and SCFA production is greatest in the caecum and the majority of SCFA are
absorbed  along  the  length  of  the  colon  (Primec  et  al.,  2017).  Thus,  SCFA  concentrations  are
highest, and pH is lowest, in the caecum, and this is not captured in faecal samples. Measuring
SCFA and pH in vivo is possible but labour-intensive, invasive and costly and was not feasible for
the measurement of a secondary outcome in this trial (Boets et al., 2015, Cummings et al., 1987,
Peters et al., 1992, Mitchell et al., 1985, Millet et al., 2010, Evans et al., 1988).
Faecal calprotectin concentrations can vary under different physiologic and environmental
conditions. In healthy controls, patients with IBD and patients with other conditions, faecal
Chapter 6: RCT microbiota and immunology results
276
calprotectin concentration was shown to be similar in several aliquots of the same sample
compared to a homogenised portion of the sample, suggesting an even distribution of faecal
calprotectin within stools (Røseth et al., 1992). Furthermore, faecal calprotectin is stable in
faeces for up to 48 hours at room temperature. Faecal samples in the current trial were collected
within 2 hours of evacuation and frozen at -80oC shortly thereafter, therefore storage should
not have affected faecal calprotectin concentrations. Significant diurnal and day-to-day variation
in faecal calprotectin was observed in a study of patients with active UC (Lasson et al., 2015).
However, this variation was most marked in patients with a high faecal calprotectin and patients
in the current trial were recruited based upon a faecal calprotectin of <250 μg/g at screening,
therefore significant faecal calprotectin fluctuations would not be expected in these patients.
This trial was unique in the measurement of immunology, a parameter omitted from the
majority of previous low FODMAP diet trials. An exception is one trial in which a decline in the
concentration of serum pro-inflammatory cytokines (IL-6, IL-8) was observed following the low
FODMAP diet (Hustoft et al., 2017). Unfortunately, circulating serum cytokines are not indicative
of the GI immune state specifically and may be elevated or reduced due to immune alterations
anywhere in the body. Therefore, a gut-homing integrin was used in the current trial to assess
the proportion of T-cells primed in the GALT to migrate to the GI tract. This indicates the level
of antigen-specific T-cell priming occurring in GALT, which could theoretically be influenced by
changes to the nature of luminal antigen contacting mucosal DC (Johansson-Lindbom et al.,
2005).
The hypothesis in this trial was that a reduction in immune-modulatory bacteria, such as
Bifidobacteria and F. prausnitzii,  following  the  low  FODMAP  diet  may  influence  mucosal  DC
phenotypes and thus influence the proportion of T-cells primed by DC to express the α4β7 gut-
homing integrin (Dudda et al., 2005). However, to date there are no studies definitively proving
that changes to GI microbiome composition directly influence T-cell gut-homing integrin
expression. Although altered proportions of circulating α4β7+ T-cells have been observed in IBD
(Fischer et al., 2015, Hedin et al., 2014), thus justifying the assessment of this marker, circulating
T-cell phenotype may not be sufficiently sensitive to reflect subtle mucosal GI immune
alterations. Analysing mucosal immune cell numbers and phenotypes might have enhanced the
assessment of the immunological impact of the diet but the aforementioned constraints
associated with colonoscopy precluded these analyses.
Flow cytometry is an efficient and powerful method allowing the simultaneous assessment of
extra- and intracellular markers on individual cells within a sample. A major limitation of flow
cytometry is that results are entirely dependent upon the gating strategies used by the
investigator (Jahan-Tigh et al., 2012), which is subject to considerable inter-observer variation.
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However, this was minimal in this trial since the same observer conducted all analysis (the thesis
author, SC). Furthermore, consistent gating strategies were employed for all samples
throughout the trial.
6.7.7 Conclusion
This trial has established that the low FODMAP diet influences the GI microbiome in patients
with IBD, notably with a reduction in immune-modulatory Bifidobacteria and F. prausnitzii.
Furthermore, in the per protocol population and patients with UC, SCFA concentrations were
reduced following the low FODMAP diet, which may represent a detrimental impact of the diet,
given the possible effects of certain SCFA on GI homeostasis (Louis et al., 2014). However, the
low FODMAP diet did not appear to negatively impact upon GI immune function, with gut-
homing T-cell proportions not affected by the diet. The relevance of these findings, and the
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7.1 Summary of findings
A large proportion of patients with IBD (~35%) continue to experience GI symptoms that meet
the criteria for a functional bowel disorder even during periods of remission (Halpin and Ford,
2012). These functional GI symptoms (FGS) are associated with poor health-related quality of
life (HR-QOL) and greater anxiety and depression (Jonefjäll et al., 2016, Jonefjall et al., 2013,
Simrén et al., 2002, Gracie et al., 2017) and represent a clinical dilemma since management with
anti-inflammatory or immune-modulatory medication is unlikely to be effective. Retrospective
(Gearry  et  al.,  2009a)  and  prospective  (Prince  et  al.,  2016)  uncontrolled  studies  and  a
randomised non-placebo controlled trial (Pedersen et al., 2017) indicate that dietary
fermentable carbohydrate restriction (low FODMAP diet) may reduce FGS in patients with IBD
in remission. Unfortunately, the difficulty in blinding dietary studies, the large placebo response
rate in IBS and the challenge of isolating the effects of specific food components make it difficult
to establish from these studies that a low FODMAP diet is effective in patients with inactive IBD.
The aim of this thesis was to explore the role of fermentable carbohydrates in FGS in IBD using
a variety of methodological approaches.
Chapter 2 utilised a dietary intake survey to demonstrate that patients with active IBD and
inactive IBD with and without FGS have lower intakes of certain fermentable carbohydrates,
including galacto-oligosaccharides (GOS) and sorbitol, compared to healthy controls. These
findings are unlikely to relate to differences in energy intake since differences were maintained
between groups when adjusted for energy intake. Patients with inactive IBD with FGS may also
be more nutritionally vulnerable than healthy controls. It is unknown whether the reduced
intake of certain FODMAPs reflects FGS induction following consumption, with subsequent
dietary avoidance.
Chapter 3 of this thesis therefore described a double-blind, placebo-controlled, crossover re-
challenge trial designed to establish whether pure FODMAP challenges induce GI symptoms in
patients with inactive IBD, while avoiding the placebo response associated with unblinded or
poorly-blinded dietary treatments and the potential confounding posed by other dietary
components that may impact GI symptoms. Following a pure fructan challenge, fewer patients
reported adequate relief of GI symptoms and the severity of abdominal pain, bloating and
flatulence was greater compared to the glucose placebo challenge. This trial established that
fructans are capable of inducing GI symptoms, thus indicating a role for FODMAPs in the
induction of FGS in inactive IBD. However, the dose of the fructan challenge was twice that of
the GOS and sorbitol challenges and the effects of equal doses of the FODMAPs are unknown.
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Furthermore, this trial does not establish that the low FODMAP diet is effective for managing
FGS in IBD.
Chapter 4 therefore described a RCT designed to compare low FODMAP dietary advice to sham
dietary advice in patients with inactive IBD and FGS, thus controlling for the appreciable placebo
response rate characteristic of IBS and IBD (Elsenbruch and Enck, 2015).
Chapter 5 demonstrated that significantly more patients reported adequate relief of GI
symptoms and lower severity of abdominal bloating and flatulence following the low FODMAP
diet compared to sham diet. The improvement in GI symptoms was accompanied by a greater
patient-perceived control of IBD and HR-QOL, while FR-QOL was not adversely affected by the
diet. The possible limitations associated with blinding in the sham diet in this trial (discussed in
section 5.11), should be taken into account when interpreting the findings.
Chapter 6 describes profound effects of the low FODMAP diet on the GI microbiota. In line with
trials  of  the  low  FODMAP  diet  in  IBS  (Staudacher  et  al.,  2017b,  Staudacher  et  al.,  2012),
Bifidobacterium longum and Bifidobacterium adolescentis and Faecalibacterium prausnitzii
were  significantly  lower  following  the  low  FODMAP  diet  compared  to  the  sham  diet.
Interestingly, the difference in total faecal SCFA between the diets failed to reach significance,
however in patients with UC, total and individual SCFA were significantly lower following the low
FODMAP diet compared to sham diet. Despite a reduction in putatively immune-regulatory
bacteria, inflammatory markers (faecal calprotectin and CRP) and peripheral T-cell phenotype
remained largely unchanged by the diet, suggesting no down-stream effects on GI immune
function.
Studies suggest that patients with IBS responding to the low FODMAP diet have a microbial and
volatile organic compound (VOC) profile compound distinct from that of non-responders,
suggesting it may be possible to predict patients most likely to respond based upon microbiome
profiles. Therefore, section 7.2 describes greater microbial alpha diversity that was observed in
patients responding to the low FODMAP diet in the RCT described in Chapters 4-6.
7.2 Gastrointestinal microbiota of low FODMAP diet responders
A  large  proportion  of  patients  experience  a  GI  symptom  improvement  following  the  low
FODMAP diet, however some do not experience a significant improvement. For example, 48%
of participants in the low FODMAP diet group in the RCT (Chapters 5) did not report adequate
relief.  The  ability  to  predict  patients  most  likely  to  respond  to  the  low  FODMAP  diet  is  an
attractive concept given the restrictive and complex nature of the diet. The gut microbiome is a
potential source of variation in response to the low FODMAP diet and has been shown to vary
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between responders and non-responders in previous studies (Chumpitazi et al., 2015, Bennet et
al., 2017).
In the RCT described in Chapters 4-6 of this thesis, the baseline microbiome composition was
compared between responders to the low FODMAP diet (reporting adequate relief at end of
trial; n=14) and non-responders (not reporting adequate relief at end of trial; n=13). There was
a higher baseline bacterial gene richness in the responders (549,318 SD 97,434 genes) compared
to the non-responders (416,001 SD 202,468 genes), which failed to reach statistical significance
(P=0.076) (Figure 7.1), while baseline Shannon index (alpha diversity) was significantly higher in
responders (3.7 SD 0.3) compared to non-responders (3.1 SD 0.8) (P=0.023) (Figure 7.1). There
was no difference in other measures of microbial diversity, including the Simpson index and the
Bray-Curtis index, between responders and non-responders at baseline.
Figure 7.1 Baseline bacterial gene richness (left panel; P=0.076) and Shannon alpha diversity index (right
panel; P=0.023) in responders (with adequate relief at end of trial) and non-responders (without
adequate relief at end of trial)
Responders were enriched in several species at baseline, including Senegalimassilia anaerobia,
Bacteroides caccae, Parabacteroides merdae, Alistipes onderdonkii, Eubacterium rectale, Blautia
obeum, Ruminococcus torques, Dorea formicigenerans, an unclassified Dorea species, Roseburia
inulinivorans and Faecalibacterium sp. CAG:82. Fewer species were enriched in non-responders
at baseline but included Blautia hansenii, Blautia sp. CAG:257, an unclassified Blautia,
Clostridium citroniae and Clostridium saccharolyticum.
Figure 7.2 represents responders’ and non-responders’ microbiome composition at baseline.













Chapter 7: Final discussion
282
more dispersed. The principle components analysis explains 26.6% of the variance in
microbiome composition between responders and non-responders but there remains a major
overlap between them, suggesting that responders and non-responders could not be completely
discriminated based upon microbiome composition.
Figure 7.2 Principle component analysis depicting baseline microbiome composition in low FODMAP
diet responders (patients reporting adequate relief at end of trial; yellow triangles) and non-responders
(patients not reporting adequate relief at end of trial; blue circles)
The mechanism explaining greater baseline bacterial gene richness (approaching statistical
significance) and alpha diversity (statistically significant) in low FODMAP diet responders is
currently unknown. Many bacterial genera previously associated with individuals with high
bacterial gene richness were those with saccharolytic capacity, such as Faecalibacterium,
Butyrivibrio, Ruminococcaceae and Dorea (Le Chatelier et al., 2013). A previous trial reported
greater baseline abundance of bacteria with saccharolytic capacity in children responding to the
low FODMAP diet (Chumpitazi et al., 2015) and in line with this, several species enriched in low
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FODMAP diet responders in this trial had saccharolytic capacity, including Eubacterium rectale,
Roseburia inulinivorans and Faecalibacterium species. One theory could therefore be that the
greater bacterial gene richness and diversity reflects greater saccharolytic and metabolic
potential of the GI microbiome, which may be associated with intestinal gas production.
Therefore, restricting fermentable substrate during the low FODMAP diet may reduce
saccharolytic and metabolic activity and increase the likelihood of a response in these individuals
due to greater impact on intestinal gas production. The greater GI symptom improvement and
a significant reduction in faecal SCFA concentrations in patients with UC, and not in CD, may
represent a greater reduction in saccharolytic fermentation during the low FODMAP diet, which
may relate to baseline microbiome composition. Although functional metagenomic analysis was
not possible within the timeframe for this thesis, future analysis of the carbohydrate-active
enzymes encoded by the GI microbiome of responders and non-responders in this trial will help
delineate this proposed mechanism of response to the low FODMAP diet.
A distinct baseline microbial profile has previously been observed in patients with IBS
responding to the low FODMAP diet (Bennet et al., 2017). However, the species discriminating
responders and non-responders were discordant with those in the current trial, which may
reflect different microbiota profiles between IBS and IBD, the different methods of microbiota
analysis (the previous trial used a ‘dybiosis’ index measuring a limited number of species,
compared with full metagenomics sequencing in the current study) and different definitions of
responders between the studies. Distinct faecal VOC profiles have also been reported in patients
with IBS responding to low FODMAP dietary advice compared to non-responders (Rossi et al.,
2018). Since faecal VOC are derived from the GI microbiome and host diet, this provides further
evidence that microbial profiles may predispose to a response to the low FODMAP diet, although
it is unclear exactly which compounds are associated with response.
Microbiome profiles have also been associated with response to other IBD therapies. In a large
RCT of ustekinumab treatment, patients with CD entering remission had a higher baseline alpha
diversity and Faecalibacterium and Bacteroides abundance compared to non-responders,
bearing a striking similarity to the findings of the current trial, although of course that study was
treating active  disease,  not  FGS as  in  the current  study (Chapter  4-6).  A  negative correlation
between baseline alpha diversity and clinical disease activity index was also identified in the
ustekinumab trial, suggesting that a lower baseline disease activity may be a confounder (Tedjo
et al., 2016).
Although this trial suggests the potential for predicting responders to the low FODMAP diet
based upon alpha diversity and the abundance of certain bacterial species, the investigation of
microbial profiles in low FODMAP diet responders was exploratory and requires confirmation in
Chapter 7: Final discussion
284
appropriately powered trials. Previous evidence also suggests an association between stool
consistency and microbial species richness (Vandeputte et al., 2016), indicating a potential
influence of clinical characteristics on this parameter of the GI microbiome that should be
considered when interpreting these findings. Further larger-scale studies targeted at identifying
microbiome composition, genetic potential and metabolite profiles in low FODMAP diet
responders are essential to reduce the number of patients unnecessarily attempting this
complex diet.
7.3 Faecal calprotectin assessment
Faecal calprotectin was measured using a rapid point-of-care kit to determine eligibility during
patient screening (section 3.4.11.3). However, baseline and end of trial calprotectin was
subsequently measured using the gold standard ELISA method (section 4.6.1.1.2).
On final data analysis it was observed that, when measured using ELISA, some patients had
baseline faecal calprotectin values exceeding the cut-off for inclusion. Further comparison of the
rapid point-of-care kit compared with ELISA showed that on average the rapid test results were
17.5  µg/g  lower  than  the  ELISA.  The  Bland-Altman  plot  (Figure  7.3)  shows  that  there  was  a
smaller difference (better agreement) between the tests at lower concentrations, while at
higher concentrations the rapid test underestimates faecal calprotectin. In line with this finding,
four participants (8%) were above the threshold for inclusion (250 µg/g) at the baseline visit,
despite a rapid test at screening indicating a faecal calprotectin <250 µg/g.
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Figure 7.3 Bland-Altman plot of the FCP concentrations obtained by the rapid test and the ELISA against
the difference between the two readings for each individual. The middle dotted horizontal line is the
mean difference between the rapid test and ELISA (-17.5 µg/g), while the upper (+156 µg/g) and lower
(-191 µg/g) horizontal dashed lines represent the limits of agreement (± 2σ)
This limitation of rapid faecal calprotectin screening tests has been highlighted previously
(Rodriguez  et  al.,  2017).  Studies  show imperfect  correlation with ELISA results  particularly  at
higher concentrations (Wassell et al., 2012, Rodriguez et al., 2017), indicating that rapid tests
may be inadequate for screening patients for clinical trial eligibility unless the faecal calprotectin
threshold for inclusion is low. The discrepancy between the tests at higher faecal calprotectin
concentrations may lead to inclusion of participants with faecal calprotectin above the
permitted threshold, as was the case in the current study for four patients.
7.4 Implications of this thesis for clinical practice
The dietary survey (Chapter 2) suggests that patients with inactive IBD with FGS may manipulate
dietary FODMAP intake and therefore this should be assessed prior to advising a low FODMAP
diet, especially since intakes of some micronutrients were significantly lower in this group
compared to healthy controls, indicating a possible greater risk of inadequate nutrient intakes
prior to starting a low FODMAP diet. This further supports the need for careful counselling and
monitoring during the diet.
The RCT described in Chapters 4-6 established that, with intensive dietetic guidance, the low
FODMAP  diet  is  effective  in  improving  FGS  in  patients  with  inactive  IBD,  although  not  all  GI
symptom measures perform equally in representing this improvement. Sub-group analysis
suggested that the low FODMAP diet may be more effective in UC, however in clinical practice
the diet may still be trialled in patients with inactive CD where indicated.
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A profound effect of the low FODMAP diet on GI microbiome composition in IBD, with a similar
pattern to that observed in IBS, is evident from the RCT described in Chapters 4-6. The effect of
FODMAP reintroduction on GI microbiota composition, and whether this returns bacterial
abundance to baseline, remains unknown. Trials of the effects of sequential FODMAP
reintroduction on GI symptoms, GI microbiota and immunology in both IBS and IBD are
therefore warranted. In patients with IBS, a decline in Bifidobacteria abundance during the low
FODMAP diet was prevented through concurrent supplementation with a Bifidobacteria and
Lactobacilli-containing supplement (Staudacher et al., 2017b). It remains to be established
whether the same would be observed in patients with IBD embarking upon a low FODMAP diet.
Patients with IBD may experience difficulties in maintaining nutrient intakes during the low
FODMAP diet and vigilant dietary counselling should focus on maintaining overall energy intake
as well as micronutrient intakes, with a focus on calcium and iron.
7.5 Recommendations for future research
The case-control study described in Chapter 2 contributes to the investigation of dietary intake
in IBD, a field currently characterized by studies featuring inappropriate dietary assessment and
heterogeneity in terms of patients recruited and methods used. However, it was not possible to
recruit the full target sample size (80 participants per study group) in the timeframe for this
thesis and the current findings require confirmation through the analysis of the full sample size
once recruited. Furthermore, it was not possible to estimate intake of non-nutrients such as
food additives, some of which (particularly emulsifiers) have been implicated in microbiota
alterations and intestinal inflammation in murine models (Chassaing et al., 2017, Chassaing et
al., 2015). Future studies of dietary intake in IBD should include food additives.
The RCT in Chapters 4-6 established that a 4-week low FODMAP diet reduced FGS in patients
with inactive IBD, and although this resulted in shifts in microbiome composition and reduced
SCFA in the PP population and patients with UC, it did not appear to adversely affect immunology
and GI inflammation. However, in clinical practice it is common for patients to embark upon a
longer-term FODMAP restriction and it is likely that the microbiome and SCFA alterations would
be exacerbated, which may induce a greater immunological effect. Therefore, the effects of, for
example, an 8 or 12-week FODMAP restriction should be investigated.
Given that a large proportion of patients in the sham diet group were able to correctly identify
diet allocation, future qualitative research should investigate the predictors of identifying the
sham diet. This may allow refinement of the sham diet to include and exclude dietary
components that increase blinding effectiveness, while maintaining nutrient and FODMAP
intakes. Since no adequately-powered feeding studies of the low FODMAP diet have been
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performed in IBD, this would provide proof-of-concept evidence of effectiveness of the diet
when followed under optimal conditions.
It is reassuring that the low FODMAP diet did not impact inflammatory markers or circulating T-
cell phenotype (Chapter 6). However, as described previously, these outcomes may not be
sufficiently sensitive to detect a subtle change in mucosal immunology following the low
FODMAP diet. This could precede overt inflammation and an investigation of mucosal DC and T-
cell phenotypes following the low FODMAP diet are warranted, although would require mucosal
biopsies at baseline and following dietary intervention.
The RCT revealed a greater microbial alpha diversity and enrichment in various species, several
with saccharolytic activity, in low FODMAP diet responders compared to non-responders. This
contributes to a mounting body of evidence that low FODMAP diet responders may be identified
prior to beginning the diet, based upon microbiome composition or the profile of metabolites
produced (Chumpitazi et al., 2015, Bennet et al., 2017, Rossi et al., 2018). However, this evidence
remains limited to exploratory post-hoc analyses of low FODMAP diet trials and requires
adequately-powered trials to establish specifically which species and metabolites are predictive
of a response. Volatile organic compounds, derived from the GI microbiome and diet, may be
altered in IBD compared to healthy controls and may be different in low FODMAP diet
responders compared to non-responders (Ahmed et al., 2016, Rossi et al., 2018). Surplus faecal
samples from the RCT will be analysed to establish whether the low FODMAP diet impacts upon
VOC profiles or whether distinct profiles are present in low FODMAP diet responders, which
could, along with microbial profiles, represent a means of predicting responders and
personalising dietetic advice in the future.
Greater efficacy of the low FODMAP diet was observed in UC compared with CD. Interestingly,
distinct microbiome alterations were observed following the low FODMAP diet in UC and CD,
and faecal SCFA concentrations were significantly reduced following the low FODMAP diet in UC
only.  These  findings  suggest  that  microbiome  composition  may  play  a  role  in  the  greater
responses in UC. The sub-group analysis halves the sample size and reduces statistical power
and larger trials are warranted to establish whether this UC-specific effect is replicated.
A major strength of metagenomic sequencing is the ability to investigate the effect of therapies
on the functional potential of the GI microbiota, which may not be represented adequately in
studies of microbiome species composition (Morgan et al., 2012). Bioinformatics analysis of
metagenomic sequencing data is complex and time-intensive and the priority in this thesis was
the assessment of microbiome composition. Analysis of the pathways encoded within the GI
microbiome may provide further insight into the those that are altered by the low FODMAP diet
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and will clarify whether the saccharolytic potential of the GI microbiota is indeed different in
responders compared to non-responders. Assessing the pathways encoded for SCFA generation,
such  as  butyrate  synthesis,  will  also  clarify  whether  a  long-term  low  FODMAP  diet  could  be
detrimental.
7.6 Conclusion of this doctoral thesis
This thesis establishes that fermentable carbohydrates are reduced in the habitual diet of people
with inactive IBD who suffer FGS and that fructans play a role in FGS generation in patients with
inactive IBD on the background of a low FODMAP diet. When intensive counselling and support
is provided by a dietitian, the low FODMAP diet is an effective therapy for the management of
FGS in patients with inactive IBD. Although the low FODMAP diet reduces abundance of
immune-modulatory bacteria in patients with inactive IBD, it does not cause alterations to
inflammatory markers and immunology in the short-term. Therefore, the low FODMAP diet is a






8.1 Re-challenge trial participant information sheet
REC reference Number: 13/LO/1878
Chief Investigator: Professor Kevin Whelan
Principal Investigator: Dr Peter Irving
Co-Investigator: Selina Cox
PARTICIPANT INFORMATION SHEET
FODMAPs as Dietary Triggers of Abdominal Symptoms in Inflammatory Bowel Disease
We would like to invite you to participate in this research project. You should only participate if
you want to; choosing not to take part will not disadvantage you in any way. Before you decide
whether you want to take part, it is important for you to understand why the research is being
done and what your participation will involve. Please take time to read the following
information carefully and discuss it with others if you wish.
We  are  providing  you  with  the  following  information  before  you  agree  to  take  part,  which
explains the purpose of this research and what it involves. Please ask any questions you have
about the information given and we will do our best to explain and provide any further details
you may need.
What is the purpose of the study?
This research study aims to help patients and health care professionals at Guy’s and St Thomas’
hospitals to learn about the effect of certain dietary carbohydrates (FODMAPs) on gut symptoms
experienced by patients with inflammatory bowel disease whilst in remission. FODMAPs are
poorly digested in the gut and can increase the water and gas production leading to functional
gut symptoms (e.g. irritable bowel syndrome or IBS) in some people. FODMAP rich foods include
wheat, onion, garlic, pulses and a few other vegetables and fruit and sugar free gums.
Functional gut symptoms are those experienced during times of inactive disease that are not
caused by inflammation and may include abdominal discomfort, abdominal bloating, diarrhoea,
wind.
This study is being conducted by a research dietitian from King’s College London in collaboration
with Guy’s and St Thomas’ NHS Foundation Trust gastroenterology services. We believe the
results of this study will be important for the future treatment and dietary management of
functional gut symptoms in patients with inflammatory bowel disease.
Who are we recruiting?
We are looking for people who have been diagnosed with inflammatory bowel disease, and who
are attending an outpatient clinic at either Guy’s or St Thomas’ Hospital as part of their care.
Eligible participants will either have been advised in the past to follow a low FODMAP diet for
the management of gut symptoms or are eligible for this dietary intervention now. Only those
people who have experienced a beneficial effect from the low FODMAP diet are eligible for this
study. People with active Crohn’s disease or ulcerative colitis will be excluded. Also, people who
have taken certain medications recently or who have had medication dose changes, those who
have had recent gut surgery or who have other psychiatric or chronic diseases will not be eligible.
Pregnant and breastfeeding women will also be excluded.
Do I have to take part?
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No. Your participation in this study is voluntary and it is entirely up to you whether you take
part. Even if you do decide to take part, you can change your mind at any time and withdraw
from the study without giving a reason. If you decide you no longer wish to take part, please
inform Selina Cox (contact details below). Any decision not to be involved in the study at any
time will not affect the standard of care you receive now or in the future. If you agree to take
part, you will be asked whether you are happy to be contacted about participation in future
studies. Your participation in this study will not be affected should you choose not to be re-
contacted.
What will happen to me if I do take part?
If  you  have  already  received  dietary  advice  for  a  low  FODMAP diet and have experienced
improvement and have control of your gut symptoms as a result, you will be asked to undergo
Screening, Test Phase and End of Trial visits (see below).
If you have not yet received dietary advice for a low FODMAP diet, then you will be asked to
come to the hospital or to King’s College London to be given low FODMAP dietary advice by a
dietitian. This is part of normal clinical practice and is the reason you have been referred by your
doctor. This advice is not part of the research study. You will be asked to follow the low FODMAP
diet for a minimum of two weeks whilst monitoring your gut symptoms until your symptoms are
satisfactorily controlled. If the low FODMAP diet does not improve your symptoms you will NOT
be eligible for participation in the study. In this case you will have a follow up appointment with
the dietitian and will be given advice on what to do next. If the low FODMAP diet improves your
symptoms, you will be asked to undergo Screening, Test Phase and End of Trial visits (see below).
Screening
If you decide to take part in the study, you will be screened by a researcher to check eligibility
for the study and to ensure you meet all the inclusion criteria and none of the exclusion criteria.
We will fully explain all the study procedures to you and the consent form will need to be signed
prior to starting the study. Once the consent form is signed you will  be asked to complete a
screening questionnaire with the researcher, including answering some questions about your
medical history and gut symptoms. This visit should take no longer than 30 minutes. You will
also have a sample of blood taken and will  be asked to provide stool sample, which you will
collect at home. You will be provided with equipment and full instructions on how to do this.
Starting the Test Phase
If your gut symptoms are satisfactorily controlled whilst following a strict low FODMAP diet you
will be eligible to take part in the study. At this time, you will be asked to come to the hospital
or King’s College London where you will be instructed on the Test Phase of the study. The Test
Phase  will  last  a  minimum  of  4  weeks  and  you  will  continue  to  follow  a  low  FODMAP  diet
throughout. During this time, you will be asked to take 4 different test drinks containing dietary
carbohydrates. You will take a different drink each week once a day for 3 days, followed by a 4-
day ‘wash-out’ period, when you continue the low FODMAP diet but don’t take any test drinks.
Throughout the 3 test days you will be asked to keep a record of your gut symptoms and bowel
habits, and to record when each drink was taken.
The order in which you take the drinks will be randomly assigned and you will not be told which
test drink you are taking when. They will be identifiable only by a code. You will be provided will




Throughout the study you will have telephone support with the researcher who will be able to
guide you through the study and answer any queries you have or advise in the case of any
adverse events or concerns.
End of trial
Once you have completed the Test Phase, you will be invited to a final appointment where you
will provide second blood and stool samples. Overall there should be 2-3 visits related to doing
this study.
Expenses
Reimbursements for expenses (e.g. travel, meals, child-care, compensation for loss of earnings,
etc) will not be available for this study.
What are the possible disadvantages and risks of taking part?
An ethical review of this study has been carried out. The low FODMAP diet and carbohydrate
food supplements have no known clinically adverse effects and have been well tolerated in
previous studies. You may experience some gut symptoms like those you have previously
experienced when not following the low FODMAP diet. There is no evidence that this will impact
in any way on your inflammatory bowel disease activity and/or result in a relapse. Some people
might find recording symptoms and/or collecting stool as part of the study embarrassing. You
will be provided a toilet insert in which to collect your sample which will make this process
easier. If you are concerned in any way, please contact one of the researchers for advice. Some
people find having blood taking may be uncomfortable. Every effort will be made to minimise
any pain or discomfort during this routine process. The test drinks do not contain anything
harmful; they only contain different carbohydrates at levels consumed within the normal diet
you were following before the low FODMAP diet. There is no evidence that these can affect your
inflammatory bowel disease.
What are the possible benefits of taking part?
The results of this study may help to answer scientific questions about whether specific dietary
carbohydrates cause functional gut symptoms in inflammatory bowel disease whilst in
remission. This may therefore help you and other people in the future, as a diet low in these
carbohydrates  (the  low  FODMAP  diet)  may  help  improve  these  symptoms  and  avoid
unnecessary drug treatments that may have unpleasant or adverse side effects. The results will
also help you identify which carbohydrates you may be sensitive to and are therefore best
avoided or kept to a minimum in your diet.
What happens at the end of the study?
At the end of the 4-week Test Phase of the study we will tell you what order you received the
test drinks in and will also provide you with advice on how to continue your diet. You may also
be booked in for a follow-up dietetic outpatient appointment if you wish.
What if there is a problem?
If you have a concern about any aspect of this study, you should speak to Selina Cox (contact
details  are  below).  We  would  not  expect  you  to  suffer  any  harm  or  injury  because  of  your
participation in this study. However, in the unlikely event of you suffering any adverse effects
because of participating in this study you can contact King's College London using the details
below for further advice and information and may be compensated through King’s College
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London’s ‘No Fault Compensation Scheme’. Professor Kevin Whelan, Professor of Dietetics, Tel:
020 7848 3858, Email: kevin.whelan@kcl.ac.uk.
Will my taking part be kept confidential?
Your participation in the study would be completely confidential. From the beginning of your
involvement, you will be given an identification number and only your number, NOT your name,
will label your completed questionnaires, diaries and other paperwork. Your data will be kept
completely anonymously and confidentially under the UK Data Protection Act 1998 and your
name will not appear anywhere in any publication or description of our findings. Personal data
and unidentifiable research data will be kept for 10 years on a research database and you may
be contacted in the future about follow up studies to this project or ethically approved research
studies of a similar nature.
What will happen if I don’t want to carry on with the study?
Taking part in this study is entirely voluntary and your decision will in no way affect your current
or future care within this Trust. You will  not lose any of your legal or ethical rights. You may
withdraw from the study at any time without affecting your routine clinical care and you are not
obliged to give reasons. However, if you withdraw because of a side effect please inform the
research team. You may be withdrawn from the study, if it is considered in your best interests.
If you withdraw from the study, we will destroy all your identifiable samples, but we will need
to use the data collected up to your withdrawal.
What will happen to any samples I give?
During the study we will collect stool and blood samples. The samples will have no personal
details on them, so your identity will not be recognisable. Portions of the samples may be stored
in a secure freezer for up to 10 years. Only members of the research team will have access to
them. After they have been used, or at the end of 10 years they will be destroyed.
What will happen to the results of the research study?
It is intended that the results of this study may be published in scientific or medical journals. You
will not be identified in any report or publication. When the data from the study has been
analysed you will receive a summary report of the results.
Who has reviewed the study?
This study has been checked by an independent group of people, called a Research Ethics
Committee to protect your safety, rights, well-being and dignity. This study has been reviewed
and given favourable opinion by the NRES Committee: London – Camberwell St Giles.
Who is organising and funding the research?
The study is organised and sponsored by King’s College London (Diabetes and Nutritional
Sciences Division, King’s College London) and funded by internal funding. The Chief Investigator
is Professor Kevin Whelan and the Principal Investigator is Dr Peter Irving.
If I’d like to participate, what should I do?
If you are interested in taking part or have any further questions or concerns at any time, then
please call  the contact  number or  write  to  the email  address  below.  Participation is  entirely
voluntary, and it is up to you to decide whether to take part. If you decide to take part, you will
be given this information sheet to keep and will be asked to sign a consent form. Remember, if
you do decide to take part you are still free to withdraw at any time and without giving a reason.
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8.2 Re-challenge trial consent form
CONSENT FORM FOR RESEARCH STUDY
Study Ethics Number: 13/LO/1878
Patient Identification Number for this trial:
Title of Project: FODMAPs as Dietary Triggers of Abdominal Symptoms in Patients with
Inflammatory Bowel Disease
Please initial to confirm
I confirm that I have read and understand the information sheet
dated ......................... for the above study.
I have had the opportunity to consider the information, ask questions and have
had these answered satisfactorily.
I understand that my participation is voluntary and that I am free to withdraw at
any time, without giving any reason, without my medical care or legal rights being
affected.
I understand that relevant sections of any of my medical notes and data collected
during the study may be looked at by responsible individuals from King’s College
London, from regulatory authorities or from the NHS Trust, where it is relevant to
my taking part in this research. I give permission for these individuals to have
access to my records.
I agree to the recording and storage of personal and unidentifiable research data
for the purposes explained to me. I understand that research information will be
anonymous. It will be treated as strictly confidential and handled in accordance
with the provisions of the UK Data Protection Act 1998.
I agree to be contacted in the future by King’s College London researchers who
would like to invite me to participate in follow up studies to this project, or in
future ethically approved studies of a similar nature
(please circle one): YES NO
I agree to the collection and storage of blood and stool samples for this study.
I agree to my GP being informed of my participation in the study.
I agree to take part in the above research study.
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8.3 Re-challenge trial sample diary day
FUNCTIONAL GUT SYMPTOM & STOOL DIARY: Test Phase
1. Every time you open your bowels today please indicate the type in the in the box(es)
 below:
BOWEL MOVEMENT 1
Please indicate its consistency using the Bristol Stool Chart at the
end of this questionnaire. Please enter a value from 1 to 7. Type
BOWEL MOVEMENT 2
Please indicate its consistency using the Bristol Stool Chart at the
end of this questionnaire. Please enter a value from 1 to 7 Type
BOWEL MOVEMENT 3
Please indicate its consistency using the Bristol Stool Chart at the
end of this questionnaire. Please enter a value from 1 to 7 Type
BOWEL MOVEMENT 4
Please indicate its consistency using the Bristol Stool Chart at the
end of this questionnaire. Please enter a value from 1 to 7. Type
BOWEL MOVEMENT 5
Please indicate its consistency using the Bristol Stool Chart at the
end of this questionnaire. Please enter a value from 1 to 7. Type
BOWEL MOVEMENT 6
Please indicate its consistency using the Bristol Stool Chart at the
end of this questionnaire. Please enter a value from 1 to 7. Type
If you open your bowels more than three times today, please add details of
subsequent stools at the end of this questionnaire.
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2. Today, do you currently have satisfactory relief of your gut symptoms? (Circle one)
Yes No
3. At the end of each day, please rate your symptoms by placing a tick in the box
























A. Abdominal pain / discomfort Absent  Mild  Moderate  Severe
(any kind of pain / discomfort in your abdomen)
B. Abdominal bloating /
distension Absent Mild Moderate Severe
(swelling in your stomach or belly)
C. Increased flatulence / passing
wind Absent Mild Moderate Severe
(release of gas from your bottom)
D. Belching or burping Absent Mild Moderate Severe
(bringing up gas through your mouth)
E. Stomach / abdominal gurgling Absent Mild Moderate Severe
(vibrations or noise in your stomach or belly)
F. Urgency to open bowels Absent  Mild  Moderate  Severe
(urgent need to open your bowels)
G. Incomplete evacuation Absent  Mild  Moderate  Severe
(feeling of inability to pass all stool)
H. Nausea Absent  Mild  Moderate  Severe
(feeling sick, but without vomiting)
I. Heartburn Absent  Mild  Moderate  Severe
(burning / discomfort behind your breastbone)
J. Acid regurgitation Absent  Mild  Moderate  Severe
(taste of sour fluid in your mouth)
K. Tiredness / lethargy Absent  Mild  Moderate  Severe





8.4 Re-challenge trial compliance diary
Intervention Test Phase No. Day: Date:
DD/MM/YY
Please take your test drink as instructed in the MORNING and complete the
following questions:
4. Please enter the Test Drink Code in
the box (this code can be found on
the side of the container provided)
5. Please indicate what time you took
your test drink (hr: min)
6. Please indicate whether you took
your drink with breakfast, a mid-
morning snack or without food
(Please circle one)
Breakfast Snack No Food
7. How much of the test drink did you
consume? (Please circle one)
All More than half
but not all
Half of it Less than half None
Please complete the following questions at the END of each Test Drink Day:
8. How much of the time today did you follow the low FODMAP diet? (Please circle
one)








9. Have you taken any new medications today or
had any changes in dose?
If yes, please provide details in the box below:
Please include details of any new medications or any medications for which you have had a
change in dose:
Please keep all of your test drink containers in the bag provided and bring them with






8.5 RCT participant information sheet
REC Reference Number: 15/LO/1684
Chief Investigator: Professor Kevin Whelan
Principal Investigator: Dr James Lindsay/Dr Peter Irving
Co-Investigator: Selina Cox
PARTICIPANT INFORMATION SHEET
(YOU WILL BE GIVEN A COPY OF THIS INFORMATION SHEET)
Dietary Interventions for Functional Gut Symptoms in Inflammatory Bowel Disease
We would like to invite you to participate in this research project. You should only participate if
you want to; choosing not to take part will not disadvantage you in any way. Before you decide
whether you want to take part, it is important for you to understand why the research is being
done and what your participation will involve. Please take time to read the following
information carefully and discuss it with others if you wish.
We  are  providing  you  with  the  following  information  before  you  agree  to  take  part,  which
explains the purpose of this research and what it involves. Please ask any questions you have
about the information given and we will do our best to explain and provide any further details
you may need.
What is the purpose of the study?
This research study aims to help patients, doctors and dietitians at Guy’s and St Thomas’ NHS
Foundation Trust and Barts Health NHS Trust to learn about the effect of certain foods and drinks
on gut symptoms, gut bacteria and inflammation in patients with inactive inflammatory bowel
disease.
Functional gut symptoms are those experienced during times of inactive disease that are not
caused by inflammation and may include abdominal discomfort, abdominal bloating, diarrhoea
and wind.
This study is being conducted as part of a PhD project in collaboration with Guy’s and St Thomas’
NHS Foundation Trust/Bart’s Health NHS Trust and King’s College London. We believe the results
of this study will be important for the future treatment and dietary management of functional
gut symptoms in patients with inflammatory bowel disease.
Who are we recruiting?
We are looking for people with inflammatory bowel disease (either Crohn’s disease or ulcerative
colitis), thought to be inactive and who are attending an outpatient clinic at either Guy’s
Hospital,  St  Thomas’  Hospital  or  The  Royal  London  Hospital  as  part  of  their  care.  Eligible
participants will have functional gut symptoms, as described above. People with active disease
will be excluded. Also, people who have taken certain medications recently or who have had
medication dose changes,  those who have had recent  or  extensive gut  surgery  or  who have
other psychiatric or chronic diseases will not be eligible. Pregnant and breastfeeding women will
also be excluded.
Do I have to take part?
No. Your participation in this study is voluntary and it is entirely up to you whether you take
part. Even if you do decide to take part, you can change your mind at any time and withdraw
from the study without giving a reason. If you decide you no longer wish to take part, please
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inform Selina Cox (contact details below). Any decision not to be involved in the study at any
time will not affect the standard of care you receive now or in the future. If you agree to take
part, you will be asked whether you are happy to be contacted about participation in future
studies. Your participation in this study will not be affected should you choose not to be re-
contacted.
What will happen to me if I do take part?
This study involves following an exclusion diet, and there are two possible diets you may be
asked to follow. One of the diets will reduce specific carbohydrates in the diet, while the other
diet is a ‘placebo’ diet. Both diets require you to make changes to the types of food you eat. For
example, depending upon which diet you are allocated to you will be asked to change your
intake of bread, pasta, rice, potatoes, apples, oranges, berries, broccoli and cucumber. Advice
will  be  given  on  how  to  make  these  changes  to  your  current  diet  in  line  with  your  food
likes/dislikes and budget.
Screening
If you express interest in taking part in the study, you will be screened by a researcher to check
whether you are eligible to take part and to ensure you meet all the inclusion criteria and none
of the exclusion criteria. We will fully explain all the study procedures to you and the consent
form will need to be signed prior to starting the study. Once the consent form is signed you will
be asked to provide a stool sample and a sample of blood (equivalent to around 1 teaspoon) will
be taken. You will be provided with equipment and full instructions on how to collect the stool
sample. These samples will be taken to check whether there may be any inflammation in your
gut. If  the levels are low enough then you may be eligible for the study.  This screening visit
should take no longer than 30 minutes.
If you meet all the inclusion and none of the exclusion criteria, you will be given a food and gut
symptom diary to complete for the next 7 days. On the final day of this week, the lead researcher
will contact you by telephone to discuss your symptom diaries and determine whether your level
of symptoms makes you eligible for the study.
Starting the Diet Phase: Baseline visit
If your gut symptoms and stool and blood inflammatory markers meet the criteria for the trial,
you will be eligible to take part. At this time, you will be asked to come for the baseline visit at
the hospital or at King’s College London (whichever you prefer).
At this visit, the following will occur:
The lead researcher will review your food and symptom diaries from the baseline week
Your weight and height will be checked
Your medical and medication history and smoking status will be recorded
You will complete two questionnaires about your quality of life, two questionnaires regarding
your inflammatory bowel disease, and one questionnaire about your gut symptoms
You will be asked to provide a stool sample. You will be provided with full instructions and
equipment to do this
A blood sample will be taken (equivalent to around 2 teaspoons)




This visit should take no longer than one hour.
Diets
At the baseline visit you will be randomly selected to follow one of two different diets:
Intervention diet
Placebo diet
You will not know which diet you have been asked to follow. One diet might help reduce gut
symptoms, and the other diet is a ‘placebo diet’. The placebo diet is used as a comparison and
is designed to appear to be like the intervention diet. Both diets will  require you to alter the
types of food you eat – however both diets will allow you to eat a wide range of foods and will
allow you to eat the right amount of nutrients. A specialist dietitian who is part of the research
team will provide the dietary advice and give you detailed written information about the diet
you need to follow. You will be asked to continue the diet for 4 weeks. During this time, you will
be telephoned weekly by the lead researcher to guide you through the study and answer any
queries you have or advise in the case of adverse events or concerns. You will  be asked how
much of the time you have followed the diet.
In the final week of the diet, you will complete food and symptom diaries (the same as those
completed in the screening week).
End of trial: follow-up visit
You  will  return  to  the  hospital  or  King’s  College  London  (whichever  you  prefer)  as  soon  as
possible following completion of the 4-week diet to meet with the lead researcher for the follow-
up visit.
At this stage, the following will occur:
The lead researcher will review your food, symptom and stool diary from week 4
Your weight will be checked
You will provide a fresh stool sample. You will be provided with equipment and full instructions
on how to do this
You will have a blood sample taken (equivalent to around 3 teaspoons)
You will complete two quality of life questionnaires, two questionnaires regarding your disease
activity, and one questionnaire about your gut symptoms.
This visit should take no longer than 40 minutes.
Expenses
Reimbursements for expenses will not be available for this study.
What are the possible disadvantages and risks of taking part?
An ethical review of this study has been carried out. The intervention diet in this study may lead
to changes in your gut bacteria, and the aim of this study will answer whether this does happen.
However, many patients with inflammatory bowel disease have followed this intervention diet
previously and no long-term problems have been reported. The placebo diet has no known
negative health effects. There is no evidence that the intervention diet or the placebo diet will
affect your inflammatory bowel disease or result in a relapse. Some people might find recording
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symptoms and/or collecting stool embarrassing. You will be provided with equipment which will
make this process easier. If you are concerned in any way, please contact one of the researchers
for advice. Some people find having blood taken may be uncomfortable. Every effort will be
made to minimise any pain or discomfort during this routine process.
What are the possible benefits of taking part?
The results of this study may help to answer scientific questions about whether specific foods
worsen functional gut symptoms in patients with inactive inflammatory bowel disease, and
whether there is any effect on the gut bacteria. This may therefore help you and other people
in the future, as this type of diet may help improve these symptoms and avoid unnecessary drug
treatments that may have unpleasant or adverse side effects.
What happens at the end of the study?
At the end of the 4-week diet we will tell you which diet you were following. We will also provide
you with advice on how to continue your diet, and if you were in the placebo diet group, you
will be offered the intervention diet advice. You may also be booked in for a follow-up dietetic
outpatient appointment if you wish.
What if there is a problem?
If you have a concern about any aspect of this study you should ask to speak to the researchers
who  will  do  their  best  to  answer  your  questions  (Selina Cox 0207 848 4552,
selina.cox@kcl.ac.uk). Your inflammatory bowel disease will continue to be monitored by your
gastroenterologist.
If you remain unhappy and wish to complain formally, you can do this through the Guy’s and St
Thomas’ Patients Advice and Liaison Service (PALS) on 0207 188 8801, pals@gstt.nhs.uk. The
PALS team are based in the main entrance on the ground floor at St Thomas’ Hospital and on
the ground floor at Guy’s Hospital in the Tower Wing.
In the event that something does go wrong, and you are harmed during the research then you
may have grounds for legal action for compensation against King’s College London but you may
have to pay your legal costs. King’s College London maintains adequate insurance to cover any
liabilities arising from the study.
Will my taking part be kept confidential?
Your participation in the study would be completely confidential. From the beginning of your
involvement, you will be given an identification number and only your number, NOT your name,
will label your completed questionnaires, diaries and other paperwork. Your data will be kept
completely anonymously and confidentially under the UK Data Protection Act 1998 and your
name will not appear anywhere in any publication or description of our findings. Personal data
and unidentifiable research data will be kept for 10 years on a research database and when you
consent to this study, you will be asked if we may contact you in the future about follow up
studies to this project or ethically approved research studies of a similar nature.
What will happen if I don’t want to carry on with the study?
Taking part in this study is entirely voluntary and your decision will in no way affect your current
or future care within this Trust. You will  not lose any of your legal or ethical rights. You may
withdraw from the study at any time without affecting your routine clinical care and you are not
obliged to give reasons. However, if you withdraw because of a side effect please inform the
research team. You may be withdrawn from the study, if it is considered in your best interests.
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If you withdraw from the study, we will destroy all your identifiable samples, but we will need
to use the data collected up to your withdrawal.
What will happen to any samples I give?
During the study we will collect stool (to measure bacteria, by-products and other markers) and
blood samples (to measure inflammation markers). The samples will have no personal details
on them, so your identity will not be recognisable; you will be identifiable only by a code, which
only the researchers will have access to. Only members of the research team will have access to
your samples. The stool samples and blood samples will be analysed by researchers at King’s
College London and their academic partners including Queen Mary University of London
(London) and Institut de la Recherche Agronomique (INRA) (Paris). Portions of the samples may
be stored in a secure freezer for up to 10 years, as they may be valuable for future research. If
we wish to use these remaining samples in future research studies, we will contact you to ask
for your consent to do so. After they have been used, or at the end of 10 years your samples will
be destroyed.
What will happen to the results of the research study?
It is intended that the results of this study may be published in scientific or medical journals. You
will not be identified in any report or publication. When the data from the study has been
analysed you will receive a summary report of the results.
Who has reviewed the study?
This study has been checked by an independent group of people, called a Research Ethics
Committee to protect your safety, rights, well-being and dignity. This study has been reviewed
and given favourable opinion by the NRES Committee: London – Dulwich.
Who is organising and funding the research?
The study is organised and sponsored by King’s College London (Diabetes and Nutritional
Sciences Division, King’s College London). The study is funded by internal funding as well as by
the Kenneth Rainin Foundation (an inflammatory bowel disease charity). The Chief Investigator
is  Professor  Kevin  Whelan  and  the  Principal  Investigators  are  Dr  Peter  Irving  (Guy’s  and  St
Thomas’ NHS Trust) and Dr James Lindsay (Barts Health NHS Trust).
If I’d like to participate, what should I do?
If you are interested in taking part or have any further questions or concerns at any time, then
please call  the contact  number or  write  to  the email  address  below.  Participation is  entirely
voluntary, and it is up to you to decide whether to take part. If you decide to take part, you will
be given this information sheet to keep and will be asked to sign a consent form. Remember, if
you do decide to take part you are still free to withdraw at any time and without giving a reason.
You may also withdraw any data or information you have already provided up until it is
transcribed for use in the final report.
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8.6 RCT consent form
Title of project: Dietary Interventions for Functional Gut Symptoms in Inflammatory Bowel
Disease
1.
I confirm that I have read the information sheet dated....................
(version............) for the above study. I have had the opportunity to
consider the information, ask questions and have had these answered
satisfactorily
2
I consent to the following:
· Three visits at King’s College London, Guy’s or St Thomas’ Hospitals,
or The Royal London Hospital
· Taking part in a four week dietary intervention
· Complete questionnaires and diaries as described in the information
sheet
3.
I understand that my participation is voluntary and that I am free to
withdraw at any time without giving any reason, without my medical
care or legal rights being affected.
4.
I agree that my stool samples can be used in the above study and I
have been made aware of how any surplus material will be stored,
used and disposed of.
5.
I agree that my blood samples can be used in the above study and I
have been made aware of how any surplus material will be stored,
used and disposed of.
6.
I understand that my samples may be sent to academic partners
outside the United Kingdom for analysis, as outlined in the patient
information sheet, but my data will be protected at all times.
7.
I understand that any blood and stool samples that are surplus to this
study will be stored securely in an anonymised form, identifiable only
by a code that only the researchers will have access to.
8.
I agree that I can be contacted following completion of the study to be
asked to give consent for my blood and stool samples to be used in
future research studies.
9.
I consent to the processing of my personal information for the
purposes explained to me. I understand that such information will be
handled in accordance with the terms of the Data Protection Act 1998.
10.
I understand that relevant sections of any of my medical notes and
data collected during the study may be looked at by responsible
individuals from regulatory authorities or from Guy’s and St Thomas’
NHS Foundation Trust or Barts Health NHS Trust, where it is relevant
to my taking part in this research. I give permission for these
individuals to have access to my records.
11. I agree to my GP being informed of my participation in the study.




IBS Severity Scoring System (IBS-SSS)
INSTRUCTIONS
This form is designed to enable us to record and monitor the severity of your IBS. It is to be
expected that your symptoms might vary over time, so please try and answer the questions
based on how you currently feel (i.e. over the last 10 days).
1. For questions where a number of different responses are possible, please circle the
response appropriate to you
2. Some questions will require you to write an appropriate response
3. Some questions require you to put a cross on a line which enables us to judge the
severity of a particular problem.
For example:
How severe was your pain?
Please put a cross (X) anywhere on the line between 0-100% in order to indicate as
accurately as possible the severity of your symptom. This example shows a severity of
appropriately 90%
IBS-SSS
1. a) Did you suffer from abdominal (tummy) pain in the last 10 days (please
circle)?






















c) Please enter the number of days that you had pain in the last 10 days.
Number of days with pain
2. a) Did you suffer from abdominal distension (bloated, swollen or tight
tummy) in the last 10 days (please circle)?
Women please ignore any distension associated with your periods
















4. Please indicate with a cross on the line below how much your Irritable Bowel
















UK Inflammatory Bowel Disease Questionnaire (UK IBDQ)
1. On how many days over the last two weeks have you had loose runny bowel
movements?
a. None (4)
b. On one or two days only (3)
c. On three to seven days (2)
d. On eight to fourteen days (i.e. more than every other day) (1)
2. On how many days over the last two weeks have you felt tired?
a. None (4)
b. On one or two days only (3)
c. On three to seven days (2)
d. On eight to fourteen days (i.e. more than every other day) (1)
3. In the last two weeks, have you felt frustrated?
a. No, not at all (4)
b. Yes, some of the time (3)
c. Yes, most of the time (2)
d. Yes, all the time (1)
4. In the last two weeks, has your bowel condition prevented you from carrying out
your work or other normal activities?
a. No, not at all (4)
b. Yes, for one or two days (3)
c. Yes, for three to seven days (2)
d. Yes, for eight to fourteen days (i.e. more than every other day) (1)
5. On how many days over the last two weeks have you opened your bowel more
than three times a day?
a. None (4)
b. On one or two days only (3)
c. On three to seven days (2)
d. On eight to fourteen days (i.e. more than every other day) (1)
6. On how many days over the last two weeks have you felt full of energy?
a. None (1)
b. On one to two days only (2)
c. On three to seven days (3)
d. On eight to fourteen days (i.e. more than every other day) (4)
7. In the last two weeks have you been worried about being admitted to hospital
because of your bowel problem?
a. No, not at all (4)
b. Yes, some of the time (3)
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c. Yes, most of the time (2)
d. Yes, all the time (1)
8. In the last two weeks did your bowel condition prevent you from going out
socially?
a. No, not at all (4)
b. Yes, some of the time (3)
c. Yes, most of the time (2)
d. Yes, all the time (1)
e. Does not apply to me
9. On how many days over the last two weeks have your bowels opened accidentally?
a. None (4)
b. On one to two days only (3)
c. On three to seven days (2)
d. On eight to fourteen days (i.e. more than every other day) (1)
10. On how many days over the last two weeks have you felt generally unwell?
a. None (4)
b. On one to two days only (3)
c. On three to seven days (2)
d. On eight to fourteen days (i.e. more than every other day) (1)
11. In the last two weeks have you felt the need to keep close to a toilet?
a. No, not at all (4)
b. Yes, some of the time (3)
c. Yes, most of the time (2)
d. Yes, all the time (1)
12. In the last two weeks, has your bowel condition affected your leisure or sports
activities?
a. No, not at all (4)
b. Yes, some of the time (3)
c. Yes, most of the time (2)
d. Yes, all the time (1)
e. Does not apply to me
13. On how many days over the last two weeks have you felt pain in your abdomen?
a. None (4)
b. On one to two days only (3)
c. On three to seven days (2)
d. On eight to fourteen days (i.e. more than every other day) (1)
14. On how many nights over the last two weeks have you been unable to sleep well




b. On one to two nights only (3)
c. On three to seven nights (2)
d. On eight to fourteen nights (i.e. more than every other night) (1)
15. In the last two weeks have you felt depressed?
a. No, not at all (4)
b. Yes, some of the time (3)
c. Yes, most of the time (2)
d. Yes, all the time (1)
16. In the last two weeks have you had to avoid attending events where there was no
toilet close at hand?
a. No, not at all (4)
b. Yes, some of the time (3)
c. Yes, most of the time (2)
d. Yes, all the time (1)
17. On how many days over the last two weeks have you had a problem with large
amounts of wind?
a. None (4)
b. On one to two days only (3)
c. On three to seven days (2)
d. On eight to fourteen days (i.e. more than every other day) (1)
18. On how many days over the last two weeks have you felt off your food?
a. None (4)
b. On one to two days only (3)
c. On three to seven days (2)
d. On eight to fourteen days (i.e. more than every other day) (1)
19. Many patients with bowel problems have worries about their illness. How often
during the last two weeks have you felt worried?
a. No, not at all (4)
b. Yes, some of the time (3)
c. Yes, most of the time (2)
d. Yes, all the time (1)
20. On how many days over the last two weeks has your abdomen felt bloated?
a. None (4)
b. On one to two days only (3)
c. On three to seven days (2)
d. On eight to fourteen days (i.e. more than every other day) (1)
21. In the last two weeks have you felt relaxed?
a. No, not at all (1)
b. Yes, some of the time (2)
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c. Yes, most of the time (3)
d. Yes, all the time (4)
22. On how many days over the last two weeks have you noticed blood with your
bowel movements?
a. None (4)
b. On one to two days only (3)
c. On three to seven days (2)
d. On eight to fourteen days (i.e. more than every other day) (1)
23. In the last two weeks have you been embarrassed by your bowel problem?
a. No, not at all (4)
b. Yes, some of the time (3)
c. Yes, most of the time (2)
d. Yes, all the time (1)
24. On how many days over the last two weeks have you wanted to go back to the
toilet immediately after you thought you had emptied your bowels?
a. None (4)
b. On one to two days only (3)
c. On three to seven days (2)
d. On eight to fourteen days (i.e. more than every other day) (1)
25. In the last two weeks have you felt upset?
a. No, not at all (4)
b. Yes, some of the time (3)
c. Yes, most of the time (2)
d. Yes, all the time (1)
26. On how many days over the last two weeks have you had to rush to the toilet?
a. None (4)
b. On one to two days only (3)
c. On three to seven days (2)
d. On eight to fourteen days (i.e. more than every other day) (1)
27. In the last two weeks have you felt angry because of your bowel problem?
a. No, not at all (4)
b. Yes, some of the time (3)
c. Yes, most of the time (2)
d. Yes, all the time (1)
28. In the last two weeks, has your sex life been affected by your bowel problem?
a. No, not at all (4)
b. Yes, some of the time (3)
c. Yes, most of the time (2)
d. Yes, all the time (1)
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e. Does not apply to me
29. On how many days over the last two weeks have you felt sick?
a. None (4)
b. On one to two days only (3)
c. On three to seven days (2)
d. On eight to fourteen days (i.e. more than every other day) (1)
30. In the last two weeks have you felt irritable?
a. No, not at all (4)
b. Yes, some of the time (3)
c. Yes, most of the time (2)
d. Yes, all the time (1)
31. In the last two weeks, have you felt lack of sympathy from others?
a. No, not at all (4)
b. Yes, some of the time (3)
c. Yes, most of the time (2)
d. Yes, all the time (1)
32. In the last two weeks, have you felt happy?
a. No, not at all (1)
b. Yes, some of the time (2)
c. Yes, most of the time (3)
d. Yes, all of the time (4)
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8.9 IBD control questionnaire
Inflammatory Bowel Disease Control Questionnaire (IBD-Control)
1. Do you believe that:
a) Your IBD has been well controlled in the
past two weeks?
Yes (2)    No (0)   Not sure (1)
b) Your current treatment is useful in
controlling your IBD
Yes (2)    No (0)   Not sure (1)
2. Over the past two weeks, have your
bowel symptoms been getting worse,
getting better or not changed?
Better (2)    No change (1)
Worse (0)
3. In the past 2 weeks, did you:
a) Miss any planned activities because of
IBD?
(e.g. attending school/college, going to
work or a social event)
Yes (0)    No (2)   Not sure (1)
b) Wake up at night because of symptoms
of IBD?
Yes (0)    No (2)   Not sure (1)
c) Suffer from significant pain or
discomfort?
Yes (0)    No (2)   Not sure (1)
d) Often feel lacking in energy (fatigued)? Yes (0)    No (2)   Not sure (1)
e) Feel anxious or depressed because of
your IBD?
Yes (0)    No (2)   Not sure (1)
f) Think you need a change to your
treatment?
Yes (0)    No (2)   Not sure (1)
4. At your next clinic visit, would you like
to discuss:
a) Alternative types of drug for controlling
IBD
Yes (0)    No (2)   Not sure (1)
b) Ways to adjust your own treatment Yes (0)    No (2)   Not sure (1)
c) Side effects or difficulties with using your
medicines
Yes (0)    No (2)   Not sure (1)
d) Symptoms that have developed since
your last visit
Yes (0)    No (2)   Not sure (1)
5. How would you rate the OVERALL control of your IBD in the past two weeks?









8.10 Harvey-Bradshaw Index and partial Mayo score
The Harvey-Bradshaw Index
Questions (Please check one box per number except for number 5):
(1) General well-being (yesterday)
 Very well = 0
 Slightly below par = 1
 Poor = 2
 Very poor = 3
 Terrible = 4
(2) Abdominal pain (yesterday)
 None = 0
 Mild = 1
 Moderate = 2
 Severe = 3
(3) Number of liquid or soft stools per day (yesterday) =
_____________________________
(4) Abdominal mass
 None = 0
 Dubious = 1
 Definite = 2
 Definite and tender = 3










Harvey Bradshaw Index Score = (Remission = <5)
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The Simple Clinical Colitis Activity Index (SCCAI)
Questions (Please check the box of the answer that best fits your symptoms over the past
week):
(1) Over the past week, what is your average number of bowel movements during the
day (not including night time)?
 0-3 (score 0)
 4-6 (score 1)
 7-9 (score 2)
 >9 (score 3)
(2) Over the past week, what is your average number of bowel movements during the
night?
 0 (score 0)
 1-3 (score 1)
 >3 (score 2)
(3) Over the past week, what has been your urgency of defecation?
 No rush (score 0)
 Hurry (score 1)
 Immediately (score 2)
 Incontinence – stool leaked out before you could get to a toilet (score 3)
(4) Over the past week, what has been the amount and frequency of blood in your
stool?
 None (score 0)
 Small traces (score 1)
 Occasionally obviously bloody (score 2)
 Usually obviously bloody (score 3)
(5) General well being
 Very well (score 0)
 Slightly below par (score 1)
 Poor (score 2)
 Very poor (score 3)
 Terrible (score 4)
(6) During the past week, have you had any of the following?
 Pyoderma gangrenosum (oozing ulcers, usually on the leg)
 Erythema nodosum (red, swollen bumps, on the shin
 Uveitis (red, painful eyes)
 Arthritis (joint pain)
 None of the above (Check any that apply; score 1 per item)
Simple Clinical Colitis Activity Score  = (Remission = <5)
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8.11 Food- related quality of life questionnaire
In the past TWO WEEKS
1
I have regretted eating and drinking















My enjoyment of a particular food or
drink has been affected by the















My IBD has meant that I have had to















I have not been able to predict how
long it will take for my body to respond
to something I have had to eat or drink



























My IBD has meant that I have been
nervous that if I eat something I will





















































I have struggled to eat the way that is
best for my IBD because of other














I have been frustrated about not















I have had to concentrate on what I




























I have felt the way that I eat and drink
























































My IBD has prevented me from getting




























I have felt that I have to be careful






















































I have been happy to eat and drink









































My IBD has meant I have had to make




























My IBD has meant that I have had to
work hard to fit my eating habits in













Hughes LD, King L, Morgan M, Ayis S, Direkze N, Lomer MC, Lindsay JO, Whelan K. Food-related
quality of life in inflammatory bowel disease: development and validation of a questionnaire. J
Crohn’s Colitis. 2016; 10: 194-201.
Chapter 8: Appendices
317
8.12 Diet acceptability questionnaire
Please circle the answer most applicable to you.
While following the research diet:










































































































10. Did any benefits of being involved in this study outweigh the burden of being on
this diet? (Please circle)
Yes
 No
11. Overall did you have to make many changes to your diet? (Please circle)
Yes
No
12. Was there a food or drink that you missed a lot? (Please circle)
Yes
No
13. If yes, what food or drink was it?



































































































8.13 Example pages of diet resources
8.13.1  Low FODMAP diet booklet
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8.13.2 Sham diet booklet
Chapter 8: Appendices
321























8.17 Case-control study participant information sheet
Case-control study participant information sheet
IRAS ID: 203156
REC Reference Number: 16/LO/0976
Chief Investigator: Dr Majella O’Keeffe
Principal Investigator: Prof Kevin Whelan/Selina Cox
PARTICIPANT INFORMATION SHEET
(YOU WILL BE GIVEN A COPY OF THIS INFORMATION SHEET)
Dietary Intake in patients with Inflammatory Bowel Disease
We would like to invite you to participate in this research project. You should only participate if
you want to; choosing not to take part will not disadvantage you in any way. Before you decide
whether you want to take part, it is important for you to understand why the research is being
done and what your participation will involve. Please take time to read the following information
carefully and discuss it with others if you wish.
We  are  providing  you  with  the  following  information  before  you  agree  to  take  part,  which
explains the purpose of this research and what it involves. Please ask any questions you have
about the information given and we will do our best to explain and provide any further details
you may need.
What is the purpose of the study?
This research study aims to help patients, doctors and dietitians at Guy’s and St Thomas’ NHS
Foundation Trust and Barts Health NHS Trust to learn about the dietary habits of patients with
inflammatory bowel disease compared to those without.
One of the aims of this study is to investigate the intake of a certain type of dietary carbohydrate
in patients with inflammatory bowel disease, as previous studies have shown that patients with
active inflammatory bowel disease may eat less of them. This may be important as these
carbohydrates may affect gut symptoms and may also influence gut bacteria which are
important in inflammatory bowel disease.
This study is being conducted as part of a PhD project in collaboration with Guy’s and St Thomas’
NHS Foundation Trust and Bart’s Health NHS Trust and King’s College London. We believe the
results of this study will be important for the future treatment and dietary management of
patients with inflammatory bowel disease.
Who are we recruiting?
We are looking for people with active or inactive inflammatory bowel disease (either Crohn’s
disease or ulcerative colitis) who are attending an outpatient clinic at either Guy’s Hospital, St
Thomas’ Hospital or The Royal London Hospital as part of their care. People who have had
medication dose changes,  those who have had recent  or  extensive gut  surgery  or  who have




We are also looking for people without inflammatory bowel disease, other gut conditions or
serious conditions to take part in this study. This will allow us to compare the dietary intake of
patients with inflammatory bowel disease to those without.
Do I have to take part?
No. Your participation in this study is voluntary and it is entirely up to you whether you take
part. Even if you do decide to take part, you can change your mind at any time and withdraw
from the study without giving a reason. If you decide you no longer wish to take part, please
inform Selina Cox (contact details below). Any decision not to be involved in the study at any
time will not affect the standard of care you receive now or in the future.
What will happen to me if I do take part?
This study involves completing a 7-day food diary which may be provided by the researcher on
the day of your normal clinic appointment, if you wish to take part. After you have completed
the diary, you will be asked to return it to the researcher at the hospital clinic or King’s College
London (Waterloo), or you will be provided with a stamped envelope to return the diary via post
if this is more convenient.
Screening
If you express interest in taking part in the study, you will be screened by a researcher to check
whether you are eligible to take part and to ensure you meet all the inclusion criteria and none
of the exclusion criteria. We will fully explain all the study procedures to you and you will be
given at least 24 hours to consider the requirements of the study prior to signing the consent
form, although this will need to be signed prior to starting the study. If you would prefer to sign
the consent form and collect your food diary on the day of your clinic appointment (e.g. if it is
more convenient) this will be possible.
Questionnaire and food diary
Once the consent form is signed you will be asked to complete a questionnaire regarding food-
related quality of life and a questionnaire about your dietary habits. The food diary will then be
explained in detail, and you will be asked to complete for the next 7-days. In this diary, you will
be asked to record everything you eat and drink with estimated portion sizes. The diary will
begin with instructions of how to complete it along with some portion size guides.
Follow-up visit
You  may  meet  with  the  lead  researcher  at  the  hospital  or  King’s  College  London  following
completion of the 7-day food diary, to collect the diary and check that it is complete. This visit
should take no longer than 15 minutes. Alternatively, you may use the stamped envelope
provided to post the completed diary to the researcher, who may contact you via telephone to
clarify any incomplete information in the diary.
Expenses
Reimbursements for expenses will not be available for this study.
What are the possible disadvantages and risks of taking part?
Completing the food diary may be burdensome. However, instructions and portion size guides
are provided to make this process easier.
What are the possible benefits of taking part?
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There are no immediate benefits to participants for taking part in this study. However, the
results of this study may help to answer scientific questions about dietary intake in patients with
inactive inflammatory bowel disease. This may therefore help you and other people in the
future, as it may aid in the development of dietary interventions in inflammatory bowel disease.
What if there is a problem?
If you have a concern about any aspect of this study you should ask to speak to the researchers
who  will  do  their  best  to  answer  your  questions  (Selina  Cox  0207  848  4552,
selina.cox@kcl.ac.uk). Your inflammatory bowel disease will continue to be monitored by your
gastroenterologist.
If you remain unhappy and wish to complain formally, you can do this through the Guy’s and St
Thomas’ Patients Advice and Liaison Service (PALS) on 0207 188 8801, pals@gstt.nhs.uk. The
PALS team are based in the main entrance on the ground floor at St Thomas’ Hospital and on
the ground floor at Guy’s Hospital in the Tower Wing. At the Royal London Hospital, the PALS
service is located on the 2nd floor Central Tower, near core lift 5 in the main building and can be
contacted on 020 3594 2040, pals@bartshealth.nhs.uk.
In the event that something does go wrong, and you are harmed during the research then you
may have grounds for legal action for compensation against King’s College London but you may
have to pay your legal costs. King’s College London maintains adequate insurance to cover any
liabilities arising from the study.
Will my taking part be kept confidential?
Your participation in the study would be completely confidential. From the beginning of your
involvement, you will be given an identification number and only your number, NOT your name,
will label your completed questionnaires, diaries and other paperwork. Your data will be kept
completely anonymously and confidentially under the UK Data Protection Act 1998 and your
name will not appear anywhere in any publication or description of our findings. Personal data
and unidentifiable research data will be kept for 10 years on a research database.
What will happen if I don’t want to carry on with the study?
Taking part in this study is entirely voluntary and your decision will in no way affect your current
or future care within this Trust. You will  not lose any of your legal or ethical rights. You may
withdraw from the study at any time without affecting your routine clinical care and you are not
obliged to give reasons. If you withdraw from the study, we will need to use the data collected
up to your withdrawal.
What will happen to the results of the research study?
It is intended that the results of this study may be published in scientific or medical journals. You
will not be identified in any report or publication. When the data from the study has been
analysed you will receive a summary report of the results.
Who has reviewed the study?
This study has been checked by an independent group of people, called a Research Ethics
Committee to protect your safety, rights, well-being and dignity. This study has been reviewed
and given favourable opinion by the NRES Committee: London City & East.
Who is organising and funding the research?
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The study is organised and sponsored by King’s College London (Diabetes and Nutritional
Sciences Division, King’s College London). The study is funded by internal funding. The Chief
Investigator is Dr Majella O’Keeffe and the Principal Investigators are Prof Kevin Whelan and
Selina Cox (King’s College London).
If I’d like to participate, what should I do?
If you are interested in taking part or have any further questions or concerns at any time, then
please call the contact number or write to the email address below. If you decide to take part,
you  will  be  given  this  information  sheet  to  keep  and  will  be  asked  to  sign  a  consent  form.
Remember, if you do decide to take part you are still free to withdraw at any time and without
giving a reason. You may also withdraw any data or information you have already provided up
until it is transcribed for use in the final report.
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8.18 Case-control study consent form
Participant ID: Please initial the boxes
1.
I confirm that I have read the information sheet dated....................
(version............) for the above study. I have had the opportunity to consider
the information, ask questions and have had these answered satisfactorily
2
I consent to the following:
· Complete questionnaires as described in the information sheet
· Complete a 7-day food diary as described in the information sheet
· Return the diary to the researcher in person or via post
3.
I understand that my participation is voluntary and that I am free to withdraw
at any time without giving any reason, without my medical care or legal rights
being affected.
4.
I consent to the processing of my personal information for the purposes
explained to me. I understand that such information will be handled in
accordance with the terms of the Data Protection Act 1998.
5.
I understand that relevant sections of any of my medical notes and data
collected during the study may be looked at by responsible individuals from
regulatory authorities or from Guy’s and St Thomas’ NHS Foundation Trust or
Barts Health NHS Trust, where it is relevant to my taking part in this research. I
give permission for these individuals to have access to my records.
6.
I agree that any anonymised data collected in this study can be used in future
research that has been approved by a recognised Research Ethics Committee. I
am aware this research may be in collaboration with a commercial company,
but that my identity will be kept anonymous.
Yes
No
7. I agree to take part in the above study.
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